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Abstract 
Introduction: Patients with end stage kidney disease (ESKD) have high mortality 
rates and a high burden of disease that negatively impacts their physical condition. 
Patients with ESKD are primarily treated with haemodialysis (HD), which is a forced 
period of inactivity and creates a catabolic state that exacerbates the physical 
deconditioning among patients undergoing HD. Exercise training programmes have a 
positive effect on physical conditioning and can also be performed intradialytically. 
However, exercise training recommendations for patients undergoing HD are high-
volume, time-demanding and physically challenging beyond what is reasonable for 
many patients undergoing HD. These patients require targeted, time-efficient 
interventions that can be performed intradialytically and ameliorate losses in physical 
conditioning. Blood flow restriction (BFR) exercise uses pressurised cuffs to restrict 
blood flow to the exercising limbs and can increase muscle size and strength more than 
equivalent-intensity non-BFR exercise training, even with low-intensity aerobic 
exercise training (AT). Blood flow restricted aerobic exercise training (BFR-AT) 
represents greater value for the time spent exercising and a markedly reduced time 
commitment for patients undergoing HD. Thus, the overall aim of this thesis was to 
assess the applicability and efficacy of intradialytic BFR-AT for patients undergoing 
HD with regard to improving their physical conditioning and overall wellbeing. 
 
Methods: This thesis presents two studies that characterise exercise training responses 
to BFR-AT in patients undergoing HD, and examine the efficacy of BFR-AT (cycling) 
compared to traditional AT (cycling) and usual care HD. Study 1 was an examination 
of the haemodynamic (heart rate [HR], systolic blood pressure [SBP], diastolic blood 
vi 
pressure [DBP], and mean arterial pressure [MAP]) and perceptual responses (rating 
of perceived exertion [RPE], rating of perceived discomfort [RPD]) of patients 
undergoing HD (n = 10) to 2 bouts of 10 mins BFR-AT (cycling) performed both 
intradialytically and interdialytically compared within-subjects to responses following 
2 bouts of 10 mins intradialytic traditional AT (cycling). Each of these three conditions 
were performed twice. Study 2 examined the efficacy of an intradialytic 12-week BFR-
AT (cycling) [BFR-CYC] exercise training programme compared with 12-weeks 
intradialytic traditional AT (cycling) [CYC] and usual care controls [CON] for 
improving muscle strength (three-repetition maximum leg extension strength), 
physical function (30-second sit to stand, six-minute walk test, and timed up and go), 
total and regional body composition, as well as physical activity behaviour (CHAMPS 
questionnaire) and symptom-related quality of life (POS-S renal questionnaire). 
 
Results: In Study 1, there was no significant difference between the conditions of 
intradialytic AT (cycling), interdialytic BFR-AT (cycling), or intradialytic BFR-AT 
(cycling) with regard to HR, SBP, DBP, MAP immediately post-exercise (P < 0.05). 
Additionally, there was a significant post-exercise hypotension for all conditions over 
the first 60 min of recovery when compared with baseline (P < 0.001) that returned to 
baseline levels before the end of HD. RPE and RPD were significantly higher during 
both intradialytic and interdialytic BFR-AT (cycling) compared with intradialytic 
traditional AT (cycling) (P < 0.05). Both RPE and RPD were also significantly higher 
following exercise bout 2 compared with exercise bout 1 (P < 0.01). In Study 2, BFR-
CYC were significantly younger than CON but not CYC (P < 0.05), and body mass 
was significantly lower in CON compared with CYC, but not compared with BFR-
CYC (P < 0.05). BFR-CYC significantly increased leg strength from baseline (25.6 ± 
vii 
4.6 kg) to 12 weeks (30.4 ± 5.9 kg) (P = 0.001), while CYC (P = 0.086) and CON (P 
= 0.126) did not. BFR-CYC significantly increased repetitions on 30STS compared 
with CYC and CON (P = 0.001) from baseline to 12 weeks, while there was no 
difference between CYC and CON. BFR-CYC significantly increased distance walked 
during 6MWT (P = 0.002) from baseline to 12 weeks. CYC also significantly increased 
distance walked during 6MWT (by 33 ± 13 m; P = 0.023), while CON did not. 
However, when adjusted for baseline and age differences there was no significant 
difference between either exercise groups for distance walked on the 6MWT. There 
was no significant change in TUG performance for any group. No notable changes in 
muscle size or body composition were observed. Weekly energy expenditure and 
symptom related quality of life improved for BFR-CYC and CYC but not CON (P < 
0.05). 
 
Conclusions: This thesis is the first research to characterise BFR-AT (cycling) for 
patients undergoing HD, finding that haemodynamic responses to low-intensity BFR-
AT (cycling) were no greater than those for traditional AT (cycling). While the 
exertion levels was higher in BFR cycling compared to standard cycling, the RPE of 
the BFR cycling was similar to what has been reported for low to moderate traditional 
AT reported in other studies. Moreover, this thesis supports the use of BFR-AT as a 
means of improving muscle strength and physical function even in the absence of any 
substantial change in muscle size and body composition. Physical wellbeing and 
symptom-related quality of life were also improved, although this was true for exercise 
in general and not specifically BFR-AT. This thesis demonstrates that BFR-AT meets 
the criteria of being a targeted, time-efficient intervention that ameliorates losses in 
physical conditioning faced by patients undergoing HD.   
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General Introduction 
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1.1 Introduction 
Chronic kidney disease (CKD) is defined by a prolonged decline in renal function that 
is typically characterised by a reduction in glomerular filtration rate (GFR) (1). The 
most severe stage of CKD is end-stage kidney disease (ESKD) (1). Patients with ESKD 
require treatment by dialysis or transplantation to survive (1). Due to the severe renal 
dysfunction that signifies ESKD, patients waiting to receive or who are ineligible for 
transplants become reliant on dialysis (2). Despite dialysis being considered one of the 
most efficacious means of treating ESKD, it does not guarantee that life can be 
sustained (3). In Australia, mortality rates after one-year on HD are between 7% and 
28%, increasing with age above 45 years (3, 4). This increase in mortality occurs parallel 
to increased prevalence of comorbidities such as diabetes and cardiovascular disease, 
as well as adverse effects including anaemia, hyperkalaemia, hypertension, uraemia, 
fatigue, depression, muscle atrophy, and reduced quality of life (2, 5-7). These adverse 
effects contribute to a progressive physical and functional decline amongst patients 
undergoing dialysis, and this is exacerbated by the increasing duration on dialysis due 
to increased survival rates, and the progression of ESKD (3, 6, 8, 9). 
Dialysis, primarily as haemodialysis (HD), is generally required on three days per 
week, for 4 to 5 hours, and represents a forced period of inactivity (2). As patients 
undergoing HD already display a reduction in physical activity (PA) levels below that 
of sedentary but otherwise healthy adults, this presents a major issue to the physical 
conditioning of patients undergoing HD (6). Specifically, patients undergoing HD have 
significant muscle weakness related to reductions in muscle size (muscle atrophy) (6, 
10). Muscle atrophy among patients undergoing HD has also been linked to reduced 
exercise capacity and performance on physical functional tasks representative of 
3 
activities of daily living (ADL), including gait speed, personal hygiene tasks, as well 
as bed and chair transfers (6, 11, 12). These are all associated with increased rates of 
disability (loss of independence), morbidity and mortality compared with otherwise 
healthy older adults (13). Exercise and increased PA have been suggested to combat the 
loss of muscle strength, muscle size, cardiorespiratory fitness and physical function 
seen in patients undergoing HD (9).  
Given the pronounced inactivity, deterioration in physical conditioning, and 
comorbidities, exercise and PA interventions including intradialytic exercise training 
programmes (programmes completed during dialysis sessions) are warranted among 
patients undergoing HD. There is emerging evidence that such interventions may 
improve the physical conditioning of patients undergoing HD, and help manage 
adverse effects such as fatigue, depression and hypertension (14-16). However, these 
adverse effects, pronounced physical deconditioning, and symptoms related to other 
comorbidities limit patients undergoing HD to low-to-moderate intensity exercise (17). 
As such, recommendations made for exercise among patients undergoing HD require 
substantial time commitment to achieve targets in muscle strength, exercise capacity, 
and physical function (18). Time commitments to which patients undergoing HD 
display significant reluctance, and therefore have not widely adopted (19, 20). 
While there is no established convention for best practice exercise prescription among 
patients undergoing HD, exercise training prescribed for this population in the 
literature is most commonly aerobic exercise training (AT) (21-32). AT is traditionally 
unable to elicit increases in muscle strength and muscle size, subsequently limiting the 
potential to significantly improve counteract muscle weakness and muscle atrophy 
4 
among patients undergoing HD (33, 34). Thus, there is scope to enhance the benefit of 
intradialytic exercise training for this patient group (13). 
One method associated with enhancing gains in muscle size and muscle strength is 
blood flow restriction (BFR) exercise training. BFR exercise is a novel technique 
where pressurised cuffs, fitted proximally on a limb, restrict blood flow to that limb 
during exercise training (35). Low-intensity BFR exercise training increases muscle size 
and muscle strength to a greater extent than that of equivalent-intensity exercise 
training, even with low-intensity exercise training (36, 37). These adaptations, as well as 
concomitant improvements in physical function seen with BFR exercise training are 
not confined to resistance training (RT), with similar results having been shown when 
BFR is utilised during AT (BFR-AT) such as walking or cycling (38-41). It is therefore 
reasonable that BFR-AT may provide greater muscle size and muscle strength 
increases for patients undergoing HD than the predominately AT programmes 
previously prescribed in the literature (42-45). Due to the ability of BFR-AT to develop 
muscle size and muscle strength where traditional AT does not, BFR-AT represents 
greater value for the time spent exercising and a markedly reduced time commitment 
for patients undergoing HD. Thus, BFR during AT as an exercise modality for patients 
undergoing dialysis warrants examination. 
 
1.2 Experimental design 
This thesis presents a pilot study and a randomised controlled trial (RCT) (Clarkson et 
al., 2017. BMC Nephrology. 18:294; Appendix A), which examine the efficacy of 
BFR-AT (cycling) conducted intradialytically for patients undergoing dialysis. The 
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first study presented in this thesis (Study 1) is a pilot study to determine the 
haemodynamic responses and perceived tolerability of intradialytic BFR-AT 
(cycling). Traditional cycling exercise performed intradialytically, and interdialytic 
BFR-AT (cycling) (exposure to BFR in a more haemodynamically stable setting) are 
used as comparators. The second study (Study 2) presented follows on from Study 1 
and includes data from the RCT, examining the potential for BFR-AT (cycling) to 
improve muscle strength, muscle size, physical function, as well as physical activity 
behaviour and symptom-related quality of life beyond traditional cycling exercise and 
usual care HD. 
1.3 Overall aims  
The overall aim of this thesis was to assess the relative applicability of intradialytic 
BFR cycling exercise for patients undergoing dialysis (Chapter 4), and to assess the 
efficacy of a BFR cycling exercise training programme for patients undergoing 
dialysis with regard to improving their muscle size and muscle strength, physical 
function, and overall wellbeing (Chapter 5). 
 
1.4 Specific aims 
1. To determine the haemodynamic responses (heart rate [HR], systolic blood 
pressure [SBP], diastolic blood pressure [DBP], mean arterial pressure [MAP]) 
immediately following blood flow restricted cycling exercise in progressively 
more haemodynamically unstable settings (interdialytic and then intradialytic) 
among patients undergoing dialysis (Chapter 4). 
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2. To determine the perceptual responses (rating of perceived exertion [RPE], 
rating of perceived discomfort [RPD]) to blood flow restricted cycling exercise 
in progressively more haemodynamically unstable settings (interdialytic and 
then intradialytic) among patients undergoing dialysis (Chapter 4). 
3. To assess the efficacy of a 12-week blood flow restricted cycling exercise 
training programme compared with traditional cycling exercise training and 
usual care controls among patients undergoing dialysis (Chapter 5) by:  
a. Comparing lower limb muscle strength (three-repetition maximum 
bilateral leg extension [3RM-LE]) 
b. Comparing physical function (functional muscle power [30-second sit-
to-stand]; dynamic balance and mobility [timed up-and-go]; functional 
muscle endurance and aerobic capacity [six-minute walk test]). 
c. Comparing lean mass (total body, appendicular, arm and leg; dual-
energy x-ray absorptiometry [DXA]) and muscle cross-sectional area 
([CSA]; thigh [25% and 50% femur]; peripheral quantitative computer 
tomography [pQCT]). 
d. Assessing physical activity behaviour (community healthy activities 
model program for seniors [CHAMPS] questionnaire) and symptom-
related quality of life (patient outcome scale – symptoms of renal 
failure [POS-S renal] questionnaire). 
4. To characterise the time course changes in acute exercise response to a blood 
flow restricted cycling exercise training programme compared with traditional 
cycling exercise training with regard to haemodynamic measures (HR, SBP, 
and DBP) and perceptual responses (RPE and RPD) (Chapter 5). 
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1.5 Specific hypotheses 
1. Haemodynamic responses (HR, SBP, DBP, and MAP) to exercise would be 
greater with blood flow restricted cycling exercise than traditional cycling 
exercise. There will be no difference between the haemodynamic responses of 
blood flow restriction exercise performed either interdialytically or 
intradialytically (Chapter 4). 
2. Perceptual responses (RPE and RPD) to blood flow restricted cycling exercise 
would be greater than those to traditional cycling exercise (Chapter 4). 
3. Compared with both traditional cycling exercise training, and usual care 
haemodialysis controls, a 12-week blood flow restricted cycling exercise 
training programme will (Chapter 5): 
a. Produce greater lower limb muscle strength. 
b. Elicit greater increases in physical function, which will decrease for 
usual care haemodialysis controls. 
c. Increase lean mass and muscle CSA. 
d. Lead to greater increases in physical activity behaviour and symptom-
related quality of life. 
4. There will be a small but significant elevation in acute haemodynamic 
responses to exercise training for blood flow restricted cycling compared with 
traditional cycling completed intradialytically. Blood flow restricted cycling 
will elicit greater perceptions of effort (RPE) and discomfort (RPD) than 
traditional cycling at the start of the study, although these will reduce over the 
course of the study such that there will be no significant difference in acute 
perceptual responses to exercise by the end of the study for blood flow 
restricted cycling compared with traditional cycling (Chapter 5). 
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1.6 Significance 
Given ESKD imparts a significant burden on the health care system both in Australia 
and globally, and the number of patients commencing HD continues to rise, 
interventions to maximise patient outcomes, improve physical conditioning, and to 
manage comorbidities are warranted. The clinical significance of such interventions is 
more impactful given the deterioration of musculoskeletal and cardiorespiratory 
fitness and the marked loss of physical function and functional independence among 
patients undergoing HD. As survival rates increase, and patients are treated with HD 
for longer time periods, this physical deterioration is exacerbated, increasing the need 
to improve quality of life and maintain functional independence. Exercise training 
interventions have been shown to improve physical conditioning and reduce the 
burden of disease for these patients and may help to allay some of the economic burden 
that ESKD places on the health-care system. However, the diverse and time-
demanding exercise training programmes utilised by patients undergoing HD in the 
literature are often met with significant reluctance from patients, and poor adoption 
and adherence rates. The findings of this thesis will present the efficacy of a novel 
moderate-intensity exercise training programme for patients undergoing dialysis. This 
evidence-based intervention will help with the clinical management of ESKD-related 
adverse effects on muscle strength, muscle size, physical function, and overall 
wellbeing for patients undergoing HD. This is also one of the first training studies to 
utilise BFR exercise in a clinical setting as a means of addressing the physical decline 
associated with chronic disease progression. 
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1.7 Organisation of the thesis 
The thesis is organised around the specific research aims noted above. In Chapter 2, a 
review of the current literature relevant to the specific aims of the thesis is presented, 
and incorporates findings from an adjunct systematic review completed as a part of 
this thesis (Appendix B). In Chapter 3, the general methods implemented in both the 
pilot study and the RCT are presented. This also includes the peer-reviewed published 
protocol for the RCT (Appendix A). In Chapter 4, results from a pilot study to explore 
the haemodynamic responses and perceived tolerability of intradialytic BFR cycling 
are presented. Chapter 5 presents the RCT, which builds on the findings of Chapter 4 
and seeks to establish the efficacy of a BFR cycling intervention. In Chapter 5, results 
from the BFR cycling RCT in patients undergoing HD are presented. In Chapter 6, a 
general discussion relevant to the specific aims of the thesis and outcomes of the pilot 
study and RCT is presented. 
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2.1 Overview 
This chapter will highlight the significant burden end-stage kidney disease (ESKD) 
places on the health-care system both internationally and within Australia, as well as 
the detrimental effect it has on the individuals who suffer from ESKD. The most 
common form of treatment for ESKD, dialysis – predominately haemodialysis (HD) – 
and the broad range of comorbidities and adverse effects that are frequently seen 
among patients undergoing HD will then be discussed. An emphasis will then be 
placed on the role that exercise training programmes can play in treating these adverse 
effects, including the current advantages and disadvantages with the prescription and 
implementation of such programmes. Finally, a novel modality of exercise known to 
augment muscle size and strength whilst using relatively low-intensities, called blood 
flow restriction (BFR) exercise will be discussed together with its prescription 
considerations and potential value to patients undergoing HD. 
 
2.2 Determining kidney function 
The kidneys are essential organs in the regulation of homeostasis and in sustaining life 
(46). The predominant function of the kidneys is filtration of the blood and removal of 
waste through urine (46). The kidneys also play essential roles in the maintenance of 
blood volume (and subsequently long-term blood pressure regulation), blood pH, and 
blood-solute concentration (47). Additionally, the kidneys may be considered endocrine 
organs as they produce erythropoietin (EPO), renin, and play a significant role in the 
activating Vitamin D (47). These hormones, respectively, are essential in stimulating 
red blood cell production from bone marrow, filtration and controlling blood volume 
(and pressure), and absorption of calcium from dietary sources (47). 
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Filtration, measured by glomerular filtration rate (GFR) is acknowledged as the 
primary index of kidney function (48). GFR is measured as the rate of filtration (ml.min-
1) adjusted for a ‘standard’ body size or surface area (1.73 m2) (1). Young individuals 
with two healthy kidneys, may have at or near 100% of kidney function, and a mean 
GFR of approximately 120-130 mL.min.1.73m-2 (1). After 20 to 30 years of age, the 
mean GFR declines by approximately 1 mL.min.1.73m-2 each year(1). A reduction in 
GFR by 30% to 40% would not always be detected and would still be considered 
normal (46). However, older adults (>60 years) with ‘normal’ functioning kidneys are 
unavoidably classified at the lower end of the ‘normal’ GFR range. 
 
Should measures of GFR fall below 60 mL.min.1.73m-2 on multiple occasions or 
evidence of kidney damage persist even without a reduction in GFR, an individual may 
be diagnosed with chronic kidney disease (CKD) (1, 2, 48). The development of CKD is 
defined by stages (Table 2.1) based on either the severity of the disease or expected 
prognosis (1, 2, 48). Once GFR falls below 25% of healthy function (<30 mL.min.1.73m-
2, kidney function stage 4) the kidneys can no longer function sufficiently leading to a 
substantial accumulation of waste products in the blood (46). 
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Table 2.1. The stages of chronic kidney disease as classified by glomerular filtration 
rate (GFR) (adapted from Johnson, D. (48)). *Dependent on persistence for more than 
three months, otherwise it may be acute kidney disease. 
 
Kidney Function Stage GFR (mL.min.1.73m-2) Classification 
 Stage I ≥90 
Normal Kidney Function 
 Stage II 60-89 
 Stage IIIa 45-59 
Chronic Kidney Disease*  Stage IIIb 30-44 
 Stage IV 15-29 
 Stage V <15 or on dialysis End Stage Kidney Disease 
 
 
2.3 Defining end-stage kidney disease 
As a practical measure of GFR, estimated GFR (eGFR) utilises measures of serum 
creatinine levels and appropriate prediction equations (2). Additionally, existing kidney 
damage can be determined by the presence of excessive amounts of proteins in the 
urine, specifically albumin (2). The most severe classification of kidney function, stage 
5 (GFR <15 mL.min.1.73m-2), is ESKD (1, 2, 48). Once kidney disease has progressed to 
ESKD, the kidneys have reached a point of total or near-total failure, resulting in an 
inability to independently filter the blood sufficiently to sustain life (46). This results in 
uraemia, a condition whereby excess fluid and waste products accumulate in the body 
to toxic levels (46). This ultimately means that individuals with ESKD require 
transplantation or must undergo dialysis in order to survive (46). Unfortunately, this 
represents a significant burden to the individual but also to the health-care system. 
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2.4 End-stage kidney disease epidemiology 
CKD is a worldwide public health issue, with the incidence rising (1). A 2010 study of 
the global burden of disease reported that the worldwide rate of deaths associated with 
CKD increased by the second highest amount of all causes of death since 1990 (49). 
Approximately 1 in 10 people worldwide have indicators of CKD such as diminished 
kidney function and excess albumin in the urine (2, 49). However, over 90% of those 
with CKD are unaware that they have it (equivalent to approximately 1.5 million 
Australians) (2). While not all of these people will suffer the magnitude of diminished 
kidney function to be classified as having ESKD, this lack of awareness reduces the 
likelihood of sufficiently early detection before renal replacement therapy (RRT) is 
required (50). Globally, ESKD was ranked eleventh among all underlying causes of 
death due to disease in 2016, totalling 1,186,600 deaths (2.2% of all deaths), an 
increase of 28.8% from 2006 (51). In Australia, ESKD was responsible for 2,243 deaths 
in 2017, a significantly lower rate than the global average (1.4% compared with 2.2% 
globally). This may be due to the accessibility of RRT under both the private and 
public national health-care systems (49, 52). 
An estimated 2 million people worldwide, and 24,000 Australians are currently 
receiving RRT (undergoing dialysis or living with a transplant) (2, 49, 53-55). The 
prevalence of RRT has risen by approximately 33% over the last decade (54). This is 
despite the population of Australia only increasing by only 14% during this time (54). 
Of these patients, over half receive dialysis as treatment for ESKD even with increases 
in the proportion of kidney transplants (54). The disparity between rates of treated 
ESKD and population growth is likely a result of the ageing population (as incidence 
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of ESKD significantly increases after 70 years of age) and increasing survival rates of 
patients with ESKD (54, 56).  
Largely due to the regularity of dialysis as a treatment, ESKD accounts for 
approximately 1 in 7 hospitalisations in Australia, making it the most common reason 
for hospitalisation nationally (53). This poses a substantial economic burden for the 
national health-care system as it is projected to cost an average of $1 billion per year 
by 2020 (55, 56). This underscores the need for improved management of ESKD that can 
provide better patient outcomes and reduce the financial burden on the health-care 
system. 
The Australian and New Zealand Dialysis and Transplant (ANZDATA) Registry 
identifies the most common cause of ESKD in 2016 as diabetes (36%), followed by 
glomuleronephritis (20%), and hypertension (15%) (57). Diabetes is the fastest growing 
chronic condition in Australia, thus, given the relationship between diabetes and 
ESKD, it is unsurprising that the prevalence of ESKD with diabetes as a comorbidity 
has almost doubled in the last decade (9,794 patients in 2016 compared with 5,111 in 
2006) (54, 57, 58). Given diabetes is a major predisposing factor to the development of 
ESKD, it may also indicate that treatment for ESKD should incorporate similar 
interventions to those delivered to people living with diabetes or hypertension, such as 
lifestyle interventions including body mass loss and regular exercise training to 
compliment RRT. Ultimately, ensuring patients can maintain independent function, 
while reducing the economic burden of health-care where possible is vital to improving 
the patient’s wellbeing (8). 
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2.5 Haemodialysis 
There are presently over 12,000 people receiving dialysis in Australia (54). When 
compared to almost 9,700 Australians living with transplant, dialysis is evidently the 
most common treatment for ESKD (54). For the majority of Australians who receive 
dialysis, this is through hospital or community-based HD (59). This process involves 
mechanical filtration of the blood to remove excess water and metabolic by-products 
that are otherwise unable to be removed by the damaged kidneys (46). In order to 
facilitate HD, patients awaiting dialysis must undergo surgery to insert a long-term 
haemodialysis catheter directly into either the internal jugular or subclavian vein, or 
preferably an arteriovenous fistula (AVF) in the arm, known to produce fewer 
complications such as infection (60). During HD, blood is drawn out through an external 
arterial access line inserted into the fistula or catheter and filtered through an external 
dialyser before being returned through a second venous access line (46). HD requires 
three-to-five sessions per week that often take 3-6 hours (46). During a single HD 
session, the patient’s entire blood volume is circulated through the dialyser once every 
15 minutes (46). As such, falls in blood pressure (BP) during HD are common (46). To 
account for this patients largely undergo HD while in a recumbent position (46). 
In Australia, mortality rates after one-year on HD are between 7% and 28%, increasing 
with age above 45 years (3, 4).  The median survival time after commencing dialysis 
ranges from 25.2 to 54 months for older adults (> 65 years) in Australia (3, 4, 12). After 
5 years on HD, only 48% of patients in Australia survive (3, 61). While this is in part 
driven by complications from common comorbidities such as diabetes and 
cardiovascular disease, it is also influenced by adverse effects faced by patients with 
ESKD undergoing HD. These include anaemia, metabolic and haemodynamic 
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regulation issues, fatigue, depression, reduced exercise capacity, muscle atrophy and 
loss of muscle strength, and reduced physical function (2, 5-7, 13, 62, 63). Further discussion 
of these adverse effects will be made in the following sections of this literature review. 
 
2.6 Adverse effects of end-stage kidney disease and dialysis 
Due to the complex and chronic nature of ESKD, treatment relies on the management 
of a broad range of adverse effects, some of which are serious in terms of medical 
outcomes (anaemia, hyperkalaemia, hypertension and hypotension), but all of which 
are serious with regard to potential negative effects on the function and wellbeing of 
patients with ESKD undergoing HD (64). Adverse effects not requiring acute medical 
intervention (fatigue, depression, physical conditioning), are often accepted as part of 
the disease by patients and clinicians (65). The ability of patients to self-manage these 
adverse effects not requiring medical intervention is strongly associated with their 
subjective and objective function and wellbeing (64). However, the symptom burden 
and impaired quality of life experienced by patients undergoing HD makes self-
management of these adverse effects onerous (65-67). The onus of self-management is 
exacerbated when the concurrent loss of physical conditioning and functional 
independence is considered (65-67). 
 
2.6.1 Anaemia 
In addition to filtration of the blood, one of the main functions of the kidneys is the 
production of erythropoietin (EPO), which is responsible for red blood cell 
proliferation when circulating oxygen tension is low (5). It is common for functional 
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abnormalities of the kidney to occur with ESKD, disrupting this process and causing 
anaemia, which is characterised by a reduced haematocrit (5). The underlying reduction 
in circulating red blood cells leads to a concurrent reduction in circulating 
haemoglobin (Hb) (5). This reduced Hb concentration is insufficient to maintain normal 
blood-oxygen levels (68). An estimated 24-32% of patients undergoing HD suffer 
anaemia, which is as much as four times the incidence of anaemia compared with the 
general population (3, 5). 
Anaemia contributes to reduced physical capacity and muscle function, reduced 
cognitive function, and markedly decreased energy levels, making it detrimental to 
quality of life and a major contributing factor to the sedentariness among patients 
undergoing HD (69). The cardiovascular system also undergoes adaptive changes to 
blood pressure and cardiac output in order to regulate tissue oxygenation (69). This may 
lead to left ventricular hypertrophy and/or dilation, and ultimately result in myocardial 
infarction or death (69). Treatments for anaemia have included blood transfusions and 
administration of recombinant human EPO (RH-EPO) (69). However, these treatments 
are costly, and there has been evidence among patients undergoing HD of increased 
thromboembolic events associated with EPO use, likely resultant from increased blood 
viscosity, stasis and clotting with an increased haematocrit (69, 70). This makes 
monitoring of Hb necessary to avoid exceeding the treatment target for patients 
undergoing HD of 100-115 g.L-1 (69, 70). Maintenance of Hb in this target range has also 
been shown to improve exercise tolerance, patient- and clinician-reported physical 
function, with no additional benefit if Hb exceeds the target range (71). One study also 
found that even with RH-EPO use amongst HD patients, only when low-to-moderate 
intensity aerobic exercise training was performed regularly were patients able to 
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maintain or marginally improve exercise capacity (measured as maximal oxygen 
uptake) (72). Thus, there is supporting evidence that regular exercise may be a suitable 
adjunct treatment for anaemia among patients undergoing HD. 
 
2.6.2 Hyperkalaemia 
With normal kidney function, there is a large concentration gradient for potassium (K+) 
between intracellular and extracellular fluid (73). At the cellular level, this concentration 
gradient is acutely maintained by ubiquitous sodium-potassium ATPase exchange 
pumps (73). More chronically, these concentrations are regulated by renal excretion of 
K+ through urine (excretion of 90-95% of daily dietary potassium load) (73). With 
ESKD, renal excretion of K+ decreases due to reduced urine production (73). Sodium-
potassium ATPase exchange pump activity cannot compensate for the subsequent 
excess serum K+, thereby resulting in chronically elevated serum K+ levels (73). Termed 
hyperkalaemia, excess serum K+ is exacerbated by the presence of metabolic acidosis, 
which is also common among patients with ESKD (74). This is worsened by imbalances 
between dietary K+ intake relative to residual kidney function, and compounded by 
treatment with renin-angiotensin-aldosterone system blockers (angiotensin-converting 
enzyme [ACE] inhibitors; angiotensin II receptor blockers [ARBs]), which are 
recommended medications for blood pressure control among patients with ESKD (74). 
While often utilised to manage the impact of hypertension and diabetes among patients 
with ESKD, these medications also inhibit renal K+ excretion (74). 
Hyperkalaemia is one of the major reasons for hospitalisation among patients 
undergoing HD, and accounts for 0.8-1.8% of the deaths among patients undergoing 
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HD (75, 76). Hyperkalaemia can result in reduced myocardial conduction velocity and 
accelerated repolarization (73). It has also been associated with paraesthesia, weakness, 
and reduced time to fatigue during exercise (73, 77). Currently treatment for 
hyperkalaemia is limited to restriction of dietary K+, correction of metabolic acidosis 
through bicarbonate solutions, and medication with K+ binders to reduce free K+, and 
loop diuretics to increase K+ secretion (78). There is support for exercise training among 
patients undergoing dialysis for reducing the negative effect of impaired K+ regulation 
on physical function, despite mixed results regarding the effectiveness of exercise for 
actually improving K+ regulation (79-81). Interestingly, while excessive serum K+ is 
associated with decreased time to fatigue, K+ regulation during maximal incremental 
cycling exercise performance is proportional to Hb concentrations (77). This suggests 
that exercise combined with management of serum K+ levels and circulating Hb may 
improve K+ clearance, time to fatigue, and overall physical function among patients 
undergoing HD. The role exercise training plays in improving the adverse effects and 
physical conditioning of patients undergoing HD will be reviewed in greater detail 
later in this literature review (see Section 2.8). 
 
2.6.3 Impaired blood pressure control 
Hypertension is both a leading cause of CKD, and a complication of ESKD due to the 
difficulty in controlling it for patients undergoing HD (2). Not only is uncontrolled 
hypertension a factor in the disease progression of ESKD, but it also increases the risk 
of coronary heart disease and stroke (2). The difficulty in managing hypertension is 
associated with the preferential use of ACE inhibitors or ARBs, due to their ability to 
protect the kidneys from further damage despite the known side effect of a reduction, 
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albeit reversible, in GFR and inhibition of renal K+ excretion (2, 74). This makes 
treatment with diuretics an indicated adjunct antihypertensive medication due to its 
ability to increase renal K+ excretion (2). As such, with additional antihypertensive 
medications depending on cardiovascular indications and comorbidities, management 
for patients with ESKD often requires three or more medications to control BP (2). 
Unfortunately, aggressive BP control for patients undergoing HD may lead to adverse 
consequences as lower pre-dialysis systolic blood pressure ([SBP] <120 mmHg) is 
associated with higher cardiovascular and all-cause mortality rates as well as reduced 
physical function compared with higher pre-dialysis systolic blood pressures (82). This 
may also suggest that BP management among patients undergoing dialysis should 
involve a risk-benefit trade-off between pre-dialysis BP targets and performance on 
measures of physical function (82). One outcome of such a trade-off may be higher BP 
targets among patients undergoing HD. An alternative may be the emerging use of 
regular exercise training programmes for this population. A single exercise session has 
been shown to produce a transient reduction in SBP of 5-15 mmHg in hypertensive 
patients undergoing HD, which can last up to 22h, and when performed chronically 
elicit improvements in physical function (83). 
In contrast, hypotension which is not uncommon among patients undergoing HD, has 
been observed to occur during 5% to 50% of HD sessions (84, 85). Intradialytic 
hypotension (IDH) has no consensus definition, although a recent review of the 
association of mortality risk with various definitions of intradialytic hypotension found 
that the most robust definitions of IDH involved absolute thresholds for SBP 
dependent on pre-dialysis basal SBP (85). SBP <90 mmHg for those with pre-dialysis 
SBP <160 mmHg, and SBP <100 mmHg for those with pre-dialysis SBP >160 mmHg 
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were the most potent definitions (85). The mechanism for IDH is still unclear although 
it has been thought to be associated with attenuated sympathetic myocardial response 
(impaired LV systolic function), blunted response to the release of catecholamines, 
and/or a reduced haemodynamic response to fluid removal during HD (86). 
With regard to the objectives of this thesis, it has been hypothesised that patients 
undergoing HD may not adequately respond to the additional sympathetic demands on 
the cardiovascular system during exercise, which may increase the incidence of 
hypotension in this population (86). However, while IDH has been one of the most 
commonly reported adverse events in studies of intradialytic exercise, it has not 
occurred more frequently than that seen in usual care HD, making it hard to attribute 
exercise with increasing the likelihood of IDH (44, 84, 87-92). 
 
2.6.4 Fatigue 
Fatigue is experienced physically, cognitively and emotionally by patients undergoing 
HD (8). It has been one of the most prevalent side-effects of ESKD, with physical 
fatigue having been identified by patients as the most troubling symptom of ESKD, 
and “tiredness” the most commonly reported symptom (8). Additionally, the impact of 
fatigue has been highlighted by one study reporting that 94% of patients undergoing 
HD would commit to increased frequency of HD if it was associated with increased 
energy levels (93). While commonly acknowledged as a symptom in over 60% of 
patients undergoing HD, there has been minimal research targeted to alleviating this 
fatigue (8, 93). 
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Fatigue has been examined in other chronic diseases such as multiple sclerosis, 
rheumatoid arthritis, and cancer with non-pharmacological interventions such as 
regular exercise identified as having been effective in helping to managing fatigue (8). 
However, fatigue has been attributed to 14-30% of the variance in daily PA levels for 
patients undergoing HD, and the most commonly reported barrier to PA for both HD 
days (67%), and non-HD days (40%) (8, 19, 94). This issue has been compounded by 
fatigue leading to patients undergoing HD becoming more sedentary, which then 
further exacerbates levels of fatigue (95). This further indicates the benefit of 
implementing exercise training programmes for patients undergoing HD, perhaps in 
shorter duration intervals than traditionally used in healthy populations, to account for 
increased levels of fatigue. An alternative exercise training prescription capable of 
providing greater value for time spent exercising over shorter duration intervals will 
be discussed later in this literature review (Section 2.10). 
 
2.6.5 Depression 
Patients undergoing dialysis display a particularly high prevalence of depression, 
affecting as many as 60% of all patients (14, 65). Hospitalisation and mortality rates 
within the first year of HD have been more than twice as high among patients with 
depression compared with patients without depression (91). Longitudinal studies in 
patients undergoing HD have reported that depression has commonly been 
undertreated, with most treatment having been focused on other adverse effects such 
as anaemia, hyperkalaemia and hypertension (91). This is problematic as depression has 
been strongly associated with mortality risk, hospitalisation, peritonitis, and exit-site 
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infections in patients undergoing HD (14). It is also noteworthy that muscle catabolism 
common to patients with ESKD has also been associated with depression (96). 
Exercise training has repeatedly been shown to improve depressive symptoms in non-
ESKD populations, it has also been explored as a treatment modality in studies among 
patients undergoing dialysis (14, 91, 97-99). Notably, the effectiveness of regular exercise 
programmes in reducing depression symptoms appears to be proportional to the 
severity of the depression, whereby exercise was more effective for patients with more 
severe depression (14). This adds further credence to the efficacy of incorporating 
regular exercise, or at least encouraging greater physical activity participation as a part 
of the routine management of patients undergoing HD. 
 
2.6.6 Reduced participation in physical activity 
As well as fatigue and depression, a lack of motivation, fear of falling, and perceived 
limitations such as lack of time, or physical disability have been identified by patients 
undergoing HD as barriers that contribute to their decreased PA levels (19, 95). 
Additionally, uraemia has been acknowledged as a primary factor in reducing the 
physical capacity of patients undergoing HD and by extension has been associated 
with reduced levels of PA in this population group (17). Patients undergoing HD are on 
average 35% less physically active than sedentary healthy individuals (17, 100). A 
potentially compounding factor is the 12-18 hours per week required for dialysis 
treatment itself during which patients are seated or reclined, essentially representing a 
forced period of inactivity (2, 101). Analysis of a subset of 2,507 US dialysis patients 
from the Dialysis Morbidity and Mortality Wave 2 study showed that 56% of patients 
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exercised less than once per week, 18% exercised 2-3 times per week, 6% exercised 
4-5 times per week, while 20% exercised daily (102). Those exercising 2-3 days per 
week or 4-5 days per week had a 26% and 30% reduction in mortality risk (102). 
Surprisingly, daily exercise showed a 6% increase in mortality risk, which could be 
attributed to potential over-reporting of physical activity given the subjective nature of 
the reported physical activity levels (102). This is made more likely by the overall robust 
and clinically significant association between exercise and survival in a separate 
analysis of the same data set (103). 
Among patients undergoing HD, those between 30 and 70 years of age completed 
between 15% and 57% less PA, respectively, than individuals without ESKD (17). This 
age-related variance will only compound going forward, with patients undergoing HD 
living longer as the efficacy of treatment improves (3). In addition to decreasing with 
age, physical activity participation also decreases with eGFR (104). Patients with CKD 
with eGFR <30 mL.min.1.73m-2 scored 10-points lower on the Duke Activity Status 
Index than those with an eGFR above that threshold (105). Further and greater declines 
in physical activity engagement were then observed on 4-year follow-up for 
participants displaying declines in eGFR >15 mL.min.1.73m-2 compared with 
participants with stable eGFR (105). Similarly, physical activity levels measured by 
accelerometry among patients undergoing HD have been reported to decline by 
approximately 3.5% per month over a 12-month period (106). 
Reduced physical activity participation is clinically relevant for patients undergoing 
HD due to its correlation with physical performance in this population group (100). The 
combined decrements seen in both daily physical activity and physical performance 
have been associated with increased morbidity, lower survival rates, and impaired 
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quality of life of patients undergoing HD (100). Moreover, in a study of available 
mortality data for 2,837 patients undergoing dialysis, a survival analysis linked 
sedentary behaviour (hazard ratio 1.62, 95% confidence interval) to a 62% increased 
risk of death within one year of commencing dialysis (Figure 2.1) (103).  
 
Figure 2.1 Survival among self-reported sedentary and non-sedentary patients 
undergoing dialysis from the Dialysis Morbidity and Mortality Wave 2 study (adapted 
from O’Hare et al. (103)) 
 
Australia’s physical activity and sedentary behaviour guidelines suggest that adults 
(and older adults) should participate in 150-300 minutes of moderate intensity physical 
activity, or 75-150 minutes of vigorous activity per week (107). However, as patients 
with ESKD display a rapid decline in physical activity status to below that of sedentary 
but otherwise healthy individuals upon commencement of HD, this may not be a 
practical recommendation. While it is unlikely that many patients undergoing HD 
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achieve these guidelines, physical activity levels are not addressed within routine care 
among this population (101). 
The lack of physical activity in routine care directly contrasts the broader dialysis 
literature, in which exercise during HD is commonly employed (6, 15, 108-112). 
Furthermore, HD offers a supervised setting for patients to exercise, and avoids 
imposing an excessive time-burden on patients by reducing the need for additional 
interdialytic exercise sessions (113). Moreover, reductions in both structured and 
incidental physical activity results in a marked reduction in the physical conditioning 
of patients undergoing HD, an issue that further exacerbates physical inactivity (100, 
102). This disconnect between the efficacious use of exercise during HD in the literature 
and the lack of implementation in routine care presents a notable opportunity to 
improve the quality of care for patients undergoing HD. 
 
2.7 Physical conditioning among patients undergoing haemodialysis  
The combined burden of the adverse effects discussed previously (see Section 2.6), as 
well as low levels of physical activity among patients undergoing HD ultimately leads 
to significant reductions in the overall physical conditioning among this population. 
For the purpose of this review, physical conditioning can be defined as a combination 
of aerobic fitness or exercise capacity, indices of muscle health such as muscle size 
and muscle strength, and the ability to perform functional tasks necessary for daily 
living and functional independence. 
Uraemia and subsequent chronic inflammation, anaemia, metabolic acidosis, 
electrolyte disorders such as hyperkalaemia, hormonal imbalances, and malnutrition 
are common factors that contribute to the progression of physical inactivity and 
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physical deconditioning (10). Both of which are major contributors to the sharp rise in 
mortality seen among patients undergoing HD compared with healthy populations (10). 
2.7.1 Reduced exercise capacity 
Exercise capacity, also commonly termed aerobic capacity, is often measured by peak 
oxygen consumption during exercise (V̇O2 peak; ml.kg-1.min-1) or peak workload 
during exercise (Watts) (114). Due to lower breathing reserve and impaired heart rate 
variability, peak workload has been shown to overestimate exercise capacity among 
patients with ESKD and other chronic cardiovascular diseases compared with V̇O2 peak (114). Several studies have utilised V̇O2 peak as a measure of exercise 
capacity among patients undergoing HD, with baseline V̇O2 peak ranging from 11.5-
18.6 ml.kg-1.min-1 during symptom limited graded exercise assessments using a cycle 
ergometer (14, 22, 115-118). This reflected an approximate 40-50% reduction in exercise 
capacity among patients undergoing HD, compared with sedentary older adults (13, 119). 
In fact, reductions in exercise capacity are proportional to the severity of CKD 
(estimated by eGFR), whereby V̇O2 peak compared with healthy subjects is reduced 
by 22% among those with early stage CKD (>45 mL.min.1.73m-2), and 34% for 
patients approaching the need for dialysis (<45 mL.min.1.73m-2) (120, 121). This decline 
in V̇O2 peak is consistent even when targeted Hb levels are maintained (122). To 
quantify the decline in exercise capacity, a V̇O2 peak of 18 ml.kg-1.min-1 represents the 
threshold below which individuals would be classified as functionally disabled, or 
unable to complete the majority of their activities of daily living (ADL) without 
assistance (118, 123).  
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Reduced sympathetic activation of the myocardium, hyperkalaemia and other 
electrolyte disturbances all reduce stroke volume, and by extension limit V̇O2 peak 
among patients undergoing HD (73, 124). This is further exacerbated by the prevalence 
and severity of anaemia in this population (117). Another factor associated with the 
lower V̇O2 peak is a reduction in muscle capillary and mitochondrial density, which is 
a limiting factor in determining the degree of oxygen utilisation by active muscle 
during exercise training (11, 47). This reduction in capillary density and mitochondria is 
associated with muscle atrophy, which is common among patients undergoing HD due 
in large part to the high levels of physical inactivity, but often also cachexia that is 
inherent to ESKD (11). 
 
2.7.2 Muscle atrophy 
Patients undergoing HD are predominately sedentary, and this is exacerbated by 
extended forced periods of inactivity on the days on which they receive treatment (2, 
100). Such decreased levels of physical activity performed by patients undergoing HD 
(see Section 2.6.6), can be detrimental to skeletal muscle mass maintenance (6, 11, 125). 
Muscle atrophy, commonly measured by muscle cross-sectional area (CSA), is 
associated with axonal degeneration of neurons (neuropathy) or abnormalities in the 
structure and function of muscle fibres resulting from cachexia and uraemia in this 
population (11). Neither of these mechanisms are completely rectified through treatment 
with HD (11). The neuropathy somewhat improves with adequate HD; however, 
structural atrophic abnormalities remain unchanged or degenerate as time on dialysis 
increases (6, 11).  
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An increase in activation of the molecular pathways leading to muscle protein 
breakdown that worsens with the progression of CKD is also a likely determinant of 
accelerated muscle atrophy among patients undergoing HD (125). Moreover, HD itself 
is a catabolic event that reduces circulating amino acids and whole-body protein 
synthesis and increases whole-body protein breakdown (126). The combined effect is a 
metabolic environment in which net whole body protein loss is 50% higher than basal 
levels among patients with ESKD (126). Alongside these factors, other known 
modulators of muscle degradation are inflammation, malnutrition, resistance to 
insulin-like growth factor-1 (IGF-1), increased myostatin, mitochondrial dysfunction 
and Vitamin D deficiency, all of which affect patients undergoing HD (127, 128).  
While there is an overall decrease in muscle CSA amongst patients undergoing HD, 
there is a greater degree of atrophy of the type II fibres (6, 11, 129). The most 
comprehensive study examining the muscle morphometry and histology of patients 
undergoing HD found a decrease in type II fibre size of almost 36% for patients 
undergoing HD compared with normal reported values for muscle from sedentary but 
otherwise healthy individuals (130). The same study showed fibre distributions (in the 
vastus lateralis) of approximately 55% and 45% for type I and type II fibres, 
respectively (11). This is contrary to the proportions seen in normal human superficial 
muscles of the lower limb, which are closer to a ratio of 1:2 for type I to type II fibres 
(131). A summary of studies that have examined the impact of ESKD and dialysis on 
muscle size (and muscle strength) has been presented in a later section of this thesis 
(see Table 2.4, Section 2.7.3)  
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2.7.2.1 Sarcopenia 
The loss of lean mass, specifically when associated with aging is more broadly 
associated with sarcopenia, as originally described by Rosenberg (132). The definition 
of sarcopenia has since evolved into a diagnostic approach to describing the 
relationship between a loss of lean mass, decreased muscle strength, and reduced 
physical function with age (133). However, there is currently no consensus operational 
definition for sarcopenia, with notable variation between the thresholds for lean mass, 
muscle strength and physical function among the most commonly used criteria (133-137). 
A recent and comprehensive comparison of the major definitions of sarcopenia 
identified that they share good negative, but poor positive agreement in identifying 
sarcopenia (Table 2.2) (133). Regardless, multiple criteria for defining sarcopenia have 
been associated with adverse health outcomes such as mortality, functional 
impairment, increased risk of falls, and fractures (133, 138-142). 
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Table 2.2 Summary of operational definitions for sarcopenia and prevalence among healthy populations (adapted from Dam et al. (133)). 
 Operational Definition  Prevalence (%) 
Criteria Physical Function Muscle Strength ALM  
Men 
(n = 7,113) 
Women 
(n = 2,950) 
 
Foundation of NIH Sarcopenia 
Project 
 
Weakness and low lean mass 
 
-- 
 
 
 
Grip strength 
Men: <26 kg 
Women: <16kg 
 
 
 
ALMBMI 
Men: <0.789 
Women: <0.512 
 1.3 2.3 
 
Slowness with weakness and 
low lean mass 
Gait Speed: ≤0.8 m/s 
 
 
Grip strength 
Men: <26kg 
Women: <16kg 
 
 
ALMBMI 
Men: <0.789 
Women: <0.512 
 0.5 1.8 
International Working Group Gait Speed: ≤1.0 m/s -- 
ALM/ht2 
Men: <7.23 kg/m2 
Women: <5.67 kg/m2 
 5.1 11.8 
European Working Group on 
Sarcopenia in Older Persons 
 
Sarcopenia 
 
 
 
Gait Speed: ≤0.8 m/s 
Grip Strength 
Men: <30 kg 
Women: <20 kg 
-- 
 
 
ALM/ht2 
Men: <7.23 kg/m2 
Women: <5.67 kg/m2 
 5.3 13.3 
Severe sarcopenia Gait Speed: ≤0.8 m/s Grip Strength 
Men: <30 kg 
Women: <20 kg 
ALM/ht2 
Men: <7.23 kg/m2 
Women: <5.67 kg/m2 
 0.7 2.9 
Abbreviations: ALMBMI = ratio of appendicular lean mass over body mass index; ALM/ht2 = ratio of appendicular lean mass over height squared. 
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These generalised definitions of sarcopenia are primarily representative of 
community-dwelling populations with relatively few comorbidities (133). General 
population definitions of sarcopenia are not representative of patients undergoing HD 
due to the heterogeneity of the population (133). Defining sarcopenia for patients 
undergoing HD is made more problematic due to the numerous and significant adverse 
effects afflicting the population, which may confound measurement of the key defining 
criteria for sarcopenia (133). While no operational definition for sarcopenia 
representative of patients undergoing HD has been created, the criteria are likely to be 
multi-faceted (Figure 2.2). In the absence of such an operational definition, most 
studies instead reference only muscle atrophy, or a combination of muscle atrophy and 
one measure of function (strength or a functional test) to characterise sarcopenia in 
this population (7, 128, 143-146). Applying this methodology among patients undergoing 
HD over the age of 50 years, 45-65% have been identified as having sarcopenia (6, 10, 
144).  
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Figure 2.2 Spectrum of sarcopenia in ESKD. Evidenced by increased muscle 
catabolism, and decreased regeneration, affecting measures of strength, physical 
function, and by extension increasing falls, fractures, immobility, disability, and 
ultimately mortality (adapted from Avin & Moorthi (128)). 
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Studies have identified sarcopenia prevalence among patients undergoing HD of all 
ages ranging from 2-63% depending on the operational definition and measurement 
instruments used (7, 143, 144). However, muscle strength was determined to be a stronger 
predictor of mortality than lean mass alone (143, 145). Women were more likely than men 
to meet the criteria of sarcopenia (145). Asian ethnicities were also more likely to meet 
the criteria for sarcopenia compared with “Black” and “White” patients (145). Moreover, 
only two of these studies reflected on the potential difficulties with assessment of the 
sarcopenia criteria, and summarised the methods required for an apt identification of 
sarcopenia (128, 144). The consensus being that for determining muscle strength and lean 
mass, the use of grip strength dynamometry for hand grip strength, and dual x-ray 
absorptiometry (DXA) to measure appendicular lean mass were the most sensitive 
measures (144). The assessment of physical function was most appropriately measured 
by gait speed (4 m walk), with the six-minute walk test (6MWT) a suitable alternative 
(128, 147). However, some additional case-by-case considerations may need to be made 
regarding the assessment of the components of sarcopenia among patients undergoing 
dialysis (Table 2.3) (144, 148). Likewise, different methodologies and cut offs may need 
to be validated separately before any operational definition of sarcopenia can be 
developed for this population (128). Identifying a robust method for assessing 
sarcopenia among patients undergoing HD would help to provide measurable criteria 
that may help in streamlining adjunct treatment targeting physical conditioning among 
this population. 
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Table 2.3 Objective assessment of muscle mass, strength and function with 
considerations for patients undergoing HD (adapted from Avin & Moorthi (128)). 
  *Dialysis considerations 
Muscle mass Bioelectrical impedance analysis 
(BIA) 
Dual X-ray Absorptiometry (DXA) 
Computerised tomography (CT) 
Magnetic resonance imaging (MRI) 
BIA – measured after mid-week 
session (in dialysis) 
Significant atrophy of skeletal 
muscle may interfere with 
measurements in some patients 
Strength Isotonic (constant load) 
dynamometry, free weights 
Isometric (constant angle) hand-
held dynamometry, 
computerised dynamometry, 
manual testing 
Isokinetic (constant velocity) 
computerised dynamometry 
Using limb contralateral to dialysis 
access 
Timing test with dialysis (pre- or 
post-dialysis) 
Function Gait speed (4 m walk) 
Six-minute walk test 
Repeated chair stand 
Timed up and go 
Upper body ergometer 
Vascular complications, 
amputations, and neuropathy in 
patients with CKD may limit 
use of certain tests 
Abbreviations: CKD = Chronic kidney disease. *Reference values/cut-offs from healthy 
populations are likely different from those for patients with CKD. 
 
2.7.3 Reduced muscle strength 
While there is a notable and expected association between muscle size and muscle 
strength, muscle strength is not dependent on muscle size alone (143). The rate of decline 
of muscle strength with age is greater than the rate at which muscle size is lost (149). 
Muscle strength can also diminish even while muscle size is maintained or increased 
(150). Thus, the cause of muscle weakness observed among patients undergoing HD has 
not been fully elucidated. General causes of muscle weakness, besides muscle atrophy, 
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can include a reduction in force production per unit of mass (myopathy), reduced 
central nervous system recruitment of motor units (central activation failure), or a 
combination of these factors (151). Indeed, the selective atrophy of type II fibres, 
recruited for higher power and force production, is likely to play a significant role in 
muscle strength deficits among patients undergoing HD as well (11). Additionally, 
lower lean body mass index, lower serum creatinine, lower Hb, increased 
inflammatory markers and reduced serum albumin are also strong correlates of muscle 
strength (143, 152). Inflammation in particular is a prominent factor associated with 
muscle strength but shows little association with muscle size loss (143). Therefore, 
approaches to attenuate reductions in muscle strength must be multi-faceted. Routine 
clinical and pharmacological care needs to manage serum creatinine, Hb changes, 
inflammation and serum albumin. Additional physical therapy such as progressive 
exercise training programmes can be used to address changes in body mass index 
likely proportional to muscle atrophy, in order to reduce loss of muscle strength. 
A summary of cross-sectional studies examining the differences in muscle strength 
and muscle size among patients with ESKD and on dialysis is provided in Table 2.4. 
When compared with sedentary otherwise healthy populations, muscle strength 
(measured by maximal voluntary contraction of the lower limb) has been between 22% 
and 28% lower for patients undergoing HD (6, 153), or up to 40% lower when measured 
using handgrip dynamometry (154). Likewise, one cross-sectional study examining 
muscle strength measured by handgrip dynamometry among 120 patients with CKD 
found greater muscle strength deficits for patients undergoing HD (22.4 ± 7.9 
kilogram-force [kgf]) than those who had early stage CKD (35.2 ± 8.7 kgf) (P < 0.01) 
(152). The same study showed a similar comparison for relative leg extensor strength 
between patients undergoing HD (0.47 ± 0.16 kilogram-force per kilo body mass 
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[kgf.kg-1]) than those who had early stage CKD (0.66 ± 0.11 kgf.kg-1) (P < 0.01) (152). 
Additionally, females showed a small, but significant increase in the rate of decline in 
muscle strength than their male counterparts (6, 152, 153). 
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Table 2.4 Cross-sectional studies examining the effect of ESKD and dialysis on muscle size and muscle strength. 
Study Sample Comparison Age Measures Findings 
Tangvoraphonkchai et al. 
(2018) (146) 
HD Patients 
(n = 459) 
Age-matched and gender-
matched normative data 68 ± 14 - Handgrip strength 
↓ Handgrip Strength 
Muscle weakness associated with: 
- Age 
- Body Mass 
- Serum albumin 
Muscle weakness 40% more likely among patients 
with comorbidities 
Yoowannakul et al. 
(2018) (145) 
HD Patients 
(n = 600) 
Division by gender and 
ethnicity (Asian, Black, White) 66 ± 15 
- Skeletal muscle mass 
- Appendicular lean 
mass 
- Handgrip strength 
- Asian patients higher prevalence of muscle 
weakness and muscle atrophy 
- Males higher muscle mass and grip strength 
Kittiskulnam et al. 
(2017) (148) 
HD Patients 
(n = 645) 
Division by muscle mass 
normalized by measures of 
body composition (BMI, BSA) 
57 ± 15 - Muscle mass (BIA) - Handgrip strength 
Significant odds ratio of having reduced grip 
strength for: 
- Muscle/BMI 
- Muscle/BSA 
- Muscle/body mass 
Kopple et al. (2015) (100) HD Patients (n = 72) 
Healthy controls  
(n = 39) 52 ± 13 - Lean body mass (kg) ↔ Lean body mass 
Isoyama et al. (2014) (143) HD Patients (n = 330) 
Within subject comparisons of 
muscle strength and muscle 
mass 
53 ± 13 
- Lean body mass 
index (kg.m-2) 
- Handgrip strength 
Decreases in handgrip strength associated with lower 
muscle mass 
Regular exercisers had higher strength and muscle 
mass 
Low combined muscle mass and muscle strength had 
lowest survival rate 
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Kim et al. (2014) (7) HD Patients (n = 95) 
Division based on EWGSOP 
criteria for sarcopenia 64 ± 10 
- Lean tissue mass 
(BMI) 
- Handgrip strength 
33.7% of patients have sarcopenia; associated with: 
- Financial status 
- Charlson comorbidity index 
- Depression 
- Cognitive dysfunction 
Hiraki et al. (2013) (152) 
ESKD 
Patients 
(n = 23) 
Stages I-IV CKD (n = 97) 68 ± 12 
- Handgrip Strength 
(kgf) 
- Leg extensor strength 
(kgf/kg) 
↓  Handgrip Strength 
↓  Leg extensor strength 
Hartmann et al. 
(2009) (155) 
CKD stages 
IV and V 
(ESKD) 
(n = 26) 
Patients with heart failure, 
COPD, or high risk of CVD 
(n = 541) 
Over 
60 
- Handgrip strength 
- Whole body lean 
mass 
↓ Handgrip strength when adjusted for whole body 
lean mass 
Carrero et al.  
(2008) (154) 
ESKD 
patients 
(n = 486) 
Age-matched controls 55 ± 15 
- Lean body mass 
- Lean body mass 
index 
- Handgrip strength 
- Mid-arm muscle 
circumference 
↓  Handgrip strength and mid-arm muscle 
circumference proportional to presence/severity of 
muscle atrophy 
Majchrzak et al. 
(2007) (125) 
HD Patients 
(n = 55) Within subject associations 47 ± 2 
- Lean body mass 
- 1RM leg-extension 
strength 
- Weekly physical 
activity levels 
- Protein stores 
Increased physical activity and total daily protein 
intake are associated with higher lean body mass. 
1RM leg-extension strength was no associated with 
lean body mass 
Hsieh et al. (2006) (118) HD Patients (n = 27) 
Non-ESKD, age-matched 
controls 
(n = 27) 
60 ± 11 - Handgrip strength ↓  Handgrip Strength 
Johansen et al. (2003) (6) HD patients (n = 38) 
Sedentary otherwise healthy 
controls 
(n = 19) 
55 ± 15 
- Mid-calf CSA 
- Isometric dorsiflexor 
MVC 
↔ Total CSA 
↓  Contractile CSA 
↓  Dorsiflexor MVC 
↓  MVC/total CSA 
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Fahal et al. 
(1997) (153) 
CAPD and 
HD patients 
(n = 49) 
Healthy controls 
(n = 27) 42 ± 15 
- Isometric leg-
extensor MVC 
- Muscle fibre area and 
prevalence by fibre 
type 
Significantly lower force production from dialysis 
patients during MVC 
 
No difference in fibre area or prevalence 
Abbreviations: HD = Haemodialysis; ESKD = End-stage kidney disease; CKD = chronic kidney disease; BIA = Bioelectrical impedance analysis; BMI = Body Mass Index 
(kg.m-2); BSA = Body surface area (m); 1RM = One-repetition maximum; CSA = Cross-sectional area; MVC = Maximal voluntary contraction; CAPD = Continuous ambulatory 
peritoneal dialysis. 
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Muscle strength has often been found to be a strong predictor of mortality among 
patients undergoing HD, even when muscle size has not (143, 145). A 7-year 
observational study examining leg extensor strength among 190 patients undergoing 
HD in Japan determined that participants with <40% of their original leg extensor 
strength at the end of the study had a 75.6% survival rate, compared with a 92% 
survival rate for those maintaining ≥40% of their leg extensor strength (156). These 
muscle strength deficit thresholds had been previously associated with ability to walk 
independently (157). Interestingly, it was observed that females made up 70% of the 
group with <40% leg extensor strength, but only 38% of the group with ≥40% leg 
extensor strength, providing support for an association between gender and the deficit 
in muscle strength among patients undergoing HD (156). This also highlights the need 
for exercise training programmes with a primary focus on attenuating muscle strength 
declines among patients undergoing HD, particularly for females, and the significant 
reduction it may have on mortality rates. Moreover, while mortality is an outcome of 
paramount concern, it is well established that muscle strength has a strong positive 
correlation with performance on assessments of physical function indicative of ADL 
and quality of life among patients undergoing HD (6, 71, 143, 145, 152, 156). Thus, improving 
muscle strength may not only help patients undergoing HD to live longer, but it may 
help them increase their quality of life and retain functional independence for longer 
as well. 
 
2.7.4 Reduced physical function 
There is inconsistency in the literature regarding a clear definition of ‘physical 
function’ and the means by which it is measured (158). However, contributing factors to 
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‘physical function’ include physiological function, daily task performance and the 
ability to engage in broader sociocultural activities (90, 158, 159). While this may be a 
broad reaching definition, it is indicative of an individual’s ability to live 
independently and retain quality of life (159). For the purposes of this literature review 
and thesis, physical function will be defined as an individual’s ability to perform ADL 
measured either subjectively through questionnaires, or objectively through 
performance tests of physical function (81, 159). 
The steep decline in physical function among patients eligible for dialysis (stages IV 
and V) has been captured extensively in the literature and summarised in Table 2.5. 
The research included a broad range of measures that formed a holistic depiction of 
the diminished physical function through subjective and objective measures (66, 82, 100, 
105, 118, 155, 160-163). Common among these studies was substantially poorer physical 
function of patients undergoing HD when compared with healthy controls (66, 100, 105, 
118, 161-163). Patients undergoing HD also had significantly reduced self-reported 
physical function compared with patients with non-CKD chronic diseases such as 
diabetes, heart failure, chronic obstructive pulmonary disorder, or cancer (155).  
Physical function deteriorates with the progression of CKD, suggesting that those with 
ESKD have even more greatly diminished physical function compared with other 
populations (152). Furthermore, the lifestyle impact of this diminished physical function 
has been highlighted in one study that reported less than 5% of patients undergoing 
HD were fully independent and did not require assistance with ADL (164). This was 
made more significant with the finding that being unable to independently complete 
ADL was a strong predictor of mortality amongst those with ESKD (164).
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Table 2.5 Cross-sectional studies exploring the effect of CKD and dialysis on physical function against comparison groups. 
Study Sample Comparison Age Measures Findings 
Kopple et al. (2015) (100) HD Patients (n = 72) 
Healthy controls  
(n = 39) 52 ± 13 
- 6MWT 
- 30STS 
- Stair climb test 
↓ 6MWT 
↓ 30STS 
↓ Time to climb 22 steps 
Abreo et al. (2014)(82) HD Patients (n = 749) 
Division by pre-HD SBP 
categories (<110; 110-129; 
130-159; >160) 
57 ± 15 - SPPB 
Significant (P < 0.05) odds ratio of scoring low on 
SPPB for: SBP > 130 mmHg; Age (per 10 years); 
Male; African American; CVD or Diabetes 
Tentori et al. (2010)(160) HD Patients (n = 10999) 
HD Patients completing 
regular exercise 
(n = 9921) 
60 ± 15 -  KDQoL-SF ↓ KDQoL-SF scores indicating poorer mental state, strength, physical function and sleep quality  
Hartmann et al. 
(2009)(155) 
CKD stages 
IV and V 
(n = 26) 
Patients with heart failure, 
COPD, or high risk of CVD 
(n = 541) 
Over 60 - SPPB ↓ SPPB score 
Altintepe et al. (2006)(66) HD Patients (n = 125) 
Non-CKD, age-matched 
controls (n = 61) 68 ± 4 
- RMI 
- SF-36 (PCS) 
↓ RMI 
↓ SF-36 (PCS and PF) 
Hsieh et al. (2006)(118) HD Patients (n = 27) 
Non-ESKD, age-matched 
controls (n = 27) 60 ± 11 
- VO2max 
- Workload (W) 
- FIM 
- WHOQOL 
- 6MWT 
↓ VO2max and maximal workload 
↓ FIM, WHOQOL scores 
↓ 6MWT distance 
Sterky & Stegmayr 
(2005)(161) 
HD Patients 
(n = 11) 
Healthy, age and gender 
matched controls 
(n = 22) 
75 
(median) 
- STS10 
- Stair climb test 
↓ STS10 repetitions 
↓ Number of staircase cycles 
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Kurella et al. (2004)(105) 
Female 
patients 
commencing 
HD 
(n = 56) 
Female patients with Stage I-II 
CKD 
(n = 2705) 
67 ± 7 - DASI - SPSMO 
↓ DASI Score indicating reduced physical function 
and physical activity levels 
↑ Sexual dysfunction 
Blake et al. (2004)(162) 
HD and PD 
patients 
(n = 12) 
Healthy, non-physically active 
controls 
(n = 12) 
42 ± 9 
- SF-36 (PF) 
- Balance (objective 
body sway) 
- 10m walk test 
- 5STS time 
↓ SF-36 (PF) 
↓ Self-dictated gait speed 
↓ Maximum gait speed 
↓ 5STS time 
Johansen et al. (2001)(163) HD Patients (n = 46) 
Healthy population normative 
data 52 ± 17 
- Gait speed 
- Stair climbing time 
- 5STS time 
↓ Gait Speed and 5STS time 
Abbreviations: HD = Haemodialysis; ESKD = End-stage kidney disease; 6MWT = Six Minute Walk Test; 30STS = 30-second sit-to-stand; SBP = Systolic blood pressure; 
KDQoL-SF = Kidney Disease Quality of Life Short Form; COPD = Chronic obstructive pulmonary disease; CVD = Cardiovascular disease; SPPB = Short Physical Performance 
Battery; RMI = Rivermead Mobility Index; SF-36 = 36-item Medical Outcome Study short form measure; PCS = Physical component scale; PF = Physical Function Scale; 
VO2max = Maximal Oxygen Consumption; W = Watts; FIM = Functional Independence Measure; WHOQOL = World Health Organization Quality of Life Questionnaire; 
STS10 = 10 Second Sit to Stand; DASI = Duke Activity Status Index; SPSMO = Sexual Problems Scale of Medical Outcomes Study; PD = Peritoneal dialysis; 5STS = Five-
time sit-to-stand; MCS = Mental component scale 
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Declining physical function has been closely linked with commencement of HD, and 
progressively declines with dialysis vintage (12). Within 3 months of commencing HD, 
less than 40% of patients maintain their pre-dialysis physical function (12). After the 
first 12 months, only 13% of patients undergoing HD maintain their pre-dialysis 
physical function (12). Much of this decline has been attributable to deterioration in 
larger muscle groups, with a more prevalent deterioration of lower limb muscle 
strength, and subsequent declines in mobility and stability (66, 152, 155, 160-163). These are 
also key factors influencing falls risk (see Section 2.7.4.1), making this attributable to 
a substantially increased mortality risk among patients undergoing HD (165). 
Additionally, the ability to perform tasks essential to functional independence 
including stair climbing, and rising from a chair as well as static and dynamic balance 
have been specifically associated with lower extremity muscle strength (166). This has 
also been one of the most reported limiting factors for physical function, as supported 
by studies measuring these functional tasks and subjective perception of physical 
function by patients undergoing HD (118, 152, 161-163). 
To quantify the decline in physical function, cross-sectional testing of functional tasks 
for 162 patients undergoing HD demonstrated that 75% of patients were unable to 
stand from a chair even once without the use of their hands or an external aid (167). 
Despite the relative task difficulty for this population, a recent study of 192 patients 
undergoing HD reported the median number (and interquartile range) of repetitions 
completed in a 30 second sit-to-stand (30STS) as 10 (7) at baseline, 9 (11) at twelve 
weeks and 8 (11) at twenty-four weeks (168). This observed linear decline was from an 
initial result lower than the mean 30STS result for sedentary older adults (11 ± 4 
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repetitions) (166). This demonstrated deterioration over a relatively short period of time, 
and the magnitude of the variance also indicated that there was a large spread in 
physical ability among patients undergoing HD (168). Similarly, patients undergoing 
HD also took 20% longer to complete a 10-repetition sit-to-stand compared with age-
predicted normative data (169). Additionally, static balance as measured by single leg 
stance duration, was not only reduced compared with age-predicted norms, but also 
progressively decreased proportional to declines in eGFR (152). 
The Timed Up and Go (TUG) mobility test requires participants to stand, walk 3m, 
turn-around, walk back, and sit again (170). It offers a more applied use of chair standing 
and gait performance, whereby the tests are combined to effectively measure mobility 
and dynamic balance in older adult and clinical populations such as those with ESKD 
(170-172). One study demonstrated that 80% of patients undergoing HD (n = 162; 75 ± 6 
years [mean ± SD]) were unable to perform the TUG in under 10 sec (a normative 
rating of poor in age-matched community-dwelling older adults) (167, 171). The TUG 
also strongly correlates with measures of gait speed including maximal gait speed and 
self-selected or comfortable gait speed (171). Multiple studies have demonstrated that 
patients undergoing dialysis exhibit a slower maximal gait speed, 15-19% lower than 
age-matched healthy controls and normative data (162, 163). Deterioration in maximal 
gait speed was also proportional to declines in eGFR with reductions of approximately 
28% from stage II to ESKD (152). This may in part have been due to an inability to 
generate the same force during the gait cycle, a result of the loss in lower extremity 
strength (see Section 2.7.3) (162). Similarly, even high functioning patients on dialysis 
have been reported to exhibit self-selected gait speeds approximately 18% slower than 
age-matched healthy controls, while the wider population of patients undergoing HD 
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displayed a 66% decrease in self-selected gait speed (162, 173). Poor performance on 
assessments of mobility among patients undergoing HD related to an almost sevenfold 
increased risk of being unable to independently complete ADL (167, 174). Not only does 
this threaten independence, but this has also been associated with an 8-26% increased 
risk of mortality (167, 174). It is, therefore, a concern that so many patients undergoing 
HD remain physically inactive, receive no recommendations surrounding exercise, and 
are not routinely assessed for physical function given that they display such severe 
declines in mobility and broader physical function. 
 
2.7.4.1 Increased risk of falls 
It is estimated that up to 47% of patients undergoing HD have fallen in the past 12 
months, and almost 30% in the past 6 months (175-178). Comparatively, amongst 
otherwise healthy older adults over the age of 65, 25-30% suffer a fall each year (179, 
180). Of those patients undergoing HD who have fallen, studies have reported 15-19% 
suffered severe injuries requiring medical attention (176, 178). This is of serious concern 
due to an overall reduction in bone mineral density in this population, which has 
resulted in between 4% and 14% of those who have fallen suffering fractures or head 
injuries requiring hospitalisation (175-177). When matched for age, gender and ethnicity, 
patients undergoing HD were four times more likely to suffer hip fractures than their 
healthy counterparts (173). This equated to up to a 50% increase in hospitalisation rates 
compared to otherwise healthy older adults (179). One prospective cohort study detailed 
4% of patients undergoing HD died within 7 days, and as a direct result of a fall-related 
injury (176). For patients undergoing HD over the age of 65, falls represent as much as 
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an 80-100% increased risk of mortality above that of those who do not suffer a fall (165, 
177). 
Further compounding the elevated morbidity and mortality rates associated with falls 
amongst patients undergoing HD is the implication that increasing risk and fear of 
falling perpetuates decreases in physical function (181). Older adults without ESKD 
have reported having a fear of falling as a result of their increased risk of falls, which 
was responsible for an accelerated rate of physical functional decline, as measured by 
capacity to perform ADL (181, 182). This is likely to translate by a greater magnitude for 
patients undergoing HD due to their lower levels of physical function, and increased 
risk of falls.  
Implementing strategies that can address falls risk in parallel to addressing other 
adverse effects of ESKD would be very valuable. Exercise training programmes, 
particularly those with a focus on strength, reactive power and/or balance, have 
demonstrated effectiveness in reducing incidence of falls in frail older adults by as 
much as 42% (183, 184). Thus, it is reasonable that a similar effect may be attained among 
patients undergoing HD. Indeed, one of the primary contentions of this literature 
review is that patients undergoing HD need to complete exercise training with a 
primary focus on improving strength, due to the multiple positive benefits strength 
increases have demonstrated among this population (see Section 2.8.2) 
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2.8 Exercise training responses among patients undergoing 
haemodialysis 
The adverse effects (see Section 2.6) and impaired physical function (see Section 2.7) 
experienced by patients undergoing HD highlights issues that are known to be 
reversible, or at least attenuated, with the use of exercise training (111, 112, 185-187). 
Exercise training has been frequently explored in the ESKD literature due to the well-
established strong correlation between physical deconditioning and many of the 
adverse effects faced by patients undergoing HD. Exercise training is also 
comparatively conservative and non-invasive compared with surgical or 
pharmacological treatments for adverse effects (34, 97, 188, 189). Additionally, exercise 
training has already been well-established for improving physical conditioning and 
reducing symptoms of the adverse effects experienced by patients with many other 
chronic diseases, further strengthening the need for its prescription (34, 97, 188, 189). 
Moreover, rigorous studies among the exercise and dialysis literature provide evidence 
purporting the benefit of exercise training programmes among patients undergoing HD 
(6, 15, 108-112). This has driven recent calls to action for the implementation of exercise 
training programmes into the routine care for patients undergoing HD (101, 190-193). 
Conversely, a number of studies have demonstrated that some exercise prescriptions 
have produced only modest or no additional benefit among dialysis patients (194-199), or 
may have improved only one of the physical domains introduced above (88, 110) (see 
Section 2.7). This section of the thesis will discuss the application of exercise training 
among patients undergoing HD with regard to improving these physical domains. 
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2.8.1 Exercise capacity responses to exercise training 
Aerobic exercise training (AT) such as cycling, or walking is known to improve 
exercise capacity and cardiorespiratory fitness among general healthy, and older adult 
populations (200, 201). Together with overall volume, the level of intensity of AT is also 
proportional to the observed improvement (202). This is also considered true of patients 
undergoing HD, with AT having been the most commonly employed exercise modality 
among studies of exercise interventions in this population (16, 18, 112, 203). Several reviews 
of AT studies in this population cite mean improvements in V̇O2 peak of 5-41% over 
three to twelve months of moderate intensity AT (13, 16, 203). Moreover, improvements 
in V̇O2 peak have been some of the most frequently cited responses to exercise 
amongst patients undergoing HD, those which compared patients undergoing dialysis 
completing exercise with non-exercise controls have been summarised in Table 2.6. 
The majority of studies included in Table 2.6 utilised intradialytic exercise, this is 
commonly due to improved adherence and recruitment rates compared with 
interdialytic exercise (116). 
Despite the generally positive effect on V̇O2 peak of exercise interventions among 
patients undergoing dialysis, some highly-cited studies still report negligible effects of 
exercise training on exercise capacity, despite concurrent improvements in objective 
physical function (194, 195). However, in one of these studies there was a large dropout 
rate (25%) exclusively from the intervention group, as well as invalid assessment of 
39 out of 96 patients on the cycling assessment used, as patients were unable to 
complete the assessment at the necessary workload (195). In the second study there was 
a surprisingly large increase in peak power measured during an incremental cycling 
test (~10% increase) for a group that had been inactive for 3 months (194), which may 
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have also been skewed by controls having a notably lower baseline peak power (66 ± 
6 W) compared with the cycling group (80.5 ± 13) (194). Moreover, one recent review 
and meta-analysis, specifically examining intradialytic cycling exercise training 
programmes found no significant improvement in V̇O2 peak (112). The included studies 
in this meta-analysis were also representative of a common limitation whereby patients 
who opt in to exercise training studies are sometimes younger and more physically 
active, having higher levels of physical function than the broader population of patients 
undergoing HD (112). For these patients, training adaptations, such as V̇O2 peak, may 
be less pronounced (81). Additionally, it should be noted that this recent review only 
included four studies in the meta-analysis for V̇O2 peak due to a lack of available data 
from other reviewed studies, limiting the generalisability of their conclusion (112). 
Another major limitation of many studies examining exercise among patients 
undergoing HD is small sample sizes, with many studies having as little as 8 to 10 
participants in each group (116, 194, 204). Despite the mixed findings regarding V̇O2 peak, 
there remains a persistent general consensus that moderate intensity exercise 
performed either intradialytically or interdialytically has a modest but significant 
effect on exercise capacity. 
One study uniquely measured resting muscle oxygen consumption ([rmV̇ O2], 
ml.100g.min-1) using near infra-red spectroscopy of patients undergoing HD (N = 54) 
before and after 6 months of a twice-daily home-based walking exercise training 
programme (205). A higher rmV̇ O2 is indicative of ischemic muscle and peripheral 
vascular disease, common among patients undergoing HD, and provides a measure of 
muscle myopathy (205). At baseline, rmV̇ O2 was twice as high in patients undergoing 
HD (0.083 ± 0.034 ml.100g.min-1) compared with healthy individuals (0.041 ± 0.020 
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ml.100g.min-1; P<0.001) (205). Following the exercise intervention, this improved to 
0.064 ± 0.024 ml.100g.min-1 (P < 0.001) in the intervention group, with no change in 
the usual care HD control group. Moreover, 40% of patients in the intervention group 
improved rmV̇ O2 to within normal range for healthy adults, further suggesting that 
resting muscle myopathy in addition to deficits in exercise capacity are reversible with 
AT in patients undergoing HD. 
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Table 2.6 Randomised controlled trials examining the effect of resistance and/or aerobic exercise training compared to a non-exercise control on 
exercise capacity or aerobic fitness in patients undergoing dialysis. 
Study Exercise Group(s) Comparison Age Timing of Delivery 
Exercise 
Type 
Duration 
(weeks) 
Findings compared 
with control 
Groussard et al. (2015) (194) HD Patients (n = 10) 
Non-exercising HD Patients 
(n = 8) 68 ± 4 Intradialytic AT 12 ↔ V̇O2peak 
Manfredini et al. (2015) (205) HD Patients (n = 28) 
Non-exercising HD Patients 
(n = 26) 67 ± 14 Interdialytic AT 26 ↓ rmV̇ O2 
Reboredo et al. (2011) (204) HD Patients (n = 10) 
Non-exercising HD Patients 
(n = 8) 47 ± 12 Intradialytic AT 12 
↑ V̇O2peak 
↑ %Predicted V̇O2peak 
Kouidi et al. (2009) (206) HD Patients (n = 30) 
Non-exercising HD Patients 
(n = 29) 54 ± 8 Intradialytic CET 44 
↑ V̇O2peak 
↑ Exercise Time 
↓ HRV 
Ouzouni et al. (2009) (207) HD Patients (n = 19) 
Non-exercising HD Patients 
(n = 14) 49 ± 14 Intradialytic CET 44 
↓ Resting HR 
↑ Exercise time 
↑ MET 
↑ VEmax 
↑ V̇O2peak 
Petraki et al. (2008) (208) HD Patients (n = 22) 
Non-exercising HD Patients 
(n = 21) 50 Intradialytic AT 30 
↑ V̇O2peak 
↑ Exercise Time 
Van Vilsteren et al. (2005) (195) HD Patients (n = 53) 
Non-exercising HD Patients 
(n = 43) 55 ± 16 
Interdialytic and 
Intradialytic CET 12 ↔ V̇O2peak 
Molsted et al. (2004) (209) HD Patients (n = 22) 
Non-exercising HD Patients 
(n = 11) 55 ± 26 Interdialytic CET 20 ↑ V̇O2𝑚𝑚𝑚𝑚𝑚𝑚 
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Konstantinidou et al. (2002) (116) 
HD Patients  
1. (n = 16) 
2. (n = 10) 
3. (n = 10) 
Non-exercising HD Patients 
(n = 12) 50 ± 11 
1. Interdialytic 
2. Intradialytic 
3. Interdialytic (Home) 
CET 26 
All Exercising groups: 
↑ V̇O2peak 
↑ V̇O2AT 
↑ VEmax 
↑ Exercise Time 
Koufaki et al. (2002) (90)  
CAPD or 
HD Patients 
(n = 18) 
Non-exercising HD Patients 
(n = 15) 54 ± 17 
Interdialytic or 
Intradialytic AT 12 
↑ V̇O2peak 
↑ V̇O2/HR 
Deligiannis et al. (1999) (210) HD Patients (n = 30) 
Non-exercising HD Patients 
(n = 30) 48 ± 12 Intradialytic AT 26 
↑ V̇O2peak 
↑ Exercise Time 
↓ HRV 
Abbreviations: HD = Haemodialysis; CAPD = Continuous ambulatory peritoneal dialysis; AT = Aerobic exercise training; RT = Resistance exercise training; CET = 
Combined aerobic and resistance exercise training; rmV̇ O2 = Resting muscle oxygen consumption (ml.100g.min-1); V̇O2peak = Peak oxygen uptake (ml.kg.min-1); V̇O2AT = 
Anaerobic threshold; VEmax = Maximal ventilation; HR = Heart rate (beats.min-1); HRV = Heart rate variability; MET = metabolic equivalent of task. 
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While notable increases in exercise capacity have be achieved with exercise training 
amongst patients undergoing HD, the improvements have been insufficient for patients 
to achieve corresponding age-predicted V̇O2 peak values observed among otherwise 
healthy individuals without ESKD (13, 211). This may be in part due to the fact that few 
patients undergoing HD can tolerate higher AT intensities which are more commonly 
associated with improvements in V̇O2 peak (13). There has been some suggestion that 
lower volume and less vigorous exercise training would be more suitable for this 
population, although this involves a trade-off in the degree of improvement in exercise 
capacity (13, 211). 
 
2.8.2 Muscle size and strength adaptations to exercise training  
With regard to exercise modality, AT has not been the only mode of exercise utilised 
in the literature when prescribing exercise for patients undergoing HD. Multiple 
studies have explored the use of progressive resistance exercise training (RT) (42, 88, 110, 
212-215) and combined exercise training (CET) utilising both AT and RT (196, 197, 209). 
Where AT is traditionally associated with improving exercise capacity and 
cardiorespiratory fitness, RT is the preferred modality for improving muscle size, 
muscle strength and bone mineral density (188). Indeed, studies have consistently shown 
that RT can counteract many adverse effects and muscular impairments that coincide 
with aging and chronic disease (216). Therefore, it has been a natural progression for 
exercise programmes among patients undergoing HD to incorporate RT. 
One of the major contributors to catabolism, and a barrier to anabolic growth among 
patients undergoing HD, is the dietary protein restriction used to delay the progression 
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of renal disease and alleviate some of the uraemic symptoms (217, 218). However, RT 
has been observed to successfully counteract this catabolism in patients undergoing 
HD with one study detailing increases in CSA of type I (24%, P = 0.031) and type II 
(22%, P = 0.045) fibres following 12 weeks RT compared with usual care controls on 
the same low-protein diets (219). This supported an earlier uncontrolled study that first 
detailed the effect of exercise for patients undergoing HD on muscle fibre morphology 
and histology, which produced similar increases in type I (26%, P < 0.05) and type II 
(24%, P < 0.05) muscle fibre CSA for vastus lateralis following CET (11). Similarly, a 
recent meta-analysis of hypertrophy with RT for patients undergoing HD showed a 
significant positive effect of lower body RT on the standardised mean difference 
(SMD) of lower body muscle mass for those completing the interventions compared 
with usual care controls (187).  
The same review highlighted a clear and significant improvement for patients 
undergoing HD following RT in standardised muscle strength outcomes compared 
with control conditions (187). One of the largest RT studies among this analysis, the 
Progressive Exercise for Anabolism in Kidney Disease (PEAK) study, compared 
upper and lower body RT during HD (n = 24) with usual care HD (n = 25), and found 
lower extremity strength increased by 15% in the RT group, and declined by 2.4% in 
the control group (P = 0.002) (88). However, in contrast to those studies mentioned 
above, and despite the rigour of both the study design and exercise prescription in this 
study, these increases in strength in the PEAK study were not accompanied by a 
concurrent increase in lower limb muscle CSA. Similarly, the addition of an anabolic 
steroid to a lower body RT programme for patients on HD has been shown to improve 
strength specific to the RT exercises used while not eliciting an improvement in 
physical function (stair climbing, gait speed or a five-time sit-to-stand test) (110). It is 
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notable that neither of these studies demonstrated that RT alone increased the CSA of 
the individual thigh muscles, except with the addition of the anabolic steroid (88, 110). 
This may suggest that changes in strength among patients on HD are primarily 
neuromuscular in nature, as has been seen in the early stages of RT in otherwise 
healthy untrained populations (220). This notion has been further supported by an 
observed concomitant increase in neuromuscular recruitment (EMG amplitude) 
parallel to increased muscle strength (221). 
Contrary to traditional understanding of exercise training responses, solely AT 
interventions have also produced increases in muscle strength among patients 
undergoing HD (31, 222). One study determined that this strength response to AT was 
accompanied by elevated levels of skeletal muscle growth factors such as insulin-like 
growth factor-1 (IGF-1), the uptake of which is known to be limited in patients 
undergoing HD (222, 223). Despite this inhibition, a higher concentration of circulating 
IGF-1 should result in an elevated net uptake that may increase skeletal muscle growth. 
However, relevant to the aims of this thesis, no study with a solely AT intervention 
has examined muscle size changes. This also highlights one of the major limitations 
with the broad spectrum of exercise prescriptions used among patients undergoing HD 
in the literature, in that there is no consistency in the exercise prescription used for 
improving muscle strength and size. Additionally, there is no clear evidence as to what 
exercise prescription for muscle strength and size would produce the highest 
participation rates or be most adhered to by patients undergoing HD.  
The optimal exercise training variables for improving muscle size and muscle strength 
have not yet been elucidated for patients undergoing HD despite the wealth of studies 
exploring AT, RT and CET. However, observations following AT, RT and CET over 
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9-24 weeks have demonstrated increases in both muscle size (2-24%) and muscle 
strength (9-47%, or as much as 80% with the addition of an anabolic steroid) compared 
with usual care controls (Table 2.7). Although, these findings are not universal, as 
multiple randomised controlled trials have reported no significant increase in strength 
following AT, RT, or CET interventions (196-198). Even so, where improvements have 
been demonstrated, these adaptations are clinically relevant and have contributed to a 
recent position statement, yet there is still a substantial need for updated clinical 
practise guidelines surrounding exercise prescription (18, 185). 
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Table 2.7 Randomised controlled trials examining the effect of resistance and/or aerobic exercise training compared to a non-exercise control on 
total body and/or regional muscle size, and muscle strength in patients undergoing HD. 
Study Exercise Group(s) Control Age Timing of Delivery 
Exercise 
Type 
Duration 
(weeks) Findings compared with control 
Thompson et al. (2016) (196) 
HD Patients 
1. (n = 8) 
2. (n = 7) 
3. (n = 8) 
HD Patients 
Completing 
stretching 
(n = 8) 
58 ± 19 Intradialytic 
1. AT 
2. RT 
3. CET 
12 ↔ Bilateral 1RM leg extension strength 
Kirkman et al. (2014) (224) HD Patients (n = 9) Non-exercising HD Patients (n = 10) 53 ± 17 Intradialytic RT 12 
↑ Thigh muscle volume 
↑ Isometric bilateral leg extensor 
strength 
Song et al. (2012) (225) HD Patients (n = 20) 
Non-exercising HD 
Patients 
(n = 20) 
53 ± 11 Interdialytic RT 12 
↑ Skeletal muscle mass 
↔ Arm muscle circumference 
↔ Handgrip strength 
↑ Leg muscle strength 
Dong et al. (2011) (198) 
HD Patients on 
nutrition supp. 
(n = 15) 
Non-exercising HD 
Patients on 
nutrition supp. 
(n = 17) 
43 ± 13 Interdialytic RT 24 ↔ Lean body mass 
↔ 1RM leg press 
Chen et al. (2010) (213) HD Patients (n = 22) 
HD Patients 
completing 
stretching exercises 
(n = 22) 
69 ± 13 Intradialytic RT 18 
↑ Leg extensor strength 
↑ Whole body lean mass 
↑Leg lean mass 
Cheema et al. (2007) (88) HD Patients (n = 24) 
Non-exercising HD 
Patients 
(n = 25) 
63 ± 14 Intradialytic RT 12 
↔ Muscle CSA 
↑ Muscle attenuation 
↑ Total strength 
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Johansen et al. (2006) (110) 
HD Patients with or 
without ND 
(n = 40) 
Non-exercising HD 
Patients 
(n = 20) 
55 ± 13 Intradialytic RT 12 
Exercise associated with ↑ in 3RM 
lower limb strength 
 
↑ Lean body mass only increased with 
use of ND 
Storer et al. (2005) (222) HD Patients (n = 12) 
Non-exercising HD 
Patients 
(n = 12) 
42 ± 8 Intradialytic AT 9 ↑ 5RM Leg press strength 
↑ Leg extension power 
Headley et al. (2002) (214)  HD Patients (n = 10) 
Non-exercising 
lead-in period prior 
to exercise 
intervention 
43 ± 4 Intradialytic RT 12 
↑ Peak torque of quadriceps 
↔ Handgrip strength 
 
DePaul et al. (2002) (197) HD Patients (n = 20) 
Non-exercising HD 
Patients 
(n = 18) 
55 ± 15 Intradialytic AT 12 ↔ 5RM Bilateral leg extension/leg curl strength 
Castaneda et al. (2001) (219) 
HD Patients on low 
protein diet 
(n = 14) 
Non-exercising HD 
patients on low 
protein diet 
(n = 12) 
65 ± 9 Interdialytic RT 12 
↑ Upper body strength 
↑ Lower body strength 
↑Type I muscle fibre area 
↑Type II muscle fibre area 
Abbreviations: HD = Haemodialysis; AT = Aerobic exercise training; RT = Resistance exercise training; CET = Combined aerobic and resistance exercise training; 1RM 
= one-repetition maximum; 3RM = Three-repetition maximum; 5RM = Five-repetition maximum; CSA = Cross-sectional area; ND = Nandrolone Decanoate. 
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2.8.3 Physical function responses to exercise training 
Due to a notable decrease in physical function with initiation of dialysis, and a 
subsequent increase in the rate of morbidity and mortality, physical function should be 
a point of focus upon engaging in, or even prior to commencing, a programme of 
dialysis treatment. Specifically, regular structured exercise training should be 
implemented to attenuate the declines in lower limb strength, mobility, and stability 
(183, 184, 226). This is even more paramount in patients undergoing HD due to such high 
risk of falls (see Section 2.7.4.1), and the substantially increased risk of mortality 
associated with the deficits in physical function seen among this population. Despite 
the wealth of literature extolling the benefits of exercise for patients undergoing HD, 
it is surprising that objective measures of physical function are used infrequently.  
Both AT and RT as well as similar means of muscular activation such as 
electromyostimulation have been observed to have beneficial effects on objectively 
measured physical function indicative of ADL in patients undergoing HD (42-45, 88, 90, 
110, 194-197, 199, 209, 213, 225, 227-236). Conversely, some prominent exercise training studies 
among patients undergoing HD have also found no improvement in physical function 
compared with usual care controls (110, 199, 225). However, each of these studies showing 
modest or no improvement in physical function also have methodological limitations. 
These limitations include employing low-to-moderate intensity AT (199), a small 
selection of RT exercises prescribed at intensities traditionally considered insufficient 
for physiological adaptations without higher volumes than those utilised (34, 110), poorly 
quantified initial loads likely leading to insufficient intensity combined with poor 
adherence (225). 
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A systematic review conducted as a part of this thesis, and published in the American 
Journal of Physiology – Renal Physiology (Appendix B) found that both AT and RT 
or other exercise interventions were mostly able to elicit notable improvements on the 
6MWT (7-26%), sit to stand tests (6-70%), grip strength (8-17%), SPPB and 
incremental shuttle walk test compared with usual care control groups (237). Mixed 
results were observed for the sit and reach flexibility test, stepping or stair climbing 
tests and only modest to no improvement were observed in the TUG, balance tests 
across all studies examining them (237). It is important to highlight that the measures of 
physical function displaying significance have been some of the most frequently used 
measures of physical function and are some of the most robust measures of physical 
function for patients with CKD (159). These findings are also clinically relevant due to 
a markedly higher prevalence of functional disability (an inability to perform at least 
one key domain of everyday activities) among patients undergoing HD when 
compared with community-dwelling older adults (67). However, despite the strong 
association between exercise training and improvements in physical function, it is not 
a component of the routine management of patients undergoing HD (238). 
Interestingly, measures of physical function that are more commonly associated with 
a specific physiological characteristic, such as sit-to-stand tests with muscle strength 
or the 6MWT with exercise capacity, also improved with exercise training modalities 
not traditionally associated with those physiological responses (166, 239-241). For 
example, significant improvement in distance walked during the 6MWT following 
exercise and compared with controls has been achieved with RT (227, 230, 231), 
electromyostimulation (43, 232), and respiratory muscle training alone (231). For shorter 
duration sit-to-stand tests more closely associated with lower limb strength, studies 
have demonstrated significant improvement compared with controls despite using only 
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AT (45, 90, 229, 233) or electromyostimulation (234). While this indicates that exercise 
regardless of modality is beneficial for improving physical function among patients 
undergoing HD, it also suggests that physical function is a multi-faceted physiological 
domain that may require multi-modal exercise to attain the greatest benefit. 
Physical function indicative of ADL is comprised of multiple physical components 
inclusive of exercise capacity, muscle strength, reactive power, balance, mobility and 
flexibility, all significantly impaired in patients undergoing HD compared with general 
age-predicted norms (242). This creates a need to improve a wide range of physical 
characteristics among patients undergoing HD. As such, multiple exercise modalities 
would be required in order to achieve the full spectrum of physical improvements for 
patients undergoing HD, and significant effort has been made to outline these exercise 
guidelines (18). While these guidelines draw on high quality research to establish such 
recommendations, the diversity of the exercise prescription variables (frequency, 
intensity, duration, etc.) used in these studies is even broader (18). This is reflected in 
the diverse exercise prescriptions used in studies examining the effects of exercise 
training on physical function for patients undergoing HD (42-45, 88, 90, 110, 194-197, 199, 209, 
213, 225, 227-236). Similarly, the variability among definitions of physical function and the 
range of tasks that constitute ADL means that studies utilise an equally varied range 
of measures when examining physical function (Table 2.8) (42-45, 88, 90, 110, 194-197, 199, 209, 
213, 225, 227-236). The 6MWT is the most common objective measure of physical function 
used by exercise studies in patients undergoing HD, and while it is a predictor of all-
cause mortality and is also associated with cardiorespiratory fitness and exercise 
capacity, it does not incorporate other domains of physical function such as strength, 
balance, or functional joint mobility (243-245). No other single measure of physical 
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function is used as often as the 6MWT among exercise training studies in patients 
undergoing HD (42-45, 88, 90, 110, 194-197, 199, 209, 213, 225, 227-236).  
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Table 2.8 Randomised controlled trials evaluating changes in objective measures of physical function following exercise intervention among 
patients with end-stage kidney disease (values presented are means ± SD). 
Study Sample Comparison Age Timing of Delivery Exercise Type Findings compared with control 
Schardong et al. (2017) (234) HD Patients (n = 11) 
Non-exercising HD 
Patients (n = 10) 61 ± 5 Intradialytic EMS 
↔ 6MWT 
↑ 30STS 
Hristea et al. (2016) (44) HD Patients (n = 7) 
Non-exercising HD 
Patients (n = 9) 70 ± 12 Intradialytic AT 
↑ 6MWT 
↑ Balance 
Liao et al. (2016) (228) HD Patients (n = 20) 
Non-exercising HD 
Patients (n = 20) 62 ± 9 Intradialytic AT ↑ 6MWT 
Manfredini et al. (2016) (229) 
CAPD or 
HD Patients 
 (n = 104) 
Non-exercising HD 
Patients (n = 123) 64 ± 14 
Interdialytic 
(Home) AT 
↑ 6MWT 
↑ STS-5 
Roxo et al. (2016) (232) HD Patients (n = 20) 
Non-exercising HD 
Patients (n = 20) 51 ± 18 Intradialytic EMS ↑ 6MWT 
Samara et al. (2016) (233) HD Patients (n = 15) 
Non-exercising HD 
Patients (n = 12) 48 ± 13 Interdialytic AT 
↑ 6MWT 
↑ TUG 
↑ STS-10 
↑ Sit-and-Reach 
Thompson et al. (2016) (196) 
HD Patients 
1. (n = 8) 
2. (n = 7) 
3. (n = 8) 
HD Patients completing 
stretching exercises (n = 8) 60 ± 7 
1. Intradialytic 
2. Intradialytic 
3. Intradialytic 
1. AT 
2. RT 
3. CET 
↔ 6MWT 
↔ 30STS 
↑ SPPB 
Groussard et al. (2015) (194) HD Patients (n = 10) 
Non-exercising HD 
Patients (n = 8) 68 ± 4 Intradialytic AT ↑ 6MWT 
Matsufuji et al. (2015) (230) HD Patients (n = 6) 
HD Patients completing 
passive ROM exercises 
(n = 11) 
70 ± 4 Intradialytic RT 
↑ 6MWT 
↑ Max STS 
↑ FIM 
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Esteve Simó et al. (2014) (227) HD Patients (n = 14) 
Non-exercising HD 
Patients (n = 26) 68 ± 16 Intradialytic RT 
↑ 6MWT 
↑ STS-10 
Wu et al. (2014) (45) HD Patients (n = 32) 
HD Patients completing 
stretching exercises 
(n = 33) 
44 ± 3 Intradialytic AT 
↑ Stair Climb 
↑ 6MWT 
↑ 60STS 
↑ STS-10 
de Lima et al. (2013) (42) 
HD Patients 
1. (n = 11) 
2. (n = 10) 
Non-exercising HD 
Patients (n = 11) 46 ± 11 
1. Intradialytic 
2. Intradialytic 
1. RT 
2. AT ↑ 4 min step test 
Pellizzaro et al. (2013) (231) 
HD Patients 
1. (n = 14) 
2. (n = 11) 
Non-exercising HD 
Patients (n = 14) 48 ± 12 
1. Intradialytic 
2. Intradialytic 
1. RT 
2. RMT ↑ 6MWT 
Dobsak et al. (2012) (43) 
HD Patients 
1. (n = 11) 
2. (n = 11) 
Non-exercising HD 
Patients (n = 10) 61 ± 8 
1. Intradialytic 
2. Intradialytic 
1. AT 
2. EMS ↑ 6MWT 
Song & Sohng (2012) (225) HD Patients (n = 20) 
Non-exercising HD 
Patients (n = 20) 53 ± 11 Interdialytic RT 
↔ Balance 
↔ Sit-and-Reach 
↔ Shoulder Mobility 
Chen et al. (2010) (213) HD Patients (n = 22) 
HD Patients completing 
light flexibility exercises 
(n = 22) 
69 ± 13 Intradialytic RT ↑ SPPB 
Koh et al. (2010) (199) 
HD Patients 
1. (n = 14) 
2. (n = 14) 
Non-exercising HD 
Patients (n = 16) 52 ± 13 
1. Intradialytic 
2. Interdialytic 
(Home) 
1. AT 
2. AT 
↔ 6MWT 
↔ TUG 
Wilund et al. (2010) (235) HD Patients (n = 8) 
Non-exercising HD 
Patients (n = 9) 60 ± 4 Interdialytic AT ↑ ISWT 
Cheema et al. (2007) (88) HD Patients (n = 24) 
Non-exercising HD 
Patients (n = 25) 63 ± 14 Intradialytic RT ↔ 6MWT 
Johansen et al. (2006) (110) HD Patients (n = 20) 
Non-exercising HD 
Patients (n = 20) 56 ± 14 Intradialytic RT 
↔ Stair Climb 
↔ Gait Speed 
↔ STS-5 
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van Vilsteren et al. (2005) (195) HD Patients (n = 53) 
Non-exercising HD 
Patients (n = 43) 55 ± 16 Intradialytic CET ↑ STS-10 
Molsted et al. (2004) (209) HD Patients (n = 22) 
Non-exercising HD 
Patients (n = 11) 48 ± 8 Intradialytic CET 
↔ Stair Climb 
↑ STS-10 
DePaul et al. (2002) (197) HD Patients (n = 20) 
HD Patients completing 
ROM exercises (n = 18) 55 ± 15 Intradialytic CET ↔ 6MWT 
Koufaki et al. (2002) (90) 
CAPD or 
HD Patients 
(n = 18) 
Non-exercising HD 
Patients (n = 15) 54 ± 17 Intradialytic AT 
↔ WALK Test 
↑ STS-5 
↑ 60STS 
Abbreviations: HD = Haemodialysis; CAPD = Continuous ambulatory peritoneal dialysis; AT = Aerobic exercise training; RT = Resistance exercise training; CET = 
Combined aerobic and resistance exercise training; EMS = Electromyostimulation; RMT = Respiratory muscle training; ROM = Range of motion; 6MWT = Six Minute Walk 
Test; 30STS = 30-second sit-to-stand; STS-5 = Five times sit-to-stand; TUG = Timed up and go; STS-10 = 10 second sit-to-stand; SPPB = Short physical performance battery; 
Max STS = Maximal repetition sit-to-stand; FIM = Functional independence measure; 60STS = 60 second sit-to-stand; ISWT = Incremental shuttle walk test; WALK test = 
North Staffordshire Royal Infirmary walk test. 
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It remains an ongoing concern that clinical pathways for the delivery of exercise 
programmes are largely non-existent (101). This was underscored by a recent editorial 
published in the British Journal of Sports Medicine, calling for clinicians to adopt 
exercise programmes into standard practice for patients undergoing HD (193). The 
editorial further elucidated that improvements in physical function among patients 
undergoing dialysis contribute to the prevention of some clinical and functional 
disabilities, reduces hospitalisations and mortality, and increases patient transplant 
eligibility (193). Additionally, the editorial highlights that not only is intradialytic 
exercise feasible regardless of age, it also displays notably higher compliance 
compared with interdialytic exercise programmes (193). This is one of the primary 
reasons that achieving the recommended exercise guidelines (18) is problematic. It is 
not possible to achieve the volume and intensities of exercise, or even all of the 
suggested types of exercise intradialytically, however there is markedly higher attrition 
and adherence issues when attempting to deliver interdialytic exercise programmes to 
patients undergoing HD  (116, 193). 
There is a paucity of high-quality RCTs of adequate power with any consistency in 
exercise prescription for patients undergoing HD (192). This makes attempts to 
standardise intradialytic exercise prescription problematic. Prescribing any exercise 
that is feasible to conduct intradialytically and can be tolerated by patients undergoing 
HD is likely to provide significant benefit and should, therefore, be incorporated into 
standard practice. However, holistic exercise prescriptions that adhere to intensity 
limitations and do not impact the time-burden faced by patients undergoing HD are 
likely to be more successful and display better uptake than high volume generalised 
prescriptions, which are unlikely to be adhered to. 
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2.9 Exercise recommendations and adherence 
One of the most variable aspects of exercise training interventions employed for 
patients undergoing HD is the timing of the exercise training sessions, which 
commonly occur on dialysis days, non-dialysis days or are self-managed at home (108, 
116). When considering the most appropriate exercise delivery mode it is important to 
identify common factors that influence exercise training adherence in this population. 
One of the earliest studies to explore this identified that patients undergoing HD were 
reluctant to complete exercise training programmes due to a lack of time, insufficient 
energy, too much trouble, presence of depression, or existing comorbid conditions (246). 
This correlated with patients’ dialysis vintage, with those commencing dialysis within 
the previous two years or those who had been on dialysis longer than five years being 
less likely to adhere to exercise training and more likely to present with depression, 
when compared with those with a dialysis vintage between two and five years (246). 
This was attributed to a greater degree of depression related to feelings of lost self-
control, which appeared to be slowly regained towards two years of HD but waned 
with long-term HD (greater than five years) (246). 
To date, only one study has directly compared timing of exercise training programme 
delivery (116). This study compared exercise training programmes completed 
intradialytically, in an out-patient programme on non-dialysis days, and a home 
exercise programme (HEP) (116). While this study found that the improvement in 
exercise capacity and physical function were more pronounced in the out-patient 
programme, it was also met with substantial attrition (24%), well above the dropout 
rate displayed in the other groups (116). Patients subjectively attributed this to 
transportation issues, or distance between home and the out-patient centre (116). Of the 
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two remaining methods of programme delivery, intradialytically or a HEP, the 
intradialytic exercise programme showed significantly greater improvements in the 
outcomes measured (116). While the quality of exercise training may be optimal on non-
dialysis days, the trade-off between benefit and practicality, as well as the preference 
of patients undergoing HD favours intradialytic exercise training programme delivery. 
Multiple reviews of exercise training for patients undergoing HD support the 
implementation of intradialytic exercise training programmes over other methods, for 
reasons beyond improved adherence as well (13, 108, 247). During HD patients are 
otherwise forced into a period of inactivity, something that is consistently identified as 
a potential confounder that may contribute to the reduction in physical function and 
exercise capacity among patients undergoing HD (13, 108). There is opportunity to 
combat this detrimental aspect of dialysis. It has also been suggested that exercise 
training may improve dialysis adequacy, by playing a role in improving solute and 
urea removal (63, 108, 248). However, there is a progressive reduction in exercise tolerance 
and changes in fluid and electrolyte balance after the initial two hours of a single HD 
session (30, 108). Thus, provided exercise training is completed within the first two hours 
of HD, it is not only well tolerated, but is likely to be well adhered to. 
The lack of consistency among exercise protocols used in the literature is an issue that 
has limited translation to routine care due to uncertainty as to what the ideal exercise 
prescription is. The only major exercise recommendations for patients undergoing HD 
to date are broad, and included a combination of aerobic, resistance and flexibility 
exercises for up to 540 minutes per week, including intradialytic and interdialytic 
exercise (18). Specifically, these included a recommendation for >240 minutes of AT 
per week (performed as up to 90 min duration sessions) at a constant intensity of up to 
72 
70% predicted maximum heart rate (18). However, these represented an upper limit to 
these exercise variables that would be too challenging for the majority of the 
deconditioned patients undergoing HD for whom exercise training would be of most 
benefit (160). Moreover, the physically- and time-demanding nature of such 
recommendations makes implementation into standard care unlikely, especially 
among a sedentary population who are lacking motivation and energy (192). Without a 
specific, simplified and consistent prescription, implementation of these guidelines 
remains an issue, one that has been highlighted previously in the literature (192). 
In the Dialysis Outcomes and Practice Patterns Study of almost 21,000 patients 
undergoing HD, 40% reported severe limitations with even moderate daily activities, 
and 45% reported very severe to moderate bodily pain when attempting to exercise 
(160). This is in addition to 38% of patients failing to identify any positive effects of 
exercise (26% reported exercise as negatively affecting them) (160). Common barriers 
identify underlying issues with such ambitious exercise prescription, with fatigue 
(67%), shortness of breath (48%), disinterest (42%), and pain on dialysis days (38%) 
at the forefront (19). It seems extremely unrealistic to set such demanding exercise 
recommendations for a population that does not generally have the physical capability 
of achieving it, nor displays the motivation in attempting to. Exercise prescription 
going forward needs to be simplified in order to maximise the benefit achieved for the 
time spent exercising, with a relatively simple and manageable exercise prescription 
that patients are able to complete within the first two hours of dialysis. 
The majority of exercise training prescribed for patients undergoing HD is low-to-
moderate intensity AT, which is generally unable to elicit muscle hypertrophy or 
strength gains and is often of insufficient intensity to maximise cardiorespiratory 
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fitness improvements (21-32). Of the studies utilising RT, most utilise intensities between 
40% and 60% one-repetition maximum (1RM), which is lower than the 70% 1RM that 
is considered the minimum to consistently produce increases in muscle strength and 
size (98, 249-254). Combined with the issues identified in the previous section (see Section 
2.8), the current exercise recommendations do not appear optimal for patients 
undergoing HD. A sedentary, unmotivated, physically limited population such as this 
requires a means of simplifying exercise training while still being able to achieve all 
the desired physiological outcomes. 
 
2.10 Blood flow restriction exercise 
A potential addition to exercise training that has not been trialled for patients 
undergoing HD is blood flow restriction (BFR). BFR exercise training is characterised 
by low-intensity exercise coupled with the application of an external pressure, usually 
via a pneumatic cuff, in order to partially restrict active limb blood flow. The literature 
around BFR exercise training challenges traditional perspectives that high-intensity 
RT is required to produce increases in muscle size and muscle strength among healthy 
populations (33, 188, 255). The novelty of BFR exercise training is the low-intensity of 
exercise training required to elicit muscle size and muscle strength adaptations to a 
larger degree than equivalent intensity non-BFR exercise (256-260). This is even true of 
AT with the addition of BFR (BFR-AT), which can increase muscle size and muscle 
strength generally considered unattainable with traditional AT. Moreover, BFR-AT 
can induce favourable adaptations without the same degree of mechanical stress 
imposed by RT (261). This represents an opportunity to optimise time spent exercising 
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for low functioning clinical populations like those with ESKD who need to counter 
muscle atrophy, improve muscle strength and even increase physical function. 
The method of application for BFR has progressed from arbitrary pressure applications 
to dynamically adjusting cuff pressure based on individual characteristics (262, 263). 
While there is still some variation in the prescription variables used with BFR in the 
literature, there are suggested methods with regard to manipulation of variables based 
on the training objectives and the nature of the exercise during which BFR is applied 
(264, 265). Variables including cuff width, cuff pressure, and duration of pressure 
application are a selection of factors that alter the effect of BFR, including the degree 
of occlusion, level of fatigue, and cardiovascular responses to the exercise (36, 266, 267). 
Collectively, the more individualised methods for applying BFR better account for the 
relative safety of the technique and have become more common in the contemporary 
literature (262, 263). In many cases, these individualised methods for applying BFR, 
which often utilise a percentage of total arterial or limb occlusion pressure, result in a 
lower absolute pressure being applied during exercise (41, 268-272) compared with some 
of the earlier and commonly cited applications of BFR which utilise high, arbitrarily 
prescribed occlusion pressures (38, 39, 273-275). Ultimately, utilizing the lowest possible 
pressure to achieve the desired physiological training response is considered the safest 
application of BFR (261). This is especially important when applying the technique 
among ‘at-risk’ populations such as patients with ESKD. 
While BFR exercise training is used predominately in single joint, isolation RT 
exercises (BFR-RT) such as leg extension for the lower limb, or bicep curls for the 
upper limb, its application during AT such as walking or cycling presents the most 
promise for clinical populations due to a smaller magnitude of some haemodynamic 
responses (such as systolic, diastolic, and mean arterial blood pressures), while having 
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no detrimental effect on other haemodynamic parameters (cardiac output, stroke 
volume) compared with BFR-RT (38, 39, 41, 256, 257, 276, 277). These smaller magnitude 
haemodynamic responses are true of older adult populations (individuals over 60 years 
of age) as well as younger, healthy populations, which is an important distinction given 
that most clinical populations are likely to consist largely of older adults due to the 
association between age and the development of chronic diseases (51, 52, 277). 
Specifically, for BFR-AT compared with BFR-RT, respectively, older adults have 
been observed to elicit significantly smaller increases in systolic blood pressure (13 ± 
4 mmHg compared with 43 ± 5 mmHg), diastolic blood pressure (6 ± 1 mmHg 
compared with 12 ± 4 mmHg), mean arterial pressure (12 ± 3 mmHg compared with 
7 ± 2 mmHg) (277). Both cardiac output and stroke volume were maintained in the 
presence of these reduced pressures (277). A recent systematic review found that 
haemodynamic responses (HR, SBP, DBP, mean arterial pressure, and rate pressure 
product) to low-intensity BFR-RT were modestly but significantly greater in 
magnitude than high-intensity non-BFR RT, and yet still within normal expected 
ranges for exercise-induced haemodynamic changes (278). In this same review, the 
author explicitly states that the method should be considered safe and viable for special 
populations, such as the elderly and cardiac patients as it does not negatively change 
haemodynamic measurements. 
Common exercise prescriptions for BFR-AT involve continuous (10 to 20 minutes) or 
intermittent exercise training (e.g. five 2-minute bouts) with concurrent BFR to the 
lower limbs (38, 39, 273, 274). This is within the range of exercise prescriptions utilised in 
the predominately AT studies among patients undergoing HD. As such, the potential 
for including BFR-AT as a means of increasing the efficacy of intradialytic exercise 
among patients undergoing HD appears promising. 
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2.10.1 Adaptations to blood flow restriction aerobic exercise training 
Increases in muscle strength, muscle size, physical function and exercise capacity 
following BFR-AT are already well established in healthy young and older adults (38, 
39, 41, 273-275, 279, 280). These are summarised in this section of this thesis (Table 2.9). The 
mechanisms that produce muscle size and muscle strength adaptations with the 
addition of BFR are unknown for this method of training. Although, it has been 
theorised that these may involve a combination of local and systemic stimuli that affect 
molecular pathways within skeletal muscle that are responsible for protein synthesis 
and degradation (39, 281-284). Alternatively, it has also been speculated that skeletal 
muscle growth may be influenced by a localised compression-induced muscle hypoxia 
distal to the cuffs, leading to preferential recruitment of type II muscle fibres, even 
with low intensity RT or AT that is predominately associated with type I muscle fibre 
activation (285-287). However, a more recent examination of heat-shock proteins 
associated with skeletal muscle damage following RT concluded that BFR-RT placed 
greater stress on Type I fibres (288). This was suggested to relate to the ability of Type 
II fibres to cope with the hypoxic nature of BFR compared with Type I fibres that are 
less able to cope with hypoxia and therefore undergo greater stress as an adaptive 
mechanism for increasing their tolerance to BFR exercise (288). This does not discount 
the greater recruitment of Type II fibres, but instead suggests that multiple adaptations 
occur to increase muscle size and muscle strength following BFR exercise. Ultimately, 
the acute mechanisms that underpin BFR are beyond the scope of this thesis. Instead, 
this section presents information on the physiological adaptations to BFR-AT. An 
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understanding of which is essential to evaluate the efficacy of BFR-AT, and its 
potential application among physically deconditioned populations such as patients 
undergoing HD. 
The most robust systematic reviews and meta-analyses covering physiological 
adaptations to BFR exercise all show modest, but significant support favouring BFR 
in terms of muscle size and strength increases (289-291). While one meta-analysis 
highlighted that high-intensity RT was preferential for increasing maximal strength, it 
also showed that BFR-RT and high-intensity RT were similar in hypertrophic response 
in both upper and lower limb training (289), similar responses have also been observed 
when comparing BFR-AT to vigorous-intensity cycling (280). Additionally, training 
inclusive of either BFR-RT or BFR-AT produced greater muscle size and strength 
increases than matched exercise, non-BFR equivalent controls (290). The largest 
standardised mean differences for muscle size and strength between an exercise 
modality and its BFR equivalent was observed for BFR-AT (290). Furthermore, one 
meta-analyses demonstrated the clinical relevance of BFR-RT among patients with 
musculoskeletal deficits undergoing rehabilitation, as it provided a more effective 
approach to low-load exercise, and was significantly more tolerable than heavy-load 
rehabilitation (291). These findings support the notion that those with a clinical need for 
simultaneously improving muscle size and muscle strength, would benefit from the 
addition of BFR. However, individuals who may be unable to complete high-intensity 
RT, or RT in general, should gain significant benefit from completing BFR-AT which 
benefits from a reduction in mechanical stress (261).
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Table 2.9 Randomised controlled trials evaluating training adaptations following aerobic exercise interventions with blood flow restriction among 
young and older adults (values presented are means ± SD). 
Study Sample Age BFR-AT Intervention Comparison(s) Duration (weeks) Findings compared with control 
Clarkson et al. (2017) (41) 
Sedentary 
older adults 
(N = 19) 
70 ± 7 
10 min walking 
(4 km.h-1); 
BFR: 60% LOP; 
4 days per week 
(n = 10) 
Same exercise without 
BFR 
(n = 9) 
6 
↑ 30STS 
↑ QCST 
↑ 6MWT 
↑ TUG 
Kim et al. (2016) (280) 
College-aged 
male adults 
(N = 31) 
22 ± 3 
20 min cycling (30% HRR); 
BFR: 160-180 mmHg; 
3 days per week 
(n = 11) 
1. 20 min VI cycling (60-
70% HRR); 
3 days per week 
(n = 10) 
 
2. non-exercising controls 
(n = 10) 
6 
Compared with VI cycling: 
↔ Leg flexion strength (↑ vs con.) 
↔ Leg extension strength (↑ vs con.) 
↑ Leg lean mass (kg) 
↔ Muscle CSA 
↔ V̇O2peak 
Ozaki et al. (2011a) (274) 
Sedentary 
middle-age to 
older adults 
(N = 23) 
67 ± 5 
20 min walking 
(45% HRR); 
BFR: 140-200 mmHg; 
4 days per week 
(n = 13) 
Same exercise without 
BFR 
(n = 10) 
10 ↑ Thigh muscle CSA 
↑ Leg flexion strength (Nm) 
Ozaki et al. (2011b) (275) 
Sedentary 
middle-age to 
older adult 
women 
(N = 18) 
66 ± 4 
20 min walking 
(4.5 km.h-1); 
BFR: 140-200 mmHg; 
4 days per week 
(n = 10) 
Same exercise without 
BFR 
(n = 8) 
10 
↑ Mid-thigh muscle CSA 
↑ Leg flexion torque (Nm) 
↑ TUG 
↔ V̇O2peak 
Sakamaki et al. (2011) (279) 
Healthy young 
male adults 
(N = 17) 
21 ± 2 
5x2 min walking (3 km.h-1); 
BFR: 160-230 mmHg; 
2 times per day, 6 days per 
week (n = 9) 
Same exercise without 
BFR 
(n = 8) 
3 ↑ Thigh muscle CSA 
↑ Lower leg muscle CSA 
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Abe et al. (2010a) (273) 
Physically 
active older 
adults 
(N = 19) 
69 
20 min walking 
(4 km.h-1); 
BFR: 160-200 mmHg; 
5 days per week 
(n = 11) 
Same exercise without 
BFR 
(n = 8) 
6 
↑ Mid-thigh and lower leg girth (cm) 
↑ Mid-thigh and lower leg CSA 
↑ Thigh and lower leg skeletal muscle 
mass (kg) 
↑ Leg flexion and extension torque 
(Nm) 
↑ 30STS 
↑ TUG 
↔ V̇O2peak 
Abe et al. (2010b) (38) 
Physically 
active young 
male adults 
(N = 19) 
23 ± 2 
15 min cycling (40% V̇O2max); BFR: 160-210 
mmHg; 
3 days per week 
(n = 9) 
45 min cycling (40% V̇O2max); 
3 days per week 
(n = 10) 
8 
↑ Thigh girth (cm) 
↑ Mid-thigh CSA 
↑ Quadriceps CSA 
↑ Thigh and Quadriceps muscle 
volume (cm3) 
↑ Leg extension strength (Nm) 
↑ Exercise time 
↑ V̇O2max 
Park et al. (2010) (292) 
College-aged 
male athletes 
(N = 12) 
20 ± 1 
5x3 min walking 
(4-6 km.h-1); 
BFR: 160-220 mmHg; 
2 times per day, 6 days per 
week 
(n = 7) 
Same exercise without 
BFR 
(n = 5) 
2 
↔ Leg flexor and extensor strength 
(Nm) 
↑ V̇O2max 
↑ VE max 
Abe et al. (2006) (39) 
Healthy young 
male adults 
(N = 18) 
21 ± 3 
5x2 min walking 
(3 km.h-1); 
BFR: 160-230 mmHg; 
2 times per day, 6 days per 
week 
(n = 9) 
Same exercise without 
BFR 
(n = 9) 
3 
↑ Isometric leg extension strength 
↑ 1RM leg press and leg curl strength 
↑ Lower limb muscle-bone CSA 
↑ Exercising V̇O2 
↑ Acute GH production 
Abbreviations: BFR = Blood flow restriction; BFR-AT = Blood flow restricted aerobic exercise training; LOP = Limb occlusion pressure; VI = Variable intensity; 30STS 
= 30 second sit-to-stand; QCST = Queen’s College step test; 6MWT = Six minute walk test; TUG = Timed up and go; HRR = Heart rate reserve; CSA = Cross-sectional area 
(cm2); V̇O2peak = Peak oxygen consumption (ml.kg.min-1); V̇O2max = Maximal oxygen consumption (ml.kg.min-1); VE max = Maximal ventilation; 1RM = One-repetition 
maximum; GH = Growth hormone. 
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The prevailing finding following BFR exercise training has been significantly greater 
muscle strength gains compared with equivalent intensity exercise without the addition 
of BFR (36, 293). Intensities as low as that associated with moderate-speed walking have 
been used in conjunction with BFR (39, 274, 275, 279). The consistent findings among 
studies of BFR-AT are increases in both muscle strength (7.1-21.8%) and muscle size 
(2.5-7.6%) following relatively short to moderate duration BFR-AT (3-10 weeks), 
while non-BFR equivalent controls demonstrated no significant change in either of 
these variables in any of these studies (38, 39, 273-275, 279, 280). Indeed, comparative studies 
were analysed in a recent meta-analysis that found an overall increase in muscle 
strength and muscle size among BFR-AT interventions (290). For example, among 72 
participants, the mean difference in muscle strength following BFR-AT beyond that 
of controls was 0.4 Nm [95% confidence intervals: 0.1, 0.6; P = 0.04] (290). Notably, 
this was higher when interventions were longer than six weeks, 0.6 Nm [95% CI: 0.4, 
0.9] compared with interventions shorter than six weeks, 0.2 Nm [95% CI: -0.5, 0.2] 
(P = 0.03) (290). Among 131 participants, the mean difference in muscle size (measured 
as mid-thigh CSA) following BFR-AT beyond that of controls was 0.32cm2 [95% CI: 
0.03, 0.61; P = 0.03] (290). Potentially due to a reduced level of muscular conditioning 
prior to intervention, older adults generally display greater increases in muscle strength 
(8.7-21.8%) and muscle size (3.1-5.8%) compared with young people (7.1-10.7% and 
2.5-4.6%, respectively) following BFR-AT over equivalent length interventions, with 
similar durations and intensity exercise programmes (38, 39, 273-275, 279, 280). This increased 
magnitude in the muscle strength and muscle size improvements seen among older 
adults following BFR-AT is of particular interest due to the significant contributions 
of muscle size and muscle strength in current definitions of sarcopenia, and the 
prevalence of muscular deconditioning among older adult populations (133). This has 
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been demonstrated in one of the earliest studies to utilise BFR-AT among older adults 
(60-78 years), specifically BFR in conjunction with walking (n = 11) compared with 
non-BFR walking controls (n = 8) (273). Participants performed treadmill walking at 67 
m.min-1 (similar to normal walking speed) for 20 minutes on five days per week for 6 
weeks. Following training, leg extension torque increased at every velocity for the 
BFR walking group (up to 12.2%, P < 0.01), while leg extension torque in the control 
walking group decreased slightly at all velocities (as much as -5.1%; P < 0.05) (273). 
Similarly, mid-thigh CSA increased by 5.8% in the BFR walking group compared with 
no change in the non-BFR walking group (P < 0.05) (273). A novel inclusion in this 
study was the measurement of physical function using the TUG and the 30STS, which 
improved by 13% and 14%, respectively, in the BFR walking group compared with no 
change in the control group (P < 0.05) (273). 
Despite the established association between increasing muscle strength and 
improvements in physical function, and the main premise of adding BFR to exercise 
training being to increase muscle size and strength, few studies measure physical 
function following BFR-AT. The previously described walking study is one of the first 
to examine physical function following BFR-AT among older adults (273). However, 
this study and most studies examining BFR-AT among older adults have only included 
a limited range of measures of physical function as secondary measures, and provided 
little detail as to the significance and implications of any significant findings (273-275). 
The only comprehensive examination of BFR-AT for improving physical function 
among older adults utilised a range of physical function measures commonly used for 
clinical assessment of older adults and reflective of a variety of ADL (41). Exercise 
training involved 6 weeks of 10-minute BFR walking completed on four days per week 
(41). Participants in the BFR walking group (n = 10) improved physical performance 
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by a greater degree than the non-BFR walking control group (n = 9) as measured by 
the 6MWT (9.1% vs 2%, respectively), 30STS (27.6% vs 8%), TUG (-11% vs -4.6%) 
and the Queen’s College step test (74.2% vs 21%) (P < 0.05) (41). Collectively, these 
measures of physical function are indicative of functional strength, exercise capacity, 
muscular endurance, dynamic balance, mobility and gait speed (166, 243, 294, 295). Thus, a 
relatively simple low-intensity BFR-AT prescription was able to enhance performance 
on measures reflective of ADL beyond that of equivalent-intensity non-BFR-AT (41). 
Finally, it is broadly accepted that traditional AT is able to increase exercise capacity, 
commonly measured as an increase in V̇O2 peak (202). These increases in V̇O2 peak are 
enhanced in deconditioned populations such as frail older adults and populations living 
with chronic disease even when AT is completed at lower intensities (97, 200, 202). Thus, 
low-to-moderate intensities of traditional AT may be sufficient to increase V̇O2 peak 
among populations such as patients undergoing HD. However, there is limited 
evidence to suggest any further benefit from the addition of BFR for increasing V̇O2 peak (38, 275, 292). Of the few studies that have examined the impact of BFR-AT on V̇O2 peak, each reported an increase in V̇O2 peak, although only one clearly quantified 
this increase whereby BFR walking increased V̇O2 peak by 11.6% (P = 0.005) 
compared with no change in the non-BFR walking control group (292). One did not 
report the amount by which V̇O2 peak increased (38), and the only one amongst them 
examining older adults did not show significance between BFR walking and non-BFR 
walking (275). Participants in this study of BFR AT among older adults were sedentary 
and thus more likely to be deconditioned, potentially enhancing the effect of AT 
regardless of the presence of BFR (202, 275). This would suggest that AT in general is 
more important for improving V̇O2 peak than the addition of BFR. Despite this, AT is 
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known to have significant benefits among patients undergoing HD (see Sections 2.8.1-
2.8.3) and as such seems a pragmatic modality to utilise among this population (292, 296, 
297). Theoretically, BFR-AT should also benefit V̇O2 peak of patients undergoing HD 
as increases in exercise capacity can be achieved through increases in capillary density 
which is reduced due to severe muscle atrophy in patients undergoing HD (11, 292). 
However, patients undergoing HD generally do not have the exercise capacity to 
complete the intensities of AT required to maximise this benefit (11). Localised 
intramuscular hypoxia induced through BFR stimulates an increased rate of capillary 
formation, which may offset the inability to complete sufficient intensities of AT (35). 
Thus, the additional benefit of BFR-AT for ESKD patients is the ability to 
simultaneously increase muscle size, muscle strength and cardiorespiratory fitness. 
 
2.10.2 Considerations for blood flow restriction exercise among 
patients undergoing haemodialysis 
BFR exercise is considered relatively safe to be utilised with most populations, 
providing considerations are made regarding participant comorbidities and acute 
monitoring (298-302). Studies have examined the acute and chronic safety of BFR 
exercise in terms of hormonal responses (283, 303), coagulation factors (259, 304), 
inflammatory markers (high-sensitivity C-reactive protein) (305) and haemodynamic 
responses (259, 283, 299, 300, 303). Collectively, these studies demonstrated that there was no 
acute increase in inflammatory markers, and despite an increase in fibrinolytic 
potential there was no concomitant increase in coagulation factors that may have led 
to thrombolytic events (259, 283, 300). While there has been an indication that some 
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haemodynamic responses are increased, the majority of these studies examine BFR-
RT (259, 283, 303, 306). One study examining the central arterial haemodynamics of BFR-
AT did show elevations in central BP (141/93 mmHg vs 105/68 mmHg for BFR-AT 
vs AT, respectively), and cardiac systolic stress, while aortic wave reflection was no 
different between BFR-AT and AT (307). However, the absolute BFR pressures used 
during the study were moderate-to-high (160 mmHg) in comparison to pressures used 
in the more contemporary studies utilising individualised pressures, with no indication 
of the device or cuff specifications used (307). Applications of high BFR pressures (i.e. 
160-250 mmHg for the lower limb) are known to exaggerate haemodynamic responses 
to BFR (262, 298), making mitigation of these outcomes possible by using a lower and 
individualised occlusion pressure (262, 308). However, direct comparisons of the 
haemodynamic responses to BFR-RT, BFR-AT, and high-intensity non-BFR 
equivalents have demonstrated that BFR-AT produced the lowest magnitude 
haemodynamic responses (SBP, heart rate [HR], stroke volume [SV], cardiac output 
[?̇?𝑄]) compared with those of both BFR-RT and high-intensity non-BFR exercise (276, 
277). Specifically, one study examined the cardiac and haemodynamic responses to 
BFR-RT (4 sets of 30, 15, 15, 15 repetitions of leg press exercise at 20% 1RM) and 
BFR-AT (4 sets of 2 mins walking at 4 km.h-1) compared with non-BFR equivalent 
exercise controls for both young (22 ± 1 years) and older adults (69 ± 1 years) (277). 
This study reported small but significant increases in SBP, HR, and ?̇?𝑄 following BFR-
AT compared with controls although this was accompanied by reduced SV (277). 
However, when compared with low-intensity RT, BFR-AT elicited significantly 
reduced SBP (138 ± 3 mmHg vs 154 ± 3 mmHg; BFR-AT vs RT respectively), HR 
was no different (89 ± 4 beats.min-1 vs 88.7 ± 3 beats.min-1), SV was increased (96.9 
± 5.9 mL vs 88.7  ± 6.1 mL), and resultant ?̇?𝑄 was mildly increased (8.4 ± 0.4 L.min-1 
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vs 7.4  ± 0.4 L.min-1) (277). These are the commonly prevailing findings among the 
BFR-AT literature, although opposing views have also been reported which suggest 
that BFR-AT may require greater cardiac work, decrease endothelial function and 
arterial compliance (309, 310). Therefore, despite the weight of evidence purporting the 
haemodynamic safety of BFR-AT, caution needs to be exhibited when utilising and 
prescribing BFR-AT, and include careful screening of participants. 
These cardiac and haemodynamic factors are important when determining the 
applicability of BFR-AT for patients undergoing HD. SBP control is of paramount 
concern in this population due to its association with mortality and acute 
cardiovascular events (83, 85, 311, 312), so the reduced peak SBP is favourable. Likewise, 
only modest variation in other cardiac and haemodynamic variables supports the use 
of BFR-AT among patients undergoing HD due to known reductions in the degree of 
sympathetic mediation of these parameters (86). While exercise has been suggested to 
predispose patients undergoing HD (and other clinical populations) to exaggerated 
sympathetic nervous system activity, the reduced impact on the cardiovascular system 
of BFR-AT combined with a moderate cuff pressure (such as 40-50% individualised 
limb occlusion pressure) mitigates this risk (261, 262, 313). 
Recently, there has been evidence to support the use of BFR in creating a chronic-
acute reduction in BP similar to that known to occur following RT, which is potentially 
beneficial in the management of hypertension (299, 314, 315). While this has primarily been 
conducted with BFR-RT compared with RT, the findings suggested that the observed 
post-exercise hypotensive effect was the same between both BFR-RT and RT within 
10 minutes of exercise recovery, although BFR-RT demonstrated a less rapid rate of 
decrease in SBP compared with RT (299, 315). This was generally considered 
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advantageous due to the positive effect for hypertension management, although it did 
highlight a consideration that needs to be made for patients undergoing HD with regard 
to extended monitoring for post-exercise hypotension. The prevalence of IDH makes 
it essential to monitor BP before, during and after performing BP altering intradialytic 
exercise (84). While there is no indication that exercise has previously exacerbated 
incidence of IDH, the influence of the BFR application warrants stringent monitoring 
to confirm this. Indeed, the lower established haemodynamic variability following 
BFR-AT compared with BFR-RT suggests that utilising BFR-AT would limit the post-
exercise BP response. There is also an extremely low recorded incidence of syncope 
following BFR exercise (300). The largest survey of BFR usage to-date reported one 
case of syncope per 12,500 people using the technique, which included older adults 
and individuals with cardiorespiratory or metabolic conditions (300). Additionally, a 
recent study exploring the use of BFR in conjunction with electromyostimulation in 
young, healthy adults (n = 21; 20 ± 3 years) reported one case of syncope and two 
cases of pre-syncopal symptoms (sweating, light-headedness, pallor) (316). However, 
this was in relation to cuff inflation to a supramaximal pressure of 250 mmHg (316). 
While an individualised, moderate cuff pressure is unlikely to exacerbate the 
prevalence of syncope or pre-syncopal symptoms. 
The use of compressive cuffs requires a restriction of blood flow in and out of the 
active limbs, and the pressures used during BFR exercise training may be set high 
enough to occlude venous return from the restricted limbs during rest. However, when 
the occluded limb becomes active, it creates a skeletal muscle pump that assists with 
venous outflow such that circulation is maintained (284). The relevance of this for 
patients undergoing HD concerns dialysis adequacy and whether BFR-AT performed 
intradialytically may influence the efficacy of the treatment. However, given there is 
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no complete occlusion during exercise there is no reason to suggest that this would 
affect dialysis adequacy. 
The theoretical benefit of BFR-AT makes its application appealing for deconditioned 
clinical populations who may be contraindicated to higher-intensity forms of exercise. 
While BFR is commonly proposed as a useful adjunct to exercise among clinical 
populations, practical applications are still infrequently examined among such 
populations (261, 317). Of the few studies that have ventured into this space, chronic 
conditions examined include stable ischaemic heart disease, hypertension, Parkinson’s 
disease and chronic fatigue syndrome although most are small cohorts and proof of 
concept studies rather than large scale RCTs (305, 314, 318-320). Only two of these studies 
explored BFR-AT, despite its potential to reduce the mechanical stress associated with 
BFR-RT (314, 318). One of these studies explored the acute haemodynamic responses 
and changes in oxidative stress among hypertensive older women (n = 16; 67.2 ± 3.7 
years), finding lower magnitude haemodynamic responses compared with high-
intensity non-BFR equivalent exercise (314). Interestingly, this study also reported a 
significant BFR-AT-induced reduction in oxidative stress, which is known to have a 
deleterious effect on blood pressure regulation and is an important mediator of 
hypertension (314). The other BFR-AT study among clinical populations used BFR-AT 
(cycling) for improving balance among patients with Parkinson’s Disease (n = 9), 
resulting in increased gait speed (16%) and 6MWT distance (7%), and decreased time 
to completion for the TUG (23%), and 5 times STS (28%). All of these improvements 
in physical function involved moderate to large effect sizes, ranging from 0.39 to 0.82 
(318). This is preliminary, but positive evidence in favour of the application of BFR-AT 
among clinical populations with altered haemodynamic control and deconditioned 
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musculoskeletal systems, and does not deter the application of BFR-AT among 
patients undergoing HD. 
 
2.10.3 Potential benefits of blood flow restriction to exercise 
adherence 
A consideration with regard to patients undergoing HD is whether they will adhere to 
prescribed exercise training programmes. It has been noted that patients undergoing 
HD participate in 35% less physical activity than age-matched sedentary individuals 
without ESKD (17). This is a prominent concern with HD as it is a forced period of 
inactivity. However, this should be viewed as an opportunity to incorporate supervised 
exercise training to counteract this adverse outcome of HD. As concluded in Section 
2.9, there is a trade-off between maximal exercise training adaptations, practicality, 
and patient preference when prescribing exercise training to patients undergoing HD 
(116). While supervised exercise training on non-dialysis days may produce moderate 
increases in exercise training adaptations compared with exercise training during HD, 
training on non-dialysis days is generally poorly adhered to, and impractical for 
patients who already have to travel to dialysis centres three times per week (116). 
To optimise exercise training during HD it is suggested that it be completed within the 
first two hours of the HD session to avoid any adverse effects of the HD including a 
reduction in exercise tolerance and changes in fluid and electrolyte balance that may 
lead to excessive fatigue and haemodynamic complications (30, 108). There is also 
evidence that BFR-AT is able to produce superior thigh muscle CSA, isometric leg 
extension and flexion strength, and physical function improvements with as little as 3-
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4 days per week of 10-15 minutes BFR-AT, compared with AT of triple the volume 
(45 minutes) (38). This positions BFR-AT as an appropriate prescription for patients 
undergoing HD, with scope for increasing volume to maintain progression of the 
exercise training. Three days per week aligns with the number of HD sessions per 
week, and the total duration is short enough to complete the exercise training within 
the first two hours of HD. Thus, BFR-AT is an alternative to traditional AT which may 
improve muscle size and strength where traditional AT may not, potentially making it 
a more efficacious exercise prescription that can be conducted within the same time 
frame (intradialytically), reducing patient burden, which may improve adherence. 
 
2.11 Summary 
CKD is one of the most prevalent chronic diseases in the world. The most debilitating 
stage of the disease, ESKD, imposes one of the largest disease-burdens on the 
Australian healthcare system. HD is the most prominent form of treatment for ESKD 
and is essential to sustain life for those with ESKD who have not received a transplant. 
However, the deleterious side-effects of HD worsen the inherent physical decline 
associated with ESKD. This results in adverse effects such as anaemia, hyperkalaemia, 
hypertension, fatigue, depression, reduced tolerance to physical activity, and 
subsequent inactivity, which exacerbates their physical deterioration. Thus, it is 
unsurprising that patients undergoing HD display significant muscle atrophy, reduced 
strength, reduced exercise capacity, and reduced physical function. All of which 
further compound the risk of falls, fractures and mortality. Interventions utilising 
exercise training, most commonly AT, demonstrate multiple health benefits to patients 
undergoing HD. These include improving indices of muscle health, exercise capacity 
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and greater independence to perform ADL. However, such interventions often lack the 
exercise training intensity to elicit targeted increases in muscle size, muscle strength, 
and physical function, as patients with ESKD are commonly contraindicated to, or 
unwilling to participate in high-intensity exercise training. Previous research has 
demonstrated the potential of BFR exercise training to provide a useful alternative 
where high-intensity exercise training is less appropriate. Specifically, combining BFR 
with AT is shown to achieve this with reduced mechanical stress compared to both 
high-intensity non-BFR equivalent exercise, and BFR-RT, while BFR-AT also limits 
the magnitude of the haemodynamic responses to the exercise. Thus, BFR-AT presents 
an opportunity for augmenting low-intensity exercise training to be able to produce 
benefits in muscle strength, size, and physical function where traditional AT, often 
prescribed in exercise and dialysis research, may not. While it is generally perceived 
that exercise works well in dialysis patients, this is not a universal finding. As such, 
BFR exercise has the potential to be more efficacious than non-BFR exercise, which 
at times has shown modest benefits among patients undergoing HD.   
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Chapter Three: 
 
Materials and Methods 
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3.1 Overview 
This thesis presents two studies that were designed to achieve the general aims listed 
within Section 1.3 and specific aims listed within Section 1.4. This chapter is copied 
content from a protocol manuscript for Study 2 published within BMC Nephrology 
(September 2017) – Appendix A. As such, the following material has previously 
undergone a process of peer review. Contents of the publication have been adapted 
within this document to be consistent with thesis formatting. Adaptations include 
changes to writing tense, terminology, referencing style, and heading structure. 
Acronyms have been made consistent with the thesis document, and details regarding 
power calculation have been updated. Common materials and methodology employed 
in the process of data collection for both Study 1 and Study 2 have been identified. 
This includes participant recruitment, inclusion and exclusion criteria, and BFR 
protocol. Additional information specific to the unique materials and methods 
employed for Study 1 can be found in Chapter 4 (see Section 4.2). Amendments and 
additional information specific to unique materials and methods employed for Study 
2 can be found in Chapter 5 (see Section 5.2). The background section of the 
publication has been partly amended to reduce repetition from previous sections of this 
thesis, although it is still predominately presented as published. 
 
Clarkson MJ, Fraser SF, Bennett PN, McMahon LP, Brumby CA, Warmington SA 
(2017). Efficacy of blood flow restriction exercise during dialysis for end stage kidney 
disease patients: protocol of a randomized controlled trial. BMC Nephrology. 18:294. 
DOI: https://doi.org/10.1186/s12882-017-0713-4 
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3.2 Introduction 
Exercise is well tolerated among patients undergoing HD and is an efficacious method 
for ameliorating these adverse symptoms characteristic of ESKD (98, 250, 251, 253). 
Heterogeneous methodology, prescription and reporting among exercise training 
studies make it difficult to draft guidelines on the dosage and mode of exercise training 
to derive the best outcomes for patients undergoing HD (13, 247). The current guidelines 
for exercise training for patients undergoing HD recommend it encompasses aerobic 
(4 sessions; 45 mins), resistance (2 sessions; 20 mins), and flexibility (7 sessions; 10 
mins) exercise (18). The cumulative time commitment for these recommendations is 
substantial, and would require training on both dialysis (during first 2 hours of dialysis) 
and non-dialysis days (18). However, most randomised controlled trials examining 
exercise regimens in ESKD have only utilised AT, most commonly stationary cycling 
(18). AT alone does not traditionally increase strength and hypertrophy, nor produce 
significant improvements in physical function, all of which are needed among this 
population (321). 
Adherence to exercise training programmes, regardless of aerobic, resistance or 
combined modalities, is also poor among patients undergoing HD, with more than 20% 
choosing not to participate, citing issues such as lack of time, lack of energy, too much 
trouble, and resistance training being too difficult (116). Of those that chose to 
participate in exercise training, the dropout rate was more than 25% for programmes 
utilising exercise training on non-dialysis days (116). 
Resistance training poses further complications in the setting of a dialysis unit as the 
required equipment is cumbersome and poses a high risk for cross-infection. Less 
cumbersome washable elastic resistance bands may be one option (62). Exercise 
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training during dialysis also needs to be completed in the first 2 hours of dialysis 
sessions (108). Therefore, finding a more efficacious solution that may provide 
improvements in all key outcomes which can still be completed during dialysis would 
be preferable. 
Exercise training combined with BFR uses pressurised cuffs fitted proximally on the 
active limbs during exercise training and can elicit the above benefits at lower exercise 
intensities than non-BFR training (39, 267). BFR may be one method for achieving 
outcomes reflective of both RT and AT while providing a simple exercise prescription 
model in the dialysis setting. BFR-AT has been shown to increase muscle size and 
strength more than equivalent-intensity non-BFR AT, while still providing comparable 
or greater improvements in exercise capacity (36, 37, 39).  
While BFR exercise training is used predominately in single joint isolation RT 
exercises such as leg extension, it has also been applied during AT such as walking or 
cycling (38, 39, 256, 257, 275). Common BFR-AT protocols utilise short exercise durations 
of 10-20 minutes (39, 273-275).  Such studies utilising BFR-AT have demonstrated 
increases in lower limb muscle size and muscle strength of 8-16%, respectively (39, 273, 
275). However, it should be noted that without BFR, low-intensity AT is generally 
insufficient to increase muscle volume or strength, unless there is previous muscle 
atrophy or the initial level of participant physical activity is extremely low (40). Even 
in such instances, improvements in muscle size and muscle strength are unlikely to be 
of similar magnitude as seen with BFR (40). 
Regardless of the presence of BFR, AT improves exercise capacity provided that the 
exercise is of sufficient intensity (202). Indeed, studies have demonstrated that low-to-
moderate intensity BFR-AT is able to increase exercise capacity when exercising at 
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intensities equivalent to 40% of peak exercise oxygen consumption (V̇O2 peak)  (273, 
275, 292).  
Studies examining the haemodynamic responses to BFR identify BFR-AT as having 
lower haemodynamic stress than high intensity RT, while providing similar outcomes 
(277, 298, 300). As such, BFR is purported to be a potentially beneficial addition to exercise 
for clinical populations who may be contraindicated to high-intensity RT. While blood 
flow restriction exercise is a novel addition to exercise among patients undergoing HD, 
pilot data from this laboratory (unpublished) indicates that haemodynamic responses 
(SBP, DBP, mean arterial pressure [MAP], heart rate [HR]) do not differ markedly 
between low-intensity BFR and non-BFR AT both performed during HD in this 
population. 
Exercise capacity and muscle strength are both key physiological factors underpinning 
physical function (159) and both can improve with BFR-AT. As declines in physical 
function, muscle strength, and exercise capacity, as well as accelerated muscle atrophy 
are common among patients undergoing HD, BFR-AT may present a more efficacious 
use of time spent exercising for this population.  
This study will examine the efficacy of BFR-AT among patients undergoing HD. We 
hypothesise that blood flow restriction aerobic exercise training will improve physical 
function, muscle strength, and muscle size among patients with ESKD beyond that of 
traditional aerobic exercise training.  
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3.2 Study design 
Study 2 is a 12-week randomised controlled trial consisting of three groups randomised 
to exercise or usual care (Figure 3.1). Participants will be randomised to one of these 
three groups: a blood flow restriction cycling exercise training group (BFR-CYC), a 
non-blood flow restriction cycling exercise training group (CYC), or a non-exercising, 
usual care control group (CON). The study was conducted according to the Declaration 
of Helsinki (1975) and ethics approval was granted by the Deakin University Human 
Research Ethics Committee, Eastern Health Human Research Ethics Committee, and 
Epworth Healthcare Human Research Ethics Committee. This study was registered 
with the Australian New Zealand Clinical Trials Registry (ANZCTR): 
ACTRN12616000121460. 
 
 
98 
 
Figure 3.1 Study Flow Chart. Abbreviations: BFR-CYC – Blood flow restriciton 
cycling group; CYC – Traditional cycling group; CON – Usual care control group; 
LOP – Limb occlusion pressure; 3RM-LE – Three-repetition Maximum Leg Extension; 
6MWT – Six minute walk test; 30STS – 30-second sit-to-stand test; TUG – Timed up 
and go; pQCT – Peripheral Quantitative Computed Tomography; iDXA – Dual X-ray 
Absorptiometry; URR – Urea Reduction Ratio; Hb – Haemoglobin; Alb – Albumin; 
K+ - Potassium; PTH – Parathyroid Hormone; PO4 – Phosphate; RPE – Rating of 
perceived exertion 
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3.3 Participant screening and recruitment 
3.3.1 Sample size calculation 
The most relevant outcome for blood flow restriction exercise training studies is leg 
extensor muscle strength, and this was used as the main primary outcome measure for 
calculating required sample size. Based on data from previous blood flow restriction 
research (38, 39, 273, 275), and previous research examining exercise training for patients 
undergoing HD (88, 197, 253), the projected changes in leg extensor muscle strength for 
each of the three groups were CON = -3%, CYC = 2%, BFR-CYC = 12%. The 
common standard deviation within group, based on the prior research was determined 
to be 15%. Thus, to achieve a power of 80% at an α level of 0.05, 20 participants per 
group were required to detect a difference between the expected means for strength 
improvement. However, based on previous work conducted by this research group a 
conservative attrition rate of 20% was expected over 3 months due to voluntary patient 
withdrawal, death, additional hospitalisation, transfer to another facility, or patients 
receiving transplants (62). Thus, a total of 72 participants were required for statistical 
power and randomly allocated to one of the three groups. 
 
3.3.2 Recruitment and screening of participants 
Participants in both Study 1 and Study 2 were recruited through recommendation and 
referral from treating physicians at a number of dialysis clinics linked to a major public 
hospital service in a large metropolitan Australian city. Additionally, nurse unit 
manager recommendations and fliers briefly outlining the study posted within the 
dialysis clinics were used to help identify prospective participants. Prospective 
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participants were screened initially face-to-face by a member of the research team. 
Following this, confirmation from the treating physician was obtained if not implied 
by referral. Participants were then required to provide written, informed consent prior 
to participation in the study. All participants were provided with a plain language 
statement and consent form (Appendix F) 
 
3.3.3 Inclusion and exclusion criteria 
Eligible participants in both studies were male and female stable patients undergoing 
chronic (>3 months) HD aged between 18 and 80 years. Participants were deemed 
medically eligible by their treating physician before participation in the present study. 
Participants were excluded if they did not understand English and were unable to 
complete or comprehend the surveys or study documents; if within the previous 12 
weeks they had participated in regular physical activity or sport (>150 min.wk-1) of 
moderate or greater intensity (201), or structured RT (>1 session.wk-1); if they had 
symptomatic peripheral vascular disease, limb ischemia, untreated symptomatic 
cardiovascular disease, or any other absolute contraindications to exercise training 
(such as musculoskeletal factors or neurological conditions) that may have affected 
their ability to perform physical assessments or exercise training protocols in the 
present study; if they were currently smokers; if they were pregnant or had required 
hospitalisation for non-dialysis reasons in the 4 weeks prior to the study’s 
commencement. Patients were also deemed unable to exercise during individual 
dialysis sessions if they presented with fluid overload (> 5% above dialysis base 
weight) as this could cause reduced cardiac reserve (322). Similarly, if patients had SBP 
> 180 mmHg, or DBP < 90 mmHg prior to exercise they were deemed unsuitable for 
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exercise on that day (excluding the first blood pressure reading before dialysis, which 
is known to be unreliable) (323). Of clinical concern was the known propensity for HD 
patients to become hypotensive during dialysis (83). Although this is uncommon, and 
our pilot data (Chapter 4) indicated this was not exacerbated by BFR, to ensure the 
safety of all patients they were monitored for chest pain/discomfort, dyspnoea, lower 
limb pain, symptoms of severe hyper- or hypotension, and other signs of adverse 
events, which were reported to the ethics committee of both the treating hospital and 
Deakin University upon occurrence. 
 
3.3.4 Randomisation 
Randomisation was conducted at a participant level prior to familiarisation and 
baseline testing and randomised participants by blocks of 3 via a computer-generated 
random number sequence by an independent researcher. Blinding of intervention 
group to clinical staff and participants was not possible once the intervention 
commenced. 
 
3.4 Exercise intervention 
Exercise training sessions occurred intradialytically for all exercising participants and 
were completed within the first 2 hours of the session to avoid loss of exercise training 
quality (30, 108). All sessions were supervised by a member of the research team. 
Exercise training sessions consisted of cycling exercise for both BFR-CYC and CYC 
groups. Both BFR-CYC and CYC groups completed a total volume of 20 min cycling 
at a relative intensity for each participant that was dictated by rating of perceived 
102 
exertion (RPE), similar to previous exercise studies among patients undergoing HD (21, 
26, 98). This was also compared to measurements of percentage age-predicted maximum 
heart rate (APHRmax) in order to determine if targeted RPE needed to be adjusted to 
account for potential discrepancies between patient subjective intensity and 
objectively observed intensity. If participants were unable to maintain the prescribed 
cadence at this workload for the full duration, they were instructed to complete as 
much of each cycling bout as possible. 
 
3.4.1 Age-predicted maximum heart rate 
APHRmax was used as a relative indicator of intensity during exercise training sessions. 
Approximately 50-70% of participant’s age-predicted APHRmax was used as an 
objective target to indicate whether participants in BFR-CYC or CYC were exercising 
at the prescribed intensity for this study. This was achieved using a fingertip heart rate 
monitor and pulse oximeter (CMS50, Contec Medical Systems Co., Ltd., 
Qinhuangdao, Hebei Province, China) placed on the second or third finger of the 
participant’s hand on the contralateral limb to their arteriovenous fistula. This was 
measured continuously and recorded during the final minute of each period of active 
cycling within a session to correspond with measures of RPE. 
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3.4.2 Blood flow restriction cycling group 
The BFR-CYC group completed an intermittent protocol of 10 min cycling, 20 min 
rest, 10 min cycling. During these sessions, participants in the BFR-CYC group had a 
BFR cuff fitted to the proximal end of each thigh, which was inflated continuously at 
50% of a pre-determined limb occlusion pressure (LOP) throughout the full duration 
of cycling. Participants were required to cycle at an RPE of 13-15 (‘Somewhat hard’ 
to ‘Hard’ on the Borg 6 to 20 scale (324)), which was expected to be equivalent to 
approximately 60% of APHRmax for each 10 min cycling period. The prescribed 
volume and intensity represented a balance between prior BFR protocols and those 
utilised in the AT components of exercise studies for patients undergoing HD, while 
accounting for potentially very low levels of physical function among the participants 
(6, 13, 169). This exercise protocol was used during BFR cycling in both Study 1 and 
Study 2. 
 
3.4.3 Blood flow restriction procedure 
Throughout Study 1 and Study 2, all applications of BFR followed the same procedure. 
BFR was applied using an automatic tourniquet system ([ATS] A.T.S 3000, Zimmer 
Inc., OH, USA). The ATS produced a defined, controlled pressure via adjustable 
pneumatic cuffs (52 cm long, 10.5 cm wide; bladder length 45 cm, bladder width 8 
cm).  The pressure was regulated to control for changes in muscle contractile pressures 
under the cuff in such a way that the occlusive pressure applied to the limb was 
constant. 
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The cuffs were applied to the proximal aspect of the thigh prior to commencing 
exercise, and gradually inflated, as detailed by Abe et al. (2006) (39). BFR pressure was 
set at 50% of pre-exercise resting limb occlusion pressure (LOP). LOP was calculated 
during a familiarisation session for participants allocated to the BFR-CYC group using 
a digital plethysmograph (Pulse Sensor, Zimmer ATS 3000, Zimmer Inc., OH, USA) 
applied to the second toe (298, 308). A seated or recumbent posture was used for LOP as 
it most closely matched the posture that was used during the exercise training sessions 
(265). To determine LOP, the pneumatic cuffs were inflated to the point at which the 
plethysmograph could no longer detect blood flow to the toe (blood flow completely 
occluded). This was done for each leg and repeated to ensure accuracy (<20 mmHg), 
and an average of these measures was taken. The 50% LOP that was to be applied 
during exercise training sessions did not fully occlude the limb in this manner and 
allowed for continuous blood flow during exercise. 
 
3.4.4 Cycling group 
The CYC group exercise training sessions required 20 min continuous cycling at an 
equivalent intensity to the BFR-CYC group. However, due to the absence of BFR, 
equivalent intensity is often reported to have a lower RPE and mildly reduced heart 
rate response, regardless of exercise modality (276, 277, 325). As such, the target RPE was 
11-12 (‘light to somewhat hard’ on the Borg 6 to 20 scale (324)) for the CYC group, 
which was expected to equate to at least 50% APHRmax. This intensity was 
recommended for intradialytic aerobic exercise in the Exercise and Sport Science 
Australia (ESSA) position statement on exercise for chronic kidney disease (18). This 
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volume is reflective of protocols used by other studies examining exercise training 
among patients undergoing HD and represents a “normal” exercise training 
prescription for this population (14, 116).  
3.4.5 Progression 
In order to ensure that training sessions maintained a sufficient intensity for all 
exercising participants, resistance applied to the pedals, cadence, or a combination of 
both variables was adjusted on a session-by-session basis by a trained exercise 
physiologist such that the required RPE target (indicative of sufficient subjective 
intensity) was achieved. This accounted for any illness or excessive fatigue that 
affected exertion during any given session. A rolling two-week average of RPE was 
monitored (on the 6-20 Borg’s RPE scale (324)) to ensure progressive overload was 
being achieved over the course of the 3-month intervention.  
 
3.4.6 Usual care control group 
Participants allocated to the usual care control group received no additional access to 
exercise training and minimal advice regarding exercise training throughout the study. 
Participants randomised to the usual care control group were given access to an 
accredited exercise physiologist member of the research team, free of charge if they 
wanted to discuss the benefits of commencing exercise training upon completion of 
the study. 
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3.5 Data collection 
Data collection occurred at baseline (T1) and 12 weeks (T2), with testing completed at 
the treating HD unit prior to the commencement of the participants’ HD session. 
Personal information, including relevant medical history was collected prior to the 
initiation of testing or intervention upon receiving participant consent. This included 
patient characteristics of age, gender, time in months that the participant has been 
receiving HD (dialysis vintage), basic anthropometric measures (height, body mass, 
and BMI), relevant comorbidities and medications, transplant status, and type of 
dialysis access. Some or all of which was taken, with approval, from the case file at 
the HD unit. The remaining data collected included all measures of muscle function 
and physical function. Body composition scans were performed on a non-dialysis day, 
separate from other testing procedures for participants who opted-in to this aspect of 
testing. Additional pathology measurements included Hb, albumin, K, parathyroid 
hormone, phosphate, urea reduction ratio (URR), Creatine Kinase and lactate. These 
measures occurred as part of routine pathology tests where possible or were requested 
out-of-cycle to coincide with the necessary period of the training intervention. Data 
was coded and stored securely at Deakin University. Data collected from those who 
withdrew from the study was not used for statistical analyses. This was accounted for 
when completing the power analysis, with an additional 20% added to the targeted 
sample size. Attrition occurred for a number of reasons, which were ascertained upon 
withdrawal where possible. 
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3.5.1 Primary outcome measures 
3.5.1.1 Lower-limb muscle strength 
Maximal lower limb muscle strength was determined using three-repetition maximum 
(3RM) leg extension (HS-LE, Life Fitness, Victoria, Australia) (34). This 3RM leg 
extension (3RM-LE) test measured the maximum weight that could be lifted for three 
consecutive repetitions of a leg extension exercise with good technique and full range 
of motion (326). 
3.5.1.2 Physical function 
Objective physical function was measured using the 30STS, TUG, and 6MWT. The 
30STS measured lower limb muscle strength and function and required participants to 
stand from a chair and then return to the seated position as many times as possible in 
30 seconds (166). The test has also displayed strong comparative validity to lower 
extremity 1RM strength testing, particularly among community-dwelling older adults 
(166). It has also demonstrated a high level of reliability among patients undergoing HD 
(ICC = 0.93) (327). 
The TUG was used as a measure of dynamic balance and mobility requiring 
participants to stand from a chair, walk to and then around a cone placed 3 m away, 
walk back to the chair, and sit back down as quickly as possible. This test was repeated 
three times, and an average time taken for accuracy purposes (328). The TUG strongly 
reflects gait speed among older adults and has shown strong test re-test reliability not 
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only among older adults, but also in patients undergoing HD (ICC = 0.91-0.96) (170, 172, 
329). 
The 6MWT is a self-paced assessment of aerobic capacity, and a strong index of all-
cause mortality in older adults (241). It required participants to walk laps of a straight 
30 m course with the objective to cover as much distance as possible in the six-minute 
duration (241). The 6MWT is a reliable measure for patients undergoing HD (ICC = 
0.93 - 0.96) (327, 330). It has also been validated against exercise capacity (V̇O2 peak) 
for patients undergoing HD, with moderate strength coefficients of correlation (r = 
0.56 – 0.73) (118, 331). 
 
3.5.2 Secondary outcome measures 
3.5.2.1 Muscle cross-sectional area and body composition 
Total and regional body composition (lean mass, fat mass and percentage fat mass) 
were assessed using iDXA (Lunar iDXA, GE Healthcare, Madison, WI). Muscle CSA 
around the femur diaphysis at 25% and 50% of femur length were assessed using 
peripheral quantitative computed tomography ([pQCT]; XCT 3000, Stratec 
Medizintechnik, Baden-Württemberg, Germany), allowing for measurements of leg 
flexor and extensor musculature. Height and body mass were also assessed using a 
portable stadiometer and scales respectively. 
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3.5.2.2 Pathology measures 
Pathology measurements were taken during routine collections completed by the 
treating hospital. The exercise intervention was timed such that these routine pathology 
measures occurred within the 4 weeks prior to the commencement of the first training 
session (or prior to the 12-week usual care monitoring period for the CON). These 
additional measures included Hb, albumin, K, parathyroid hormone, and phosphate. 
URR was also measured by the treating hospital as a part of patients’ quarterly 
pathology tests, providing it was within the 4 weeks prior to patients commencing their 
exercise intervention. If this was not achievable in a timely manner, an additional 
measure of URR was requested for a single dialysis session prior to the 
commencement of the exercise intervention. 
Two additional measures of URR, Creatine Kinase and lactate were also required 
outside of the normal regimen for patients in either of the exercise training intervention 
groups, once during the first week of the exercise training intervention, and again 
during the final week of the exercise training intervention. An additional out-of-cycle 
measure of URR was also required by participants in the usual care control group, 
unless this was scheduled to be completed within 2 weeks following their 12-week 
monitoring period for this study as a part of their quarterly routine pathology test. All 
measures were conducted at the beginning and upon completion of a single dialysis 
session to establish the difference in each marker over the course of that session. This 
allowed for analysis of the impact of exercise and specific exercise intervention types 
(BFR-CYC and CYC) on dialysis adequacy, as well as providing objective proof that 
there was no major tissue damage as a result of the intervention. 
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3.5.2.3 Physical activity levels 
The Community Healthy Activities Model Program for Seniors (CHAMPS) physical 
activity survey was used to assess participation in a comprehensive list of low, 
moderate and vigorous physical activities (332). This questionnaire provided 
information about changes in physical function and physical activity behaviour over 
the course of the study. 
3.5.2.4 Symptom related quality of life 
The POS-S renal questionnaire was given to patients during the familiarisation session 
to assess their quality of life in direct relation to the symptoms experienced as a part 
of their condition (333). This questionnaire provided feedback about any changes 
experienced by patients regarding quality of life and disease-specific symptoms as a 
result of the intervention. 
 
3.5.3 Statistical analysis 
All statistical analyses were performed using SPSS 22.0 (IBM Corp, Chicago IL, 
United States of America). Participant characteristic and demographic data was 
presented using descriptive statistics and compared using independent t-tests for 
continuous variables and chi-square tests for categorical variables. The distribution of 
data was assessed for normality with a Shapiro-Wilks test (P > 0.05). Non-normally 
distributed data was to be compared using the Friedman non-parametric test. 
Otherwise, comparisons between groups for all continuous primary and secondary 
variables measured was made using a mixed model analysis of variance (ANOVA). A 
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significance level of P < 0.05 was adopted for all statistical tests or smaller where 
adjusted for multiple comparisons. All data was presented as means ± SEM unless 
stated. 
 
3.6 Discussion and Conclusion 
This study was the first to explore the efficacy of BFR-AT among patients undergoing 
HD. Additionally, it is one of the first to explore a battery of common clinical measures 
of physical function following a BFR-AT programme. The main objective of the study 
was to determine the efficacy of BFR-AT for improving the strength and physical 
function of patients undergoing HD.  
While exercise during HD is not a novel concept in the broader literature, the current 
exercise recommendations present a significant time and physical burden for patients 
undergoing HD and does not have an established role in clinical practice. Therefore, 
this study was important given the well documented deficits in strength and physical 
function for patients undergoing HD in conjunction with the rarity with which any 
exercise is adopted not only intradialytically, but in the broader population. It may also 
be valuable to include measures related to vascular stiffness (e.g. pulse wave velocity 
and vascular-related microRNAs) in future studies, as this has also been shown to 
improve with exercise training, and may be enhanced with the addition of BFR (121, 274, 
334). 
It was expected that this study would provide an improved understanding of the role 
that BFR-AT can play in providing an efficacious modality of intradialytic exercise 
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for patients undergoing HD, which caters to the population’s lower initial level of 
physical function and overall conditioning.  
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Chapter Four: 
 
Haemodynamic and Perceptual Responses to 
Cycling and Blood Flow Restriction Cycling 
among Patients Undergoing Dialysis (Study 1) 
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4.1 Introduction 
The literature review presented earlier in this thesis demonstrates that reduced exercise 
capacity, skeletal muscle atrophy and impaired physical function can be improved for 
patients undergoing HD. Generally, this is attempted through AT and/or RT performed 
intradialytically where low- to moderate-intensity exercise is considered safe and well-
tolerated (13, 18, 203, 335, 336). However, not all studies using standard exercise, in particular 
those employing solely cycling exercise, result in marked improvements in muscle 
size, muscle strength, exercise capacity, or physical function, and rarely are 
improvements observed across all of these physiological domains. This is compounded 
due to exercise not being widely adopted among this population group, with most 
patients undergoing HD displaying a significant reluctance to exercise (116, 337). Any 
proposed exercise intervention needs to be safe, tolerable and more efficacious than 
the current alternatives. 
This thesis aims to establish BFR-AT as a viable alternative to traditional intradialytic 
exercise as it has been established that BFR-AT can enhance skeletal muscle strength 
and cross-sectional area more than equivalent-intensity non-blood flow restriction 
exercise, despite typically employing low exercise intensities (36, 37, 40, 293, 338-340). While 
AT alone has not traditionally elicited gains in muscle size and strength, especially at 
the low volumes used in many exercise and dialysis studies (18, 199, 203, 335), BFR-AT has 
done so and continues to confer common adaptations of improved exercise capacity 
and physical function, especially in deconditioned populations (41, 293). This positions 
BFR-AT as an interesting prospect for patients undergoing HD, as it can potentially 
elicit significant improvements across the full range of physiological domains, which 
has not generally been observed in previous exercise and dialysis studies. 
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Exercise induces acute changes to haemodynamics, in particular an elevation in SBP 
(341). This is sometimes, and potentially more commonly in patients undergoing HD 
(89), followed by significant post-exercise hypotension (PEH) (83). It is possible that the 
observed PEH among patients undergoing HD is a standard exercise response 
superimposed onto the BP lowering effect of HD, which may create the appearance of 
exacerbating PEH compared with pre-dialysis CKD patients (89). This is also supported 
by one study finding no significant difference in post-exercise SBP recovery between 
patients with known dialysis-induced hypotension, patients with no previous dialysis-
induced hypotension, and no CKD controls (86). Regardless, both the SBP elevation 
and PEH are usually, but not exclusively self-resolving and largely asymptomatic (83, 
89, 341).  
This is of concern when programming exercise for patients undergoing HD, as their 
haemodynamics are known to be unstable both during and following HD (85, 312). This 
instability is further complicated as patients undergoing HD exhibit a high incidence 
of vascular disease (peripheral, cerebral, coronary) and other cardiovascular diseases 
(53). Additionally, the high prevalence of autonomic dysfunction and the use of BP 
regulating medications further exposes patients undergoing HD to haemodynamic 
instability during HD (311). Symptomatic intradialytic hypotension (IDH) is of 
particular concern due to the relationship between IDH and vascular access 
thrombosis, inadequate dialysing, and mortality (85). Thus, while exercise is considered 
safe to perform intradialytically, it requires vigilant monitoring of the haemodynamic 
responses. 
The magnitude of haemodynamic responses to the more frequently utilised BFR-RT 
has typically been greater than for equivalent-intensity non-BFR exercise (278). 
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However, this response has been markedly lower for BFR-AT such as cycle ergometer 
exercise when compared with BFR-RT, possibly due to reduced mechanical 
requirements and a lower exercise intensity with BFR-AT (261, 276). Notably, this 
reduced haemodynamic response was also lower than with low-intensity traditional 
RT that is widely approved as safe for patients undergoing HD (18, 276, 277). However, 
BFR exercise has not been evaluated in patients with moderate to advanced chronic 
kidney disease (CKD) or ESKD either intradialytically or interdialytically. 
Therefore, the primary aim of Study 1 was to determine the haemodynamic responses 
(HR, SBP, DBP and MAP) immediately following BFR-AT in progressively more 
haemodynamically unstable settings (interdialytic followed by intradialytic exposure 
to BFR-AT) among patients undergoing dialysis. The secondary aim of Study 1 was 
to determine the perceptual responses (RPE and RPD) to BFR-AT in progressively 
more haemodynamically unstable settings among patients undergoing dialysis. It is 
hypothesised that the haemodynamic responses (HR, SBP, DBP, MAP) to exercise 
would be greater with blood flow restricted cycling exercise than traditional cycling 
exercise, and that there will be no difference between the haemodynamic responses of 
blood flow restriction exercise performed either interdialytically or intradialytically. 
Additionally, it is hypothesised that the perceptual responses (RPE and RPD) to blood 
flow restricted cycling exercise would be greater than those to traditional cycling 
exercise 
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4.2 Specific Methods 
The majority of the methodology for Study 1 was unique to that presented in Chapter 
3. However, some similarities including participant screening and recruitment (Section 
3.3), and blood flow restriction procedure (Section 3.4.3) remained the same. As such, 
these have not been included in the following specific methods section. 
4.2.1 Study Design 
Study 1 utilised a repeated measures design. Ten participants (n = 7 male; Table 4.1) 
were recruited as described in Section 3.3. All participants underwent six supervised 
cycling exercise sessions over a fifteen-day period aligning with each participant’s 
regular dialysis schedule. Ethics approval for this study was granted by both the 
Eastern Health Human Research Ethics Committee and the Deakin University Human 
Research Ethics Committee. All participants were provided with a plain language 
statement and consent form (Appendix E). 
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Table 4.1 Participant characteristics
Variable N = 10 
Male (n) 7 
Age (years) 61 ± 13 
HD Vintage (years) 5.6 ± 3.7 
Dialysis base weight (kg) 68.23 ± 15.51 
Resting brachial SBP (mmHg) 137 ± 14 
Limb Occlusion Pressure (mmHg) 223 ± 17 
BFR cuff pressure (mmHg) 112 ± 9 
Exercise load (W) 21 ± 6 
Data are mean ± SD.
4.2.2 Sample Size Calculation 
The most sensitive indicator of intradialytic haemodynamic instability for patients 
with ESKD is change in SBP (84, 85). Therefore sample size calculations were 
influenced by known SBP response to exercise. However, there was no existing data 
from which to inform a sample size calculation looking at a difference in SBP response 
to exercise with BFR and non-BFR cycling exercise among patients undergoing HD. 
As such, expected changes for each condition in the present study was estimated based 
on previous data detailing a pooled mean change in SBP of  16 ± 7 mmHg for standard 
non-BFR cycling exercise compared with no increase in SBP for non-exercising 
controls among patients undergoing HD (63, 89, 342). Other prior research suggests a 
modest increase in SBP response (~6 mmHg) to BFR-AT among elderly adults 
compared with traditional AT should be expected (277). The sample size calculation 
used a repeated measure ANOVA for these 3 expected outcomes. This suggested that 
8 participants would provide 80% power at an α level of 0.05 to derive significance 
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for these estimated changes in SBP immediately following each exercise bout. Due to 
known issues with adherence among patients undergoing HD, we recruited an extra 
two participants (25%) to ensure adequate power. Sample size calculations were 
completed using G*Power 3 statistical software package (343). 
4.2.3 Exercise training 
Participants were examined under three ‘conditions’, with each comprising exercise 
sessions on two days, separated by one day (Figure 4.1). These conditions did not align 
with the groups utilised in Study 2 (described in Chapter 3) and have been defined 
separately in this section. The order of conditions was the same for each participant. 
Condition 1 was non-BFR cycling performed intradialytically (noBFR-HD), to 
represent a “baseline” response to intradialytic cycling when participants are 
considered to be at their most haemodynamically unstable due to the process of HD 
(311). Condition 2 was BFR-AT (cycling) performed interdialytically (BFR-noHD), to 
evaluate BFR which may cause heightened haemodynamic responses, while 
participants were more haemodynamically stable without the influence of HD (278, 311). 
Condition 3 was BFR-AT (cycling) performed intradialytically (BFR-HD), which 
examined the higher haemodynamic requirements of BFR-AT while patients were also 
exposed to greater haemodynamic instability during HD (311).
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Figure 4.1 Study design: Timing of exercise sessions. Abbreviations: noBFR-HD – Non-blood flow restriction intradialytic cycling; BFR-noHD 
– Blood flow restriction cycling performed interdialytically; BFR-HD – Blood flow restriction intradialytic cycling; Shaded blocks indicate non-
dialysis day. 
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For conditions conducted intradialytically, participants underwent exercise during the 
first 2 hours of HD and were also screened for subjective changes in lower limb muscle 
cramps and restless legs known to affect patients over the course of HD (30, 108). All 
sessions were monitored by an accredited exercise physiologist as part of the research 
team. 
On each day, cycling was completed on an electronically braked cycle ergometer 
(LODE Excalibur 911905, Lode B. V., Groningen, The Netherlands) positioned to the 
side of each participant’s dialysis chair allowing them to remain seated on their chair, 
rotated such that their legs could reach the pedals from behind the cycle ergometer. 
This was always to the same side as the dialysis machine, to allow participants to have 
their fistula arm supported and avoid access lines from moving excessively during the 
active portions of the exercise session. 
All cycling sessions followed the same structure (Figure 4.2). Each session included 
an unloaded 5-minute cycling warm up and cool down at a participant-selected 
cadence. The main component of the exercise session consisted of two 10-minute 
bouts of cycling separated by a 20-minute rest period. This was to align with the 
proposed BFR-AT prescription described in the methodology in Section 3.4.2. The 
prescribed volume and intensity reflected a balance between entry-level, multiple bout 
blood flow restriction protocols and traditional aerobic training components from other 
HD studies (6, 13, 169). Workload for each 10-minute bout was between 10 W and 30 W, 
which is equivalent to a low-to-moderate RPE (324). RPE was also provided by 
participants during the final 30 seconds of each exercise bout (43, 194, 222). This workload 
remained constant across all conditions. 
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Figure 4.2 Single session timeline: Timing of measures indicated on the single session timeline. Abbreviations: LOP – Limb occlusion 
pressure; HR – Heart rate; SBP – Systolic Blood pressure; DBP – Diastolic Blood pressure; MAP – Mean arterial pressure; RPE – rating 
of perceived exertion; RPD – rating of perceived discomfort. 
 123 
4.2.4 Measurements 
All data collection procedures for the outcome measures detailed in this section are 
relevant to Study 1. However, they were not addressed in the general materials and 
methods section of this thesis (Chapter 3).  
 
4.2.4.1 Heart Rate and Blood Pressure 
For all sessions, haemodynamic measures were taken at baseline, immediately prior 
to, and immediately following each exercise bout (Figure 2). Haemodynamic measures 
included HR, SBP, DBP and MAP. In addition, haemodynamic measures were taken 
at 20-minute intervals until 60 minutes post exercise (Figure 2). HR, SBP, DBP and 
MAP were measured using the dialysis machines (4008S NG, Fresenius Medical Care 
Australia Pty Ltd, Milsons Point, New South Wales). These dialysis machines took 
approximately 30 seconds to take the desired measures, so post-exercise measures 
(‘End-bout 1’ and ‘End-bout 2’) are within the first 30 seconds following completion 
of each exercise bout. 
In addition, measurements of end-HD SBP and DBP were retrieved post-hoc from 
stored hospital records by a nephrologist from the treating organisation, as these data 
are collected routinely by renal nurses at the completion of each HD session. These 
data are not available for the BFR-noHD condition. 
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4.2.4.2 Perceptual Measures 
In the final minute of each of the main exercise bouts, participants were asked to 
provide a RPE and a RPD on a Borg scale ranging from 6 (no exertion/no discomfort) 
to 20 (maximal exertion/maximal discomfort) (324). As a standard precaution, all 
participants were monitored for, or asked to report, chest pain/discomfort, dyspnoea, 
lower limb pain, symptoms of severe hyper- or hypotension, and other signs of adverse 
events. The occurrence of leg cramping or restless legs was also monitored, although 
no notable outcomes were reported. 
 
4.2.5 Statistical Analysis 
All statistical analyses were performed using SPSS 22.0 (IBM Corp, Chicago IL, 
United States of America). Continuous variables were compared using a mixed model 
analysis of variance (ANOVA) using within factors (time, session), and between 
factors (condition) for which significance was set at an α level less than 0.05. 
As there was no statistical difference between the first and second sessions within each 
condition (noBFR-HD, BFR-noHD, BFR-HD), the data for each participant was 
averaged and a subsequent analysis was performed, allowing for a direct comparison 
of conditions. To achieve this, comparisons between each condition for all continuous 
variables was made using a mixed model ANOVA using within factors (time), and 
between factors (condition). Mauchly’s test for sphericity was used to assess equality 
of variance, and if violated a Greenhouse-Geisser correction was applied. A significant 
α level of less than 0.05 was adopted for all statistical tests. All outcome data are 
presented as means ± SEM unless stated. 
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4.3 Results 
 
4.3.1 Haemodynamic Measures 
There was a main effect for time for HR [F(8, 216) = 76.09, P = 0.00], SBP [F(8, 216) 
= 52.81, P = 0.00], DBP [F(8, 216) = 17.44, P = 0.00], and MAP [F(8, 216) = 37.47, 
P = 0.00], such that they increased with exercise and returned to baseline following 
the 60-minute recovery period (Figure 4.3). In addition, there was a post-exercise 
hypotension evident for all conditions over the first 60 min of recovery when compared 
with baseline (P < 0.001). The lowest recovery measures for SBP, DBP and MAP were 
12 mmHg, 5 mmHg, and 11 mmHg lower than baseline, respectively. There was no 
main effect for condition or interaction between time and condition in any of these 
haemodynamic measures.
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Figure 4.3 Haemodynamic responses to both blood flow restriction, and non-blood flow restriction exercise among patients on dialysis. Figure 
representative of changes in a) Heart rate, b) Systolic blood pressure, c) Diastolic blood pressure, and d) Mean arterial pressure. # = significantly 
different to baseline (P < 0.001).
a) b) 
d) c) 
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4.3.2 Perceptual Measures 
There was a main effect for exercise bout for RPE [F(1, 27) = 21.00, P = 0.00] and 
RPD [F(1, 27) = 11.88, P = 0.002], as well as a main effect for condition for RPE [F(2, 
27) = 3.43, P = 0.047] and RPD [F(2, 27) = 33.33, P = 0.00] (Figure 4.4). However, 
there was no interaction for bout and condition for either RPE [F(2, 27) = 0.859, P = 
0.435], or RPD [F(2, 27) = 2.14, P = 0.14]. Specifically, RPE was significantly higher 
following exercise bout 2 (16 ± 0) than following exercise bout 1 (14 ± 0) (P < 0.001). 
RPE was also significantly lower for noBFR-HD (13 ± 1) than for both BFR-noHD 
(16 ± 1) and BFR-HD (16 ± 1) (P < 0.05), with no significant difference between BFR-
noHD and BFR-HD. RPD was significantly higher following exercise bout 2 (13 ± 0) 
than following exercise bout 1 (12 ± 0) (P < 0.01). RPD was also significantly lower 
for noBFR-HD (9 ± 1) than for both BFR-noHD (15 ± 1) and BFR-HD (15 ± 1) (P < 
0.001), with no significant difference between BFR-noHD and BFR-HD. 
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Figure 4.4 Perceptual responses to both blood flow restriction, and non-blood flow restriction 
exercise among patients on dialysis. Figure representative of a) rating of perceived exertion, 
and b) rating of perceived discomfort immediately following each exercise bout within a 
session. # = Exercise bout 2 significantly different from bout 1 (P < 0.001). * noBFR-HD 
significantly lower than both BFR conditions (P < 0.001). 
 
  
a) 
b) 
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4.4 Discussion 
Study 1 was the first to demonstrate the application of blood flow restriction aerobic 
exercise for patients undergoing HD. The major findings show that the haemodynamic 
responses (HR, SBP, DBP, and MAP) are not significantly different immediately 
following intradialytic BFR-AT (cycling) (BFR-HD) compared with either 
interdialytic BFR-AT (cycling) (BFR-noHD), or to intradialytic BFR-AT (cycling) 
(noBFR-HD). Following exercise all blood pressure measures (SBP, DBP, MAP) were 
significantly lower compared with pre-exercise levels across all conditions, which 
continued through the first 60-minutes of recovery. This is similar to post-exercise 
blood pressure reductions observed previously among studies examining time-course 
changes in blood pressure with intradialytic AT (83, 341, 342). However, in the present 
study the haemodynamic responses were not significantly different between 
conditions, therefore responses to BFR can be considered similar to what would 
typically be expected from intradialytic AT. 
The US National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative 
guidelines define IDH as a decrease in SBP ≥ 20 mmHg or MAP ≥ 10 mmHg with 
accompanying symptoms (85). However, the potency of various IDH definitions 
suggest that absolute thresholds of SBP < 90 mmHg for those with pre-HD SBP < 160 
mmHg, and SBP < 100 for those with pre-HD SBP > 160 mmHg display more robust 
associations with mortality (85). In the present study there were only two occasions 
where such readings were accompanied by symptoms of hypotension, both of which 
were reported as adverse events. However, the overall mean data from the present 
study indicates that neither the fall in systolic blood pressure or mean arterial pressure, 
nor the lowest absolute mean values for blood pressure measurements were 
representative of IDH. In addition, blood pressure data collected post-hoc from dialysis 
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records suggested that all blood pressure measures returned to pre-exercise levels after 
the recovery period and prior to the conclusion of HD (Figure 4.3). The present study 
did not include a non-exercising control, and so it is difficult to ascertain how much of 
the reduction in blood pressure measures was attributable to the exercise intervention, 
and how much was attributable to fluid removal during the dialysis treatment itself. 
Thus, the results of the present study suggest that intradialytic BFR-AT can be 
considered a suitable alternative exercise, at least with respect to these definitions of 
IDH. 
The absence of any main effects for condition across all haemodynamic measures in 
the present study suggests that neither the application of blood flow restriction to the 
exercise, nor whether exercise was completed on or off HD significantly affected the 
response. Therefore, it does not appear that BFR-AT should be considered any less 
suitable from a haemodynamic perspective compared with traditional exercise 
regimens recommended for patients undergoing HD. Undertaken chronically, BFR-
AT may in fact be preferable if it provides greater enhancement to muscle size, strength 
and physical function among patients undergoing HD, although this requires further 
research. 
The perceptual responses during both BFR conditions were significantly higher than 
the non-BFR condition. However, perceptual responses were still lower than common 
perceptual responses to moderate-intensity RT that is considered a safe mode of 
exercise in this population (18, 187, 209). While BFR-AT in the present study was 
generally perceived as being more challenging, both perceived effort and perceived 
discomfort (or equivalent) were still of lower magnitude than reports from high-
intensity non-BFR for which similar gains in muscle size, muscle strength, and 
physical function may be expected when undertaken chronically as part of a training 
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programme (276, 277). Furthermore, previous studies have highlighted that perception of 
effort and discomfort with BFR subsides with repeated use of the technique, 
approaching that of equivalent non-BFR (41, 276). With such a reduction in perceptual 
responses following repeated use of BFR, it seems unlikely that BFR would dissuade 
participation in a training programme or adversely affect exercise adherence beyond 
what is already seen among patients undergoing HD. It is also noteworthy that 
participants completing non-BFR cycling suggested that their reporting of perceived 
discomfort reflected more whole-body discomfort than specific to the region in which 
the cuffs may be fitted. For future studies, this may indicate that this measure would 
be more appropriate as a within-subject measure for BFR groups only. 
 
4.4.1 Adverse Events 
One case of exercise-related syncope occurred with BFR-HD (blood pressure 88/68). 
Ultrafiltration was stopped, a saline bolus administered, and the patient was reclined, 
after which blood pressure returned to a normal range for the participant within one 
minute. The participant was monitored for the remainder of HD. No prolonged effects 
of the adverse event occurred, and the participant chose to remain enrolled in the study, 
completing the BFR-HD condition with no adverse effects. On one additional 
occasion, a participant reported feeling light-headed in recovery (BP recorded as 
85/56), during which ultrafiltration was stopped briefly. However, this was self-
resolving, and ultrafiltration was resumed within a few minutes. 
Despite both of these instances of symptomatic IDH occurring following BFR-HD, 
which may imply a temporal association with that condition, both participants 
completed another BFR-HD session as per the study protocol, without issue. As these 
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were two episodes among 60 sessions, 40 of which occurred during HD, it is difficult 
to imply cause and effect between either the exercise or the BFR and the symptomatic 
IDH. As prevalence of IDH is reported to range from 15% to 50% of HD sessions, the 
5% prevalence in the present study is also below expectation (85). This further supports 
that BFR among patients undergoing HD is a viable alternative, but also indicates that 
constant monitoring of haemodynamic variables is necessary to ensure that these 
adverse events are captured. 
One participant suffered a venous needle extravasation when repositioning themselves 
on their dialysis chair following an exercise session leaving the participant with 
bruising for several days. This was not a result of the exercise intervention itself but 
occurred during a session and warranted reporting. This highlights a limitation of the 
study whereby patients had to be positioned to the side of their dialysis chairs without 
back support during the present study. This may not only have resulted in excessive 
movement increasing the risk of venous needle extravasation, but additional fatigue of 
the postural muscles which may ultimately reduce biomechanical efficiency and may 
increase haemodynamic responses to exercise. Moreover, patients reported that this 
postural fatigue was excessively uncomfortable towards the end of the exercise bouts. 
Future studies utilising this exercise modality would benefit from a simpler, and more 
practical exercise equipment set up, whereby participants can remain in their normal 
seated position during HD. This may involve the use of commercial pedal sets which 
are able to be fitted to the dialysis chair, or customised cycle ergometers which can be 
positioned in front of the dialysis chair more easily. This may also reduce some patient 
discomfort caused by a lack of postural support in the present study. 
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An additional limitation of this study was that the order of conditions was not randomly 
assigned to participants. Under advice from the consulting nephrologists from the 
treating organisation, and due to the relatively unknown nature of BFR exercise during 
dialysis, the order of conditions should expose patients to BFR in progressively less 
haemodynamically stable settings, based on the present understanding of exercise in 
dialysis (no-BFR during HD, BFR off-HD, BFR during HD). This may have impacted 
on the perception of BFR-exercise as patients would have been more accustomed to 
BFR by the time they completed BFR during HD). One final limitation was the 
absence of a no-BFR off-HD session. However, it is well established that recruitment 
to exercise studies performed outside of dialysis is difficult (19, 113). Due to the time 
constraints on the present study, removing the two additional no-BFR off-HD sessions 
was determined to be necessary to maximise recruitment.   
  
4.4.2 Conclusion 
The present study supports the notion that blood flow restriction aerobic exercise is a 
tolerable and viable alternative mode of exercise for patients with ESKD. While 
perceived to be more challenging, the haemodynamic response to blood flow 
restriction aerobic exercise suggests that there is no greater cardiovascular stress than 
equivalent aerobic exercise without blood flow restriction. Given the known increases 
in muscle size, strength and physical function associated with chronic training using 
blood flow restriction exercise over a non-blood flow restriction equivalent (41, 293), it 
would seem a valuable exercise modality for populations such as patients with ESKD, 
who are contraindicated to or unlikely to participate in exercise of sufficient intensity 
to achieve these beneficial musculoskeletal adaptations. Therefore, our demonstration 
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of the haemodynamic response and tolerability of blood flow restriction exercise as a 
technique is a meaningful step towards improving the physical outcomes for these 
patients.  
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Chapter Five: 
 
The Effect of Blood Flow Restriction Cycling on 
Muscle Strength and Physical Function in 
Patients Undergoing Haemodialysis (Study 2) 
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5.1 Introduction 
Exercise training has already been established as having a modest effect on muscle 
strength, muscle size, and physical function among patients with ESKD, although 
rarely across all of these domains with a single exercise intervention (see Section 2.8). 
Likewise, it has also been established that the exercise recommendations made in the 
literature exceed the abilities of most patients undergoing HD, are unlikely to have 
significant patient uptake, or be well adhered to (13, 19, 108, 160, 192, 247). Moreover, 40% of 
patients undergoing HD have reported severe limitations with even moderate intensity 
daily activities, and 45% report very severe to moderate pain when attempting to 
exercise (160). This limits the intensity and volume of exercise that can be prescribed 
for patients undergoing HD. Indeed, patients undergoing HD are unlikely to engage in 
or adhere to exercise unless it is performed intradialytically (98). While studies have 
also explored interdialytic exercise training programmes, intradialytic exercise 
training programmes have reported a significantly increased adherence rate (15-25% 
higher) (30, 98, 321) and a reduced rate of dropouts (17-21%) compared with interdialytic 
exercise (24-33%) (116, 344). Additionally, despite the deconditioning observed in these 
patients and the need to improve muscle size and strength, and with RT traditionally 
employed to achieve these gains, RT has shown poorer compliance than AT (195, 321). 
As such, the majority of studies examining exercise for patients undergoing HD, have 
utilised AT alone (16, 18, 112, 203). The primary focus for exercise training programmes 
among patients undergoing HD has shifted towards low-to-moderate intensities in low 
volumes completed intradialytically in order to achieve wide-scale acceptance and 
involvement in exercise programmes. However, this subsequently means that many 
studies have not demonstrated that exercise, in particular AT, can increase muscle size 
or muscle strength (196-199). 
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Further issues arise from the inconsistency with which exercise is prescribed for 
patients undergoing HD (192). Patients undergoing HD traditionally require exercise 
that can develop exercise capacity, muscle strength, muscle size, and physical function 
that to achieve requires multiple exercise modalities (34, 97, 188). This has not only led to 
broad guidelines that include large volumes and multiple exercise modalities but make 
it difficult to provide clarity as to the ‘ideal’ exercise prescription (18, 192). This has 
broader implications, as it creates difficulty when advocating exercise to renal 
specialists and HD unit nursing staff who mostly have little knowledge of exercise 
prescription (192). It also deters patients undergoing HD from participation due to the 
large time-burden, and onerous physical requirements (246). 
As described in Chapter 2 of this thesis, BFR-AT may be one method for achieving 
outcomes reflective of both RT and AT simultaneously. BFR-AT has been shown to 
increase muscle size and strength more than equivalent-intensity non-BFR-AT, while 
still providing comparable or greater improvements in exercise capacity (36, 37, 39). 
Given BFR-AT is understood to have improved physical function indicative of ADL 
among older adults, it provides a suitable starting point in simplifying exercise 
prescription for patients undergoing HD (41). 
In Study 1 (Chapter 4), it was demonstrated that BFR-AT (cycling) could be 
undertaken safely by patients undergoing HD. There was no significant difference 
between the haemodynamic responses to BFR-AT (cycling) or equivalent intensity 
non-BFR cycling when both were conducted intradialytically. While BFR-AT was 
perceived as requiring more effort (greater RPE) than its non-BFR equivalent, the 
magnitude of the RPE reported was still indicative of moderate intensity exercise (324, 
345). However, despite the higher RPE there was no concomitant elevation in 
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participant haemodynamic responses that would have been expected with increased 
exercise intensity (324, 345). Ultimately, Study 1 highlighted that intradialytic BFR-AT 
can be both safe and tolerable for patients undergoing HD. 
To further explore the application of BFR-AT (cycling) for patients undergoing HD, 
Study 2 aims to establish the efficacy of 12 weeks BFR-AT, compared with traditional 
cycling exercise training among patients undergoing dialysis by comparing the 
primary outcome of lower limb muscle strength. Secondary outcomes which also 
contribute to establishing the efficacy of BFR-AT include measures of physical 
function, body composition and muscle size. The ‘traditional’ cycling prescription is 
one commonly used by studies examining cycling exercise training among patients 
undergoing HD (14, 16, 112, 116, 203). Comparing against a usual care control group provides 
a baseline against which to compare the magnitude of any intervention-induced 
changes in outcomes. Study 2 also aims to assess whether a BFR-AT prescription 
affects physical activity behaviour and symptom-related quality of life for patients 
undergoing HD compared with the traditional cycling prescription, and using usual 
care controls. Additionally, Study 2 represents an opportunity to characterise the time 
course changes in acute exercise response to BFR-AT compared with traditional 
cycling exercise training with regard to haemodynamic measures (HR, SBP, and DBP) 
and perceptual responses (RPE and RPD). 
 
 
5.2 Specific methods 
Study 2 follows the methodology presented in Chapter 3 and published as a protocol 
paper (Appendix A). Specifically, the study details and terminology used in the present 
 139 
chapter is described in the study design section of Chapter 3 (see Section 3.2). 
Additional amendments were made to this protocol following completion of Study 1 
(Chapter 4) and are presented below. 
 
5.2.1 Equipment 
In Study 1, an electronically braked cycle ergometer (LODE Excalibur 911905, Lode 
B. V., Groningen, The Netherlands) was positioned to the side of each participant’s 
dialysis chair (see Study 1 [Chapter 4]). An inability to completely lower the foot rests 
on the dialysis chairs at the majority of study sites did not allow for the cycle ergometer 
to be positioned directly in front of participants. In Study 1 this required that an arm 
of the dialysis chairs had to be lifted and participants had to rotate on their chair to get 
into the correct position behind the cycle ergometer. This posed multiple issues 
including a lack of postural support for participants while cycling, as well as an 
increased likelihood of excessive movement of the fistula arm, elevating the risk of 
venous needle extravasation (346). The lack of postural support caused noted discomfort 
to participants in Study 1 related to fatigue of postural muscles, with this fatigue 
potentially leading to an elevation in the blood pressure response to the exercise. 
Given these issues, it was determined that commercial pedal sets (U4B pedals, Bionic 
Medizintechnik GmbH, Friedrichsdorf, Germany) designed to fit to the dialysis chairs 
at the majority of study sites, and customised pedal sets (Monark 881E, Monark 
Exercise AB, Vansbro, Sweden) that could be positioned in front of the dialysis chairs 
at the remaining sites would be a more feasible option (Figure 5.1). The commercial 
pedal sets designed to fit the dialysis chairs had no capacity to quantify workload, 
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hence the use of RPE. Conversely, the customised pedal sets used at other sites allowed 
for a similar quantification of workload and progression to the original design used in 
the pilot study, without the need to move patients or have them positioned in 
uncomfortable or biomechanically inefficient positions. While this did not affect the 
protocol due to exercise intensity being prescribed as target RPE, it was not possible 
to accurately quantify the workload or cadence on the commercial pedal sets. 
a) 
 
 
 
 
  
BFR cuffs 
Dialysis 
access 
BP cuff 
Commercial 
pedal set 
BFR 
machine 
 141 
b) 
 
Figure 5.1 Equipment setup at different sites. a) commercial pedal set designed to fit 
dialysis chair and b) customised pedal set positioned in front of patients’ dialysis chair. 
5.2.2 Sample size calculations 
At the time of publication of the protocol paper describing the methodology in Chapter 
3, there was no existing data to accurately determine the required number of 
participants to achieve statistical power. The conservative ‘expected’ change estimates 
detailed in Chapter 3 (see Section 3.3.1) were lower than observed changes from 
preliminary study data. As a part of the ethics review process, we used preliminary 
data from our study to provide a more realistic estimate of the required power. The 
subsequently revised projected percentage changes in leg extensor muscle strength for 
each of the three groups was updated to CON = -10%, CYC = 7%, BFR-CYC = 19%, 
with a pooled standard deviation of 7%. The sample size calculation used a repeated 
measure ANOVA with between factors being the three groups. To achieve a power of 
BFR 
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BP cuff 
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80% at an α level of 0.05, 9 participants in total (3 per group) were required to detect 
a difference between the expected mean change for leg strength. Additional sample 
size estimates were made for the prominent secondary outcomes, namely the measures 
of physical function based on the preliminary data. These collectively indicated that to 
achieve a power of 80% at an α level of 0.05, 21 participants (7 per group) would be 
required for the 30STS, 36 participants (12 per group), for the 6MWT, and 15 
participants (5 per group) for the TUG. Previous studies commonly reported dropout 
rates of approximately 15-25% (321), therefore up to 42 participants (14 per group) 
would be required to achieve statistical power for all included measures. Sample size 
calculations were completed using G*Power 3 statistical software package (343). 
 
5.2.3 Statistical analysis 
There were substantial changes made to the statistical analyses conducted. The 
distribution of data was assessed for normality with a Shapiro-Wilks test (P > 0.05). 
Otherwise, comparisons between groups for all continuous primary and secondary 
variables measured was made using a mixed model analysis of variance (ANOVA). A 
significance level of P < 0.05 was adopted for all statistical tests, or smaller where 
adjusted for multiple comparisons. All data was presented as means ± SEM unless 
stated. Group by time comparisons were assessed using a complete-case analysis for 
each outcome measure of interest, in which data were excluded for a participant if 
baseline and 12-week values were not both obtained (n = 1). Additionally, the revised 
statistical power utilised expected absolute changes in the means for the included 
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measures and thus, a one-way ANOVA of the absolute change from pre- to post- 
testing by group was completed. 
To account for significant baseline differences for 6MWT, TUG, and WEE as well as 
between group differences for the age of participants, an analysis of covariance 
(ANCOVA) was used to assess the absolute change from baseline to 12 weeks. This 
included a model that adjusted for baseline alone, a second model adjusted for age 
alone, and a third model that adjusted for both baseline and age. For consistency, this 
was also completed for all physical outcome measures (3RM-LE, 6MWT, 30STS, 
TUG) and questionnaire data (CHAMPS and POS-S renal). All post hoc testing was 
conducted using Fisher’s least significant difference test. 
Assessment of body composition and thigh muscle CSA was an optional component 
of Study 2 to reduce participant time burden and maximise recruitment. Of the 
participants who opted-in for DXA and pQCT (n = 13) three were lost to follow up, 
resulting in only one participant allocated to CON contributing data to these outcomes 
at both baseline and 12 weeks. As such, comparisons to CON were not included in the 
statistical analyses for these measures. A linear mixed model was used to evaluate 
changes in lean mass and thigh muscle CSA between BFR-CYC and CYC, as this 
statistical method can account for lost data. Due to limited participant numbers, this 
was only completed as an unadjusted model. Where possible all randomised subjects 
who opted-in were included in the analyses. However, pQCT data for the 50% femur 
site were not able to be collected for one participant in CYC who was unable to be 
correctly position within the measurement gantry. Similarly, pQCT data for the right 
25% femur site for one participant in BFR-CYC was lost to movement artefact despite 
multiple scan attempts. Baseline measures and changes in outcome variables were 
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presented as means ± standard deviations or 95% confidence intervals unless indicated 
otherwise. A significance level of P < 0.05 was adopted for all these statistical tests. 
Finally, one participant was removed from the analyses of the CHAMPS questionnaire 
as an outlier. This was due to estimated weekly energy expenditure (WEE [cal.wk-1]) 
being more than 2SD above the mean, and not meeting the demographic for which the 
CHAMPS questionnaire was validated (332). 
 
5.3 Results 
Participant characteristics for each group are shown in Table 5.1. BFR-CYC were 
significantly younger than CON but not CYC. Among the anthropometric variables, 
body mass was significantly lower in CON compared with CYC, but not compared 
with BFR-CYC. Additionally, body mass index (BMI [kg.m-2]) was quite diverse and 
despite no significant difference between groups, the mean BMI of CYC indicated that 
participants were on average ‘obese’ (>30 kg.m-2) for CYC, compared with 
‘overweight’ (25-29.9 kg.m-2) for both BFR-CYC and CON. Resting DBP was 
significantly higher for BFR-CYC than CYC, but not CON (P < 0.05). Otherwise, 
there were no other differences between groups for height, body mass index, HD 
vintage, resting HR, and resting SBP (P > 0.05). Notably, while there was no difference 
between groups for HD vintage, CON appeared to have a much longer HD vintage 
accompanied by much larger variance. There appeared to be a trend towards a higher 
BMI for CYC and a classification of ‘obese’ pursuant to their mean BMI at baseline, 
despite no significant difference between groups, prompted the additional use of BMI 
as a covariate in all ANCOVAs (along with Age and Baseline measures, see Section 
5.2.3). However, likely due to BMI not being statistically different between groups, 
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BMI did not impact any of the outcome measures, and so is not presented as an 
included model for the outcome measures in Sections 5.3.3 through 5.3.7. 
 
Table 5.1 Baseline participant characteristics, exercise intervention intensity, and limb 
occlusion pressure (LOP) by group. 
 BFR-CYC CYC CON 
n 7 7 7 
Age (years) 54.0 ± 22.6 † 72.3 ± 5.4 74.1 ± 7.6 
Height (cm) 164.5 ± 10.1 170.6 ± 7.6 157.9 ± 4.6 
Body mass (kg) 68.4 ± 11.0 86.7 ± 16.0 † 64.3 ± 16.3 
Body mass index (BMI; kg.m-2) 26.3 ± 4.8 30.5 ± 7.0 26.1 ± 5.5 
Haemodialysis vintage (months) 31.2 ± 32.8 29.9 ± 24.7 69.4 ± 61.7 
LOP (mmHg) 214 ± 31 - - 
Training session LOP 
(50% LOP; mmHg) 107 ± 16 - - 
Resting HR (beats.min-1) 73.4 ± 11.4 68.0 ± 9.8 69.4 ± 9.1  
Resting SBP (mmHg) 136.7 ± 15.3 139.6 ± 10.7 140.7 ± 24.5 
Resting DBP (mmHg) 73.7 ± 16.1 ‡ 58.4 ± 7.5 64.7 ± 13.9 
Data are: mean ± standard deviation. ‡ indicates BFR-CYC significantly different to CYC (P < 0.05). 
† indicates significantly different to CON (P < 0.05). ABBREVIATIONS: LOP = Limb occlusion 
pressure; HR = Heart rate; SBP = Systolic blood pressure; DBP = Diastolic blood pressure; RPE = 
Rating of perceived exertion. 
5.3.1 Recruitment, adherence and attrition 
Across three study sites, with a maximum total capacity of 180 patients undergoing 
HD (excluding patients undergoing nocturnal HD), a total of 66 participants were 
identified by HD unit staff and nephrologists as prospective participants that met the 
inclusion criteria (see Section 3.3.3). All of these identified patients were approached 
and invited to take part, and 29 agreed to participate in the study. Of these participants, 
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one was subsequently deemed medically ineligible as per inclusion and exclusion 
criteria. Consent was provided by 28 prospective participants. Between providing 
consent and proposed pre-testing time, 7 participants became ineligible (2 changed HD 
unit, 1 received a kidney transplant, 1 developed pronounced chronic BP instability, 1 
had a fall at home resulting in fracture, 1 had gastrointestinal surgery, and 1 entered 
another conflicting research study). The remaining 21 participants underwent pre-
testing and were then randomised to BFR-CYC, CYC or CON. The 21 participants 
included in Study 2 represent 12% of the patients undergoing HD at the included study 
sites. 
Of the 21 participants who commenced the study protocol, one was lost to follow-up 
over the 12-week period (Figure 5.2). This participant, who was allocated to BFR-
CYC, died due to reasons unrelated to the study after completing 8 weeks of the study 
training programme. On average, participants in BFR-CYC completed 84% of all 
training sessions in full (30 ± 6 sessions). Comparatively, participants in CYC 
completed 72% of all training sessions in full (26 ± 10 sessions). While this was a 
notable difference, it was not a statistically significant difference between groups for 
total sessions completed [F(1,12) = 0.923, P = 0.356). 
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Figure 5.2 Flow chart of participants through the study (adapted from Clarkson et al. 
(347)) BFR-CYC – Blood flow restriction cycling group; CYC – Traditional cycling 
group; CON – Usual care control group; LOP – Limb occlusion pressure; 3RM-LE – 
Three-repetition Maximum Leg Extension; 6MWT – Six minute walk test; 30STS – 30-
second sit-to-stand test; TUG – Timed up and go; pQCT – Peripheral Quantitative 
Computed Tomography; DXA – Dual X-ray Absorptiometry; RPE – Rating of 
perceived exertion. 
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5.3.2 Training data 
5.3.2.1 Training heart rate 
A main effect for time was present for HR [F(35, 420) = 1.76, P = 0.006], whereby 
mean exercise HR among exercising participants, exclusive of exercise group 
decreased over the duration of the exercise training programme (Figure 5.3). There 
was no main effect for group [F(1,12) = 2.16, P = 0.167). However, there was a group 
by time interaction for HR [F(35, 420) = 1.50, P = 0.037], whereby the post hoc 
analysis showed HR to be significantly (P < 0.05) or nearly significantly (P < 0.08) 
higher for BFR-CYC for sessions at the start of the 12-week exercise training 
programme, while converging with CYC HR such that exercise HR was not 
significantly different by the end of the 12-week exercise training programme.  
 
Figure 5.3 Heart rate training data for 12 weeks blood flow restriction intradialytic 
cycling (BFR-CYC) and traditional cycling (CYC). # indicates main effect for time (P 
< 0.05). * indicates BFR-CYC diff to CYC (P < 0.05). ? indicates BFR-CYC nearing 
significant difference to CYC (P < 0.08) 
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5.3.2.2 Immediate post-training systolic blood pressure 
There was a main effect for time for SBP immediately post-exercise [F(35, 420) = 
1.86, P = 0.003], indicating that SBP changed across the course of the exercise training 
programme (Figure 5.4). However, there was no obvious pattern associated with the 
time course changes observed for SBP. There was no main effect for group [F(1,12) = 
0.29, P = 0.601] and no group by time interaction [F(35,420) = 0.94, P = 0.571]. 
 
 
Figure 5.4 Systolic blood pressure training data for 12 weeks blood flow restriction 
intradialytic cycling (BFR-CYC) and traditional cycling (CYC). # indicates main 
effect for time (P < 0.05). 
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5.3.2.3 Immediate post-training diastolic blood pressure 
There was no main effect for time for DBP immediately post-exercise [F(35,420) = 
1.30, P = 0.122]. A main effect for group between BFR-CYC and CYC existed across 
the duration of the exercise training programme for DBP [F(1, 12) = 5.07, P = 0.044] 
such that BFR-CYC recorded higher DBP than CYC (Figure 5.5). However, this 
difference was present throughout the exercise intervention and did not appear to 
change as a result of the exercise training programme. Moreover, there was no group 
by time interaction [F(35,420) = 0.75, P =0.851]. 
 
 
Figure 5.5 Diastolic blood pressure training data for 12 weeks blood flow restriction 
intradialytic cycling (BFR-CYC) and traditional cycling (CYC). ^ indicates a main 
effect for group between BFR-CYC and CYC (P < 0.05). 
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5.3.2.4 Training rating of perceived exertion 
There was a main effect for time for RPE [F(35, 420) = 1.47, P = 0.043]. Mean RPE, 
exclusive of group decreased slightly over the first half of the exercise training 
programme. This returned to baseline levels with the implementation of progression 
in the second half of the exercise training programme (Figure 5.6).  There was no main 
effect for group [F(1,12) = 1.41, P = 0.259], and no group by time interaction 
[F(35,420) = 0.621, P = 0.957]. Additionally, while RPE was within the targeted 
ranges for each group, there was no significant difference between BFR-CYC and 
CYC for mean training RPE. 
 
 
Figure 5.6 Rating of perceived exertion training data for 12 weeks blood flow 
restriction intradialytic cycling (BFR-CYC) and traditional cycling (CYC). # indicates 
main effect for time (P < 0.05). 
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5.3.2.5 Training rating of perceived discomfort 
Training RPD was only collected for BFR-CYC, hence there was no between group 
comparison (in response to Section 4.4), there was a main effect for time [F(35, 210) 
= 3.26, P = 0.000], whereby RPD decreased over the course of the study (Figure 5.7). 
For example, post hoc testing identified that after the first two weeks of training, RPD 
was significantly lower than baseline in 27 out of the 30 remaining sessions (P < 0.05). 
 
Figure 5.7 Rating of perceived discomfort training data for 12 weeks blood flow 
restriction intradialytic cycling (BFR-CYC) and traditional cycling (CYC). # indicates 
main effect for time (P < 0.001).  
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5.3.3 Muscle strength 
Baseline 3RM-LE was not significantly different between groups (P > 0.05) (Figure 
5.8). There was a main effect for time [F(1, 17) = 6.68, P = 0.019], indicating an 
increase in 3RM-LE from baseline to 12 weeks independent of group. There was no 
main effect for group [F(2,17) = 1.42, P = 0.269), although there was a significant 
group by time interaction [F(2, 17) = 8.43, P = 0.003] such that BFR-CYC significantly 
increased from baseline (25.6 ± 4.6 kg) to 12 weeks (30.4 ± 5.9 kg) (P = 0.001), while 
CYC (P = 0.086) and CON (P = 0.126) both remained unchanged from baseline to 12 
weeks. 
 
Figure 5.8 Three-repetition maximum leg extension strength at baseline and 12 weeks 
for blood flow restriction cycling (BFR-CYC), non-blood flow restriction cycling 
(CYC) and usual care controls (CON). Figures represent mean ± SEM. # indicates 
main effect for time from baseline to 12 weeks (P < 0.05); * indicates group different 
at 12 weeks compared with baseline (P < 0.01). 
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For the absolute change in leg-extension strength there was a main effect for group 
[F(2, 17) = 11.09, P = 0.001] (Figure 5.9). Post-hoc analysis showed that the absolute 
3RM-LE strength to increase for BFR-CYC (4.7 ± 3.9 kg) significantly greater than 
for CYC (1.4 ± 1.5 kg; P = 0.026), and both BFR-CYC and CYC significantly 
increased leg strength compared with CON (-1.7 ±1.6; P < 0.05). 
  
Figure 5.9 Absolute change in three-repetition maximum leg extension strength for 
blood flow restriction cycling (BFR-CYC), non-blood flow restriction cycling (CYC) 
and usual care controls (CON). Figure represents individual participant data points, 
lines indicate mean ± SD. † indicates BFR-CYC significantly different to both CYC 
and CON (P < 0.05). ‡ indicates significantly different to CON (P < 0.05). 
 
When adjusted for baseline strength, there was a significant difference between groups 
for the absolute change in 3RM-LE strength from baseline to 12 weeks [F(2,16) = 9.12, 
P = 0.002] (Table 5.2). Post hoc analyses indicated that absolute change in 3RM-LE 
strength was greater for both BFR-CYC and CYC compared with CON (P = 0.001, 
and P = 0.049, respectively). However, absolute change in 3RM-LE strength for BFR-
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CYC was also significantly greater than CYC (P = 0.033) in this model. The estimated 
marginal means demonstrate the magnitude of the adjusted absolute change in 3RM-
LE strength for BFR-CYC (4.6 ± 1.1 kg) compared with CYC (1.3 ± 1.0 kg) and CON 
(-1.6 ± 1.0 kg). Adjusting for age, there was still a significant difference between 
groups for 3RM-LE strength [F(2,16) = 5.76, P = 0.013]. Post hoc analyses showed 
that absolute change in 3RM-LE strength was greater for both BFR-CYC (4.7 ± 3.9 
kg, P = 0.006) and CYC (1.4 ± 1.5 kg, P = 0.027) compared with CON (-1.7 ± 1.5 kg). 
However, there was surprisingly no difference between BFR-CYC and CYC in this 
model. When adjusting for both age and baseline, there was also a significant 
difference between groups for the absolute change in 3RM-LE strength from baseline 
to 12 weeks [F(2,15) = 4.53, P = 0.029]. Post hoc analyses indicated that the adjusted 
absolute change in 3RM-LE strength was greater for both BFR-CYC (3.5 ± 1.2 kg, P 
= 0.012) and CYC (1.7 ± 1.0 kg, P = 0.046) compared with CON (-1.0 ± 1.0 kg) 
However, again there was no difference between BFR-CYC and CYC in this model. 
 
Table 5.2 Estimated marginal means for the absolute change in 3RM-LE (kg) by 
models of covariance adjusting for baseline (model 1), age (model 2) and both age and 
baseline (model 3). P-value indicates significance between groups for each adjusted 
model. 
3RM-LE estimated marginal means (kg) 
  BFR-CYC CYC CON P-Value 
Model 1 4.60 ± 1.04 † 1.34 ± 0.95 ‡ -1.59 ± 0.98 0.002 
Model 2 4.72 ± 3.86 ‡ 1.39 ± 1.54 ‡ -1.73 ± 1.53 0.013 
Model 3 3.50 ± 1.11 ‡ 1.73 ± 0.90 ‡ -1.03 ± 0.94 0.029 
Data are: mean ± SEM. † indicates BFR-CYC significantly different to both CYC and CON (P < 0.05). 
‡ indicates significantly different to CON (P < 0.05). ABBREVIATIONS: BFR-CYC = Blood flow 
restricted cycling group; CYC = traditional cycling group; CON = usual care control group; 3RM-LE = 
3-repetition maximum leg extension. 
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5.3.4 Physical function 
5.3.4.1 30 second sit-to-stand 
There was a main effect for time for 30STS [F(1,17) = 4.97, P = 0.022], indicating 
improvement over the 12-week programme (Figure 5.10). There was also a main effect 
for group for 30STS [F(2,17) = 3.64, P = 0.048], indicating that the repetitions for 
30STS were greater for BFR-CYC compared with both CYC and CON (P < 0.05). 
Additionally, there was a group by time interaction for 30STS [F(2,17) = 5.21, P = 
0.017]. Post hoc analyses identified that there were no baseline differences between 
groups for 30STS. BFR-CYC significantly increased repetitions on 30STS (by 2 ± 1 
repetitions; P = 0.001) compared with CYC and CON from baseline to 12 weeks, while 
there was no difference between CYC and CON and neither significantly increased 
performance. 
 
Figure 5.10 30 Second sit-to-stand at baseline and 12 weeks following blood flow 
restriction cycling (BFR-CYC), non-blood flow restriction cycling (CYC) and usual 
care (CON). Figures represent mean ± SEM. # indicates main effect for time from 
baseline to 12 weeks (P < 0.05); * indicates group different at 12 weeks compared with 
baseline (P < 0.05). † indicates BFR-CYC significantly different to both CYC and 
CON (P < 0.05). 
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For the absolute change there was a main effect for group [F(2,17) = 4.89, P = 0.021]. 
BFR-CYC increased repetitions on 30STS (2 ± 1.4) by a significantly larger amount 
than both CYC (-0.1 ± 1.2; P = 0.01) and CON (0.1 ± 1.3; P = 0.022), while there was 
no difference between CYC and CON (Figure 5.11). 
 
Figure 5.11 Absolute change in 30 second sit to stand following 12 weeks blood flow 
restriction cycling (BFR-CYC), non-blood flow restriction cycling (CYC) and usual 
care (CON). Figures represent individual participant data points, lines indicate mean 
± SD. † indicates BFR-CYC significantly different to both CYC and CON (P < 0.05). 
 
When adjusted for baseline, the absolute change in 30STS from baseline to 12 weeks 
was significantly different between groups [F(2,16) = 4.96, P = 0.021] (Table 5.3). 
Post hoc analyses identified significant differences between BFR-CYC and both CYC 
(P = 0.009) and CON (P = 0.018) When comparing the estimated marginal means, the 
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magnitude of the adjusted change in 30STS repetitions for BFR-CYC was 2.20 ± 0.63 
repetitions, compared with no change in CYC or CON. However, adjusting for age 
alone showed only near significant difference between groups [F(2,16) = 3.38, P = 
0.060]. Although, when adjusted for both age and baseline, there was again a 
significant difference for the absolute change in 30STS between groups [F(2,15) = 
3.52, P = 0.049]. 
 
Table 5.3 Estimated marginal means for the absolute change in 30-second sit to stand 
by models of covariance adjusting for baseline (model 1), age (model 2), and both age 
and baseline (model 3). P-value indicates significance between groups for each 
adjusted model. 
30-second sit to stand estimated marginal means 
  BFR-CYC CYC CON P-Value 
a) 30STS         
Model 1 2.20 ± 0.59 † -0.21 ± 0.51 0.04 ± 0.52 0.021 
Model 2 2.06 ± 0.65 -0.16 ± 0.53 0.11 ± 0.54 0.060 
Model 3 2.14 ± 0.67 † -0.18 ± 0.53 0.09 ± 0.54 0.049 
Data are: mean ± SEM. † indicates BFR-CYC significantly different to both CYC and CON (P < 0.05). 
ABBREVIATIONS: BFR-CYC = Blood flow restricted cycling group; CYC = traditional cycling 
group; CON = usual care control group; 30STS = 30 second sit-to-stand. 
 
5.3.4.2 Six-minute walk test 
There was a main effect for time for 6MWT [F(1,17) = 3.76, P = 0.002], indicating 
improvement over the 12 weeks (Figure 5.12). There was a main effect for group for 
6MWT [F(2,17) = 9.29, P = 0.002], whereby BFR-CYC walked a significantly greater 
distance than CYC (P = 0.013) and CON (P = 0.002). There was also a group by time 
interaction for 6MWT [F(2,17) = 3.76, P = 0.044]. Post hoc analyses identified that 
BFR-CYC significantly increased distance walked during 6MWT (by 51 ± 14 m; P = 
0.002) from baseline to 12 weeks. CYC also significantly increased distance walked 
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during 6MWT (by 33 ± 13 m; P = 0.023), while CON did not. However, baseline 
differences were also observed for 6MWT whereby BFR-CYC covered more distance 
in 6MWT during pre-testing than both CYC and CON (P < 0.05). 
 
 
Figure 5.12 Six-minute walk test at baseline and 12 weeks following blood flow 
restriction cycling (BFR-CYC), non-blood flow restriction cycling (CYC) and usual 
care (CON). Figures represent mean ± SEM. # indicates main effect for time from 
baseline to 12 weeks (P < 0.05); * indicates group different at 12 weeks compared with 
baseline (P < 0.05). † indicates BFR-CYC significantly different to both CYC and 
CON (P < 0.05). 
 
For the absolute change in 6MWT, there was no significant difference between groups, 
although this was close to significant [F(2,17) = 3.325, P = 0.060], and post hoc testing 
suggested a difference between BFR-CYC and CON (P = 0.022) (Figure 5.13). When 
adjusted for baseline, there was also no difference between groups in absolute change 
for 6MWT from baseline to 12 weeks [F(2,16) = 1.94, P = 0.176] (Table 5.4). 
Similarly, when adjusting for age alone there was no difference between groups 
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[F(2,16) = 2.78, P = 0.092]. When adjusted for both age and baseline, there was still 
no significance for the absolute change in 6MWT [F(2,15) = 1.91, P = 0.183]. 
 
Figure 5.13 Absolute change in six-minute walk test following 12 weeks blood flow 
restriction cycling (BFR-CYC), non-blood flow restriction cycling (CYC) and usual 
care (CON). Figures represent individual participant data points, lines indicate mean 
± SD. ‡ indicates significantly different to CON (P < 0.05). 
 
 
Table 5.4 Estimated marginal means for the absolute change in six-minute walk test 
by models of covariance adjusting for baseline (model 1), age (model 2), and both age 
and baseline (model 3). P-value indicates significance between groups for each 
adjusted model. 
Six-minute walk test estimated marginal means 
  BFR-CYC CYC CON P-Value 
b) 6MWT         
Model 1 49.35 ± 18.57 33.07 ± 13.92 2.63 ± 14.84 0.176 
Model 2 53.30 ± 16.82 31.71 ± 13.75 0.61 ± 14.06 0.092 
Model 3 51.07 ± 19.59 32.36 ± 14.42 1.86 ± 15.38 0.183 
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Data are: mean ± SEM. † indicates BFR-CYC significantly different to both CYC and CON (P < 0.05). 
ABBREVIATIONS: BFR-CYC = Blood flow restricted cycling group; CYC = traditional cycling 
group; CON = usual care control group; 6MWT = Six-minute walk test. 
 
5.3.4.3 Timed up and go 
Baseline differences were observed for TUG (Figure 5.14) whereby BFR-CYC 
completed TUG quicker than both CYC and CON (P < 0.05). However, there was no 
main effect for time for TUG [F(1,17) = 3.52, P = 0.078]. There was a main effect for 
group for and TUG [F(2,17) = 5.03, P = 0.019]. Post hoc analyses indicated that BFR-
CYC completed TUG quicker compared with both CYC (P = 0.049) and CON (P = 
0.021), while there was no difference between CYC and CON (P = 0.841). There was 
no group by time interaction for TUG [F(2,17) = 0.78, P = 0.473].  
 
Figure 5.14 Timed up and go at baseline and 12 weeks following blood flow 
restriction cycling (BFR-CYC), non-blood flow restriction cycling (CYC) and usual 
care (CON). Figures represent mean ± SEM. # indicates main effect for time from 
baseline to 12 weeks (P < 0.05); † indicates BFR-CYC significantly different to both 
CYC and CON (P < 0.05). 
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When analysing the absolute change, there was no significant difference between 
groups [F(2,17) = 0.78, P = 0.473] (Figure 5.15). After adjusting for baseline, there 
was no difference between groups [F(2,16) = 0.72, P = 0.501]. Likewise, when 
adjusting for age, there was also no difference [F(2,16) = 0.84, P = 0.449]. Finally, 
when adjusted for both age and baseline, there was no significance for the absolute 
change in TUG [F(2,15) = 0.76, P = 0.487] (Table 5.5). 
 
Figure 5.15 Absolute change in timed up and go following 12 weeks blood flow 
restriction cycling (BFR-CYC), non-blood flow restriction cycling (CYC) and usual 
care (CON). Figures represent individual participant data points, lines indicate mean 
± SD. 
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Table 5.5 Estimated marginal means for the absolute change in timed up and go by 
models of covariance adjusting for baseline (model 1), age (model 2), and both age 
and baseline (model 3). P-value indicates significance between groups for each 
adjusted model. 
Timed up and go estimated marginal means 
  BFR-CYC CYC CON P-Value 
c) TUG         
Model 1 -0.85 ± 0.45 -0.19 ± 0.37 -0.15 ± 0.38 0.501 
Model 2 -0.89 ± 0.45 -0.16 ± 0.37 -0.14 ± 0.38 0.449 
Model 3 -0.90 ± 0.49 -0.16 ± 0.38 -0.13 ± 0.40 0.487 
Data are: mean ± SEM. † indicates BFR-CYC significantly different to both CYC and CON (P < 0.05). 
ABBREVIATIONS: BFR-CYC = Blood flow restricted cycling group; CYC = traditional cycling 
group; CON = usual care control group; TUG = Timed up and go. 
 
5.3.5 Muscle size and body composition 
5.3.5.1 Muscle size 
Data provided by pQCT and DXA was more extensive than the data presented below. 
The following tables outlining muscle CSA and body composition display only 
relevant measures likely to be affected in the present study (Table 5.6 and Table 5.7). 
However, this was only conducted on participants who elected to complete these scans, 
resulting in a reduced number of participants for the analyses of these secondary 
outcome measures. For tables displaying the complete range of outcomes measured by 
the pQCT and DXA, please see Appendix C and Appendix D, respectively. 
Baseline, within- and between-group values and changes in muscle CSA and muscle 
density are shown in Table 5.6. At baseline, bilateral 25% femur muscle CSA was 
significantly higher for CYC than for both BFR-CYC and CON (P < 0.05). At 12 
weeks, 25% left femur muscle CSA was significantly reduced from baseline in BFR-
CYC (P < 0.05). Participants in CYC increased 25% left femur muscle CSA, and 
164 
percentage of total CSA that was muscle (both P < 0.05). No other significant within-
group changes were observed. There was a significant between-group net difference 
for 25% left femur muscle CSA percentage of 2.0 ± 0.7% between the decrease 
observed in BFR-CYC and the increase observed in CYC (P = 0.002).   
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Table 5.6. Mean baseline and 12 weeks pQCT results for muscle cross-sectional area (CSA) and muscle density, within-group changes 
relative to baseline and between-group net differences for the change after 12 weeks blood flow restriction cycling (BFR-CYC), traditional 
cycling (CYC) or usual care HD (CON). 
 Baseline values and within group changes  
 BFR-CYC CYC CON   Between-group effects 
 n Mean ± SD Mean (95% CI) n 
Mean ± SD 
Mean (95% CI) n 
Mean ± SD 
Mean (95% CI) 
Net diff, BFR-CYC v CYC 
(95% CI) 
25% right femur muscle CSA (cm2) 
     Baseline 6 55.3 ± 6.5 4 76.5 ± 37.3 † 2 58.3 ± 7.6 
0.5 (-1.2, 2.1) 12-week 4 58.3 ± 7.6 4 77.1 ± 37.7 † 1 54.9 ± 0.0 
     ∆ 12-week 4 1.1 (-0.3, 2.6) 4 0.6 (-0.1, 1.4) 1 - 
25% right femur muscle CSA (%) 
     Baseline 6 51.3 ± 13.4 4 51.2 ± 15.6 2 48.1 ± 2.1 
-0.3 (-1.8, 1.1) 12-week 4 51.1 ± 13.1 4 51.3 ± 15.2 1 46.9 ± 0.0 
     ∆ 12-week 4 -0.2 (-1.1, 0.7) 4 0.1 (-1.0, 1.3) 1 - 
25% left femur muscle CSA (cm2)  
     Baseline 6 55.1 ± 7.9 4 73.0 ± 32.9 † 2 53.3 ± 4.6 
-1.7 (-4.1, 0.7) 12-week 5 55.3 ± 9.3 4 74.9 ± 34.9 † 1 51.5 ± 0.0 
     ∆ 12-week 5 0.2 (-1.5, 1.9) 4 1.9 (0.2, 3.7) # 1 - 
25% left femur muscle CSA (%) 
     Baseline 6 50.9 ± 13.6 4 50.3 ± 14.8 2 46.0 ± 4.1 
-2.0 (-3.3, -0.7) ^ 12-week 5 50.0 ± 15.2 4 51.4 ± 15.6 1 43.4 ± 0.0 
     ∆ 12-week 5 -0.9 (-1.8, -0.1) # 4 1.1 (0.1, 2.0) # 1 - 
50% right femur muscle CSA (cm2) 
     Baseline 6 96.8 ± 11.7 3 104.6 ± 49.9 2 97.0 ± 4.3 
0.9 (-1.9, 3.9) 12-week 5 98.2 ± 8.7 3 105.2 ± 50.6 1 94.1 ± 0.0 
     ∆ 12-week 5 1.4 (-0.7, 3.6) 3 0.5 (-0.5, 1.6) 1 - 
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50% right femur muscle CSA (%) 
     Baseline 6 60.8 ± 14.8 3 58.3 ± 17.2 2 63.7 ± 4.6 
0.1 (-1.9, 2.0) 12-week 5 60.6 ± 15.5 3 58.0 ± 17.3 1 60.2 ± 0.0 
     ∆ 12-week 5 -0.2 (-1.4, 1.1) 3 -0.3 (-1.7, 1.1) 1 - 
50% left femur muscle CSA (cm2) 
     Baseline 6 92.6 ± 12.4 3 99.1 ± 43.7 2 95.1 ± 11.2 
0.2 (-5.3, 6.1) 12-week 5 94.4 ± 16.3 3 100.7 ± 44.0 1 89.8 ± 0.0 
     ∆ 12-week 5 1.8 (-2.5, 6.1) 3 1.6 (-0.0, 3.2) 1 - 
50% left femur muscle CSA (%) 
     Baseline 6 58.3 ± 15.4 3 57.5 ± 16.3 2 62.0 ± 8.1 
-0.5 (-2.5, 1.6) 12-week 5 57.7 ± 18.1 3 57.4 ± 15.9 1 56.7 ± 0.0 
     ∆ 12-week 5 -0.6 (-2.1, 1.0) 3 -0.1 (-0.6, 0.3) 1 - 
Data are: baseline unadjusted mean ± standard deviation (SD); within-group unadjusted mean absolute change with 95% confidence interval (CI); net difference 
(95% CI) were calculated by subtracting unadjusted within-group absolute changes from baseline to follow-up. # indicates significant change from baseline to 12 
weeks (P < 0.05). ^ indicates significant main effect for group (between BFR-CYC and CYC; P < 0.01). † indicates CYC was significantly different to both BFR-
CYC and CON. ABBREVIATIONS: BFR-CYC = Blood flow restricted cycling group; CYC = traditional cycling group; CON = usual care control group; CSA = 
cross-sectional area.
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5.3.5.2 Body composition 
Baseline, within- and between-group values and changes in lean mass and fat mass are 
shown in Table 5.7. At 12 weeks, BFR-CYC participants increased total body fat mass 
by 1.0 ± 0.2kg (P < 0.001), percentage total body fat mass by 0.8 ± 0.2% (P < 0.001), 
and small but significant increases in leg, trunk, android, and gynoid fat mass (P < 
0.05). Similarly, at 12 weeks CYC showed increased total body fat mass 0.6 ± 0.2kg 
(P = 0.017) as well as trunk and abdominal subcutaneous fat mass (P < 0.001). There 
were no other significant within-group changes. There were no significant between 
group differences.  
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Table 5.7. Mean baseline and 12 weeks DXA results for body composition, within-group changes relative to baseline and between-group 
net differences for the change after 12 weeks blood flow restriction cycling (BFR-CYC), traditional cycling (CYC) or usual care HD 
(CON). 
 Baseline values and within group changes  
 BFR-CYC CYC CON Between-group effects 
 n Mean ± SD Mean (95% CI) n 
Mean ± SD 
Mean (95% CI) n 
Mean ± SD 
Mean (95% CI) 
Net diff, BFR-CYC v CYC 
(95% CI) 
Total body lean mass (kg) 
Baseline 7 42.5 ± 3.7 4 50.1 ± 12.1 2 43.4 ± 2.9 
0.4 (-0.7, 1.5) 12 weeks 5 43.1 ± 4.4 4 50.3 ± 11.9 1 46.6 ± 0.0 
     ∆ 12-week 5 0.6 (-0.2, 1.3) 4 0.2 (-0.6, 1.0) 1 - 
Appendicular lean mass (kg) 
Baseline 7 18.3 ± 1.6 4 22.7 ± 6.8 2 19.0 ± 1.4 
0.4 (-0.3, 1.1) 12 weeks 5 18.6 ± 1.8 4 22.6 ± 6.8 1 20.1 ± 0.0 
     ∆ 12-week 5 0.3 (-0.1, 0.7) 4 -0.1 (-0.7, 0.5) 1 - 
Leg lean mass (kg) 
Baseline 7 13.7 ± 1.2 4 16.7 ± 4.6 2 14.1 ± 1.5 
0.1 (-0.5, 0.8) 12 weeks 5 13.6 ± 0.9 4 16.8 ± 4.7 1 15.3 ± 0.0 
     ∆ 12-week 5 0.1 (-0.2, 0.5) 4 0.0 (-0.6, 0.6) 1 - 
Total body fat mass (kg) 
Baseline 7 25.9 ± 11.7 4 33.8 ± 9.0 2 29.5 ± 5.9 
0.4 (-0.2, 1.1) 12 weeks 5 26.9 ± 12.3 4 34.4 ± 8.5 1 34.4 ± 0.0 
     ∆ 12-week 5 1.0 (0.6, 1.4) * 4 0.6 (0.1, 1.0) * 1 - 
Total body fat mass (%) 
Baseline 7 35.1 ± 12.6 4 38.9 ± 2.0 2 39.2 ± 3.2 
0.4 (-0.1, 0.9) 12 weeks 5 35.9 ± 14.3 4 39.3 ± 1.8 1 41.3 ± 0.0 
     ∆ 12-week 5 0.8 (0.5, 1.1) * 4 0.4 (-0.1, 0.9) 1 - 
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Leg fat mass (kg) 
Baseline 7 6.6 ± 3.0 4 8.3 ± 1.6 2 6.6 ± 1.5 
-0.1 (-0.4, 0.3) 12 weeks 5 6.7 ± 2.8 4 8.5 ± 1.4 1 7.7 ± 0.0 
     ∆ 12-week 5 0.1 (0.0, 0.2) * 4 0.2 (-0.2, 0.6) 1 - 
Trunk fat mass (kg) 
Baseline 7 15.6 ± 8.3 4 20.9 ± 8.3 2 19.4 ± 3.5 
0.1 (-0.2, 0.5) 12 weeks 5 16.2 ± 8.2 4 21.4 ± 8.0 1 22.1 ± 0.0 
     ∆ 12-week 5 0.6 (0.4, 0.9) * 4 0.5 (0.2, 0.7) * 1 - 
Android fat mass (kg) 
Baseline 7 2.8 ± 1.7 4 3.9 ± 1.8 2 3.9 ± 1.1 
0.2 (-0.0, 0,3) 12 weeks 5 3.0 ± 1.7 4 3.9 ± 1.8 1 4.7 ± 0.0 
     ∆ 12-week 5 0.2 (0.1, 0.3) * 4 0.0 (-0.0, 0.1) 1 - 
Gynoid fat mass (kg) 
Baseline 7 3.6 ± 1.7 4 4.5 ± 1.1 2 3.9 ± 0.9 0.2 (-0.0, 0.3) 
12 weeks 5 3.7 ± 1.6 4 4.4 ± 0.9 1 4.7 ± 0.0 
 
     ∆ 12-week 5 0.1 (0.0, 0.1) * 4 -0.1 (-0.3, 0.1) 1 - 
Abdominal visceral fat mass (kg) 
Baseline 7 1.6 ± 1.4 4 2.9 ± 2.3 2 2.7 ± 5.7 
0.2 (-0.2, 0.4) 12 weeks 5 1.7 ± 1.4 4 2.9 ± 2.3 1 2.7 ± 0.0 
     ∆ 12-week 5 0.1 (-0.2, 0.3) 4 -0.1 (-0.1, 0.0) 1 - 
Abdominal subcutaneous fat mass (kg) 
Baseline 7 1.1 ± 0.8 4 1.0 ± 0.8 2 1.2 ± 1.1 
0.0 (-0.2, 0.2) 12 weeks 5 1.2 ± 0.6 4 1.1 ± 0.9 1 2.1 ± 0.0 
     ∆ 12-week 5 0.1 (-0.1, 0.3) 4 0.1 (0.0, 0.2)* 1 -  
Data are: baseline unadjusted mean ± standard deviation (SD); within-group unadjusted mean absolute change with 95% confidence interval (CI); net difference 
(95% CI) were calculated by subtracting unadjusted within-group absolute changes from baseline to follow-up. * indicates significant change from baseline to 12 
weeks (P < 0.05). ABBREVIATIONS: BFR-CYC = Blood flow restricted cycling group; CYC = traditional cycling group; CON = usual care control group.
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5.3.6 Physical activity behaviour 
There was a main effect for time for WEE [F(1,16) = 13.84, P = 0.002], indicating an 
increase in physical activity behaviour at the conclusion of the 12-week training 
programme (Figure 5.16). There was also a main effect for group [F(2,16) = 5.92, P = 
0.012] with BFR-CYC reporting significantly higher WEE than CYC and CON (both 
P < 0.05), but no difference between CYC and CON (P = 0.205). Moreover, there was 
a group by time interaction [F(2,16) = 7.36, P = 0.005], indicating that group had an 
effect on the magnitude of the difference in WEE exclusive of study-related exercise 
after 12 weeks. Post hoc analyses identified that WEE significantly increased for BFR-
CYC (P < 0.001) and CYC (P = 0.046) but not for CON (P = 0.546). However, there 
was also a baseline difference between BFR-CYC and CON for WEE (P = 0.013), but 
no other between group differences at baseline. 
 
Figure 5.16 Physical activity behaviour at baseline and 12 weeks for blood flow 
restriction cycling (BFR-CYC), non-blood flow restriction cycling (CYC) and usual 
care controls (CON). Figures represent mean ± SEM. # indicates main effect for time 
from baseline to 12 weeks (P < 0.05); * indicates group different at 12 weeks compared 
with baseline (P < 0.01). † indicates BFR-CYC significantly different to both CYC 
and CON (P < 0.05). ‡ indicates significantly different to CON (P < 0.05). 
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Analysis of the absolute change in WEE from baseline to 12 weeks showed a main 
effect for group [F(2,16) = 4.94, P = 0.021] (Figure 5.17). Post hoc analyses indicated 
that the absolute change in WEE was greater for BFR-CYC compared with CON (P = 
0.006) but not CYC (P = 0.083), as well as no difference between CYC and CON (P 
= 0.176).  
 
Figure 5.17 Absolute change in physical activity behaviour (as weekly energy 
expenditure) following 12 weeks blood flow restriction cycling (BFR-CYC), non-
blood flow restriction cycling (CYC) and usual care controls (CON). Figure represents 
individual participant data points, lines indicate mean ± SD. ‡ indicates significantly 
different to CON (P < 0.05). 
 
When controlling for either baseline WEE, there was no significant effect by group for 
absolute change in WEE between baseline and 12 weeks [F(2,15) = 1.22, P = 0.323]. 
This was also the case when adjusting for age individually [F(2,16) = 3.22, P = 0.067]. 
Likewise, after controlling for both baseline WEE and age together, there was no 
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significant effect by group for absolute change in WEE at 12 weeks [F(2,14) = 1.71, P 
= 0.216]. 
 
5.3.7 Symptom-related quality of life 
There was a main effect for time for POS-S renal score [F(1,17) = 6.03, P = 0.025], 
although there was no main effect for group [F(2,17) = 2.67, P = 0.098] (Figure 5.18). 
Additionally, there was a group by time interaction [F(2,17) = 4.43, P = 0.028] 
whereby POS-S renal scores were decreased at 12 weeks for both BFR-CYC (P = 
0.027) and CYC (P = 0.014). No significant differences were present at baseline for 
scores on the POS-S renal questionnaire. BFR-CYC was significantly lower than CON 
at 12 weeks (P = 0.031) with no other differences between groups at 12 weeks.  
 
Figure 5.18 Symptom-related quality of life at baseline and 12 weeks for blood flow 
restriction cycling (BFR-CYC), non-blood flow restriction cycling (CYC) and usual 
care controls (CON). Figures represent mean ± SEM. # indicates main effect for time 
from baseline to 12 weeks (P < 0.05); * indicates group different at 12 weeks compared 
with baseline (P < 0.01). ‡ indicates significantly different to CON (P < 0.05). 
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Analysis of the absolute change in POS-S renal scores showed a main effect for group 
[F(2,17) = 4.43, P = 0.028] (Figure 5.19). Post hoc analyses indicated that the absolute 
change in POS-S renal scores was significantly greater for both BFR-CYC and CYC 
than CON (P < 0.05). There was no difference between BFR-CYC and CYC (P = 
0.933) for the absolute change in POS-S renal scores. 
 
Figure 5.19 Absolute change in symptom-related quality of life following 12 weeks 
blood flow restriction cycling (BFR-CYC), non-blood flow restriction cycling (CYC) 
and usual care controls (CON). Figure represents individual participant data points, 
lines indicate mean ± SD. ‡ indicates significantly different to CON (P < 0.05).  
 
After adjusting for baseline score, there was a significant effect by group for absolute 
change in POS-S renal scores at 12 weeks [F(2,16) = 4.93, P = 0.022] (Table 5.8). Post 
hoc analyses showed there was a significant difference between BFR-CYC and CON 
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(P = 0.015), as well as between CYC and CON (P = 0.023). Comparing the estimated 
marginal means showed that the largest adjusted decrease in POS-S renal score 
occurred following BFR-CYC (-1.79 ± 0.70) compared to CYC and CON (-1.39 ± 
0.62 and 0.64 ± 0.60, respectively). Similarly, when adjusting for age, there was a 
significant effect by group for absolute change in POS-S renal scores at 12 weeks 
[F(2,16) = 4.65, P = 0.026]. Post hoc analyses showed a significant difference between 
BFR-CYC and CON (P = 0.024), as well as between CYC and CON (P = 0.017). 
Comparing the estimated marginal means showed that the largest adjusted decrease in 
POS-S renal score occurred following BFR-CYC (-1.80 ± 0.73) compared to CYC and 
CON (-1.46 ± 0.59 and 0.72 ± 0.61, respectively). Significance remained after also 
adjusting for both age and baseline POS-S renal score [F(2,15) = 4.43, P = 0.031]. Post 
hoc analyses in this model showed a significant difference between BFR-CYC and 
CON (P = 0.023), as well as between CYC and CON (P = 0.026). Comparing the 
estimated marginal means for this model showed that the largest adjusted decrease in 
POS-S renal score occurred following BFR-CYC (-1.90 ± 0.79) compared with CYC 
and CON (-1.36 ± 0.65 and 0.70 ± 0.65, respectively).  
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Table 5.8 Estimated marginal means for the absolute change in symptom-related 
quality of life by models of covariance adjusting for baseline (model 1), age (model 
2), and both age and baseline (model 3). P-value indicates significance between groups 
for each adjusted model. 
POS-S renal estimated marginal means 
  BFR-CYC CYC CON P-Value 
Model 1 -1.79 ± 0.66 † -1.39 ± 0.59 ‡ 0.64 ± 0.57 0.022 
Model 2 -1.80 ± 0.73 ‡ -1.46 ± 0.59 ‡ 0.72 ± 0.61 0.026 
Model 3 -1.90 ± 0.74 ‡ -1.36 ± 0.61 ‡ 0.70 ± 0.61 0.031 
Data are: mean ± SEM. † indicates BFR-CYC significantly different to both CYC and CON (P < 0.05). 
‡ indicates significantly different to CON (P < 0.05). ABBREVIATIONS: BFR-CYC = Blood flow 
restricted cycling group; CYC = traditional cycling group; CON = usual care control group; POS-S 
renal = Patient outcome scale – symptoms of renal failure questionnaire. 
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5.4 Discussion 
The major finding of the present study was an apparent increase in leg strength 
following the 12-week exercise training programme for BFR-AT (cycling) when 
compared with traditional AT (cycling) and usual care HD. In addition, some aspects 
of physical function improved more following BFR-AT (cycling) with an observed 
improvement in 30STS and 6MWT, whereas traditional AT (cycling) increased 
performance of 6MWT only. However, adjusting for age and baseline showed 
significant improvements for only 30STS following BFR-AT, with no improvements 
in physical function observed following traditional AT (cycling). Usual care controls 
did not change from baseline for any measure of physical function. Changes in body 
composition and muscle size were modest and inconsistent, showing within-group 
discrepancies in muscle size between legs. Between group effects were observed for 
both physical activity behaviour and subjective symptom-related quality of life with 
both BFR-AT (cycling) and traditional AT (cycling) producing a patient-reported 
increase in WEE and feeling less adverse effects from HD-related symptoms at 12 
weeks compared with usual care controls. The pedals used in the present study (see 
Section 5.2.1) also increased the applicability of findings from the present study as the 
pedal sets are easily accessed by HD units. 
In the present study, muscle strength improved as a result of 12 weeks BFR-AT 
(cycling)more so than traditional AT (cycling) or with usual care HD. As a technique, 
BFR has most commonly been attributed with enhancing muscle strength beyond that 
achieved with non-BFR equivalent-intensity exercise, and that is supported by the 
results of the present study (290, 291). That this has been achieved with BFR-AT while 
avoiding the mechanical and haemodynamic stresses associated with RT is important 
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to populations such as patients undergoing HD (261). Relative to baseline values, the 
absolute increase in leg extension strength observed for BFR-CYC in the present study 
(15.9 ± 5%) was also comparable to the 8.7-21.8% reported by other studies following 
BFR-AT in older adults (273-275, 279, 280). While a significant increase in leg strength was 
also observed for CYC when compared to CON, the absolute change in leg strength 
from baseline to 12 weeks for BFR-CYC (4.7 ± 1.6 kg) was more than two-fold that 
of CYC (1.4 ± 1.5kg). This significance remained after adjusting for baseline. 
Moreover, after adjusting for age alone, as well as adjusting for both age and baseline 
combined also retained a significant difference between absolute strength increases for 
BFR-CYC compared with CYC. While adjusting for the difference in mean age 
between groups may have reduced the magnitude of the between group effect, this may 
be explained by the strength data having been affected by two comparatively young 
participants in the present study who were both randomly allocated to BFR-CYC. 
Previously, increases in muscle strength following BFR exercise training have 
generally been lower among young people (7.1-10.7%) (38, 39). However, in the present 
study the young participants achieved greater increases in strength albeit with a small 
sample (n = 2; 7.2 ± 4.5 kg, equivalent to a 27% increase in leg strength). This may be 
characteristic of patients undergoing HD, possibly due to the progressive decline in 
physical conditioning associated with the age-related progression of ESKD. 
The measures of physical function used in the present study were indicative of a range 
of different physiological attributes. The 30STS strongly correlates with lower 
extremity muscle strength (166, 327). Therefore, it is not surprising that there was 
significant improvement in BFR-CYC parallel to improvements in muscle strength. In 
contrast, there was no improvement observed for either CYC or CON, again reflecting 
the outcomes of 3RM-LE in the present study. Additionally, when examining the 
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absolute change in 30STS there was also a significant difference between BFR-CYC 
and both other groups, further highlighting the magnitude of the observed differences. 
That this was still evident when adjusting for baseline values and the combination of 
both age and baseline adds weight to this finding. Although, a loss of significance 
when adjusting for age alone suggests that low sample size and homogeneity of 
participants was a limitation for these analyses. Several studies have demonstrated 
improvements in multiple sit-to-stand tasks following exercise training among patients 
undergoing HD (45, 90, 205, 209, 227, 230, 233, 234). However, only two of these utilised solely 
intradialytic AT, and both were of equal or longer duration to that used in the present 
study (45, 90). The magnitude of 30STS improvement for BFR-CYC in the present study 
was also similar to that observed previously following BFR-AT in older adults (41). 
This study among older adults also suggested that an improvement in 30STS would 
reflect an improvement in muscle strength (41). However, unlike the present study, there 
was no direct measure of muscle strength for comparison. The parallels in 3RM-LE 
and 30STS in the present study further suggest that the observed improvement in 
30STS for BFR-CYC is likely explained by significant muscle strength improvements 
compared with both CYC and CON. 
Baseline differences for the other two measures of physical function, 6MWT and TUG, 
made it difficult to draw conclusions from the results of these measures. Moreover, 
that these measures were notably underpowered (see Section 5.2.2) further increases 
the difficulty with generalising these results. This lack of generalisability was 
compounded by there being no difference between groups for the absolute changes 
from baseline to 12 weeks in both 6MWT and TUG, as well as no significant difference 
between groups when adjusting for baseline and age. Before the adjustment for age or 
baseline, both BFR-CYC and CYC appeared to improve performance on the 6MWT. 
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This was notable given that 6MWT is indicative of exercise capacity, known to 
improve with AT (118, 327, 330, 331). Given that both BFR-CYC and CYC utilised AT as a 
modality, improvement on the 6MWT would suggest that despite the low-to-moderate 
intensity, the exercise training in the present study may have been sufficient to improve 
functional exercise capacity, and potentially more so with the addition of BFR. Again, 
this would support findings from a previous study examining physical function 
following BFR-AT among older adults, whereby 6MWT improved to a greater extent 
following 6 weeks walking training with BFR (41). Although, in that same study, TUG 
also improved following walking training with BFR, beyond that of non-BFR walking 
training (41). In contrast to those results, TUG in the present study did not show any 
significance between groups or over time compared with usual care inactive controls 
(besides baseline differences between groups). One primary difference in 
methodologies in the present study was the use of BFR-AT (cycling) instead of BFR 
walking used in the earlier study. The timed up and go is a measure of dynamic balance 
and mobility and, therefore, benefits would seem more likely from exercises that 
incorporate both balance and similar mobility, such as walking (170, 172, 329). In the 
present study, semi-recumbent cycling from a reclining chair provided no direct 
challenge to balance and involved reduced hip range of motion compared with 
walking. This may have helped to explain the lack of any significant change for the 
TUG in the present study.  
Conclusions regarding muscle size and body composition findings in the present study 
were limited with regard to both interpretation and generalisability. The overall sample 
size of the study was already small and given that the scans required to examine muscle 
size and body composition were an optional component for participants, the sample 
for these outcomes was even smaller (n = 10). In fact, with only one participant in 
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CON completing both time points for these measures, it was not possible to compare 
BFR-CYC and CYC to CON. From the data available, BFR-CYC showed a decrease 
in muscle CSA at 25% of femur length for the left leg, compared with an increase in 
CYC. However, a significant baseline difference for bilateral 25% femur length 
muscle CSA between BFR-CYC and CYC made elucidating any meaningful result 
difficult with regard to CSA. The DXA measures of body composition showed both 
absolute and percentage total body fat mass increased for BFR-CYC, as well as leg, 
trunk, android and gynoid fat mass, which indicated overall fat mass gains in BFR-
CYC. Those in CYC increased absolute total body fat mass, trunk fat mass, and 
abdominal subcutaneous fat mass. Diet and other factors that may have contributed to 
increases in fat mass were not controlled for in this study, so it was likely that 
extraneous variables may have contributed to fat mass increases seen for both 
exercising groups, but to a greater extent for BFR-CYC. Likewise, dietary factors such 
as the required low-protein diets for patients undergoing HD may have impacted 
muscle mass, as a net positive protein gain is required for building muscle mass (219). 
Interestingly, the apparent lack of change in muscle size observed among these limited 
results (or the slight decrease in thigh muscle CSA for the left leg only) following 
BFR-AT (cycling) were in contrast to the expected findings given the increase seen in 
3RM-LE strength in the present study. However, increases in muscle mass are 
potentially diminished among patients undergoing HD due to neuropathy, 
inflammation and the catabolic state induced by HD that reduces whole-body protein 
synthesis and increases whole-body protein breakdown (126). Previous studies 
examining exercise training to improve muscle CSA among patients undergoing HD 
have also acknowledged that with RT alone it is difficult to increase thigh muscle CSA 
among this population, especially without the addition of an anabolic steroid (88, 110). 
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This may suggest that the changes observed in muscle strength amongst patients on 
HD are primarily neurological in nature, as is seen in the early stages of RT in 
otherwise healthy untrained populations (220, 221). Indeed, this was recently purported 
to be one possible primary driver of strength following low-intensity BFR exercise 
(269). However, that was also following BFR-RT, and it has already been established 
that muscle hypertrophy is likely reduced following BFR-AT compared with BFR-RT 
(261, 290). 
Subjective measures of physical activity behaviour and symptom-related quality of life 
both improved for BFR-CYC and CYC, while no change was seen among CON. 
Collectively, this suggests that introducing exercise, regardless of the format (BFR-
AT (cycling) or traditional AT (cycling)), made participants more likely to complete 
physical activity outside of HD as determined by WEE. Likewise, there is the 
possibility that this increase in WEE and therefore physical activity in general may 
have had an influence on other outcomes in this study including lower limb strength 
and measures of physical function. However, while a single statistical outlier was 
removed from the WEE analyses, the change data may have been skewed by another 
single data point in the BFR-CYC group which was notably (although not 
significantly) higher. However, this data point not being a significant outlier should 
ultimately not detract from the findings regarding WEE in the present study. The 
CHAMPS questionnaire takes into account both incidental, ADL, as well as structured 
exercise (332). For patients undergoing HD, WEE is already low as a result of minimal 
physical activity participation, so any increase in incidental or structured exercise has 
the potential to play a significant role in improving overall health outcomes, and 
reducing mortality (102, 103). The observed concurrent decrease in POS-S renal score 
among both exercise training groups in the present study may have reflected a reduced 
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impact of ESKD-related symptoms. This may have also indicated that regular exercise 
(leading to subsequent increases in daily physical activity) was a viable method for 
managing these symptoms. As there was no clear indication of either exercise training 
group having a greater effect than the other, it also supported the generalised notion 
that delivering any exercise to patients undergoing HD can have a positive short-term 
impact. It may be that the benefit is purely psychological and overcomes fear-
avoidance behaviours among this population characterised by a lack of confidence 
with exercise due to severe limitations with daily activities (160). Another explanation 
may be that repeated exercise training sessions allow patients to experience first-hand 
the positive effects of exercise on energy levels, mobility, and satisfaction at being 
able to complete the exercise where they had previously lacked confidence (160). While 
both exercise training groups in the present study elicited positive improvements in 
physical activity behaviour and symptom-related quality of life, it was unclear how 
long-lasting these changes may be. This may be something that would benefit from 
long-term follow up. 
A component of delivering the exercise training sessions in the present study was close 
monitoring of haemodynamic and perceptual responses as both a safety precaution and 
to monitor the gauges of intensity (RPE, as well as HR as a comparator) as detailed in 
the methods for the present study (Chapter 3). This training data suggests that there 
was no change in BP immediately following exercise for BFR-CYC or CYC over the 
course of the study. The higher DBP observed at baseline for BFR-CYC corresponded 
to the significant difference in resting DBP between BFR-CYC and CYC, and the lack 
of change across the duration of the study further suggested that there was no effect of 
group on DBP. 
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The group by time interaction for training HR was likely driven by the near significant 
differences between groups across the earlier weeks (see Figure 5.3), as it is unlikely 
that the one significantly different time point would drive such an interaction. HR 
appeared higher for BFR-CYC compared with CYC at the start of the training 
programme before converging at around the 8-week time point of the programme. This 
may suggest a training adaptation for aerobic fitness, whereby the increase in fitness 
was more pronounced for BFR-CYC than for CYC. A greater increase in aerobic 
fitness for BFR-CYC in conjunction with larger increases in muscle strength and 
physical function emphasises the efficacy of BFR-AT as a training modality for 
patients undergoing HD.  
Adaptations to peak exercising HR similar to this have also been observed in other 
BFR-AT studies (276, 277). The convergence of HR over the duration of the training 
programme in the present study may also have suggested potential adaptation to the 
BFR-AT (cycling), as BFR exercise has been shown to elicit a small but significant 
increase in heart rate compared with equivalent non-BFR exercise (276, 277). This would 
indicate that training intensity needed to be progressed in response to the potential 
increase in fitness (characterised by a reduction in peak exercise HR). However, 
intensity was dictated by RPE, and there was no observed increase in the two-week 
rolling average of RPE that required a consistent increase in programmed intensity as 
per study protocol. Despite this, mean RPE was within the targeted ranges for BFR-
CYC (13-15 on the Borg scale) and CYC (11-12 on the Borg scale). However, there 
was no statistical difference between RPE for BFR-CYC and CYC. Again, this 
indicated that there was potential to further increase the training load for BFR-CYC, 
which may have resulted in more prominent effects observed for both primary and 
secondary outcome measures. 
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5.4.1 Limitations 
Findings from the present study were limited by the small sample size. As detailed in 
the sample size calculation of the methods for the present study, the objective was to 
achieve statistical power for muscle strength measures, however additional 
participants would have been required to be 80% powered for all measures of physical 
function. Post hoc power analyses also suggested that at an α level of 0.05 and with 
the mean differences observed for 3RM-LE in the present study, the power achieved 
was 97% for that measure. Conversely, the same method of post hoc power analyses 
suggested that the measures of physical function with the observed mean differences 
from the present study were powered at approximately 50-75% and would have 
required 27-36 participants to achieve statistical power. This has been one of the most 
commonly reported limitations of exercise training studies among patients undergoing 
HD (21, 28, 29, 79, 109, 112, 178, 215, 219, 222, 230, 247, 321, 348, 349). As highlighted in the results for 
the present study, logistical constraints and a lower than expected recruitment rate 
(~12%) resulted in the low sample size. This recruitment rate was far lower than the 
40% mean recruitment rate that has been previously reported across multiple 
intradialytic exercise training studies (96, 110, 116, 203, 219, 227, 230, 350). Moreover, it was 
equivalent to the least successful recruitment rates among these studies of 10% (350) 
and 13% (219). Over the 18 months during which recruitment occurred there was also 
relatively little turnover of patients at any of the study sites. This is characteristic of 
this population with patients undergoing HD confined to regular HD indefinitely, 
ultimately making them reluctant to commit to additional activities, exercise or 
otherwise. Recruitment was further limited by the lower number of total patients to 
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which the researchers had access due to the study’s logistical limitations. Additionally, 
recruitment stratified for a range of participant characteristics such as HD vintage and 
BMI (see Section 5.3) would have been ideal. However, with the limitations to 
recruitment in the present study, this would have been virtually impossible. Being able 
to effectively analyse these factors as covariates would require far greater numbers, 
not feasible within the present study. 
The present study was not blinded such that the participant and the researcher knew 
the training group to which participants were allocated. The same researcher also 
conducted the majority of participant training and all participant testing sessions as 
well as performing all statistical analyses. Therefore, results may have been subject to 
participant and/or experimenter bias (351). The effect of this potential bias was minimal 
for multiple objective measures such as pQCT, DXA and subjective questionnaires. 
However, this does not eliminate the potential bias for other measures and subsequent 
conclusions drawn within either of the experimental chapters of this thesis based on 
muscle strength or physical function changes following BFR-AT among patients 
undergoing HD. 
It is also worth noting that the present study only involved a single familiarisation 
session. Within that session, clients were familiarised with the measures of physical 
function they would be performing and the equipment they would be using during 
exercise training sessions. However, familiarisation with 3-RM strength testing did not 
occur in full, such that all patients were familiarised with the leg extension machine 
but did not experience the exercise at an intensity that would replicate the required 
exertion for lifting near-maximal weights prior to completing baseline testing. 
Multiple familiarisations with strength testing equipment has previously been reported 
to reduce improvements in measured muscle strength resultant from improved motor 
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coordination and/or other neural adaptations, rather than the intervention (352). Prior 
familiarisation also increases strength testing reliability and minimises learning effects 
among older adults (353). However, the present study sought to minimise this effect by 
using progressively loaded warm up sets of 5-10 repetitions prior to the strength 
assessments, which have previously been shown to display high comparative 
reliability to familiarisation with similar strength testing (ICC > 0.91) in multiple 
muscle groups (354). Additionally, due to similar initial exposure to testing protocols 
and equipment, it was likely that the magnitude of strength changes due to learning 
effects was similar between groups. Therefore, while strength adaptations for training 
groups in the present study may have in fact been lower than values reported, it was 
expected that the influence of these factors would be negligible on any between-group 
differences identified in the present study. 
Given the relative inexperience with exercise for most participants, in conjunction with 
chronic exposure to a potentially uncomfortable stimulus with the BFR cuffs, 
increased pain tolerance may also have influenced improvements in strength testing 
for BFR-CYC. However, the compression induced discomfort of BFR is also quite 
perceptually different to the discomfort experienced during a 3RM leg extension test, 
so without a means to measure tolerance of non-localised discomfort (RPD was 
specific to the proximal thigh, where the cuffs were located), it is difficult to draw 
conclusions regarding this factor. 
Due to poor reporting of RPD in study 1, the decision was made not to record RPD for 
participants in CYC. When participants were not wearing the BFR cuffs during 
exercise, they had a very difficult time conceptualising perceived discomfort specific 
to the proximal thigh. This may have provided a novel addition with regards to the 
perception of BFR over a longer duration training study in this population. Without a 
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group by time interaction for this variable it is not possible to determine whether the 
reduction in RPD was a training effect or a patient-specific adaptation to the 
discomfort. 
Finally, there was some indication that the intensity could have been increased for 
BFR-CYC. However, this was a potential drawback of using RPE as the primary guide 
for intensity. As a subjective measure there may have been some degree of participant 
reporting bias, whereby they became comfortable reporting a certain intensity, and the 
sensitivity of the measure was affected. Future studies should utilise a more objective 
method for monitoring intensity or an alternative method for ensuring progressive 
overload. 
 
5.4.2 Adverse events 
Across 393 completed exercise sessions there were five cases of symptomatic 
intradialytic hypotension (IDH) (for definition see Chapter 4). During four of these 
instances, ultrafiltration was stopped, in two instances a saline bolus was administered, 
and the patients were reclined. Additionally, one of these patients was given an oxygen 
mask for several minutes. In each case blood pressure returned to within a normal 
range for each participant within three minutes, except for the patient receiving oxygen 
for whom blood pressure took five minutes to normalise. The participants were 
monitored for the remainder of HD. No prolonged effects of any of these adverse 
events occurred, and all participants chose to remain enrolled in the study, in each case 
completing at least eight subsequent sessions with no adverse effects. On one 
additional occasion, a participant reported feeling light-headed during the final minute 
188 
of exercise, upon which exercise was immediately stopped (blood pressure 81/63). 
However, this was self-resolving, without requiring nurse intervention. There were 
two additional cases where asymptomatic IDH occurred and was only detected in the 
post-exercise blood pressure reading. However, both of these instances were self-
resolving within one minute. 
Among the five cases of symptomatic IDH, three occurred following BFR-CYC and 
two following CYC, which detracted from the implication from Study 1 that there may 
be a temporal association between BFR-CYC and IDH. This also represented < 2% 
incidence of IDH, even when asymptomatic IDH was accounted for. This was lower 
than the incidence of that seen in Study 1 and over a much larger sample size, as well 
as a much lower incidence than the 15% to 50% of HD sessions during which IDH has 
been reported in the literature (85). This reemphasises that BFR-AT is a viable 
alternative for intradialytic exercise, with no indication that it results in any increase 
in adverse events beyond that of non-BFR AT performed intradialytically, or 
potentially even usual care HD. 
 
5.4.3 Conclusion 
The present study supported the use of BFR-AT for promoting muscle strength and 
physical function among patients undergoing HD. The observed increase in strength 
occurred in the absence of muscle size adaptations, which may be contrary to much of 
the established BFR literature. Additionally, general fitness (as indicated by HR 
response to training) appeared to improve for both groups, with more pronounced 
increases in strength and physical function for BFR-CYC. Furthermore, the present 
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study supported the concept of any exercise being beneficial when applied to patients 
undergoing HD, as both exercise training groups produced improved patient-reported 
physical activity behaviour and symptom-related quality of life. Overall, the study also 
provided insight into the novel application of BFR-AT among a clinical population 
with pronounced physical limitations. It successfully characterised the training 
responses observed among these patients as both immediate post-exercise 
haemodynamic responses, and perceptual responses. However, the lack of significant 
difference between the intensities for BFR-CYC and CYC suggested that the exercise 
prescription may have been overly conservative, given BFR-AT has generally been 
associated with significantly higher RPEs than non-BFR equivalent-intensity exercise. 
Thus, future research should proceed to increase the intensity and/or complexity of 
BFR-AT prescriptions when dealing with clinical populations, in order to maximise 
the stimulus and subsequent outcomes of BFR-AT. 
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Chapter Six: 
Conclusions and Future Directions 
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6.1 Overview 
This chapter presents concluding remarks addressing the key findings related to the 
studies characterising BFR-AT (cycling) exercise and describing the physiological 
adaptations to chronic BFR-AT (cycling) in this thesis. As discussed in Chapter 2, the 
physical deconditioning and adverse effects experienced by patients undergoing HD 
can be largely attenuated by exercise training. However, the existing exercise 
recommendations present a high volume, physically demanding prescription that is 
unlikely to be adhered to by sedentary and extremely unmotivated patients undergoing 
HD. This population group requires exercise training that is targeted and an effective 
means of ameliorating losses in physical conditioning. The overall aims of this thesis 
were firstly to assess the relative safety and applicability of intradialytic BFR-AT 
(cycling) exercise for patients undergoing dialysis. Secondly, this thesis aimed to 
assess the efficacy of a BFR-AT (cycling) exercise training programme for patients 
undergoing dialysis with regard to improving muscle size, muscle strength, physical 
function, and overall wellbeing. In addressing these aims, this thesis characterised the 
physiological responses to BFR-AT (cycling) exercise training compared with 
traditional cycling exercise training among patients undergoing HD. The studies that 
contributed to this thesis represented the first application of BFR-AT among patients 
undergoing HD for improving physical conditioning. The outcomes of these studies 
provide valuable information to inform future applications of BFR-AT among not only 
patients undergoing HD, but other chronic disease populations that may experience 
similar physical deconditioning. 
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6.2 Key findings and limitations 
The effects of BFR-AT are relatively unknown among chronic disease populations 
with pronounced physical deconditioning for whom the intensities or mechanical 
demands of traditional exercise may be contraindicated. However, BFR-AT has been 
proposed as an alternative to traditional exercise among such populations due to its 
propensity for enhancing muscle size and strength with low-to-moderate intensities, 
and reduced mechanical stress (261). Study 1 (Chapter 4) was the first to characterise 
BFR-AT (cycling) performed by patients undergoing HD. This study demonstrated 
that haemodynamic responses to exercise performed intradialytically did not differ 
significantly between BFR-AT and traditional AT. Similarly, BFR-AT performed 
intradialytically did not produce significantly elevated haemodynamic responses 
compared with BFR-AT performed interdialytically. In Study 2 (Chapter 5) there were 
no significant differences observed between the blood pressure responses to BFR-AT 
(cycling) compared with traditional AT (cycling). Heart rate showed a significant 
group by time interaction whereby it was initially higher for BFR-AT (cycling), before 
returning to that of traditional AT (cycling) across the duration of the exercise training 
programme. Ultimately, this further demonstrated the safety of BFR as a technique 
among clinical populations, especially when exercise was performed as BFR-AT and 
not the more commonly utilised BFR-RT which induces greater haemodynamic stress 
(276, 277, 313). Despite this, several cases of symptomatic intradialytic hypotension 
occurred following both forms of exercise in both Study 1 and Study 2. However, the 
incidence of these hypotensive events observed in both studies was notably lower than 
commonly reported incidence rates among usual care HD (85), although no cases were 
observed for participants receiving usual care in the present study. Thus, while 
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haemodynamic monitoring was important for all intradialytic exercise, BFR-AT was 
deemed suitable to perform intradialytically. 
Perceptual responses to BFR-AT (cycling) among patients undergoing HD were also 
characterised in Study 1. Both perceived exertion and discomfort were significantly 
higher for BFR-AT (cycling) (both intradialytic and interdialytic) compared with 
traditional AT (cycling). However, this aligned with previous studies reporting that 
comparative intensities were often perceived as being more difficult initially with the 
application of BFR but after short-term chronic application, perceptual differences 
decreased towards that of the non-BFR equivalent (41, 325). As a result, exercise intensity 
in Study 2 was prescribed based on ratings of perceived exertion (RPE). While both 
groups achieved the targeted RPE ranges in Study 2, there was no observed decrease 
in RPE following chronic application of BFR and thus exercise intensity was not 
progressed as per protocol. The decline observed in peak training heart rate for BFR-
AT (cycling) suggests that participants may have increased their exercise capacity or 
exercise tolerance, without concomitant decreases in RPE. This highlighted a potential 
limitation with the study design for Study 2. Using a subjective measure to determine 
intensity meant that if this was inaccurately reported by participants then progressive 
overload may not have been achieved. This potentially limits the degree of any 
physiological adaptation to BFR-AT (cycling) in Study 2. Regardless, the reported 
perceptual measures for both effort and discomfort were both at or below ratings of 
‘Hard’ on the Borg scale, which is indicative of moderate intensity and mild 
discomfort, indicating that BFR-AT was tolerable and within the capacity of patients 
undergoing HD. 
The primary finding from Study 2 was an increase in 3RM leg extension strength 
following 12 weeks BFR-AT (cycling), while in contrast muscle strength remained 
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unchanged following 12 weeks traditional cycling and usual care controls. This 
reinforced the understanding that BFR-AT can produce significant gains in muscle 
strength beyond that of equivalent-intensity AT. Moreover, this was the first study to 
demonstrate this following BFR-AT among patients undergoing HD. However, the 
observed increase in 3RM leg extension strength occurred without any change in thigh 
muscle size. This was contrary to some BFR-AT studies that have reported significant 
increases in muscle size with short duration exercise training programmes (274, 275, 334), 
and suggests that the observed increases in 3RM leg extension strength were 
attributable to neural adaptations similar to those seen in the early stages of resistance 
training (33, 355). This may have also been explained by the difficulty patients 
undergoing HD have with maintaining or increasing muscle mass due to cachexia, and 
the presence of neuropathy, inflammation, and the catabolic state induced by HD that 
negatively affect net whole-body protein balance (126). This is compounded by the 
chronic restriction of dietary protein intake imposed on patients undergoing HD as one 
method for slowing disease progression (217). In the present study, an insufficient 
number of participants from the usual care control group opted-in to body composition 
and lean mass assessments. Thus, there was no comparator against which to determine 
whether exercise training offset a potential decrease in muscle mass with usual care 
HD, or if the lack of change in muscle size was consistent across all groups. 
Study 2 identified that BFR-AT (cycling) improved physical function more than 
traditional AT (cycling), specifically the 30-second sit-to-stand and the six-minute 
walk test. However, when adjusting for baseline, only the 30-second sit-to-stand 
remained significant. This aligned with the observed increases in strength, likely due 
to the apparent relationship between 30-second sit-to-stand and muscle strength (239). 
However, it is difficult to draw any assumptions for the measures of physical function 
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from Study 2, due to smaller sample size than the predicted number of participants 
required for statistical power in these measures. 
Other secondary outcomes observed from Study 2 included significant increases in 
physical activity behaviour outside of the study and improved symptom-related quality 
of life for both exercise groups by the end of the 12-week exercise training programme. 
While there was ultimately no difference between either exercise training group, it was 
notable that involvement in a simple exercise training programme encouraged greater 
physical activity participation and reduced the burden of ESKD-related symptoms. 
These findings are even more important for patients undergoing HD due to the well-
established relationship between physical inactivity and mortality, as well as the 
severity of ESKD-related symptoms experienced by this population group (102). 
This thesis was the first to characterise BFR-AT among patients undergoing HD, and 
determine its efficacy for improving muscle size, muscle strength, and physical 
function. It was clear that BFR-AT was a suitable alternative to more traditional 
exercise modalities for patients undergoing HD, even when performed 
intradialytically. Additionally, it was evident that BFR-AT performed intradialytically 
elicited muscle strength increases that have not generally been associated with 
traditional non-BFR AT. There was also significant support for physical function 
improvements being greater following BFR-AT compared with AT. However, this 
requires further examination with a larger sample size. Importantly, the increases 
observed in muscle strength were achieved with a low-volume, low-to-moderate 
intensity exercise prescription that was manageable for, and well-received by dialysis 
patients, as well as being simple to incorporate intradialytically. With further research 
to refine the exercise prescription, BFR-AT presents as a valuable means for delivering 
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effective exercise programmes to patients undergoing HD with greater value for time 
spent exercising than traditional exercise training prescriptions. 
Both Study 1 and Study 2 were among the first to provide proof of concept for the use 
of BFR-AT among patients suffering from a chronic disease. Despite being purported 
as significantly beneficial for these clinical populations (261, 356), few studies have 
produced empirical evidence supporting the applicability of BFR-AT for these 
populations. Among those that have used BFR among clinical populations, all have 
utilised smaller sample sizes than that used in Study 2 (n = 9-19) (305, 314, 318, 319). 
Therefore, the findings of this thesis contribute significantly to this knowledge base. 
This is especially true when considering that patients undergoing HD display some of 
the highest levels of deconditioning and functional limitations of any chronic disease 
population (155, 357). Thus, demonstrating that BFR-AT was applicable to patients 
undergoing HD may, by extension, demonstrate that it is suitable for other clinical 
populations with less haemodynamic instability, but who may also be contraindicated 
to the mechanical and haemodynamic stress imposed by traditional moderate-to-high 
intensity exercise. 
 
6.2.1 Recruitment, adherence and attrition 
The underlying issues with achieving statistical power in Study 2 related to known 
difficulty recruiting patients undergoing HD to engage in exercise training 
programmes (19, 109, 113), as well as limited resources and personnel available when 
conducting the present study. To complete intradialytic exercise sessions, there was 
only a finite window of time (during the first 2 hours of scheduled HD sessions) in 
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which exercise sessions could be conducted (see Section 2.9). As more than 80% of 
exercise training sessions in the present study were conducted by the PhD candidate 
across three sites, this limited the number of participants that could be completed 
during any given dialysis shift. The logistics of this confined the study to three sites 
over 18 months. While these sites allowed access to 180 patients, only 66 (~37%) met 
the study criteria, among whom there was almost a 45% refusal rate. There was a 
further 25% attrition from the 28 who consented to the study prior to engaging in any 
study activities, and this often meant that there were only one or two participants per 
dialysis shift. Collectively, this meant that only ~12% of patients to which researchers 
had access successfully completed the study. As discussed in Chapter 5 (see Section 
5.4.1) recruitment was far lower than expected based on previous intradialytic exercise 
training studies (96, 110, 116, 203, 219, 227, 230, 350). This limited any generalisations that may 
have been possible based on the results of this thesis. 
Across the exercise training programme in Study 2, one participant was lost to follow 
up. The participant, who was allocated to BFR-CYC, died due to reasons unrelated to 
the study 8 weeks into the training programme. Overall, participants in the exercise 
training groups completed 78% of training sessions. This was similar to previously 
reported adherence rates (75%) among non-dropouts in intradialytic exercise training 
programmes (113, 116, 199). Participants in BFR-CYC completed 84% of all training 
sessions. Comparatively, participants in CYC completed 72% of all training sessions. 
However, while 78% may be an expected level of adherence to an exercise training 
programme among patients with HD, it is only considered ‘moderate’ adherence, and 
is not ideal for eliciting physiological adaptations to exercise training (113). 
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6.3 Future Directions 
Among the key findings reported in this thesis, perhaps the most notable takeaway for 
future research was that BFR-AT can be performed by a high-risk chronic disease 
population such as patients undergoing HD with no significant elevation in 
haemodynamic stress compared with equivalent intensity non-BFR exercise. That the 
incidence of adverse events observed in both Study 1 and Study 2 (namely intradialytic 
hypotension) was lower than that observed in usual care HD further supports the 
suitability of BFR-AT for this population. Future studies can further improve the 
evidence supporting this by prescribing longer duration continuous BFR applications, 
moving away from the entry-level repeated bout model. This has been shown to be 
more effective than intermittent pressure applications and has successfully induced 
both muscle strength and muscle size adaptations following relatively short-duration 
BFR-AT programmes among healthy adults (41, 275, 358, 359). Such a change in 
prescription would benefit from continuous, real-time haemodynamic monitoring 
during exercise which may be able to detect an inflection point at which any potential 
haemodynamic increases arise. This would be important in understanding the 
thresholds to work within when prescribing BFR-AT for at risk populations such as 
patients undergoing HD. 
As demonstrated in Study 2, BFR-AT has also shown promise for enhancing muscle 
strength adaptations with simple, low-intensity, and easily administered cycling 
exercise beyond what may be achieved without BFR. For a population that displays 
marked physical deconditioning, the decreased time-commitment, reduced mechanical 
stress, and comparable haemodynamic responses during BFR-AT represent a 
significant advantage over current exercise recommendations (18). The generalisability 
of other observed training adaptations made in Study 2, such as changes in physical 
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function, was limited by a small sample size. However, the general outcome from the 
results of this study supported improvement in these measures, similar to that observed 
for muscle strength. Likewise, the measures of muscle size and body composition from 
Study 2 were limited by an even smaller sample size and lacked a control comparison. 
While there was an indication that muscle size was at least retained among both 
exercise training groups, it was unclear if this aligned with patients undergoing usual 
care HD, or if it attenuated a loss in muscle size associated with ESKD progression or 
the catabolic effects of HD. These findings would need to be confirmed and elaborated 
upon by studies with greater time and personnel resources available to complete larger-
scale trials using similar outcome measures. 
 
6.4 Conclusion 
This thesis presented a novel application of BFR-AT among a high-risk clinical 
population. Characterisation of BFR-AT among patients undergoing HD demonstrated 
that it was suitable in terms of both haemodynamic and perceptual responses for these 
patients, even when performed intradialytically, when patients were at their most 
haemodynamically unstable. BFR-AT imposed no greater risk of adverse events than 
traditional exercise, which has been recommended for this population, or even for 
usual care HD. Adherence to BFR-AT was also comparable or greater than for 
traditional cycling both in this thesis and in multiple previous studies exploring 
intradialytic AT. 
Investigation into the efficacy of BFR-AT for improving muscle strength, muscle size, 
physical function and overall wellbeing produced mixed but collectively positive 
results. Muscle strength, and some measures of physical function were improved 
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following BFR-AT, even in the absence of any substantial change in muscle size and 
body composition. Physical wellbeing, measured as physical activity behaviour and 
symptom-related quality of life was also improved, although this was true for exercise 
in general and not specifically BFR-AT. These adaptations have been common among 
the broader BFR-AT literature, but represented a novel finding specific to patients 
undergoing HD. Established exercise recommendations for this population are high-
volume, time-demanding, and physically challenging beyond what is reasonable for a 
large number of patients undergoing HD. The physical adaptations elicited by BFR-
AT in this thesis represented a simplified exercise prescription at a manageable 
intensity, all performed intradialytically. This ultimately increased the value-for-time 
spent exercising for patients undergoing HD, an outcome that is significant given the 
resistance to exercise previously observed among this population. 
Overall, this thesis has contributed to the literature supporting broader applications of 
BFR as an adjunct to traditional exercise. Specifically, it has highlighted the practical 
application of BFR-AT for clinical populations as an alternative to higher-intensity 
exercise to which they may be contraindicated or lack the motivation to perform. This 
work should encourage broader acceptance of BFR-AT among at-risk populations who 
require targeted interventions that ameliorate losses in physical conditioning.  
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Abstract
Background: Exercise during haemodialysis improves strength and physical function. However, both patients and
clinicians are time poor, and current exercise recommendations add an excessive time burden making exercise a
rare addition to standard care. Hypothetically, blood flow restriction exercise performed during haemodialysis can
provide greater value for time spent exercising, reducing this time burden while producing similar or greater
outcomes. This study will explore the efficacy of blood flow restriction exercise for enhancing strength and physical
function among haemodialysis patients.
Methods: This is a randomised controlled trial design. A total of 75 participants will be recruited from
haemodialysis clinics. Participants will be allocated to a blood flow restriction cycling group, traditional cycling
group or usual care control group. Both exercising groups will complete 3 months of cycling exercise, performed
intradialytically, three times per week. The blood flow restriction cycling group will complete two 10-min cycling
bouts separated by a 20-min rest at a subjective effort of 15 on a 6 to 20 rating scale. This will be done with
pressurised cuffs fitted proximally on the active limbs during exercise at 50% of a pre-determined limb occlusion
pressure. The traditional cycling group will perform a continuous 20-min bout of exercise at a subjective effort of 12
on the same subjective effort scale. These workloads and volumes are equivalent and allow for comparison of a
common blood flow restriction aerobic exercise prescription and a traditional aerobic exercise prescription. The
primary outcome measures are lower limb strength, assessed by a three repetition maximum leg extension test, as
well as objective measures of physical function: six-minute walk test, 30-s sit to stand, and timed up and go.
Secondary outcome measures include thigh muscle cross sectional area, body composition, routine pathology,
quality of life, and physical activity engagement.
Discussion: This study will determine the efficacy of blood flow restriction exercise among dialysis patients for
improving key physiological outcomes that impact independence and quality of life, with reduced burden on
patients. This may have broader implications for other clinical populations with similarly declining muscle health
and physical function, and those contraindicated to higher intensities of exercise.
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Background
End-stage kidney disease (ESKD) is the 5th stage of
chronic kidney disease, characterised by a failure of the
kidneys to adequately filter blood [1]. ESKD is estimated
to affect as many as 2 million people worldwide, ap-
proximately half of whom do not receive adequate treat-
ment [2, 3]. Treatment requires either transplantation,
or if transplantation is unavailable patients are solely re-
liant on regular dialysis [4]. Largely due to the regularity
of dialysis as a treatment, ESKD is among the most com-
mon reasons for hospitalisation [2]. However, despite
dialysis being considered one of the most efficacious
means of treating ESKD, it does not guarantee that life
can be sustained, with 12 month mortality rate following
initiation of dialysis estimated to be 10–12% [5].
ESKD patients suffer from anaemia, fatigue, muscle at-
rophy, decreased aerobic capacity, reduced participation
in physical activity, increased risk of falls, and decreased
quality of life [4, 6–8]. Patients with ESKD also demon-
strate significant decline in physical function and tasks
reflective of activities of daily living [9–13]. This dimin-
ished physical function leads to a significant loss of
independence with 95% of people with ESKD not fully
independent and in need of assistance with at least one
activity of daily living (ADL) [14]. This is more signifi-
cant considering that an inability to independently
complete ADLs is a major predictor of mortality for
ESKD [14]. Exercise is well tolerated among patients
with ESKD and is an efficacious method for ameliorating
these adverse symptoms characteristic of ESKD [15–18].
Heterogenous methodology, prescription and report-
ing among ESKD exercise studies make it difficult to
draft guidelines on the dosage and mode of exercise
training to derive the best outcomes for ESKD patients
[8, 19]. The current guidelines for exercise training with
ESKD recommend it encompasses aerobic (4 sessions;
45 mins), resistance (2 sessions; 20 mins), and flexibility
(7 sessions; 10 mins) exercise [20]. The cumulative time
commitment for these recommendations is substantial,
and would require training on both dialysis (during first
2 h of dialysis) and non-dialysis days [20]. However,
most randomised controlled trials examining exercise
regimens in ESKD have only utilised aerobic training,
most commonly stationary cycling [20]. Aerobic exercise
training alone does not traditionally increase strength
and hypertrophy, nor produce significant improvements
in physical function, all of which are needed among this
population [21].
Adherence to exercise training programs, regardless of
aerobic, resistance or combined modalities, is also poor
among ESKD patients, with more than 20% choosing
not to participate, citing issues such as lack of time, lack
of energy, too much trouble, and resistance training be-
ing too difficult [22]. Of those that chose to participate
in exercise training, the dropout rate was more than 25%
for programs utilising exercise training on non-dialysis
days [22]. While there is still an increased dropout rate
among patients with ESKD when exercise is completed
intradialytically (approximately 17%) [22], it is lower than
that seen on non-dialysis days. This suggests that intradia-
lytic exercise is still preferable with regards to participant
retention than exercise on non-dialysis days.
Resistance training poses further complications in the
setting of a dialysis unit as the required equipment is
cumbersome, and poses a high risk for cross-infection.
Less cumbersome washable elastic resistance bands may
be one option [23]. Exercise training during dialysis also
needs to be completed in the first 2 h of dialysis
sessions [24]. Therefore, finding a solution that may
provide improvements in all key outcomes as efficiently
as possible, allowing for completion during dialysis
would be preferable.
Blood flow restriction exercise training uses pres-
surised cuffs fitted proximally on the active limbs during
exercise training, and can elicit the above benefits at
lower exercise intensities than non- blood flow restric-
tion training [25, 26]. Blood flow restriction may be one
method for achieving outcomes reflective of both resist-
ance, and aerobic exercise training while providing an
efficient, simple exercise prescription model in the dialysis
setting. Blood flow restriction aerobic exercise training has
been shown to increase muscle size and strength more
than equivalent-intensity non-blood flow restriction aer-
obic exercise training, while still providing comparable or
greater improvements in cardiovascular fitness [25, 27, 28].
While blood flow restriction exercise training is used
predominately in single joint isolation resistance training
exercises such as knee extension, it has also been applied
during aerobic exercise training such as walking or
cycling [25, 29–32]. Common blood flow restriction
aerobic exercise training protocols utilise short exercise
durations of 10 to 20 min [25, 32–34]. Such studies utilis-
ing blood flow restriction with aerobic exercise training
have demonstrated increases in lower limb muscle volume
and strength of up to 8% and 16%, respectively [25, 32, 33].
However, it should be noted that without blood flow re-
striction, low-intensity aerobic exercise training is generally
insufficient to increase muscle volume or strength, unless
there is previous muscle atrophy or the initial level of
participant physical activity is extremely low [35]. Even in
such instances, improvements in muscle volume and
strength are unlikely to be of similar magnitude as seen
with blood flow restriction [35].
Regardless of the presence of blood flow restriction,
aerobic exercise training improves aerobic fitness pro-
vided that the exercise is of sufficient intensity [36].
Indeed, studies have demonstrated that low-to-moderate
intensity blood flow restriction aerobic exercise training
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is able to increase aerobic capacity when exercising at
intensities equivalent to 40% of peak exercise oxygen
consumption (⩒O2peak) [32, 33, 37].
Studies examining the haemodynamic responses to
blood flow restriction identify blood flow restriction aer-
obic exercise training as having lower haemodynamic
stress than high intensity resistance training, while pro-
viding similar outcomes [38–40]. As such, blood flow re-
striction is purported to be a potentially beneficial
addition to exercise for clinical populations who may be
contraindicated to high-intensity resistance training.
While blood flow restriction exercise is a novel addition
to exercise among ESKD patients, pilot data from this
laboratory (unpublished) indicates that haemodynamic
responses (systolic blood pressure, diastolic blood pres-
sure, mean arterial pressure, heart rate) do not differ
markedly between low-intensity blood flow restriction
and non-blood flow restriction aerobic exercise both
performed during haemodialysis in this population.
Aerobic capacity and muscle strength are both key
physiological factors underpinning physical function [41]
and both can improve with blood flow restriction aer-
obic exercise training. As declines in physical function,
muscle strength, and aerobic capacity, as well as acceler-
ated muscle atrophy are common among patients with
ESKD, blood flow restriction aerobic exercise training
may present an opportunity to increase the efficiency of
time spent exercising for this population.
This study will examine the efficacy of blood flow
restriction aerobic training among patients with ESKD
on haemodialysis (HD). We hypothesise that blood flow
restriction aerobic exercise training will improve physical
function, muscle strength, and muscle size among patients
with ESKD beyond that of traditional aerobic exercise
training.
Methods
Design
This is a 12-week randomised controlled trial consisting
of three groups randomised to exercise or usual care
(Fig. 1). Participants will be randomised to one of three
groups: a blood flow restriction cycling exercise training
group (BFR-C), a non-blood flow restriction cycling
exercise training group (CYC), or a non-exercising, usual
care control group (CON).
Sample size calculation
The most relevant outcome for blood flow restriction
training studies is knee extensor muscle strength, and
this was used as the main primary outcome measure for
calculating required sample size. Based on data from
previous blood flow restriction research [25, 29, 32, 33],
and previous exercise for ESKD research [18, 42, 43], the
projected percentage changes in knee extensor muscle
strength for each of the three groups are CON = −3%,
CYC = 2%, BFR-C = 12%. The common standard devi-
ation within group, based on the prior research was
determined to be 15. Thus, to achieve a power of 80% at
an α level of 0.05, 20 participants per group will be re-
quired to detect a difference between the expected
means for percentage strength improvement. However,
based on previous work conducted by this research
group a conservative attrition rate of 20% is expected
over 3 months due to voluntary patient withdrawal,
death, additional hospitalisation, transfer to another
facility, or patients receiving transplants [23]. Thus, a
total of 75 participants will be recruited and randomly
allocated to one of the three groups.
Recruitment and screening of participants
Participants will be recruited through recommendation
and referral from treating physicians at a number of
dialysis clinics linked to a major public hospital service
in a large metropolitan Australian city. Additionally,
nurse unit manager recommendations and fliers briefly
outlining the study posted within the dialysis clinics will
be used to help identify prospective participants. Prospect-
ive participants will be screened initially face-to-face or via
telephone by a member of the research team. Following
this, confirmation from the treating physician will be
obtained if not implied by referral. Participants will be
required to provide written, informed consent prior to
participation in the study.
Inclusion and exclusion criteria
Eligible participants will be male and female stable chronic
(>3 months) haemodialysis patients aged between 18 and
80 years. Participants will be deemed medically eligible by
their treating physician before participation in the present
study. Participants will be excluded if they do not under-
stand English and are unable to complete or comprehend
the surveys or study documents; if within the previous
12 weeks they have participated in regular physical activity
or sport (>150 min.wk.−1) of moderate or greater intensity
[44], or structured resistance training (> 1 session.wk.−1);
if they have symptomatic peripheral vascular disease, limb
ischemia, untreated symptomatic cardiovascular disease,
or any other absolute contraindications to exercise train-
ing (such as musculoskeletal factors or neurological condi-
tions) that may affect their ability to perform physical
assessments or exercise training protocols in the present
study; if they are currently smokers; or if they are pregnant
or have required hospitalisation for non-dialysis reasons in
the 4 weeks prior to the study’s commencement. Patients
will also be deemed unable to exercise during individual
dialysis sessions if they present with fluid overload (> 5%
above dialysis base weight) as this can cause reduced car-
diovascular reserve [45]. Similarly, if patients have systolic
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blood pressure > 180 mmHg, or diastolic blood pres-
sure < 90 mmHg prior to exercise they will be deemed
unsuitable for exercise on that day (excluding the first
blood pressure reading before dialysis, which is known to
be unreliable) [46]. Of clinical concern is the known pro-
pensity for HD patients to become hypotensive (poten-
tially more so post-exercise) during dialysis [47]. Although
this is uncommon and our pilot data indicates this is not
exacerbated by blood flow restriction, to ensure the safety
of all patients they will be monitored for chest pain/dis-
comfort, dyspnoea, lower limb pain, symptoms of severe
hyper- or hypotension, and other signs of adverse events,
which will be reported to the ethics committee of both the
treating hospital and Deakin University.
Randomisation
Randomisation will be conducted at a participant level
prior to familiarisation and baseline testing, and will
randomise participants by blocks of 4 via a computer-
generated random number sequence by an independent
researcher. Blinding of intervention group to clinical
staff and participants will not be possible once the
intervention commences.
Fig. 1 Study Flow Chart. BFR-C – Blood flow restriciton cycling group; CYC – Traditional cycling group; CON – Usual care control group; LOP – Limb
occlusion pressure; 3RM LE – Three-repetition Maximum Leg Extension; 6MWT – 6 min walk test; STS30–30-s sit-to-stand test; TUG – Timed up and go;
pQCT – Peripheral Quantitative Computed Tomography; iDXA – Dual X-ray Absorptiometry; URR – Urea Reduction Ratio; Hb – Haemoglobin;
Alb – Albumin; K+ − Potassium; PTH – Parathyroid Hormone; PO4 – Phosphate; RPE – Rating of perceived exertion
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Exercise intervention
Exercise training sessions will occur intradialytically for
all exercising participants and will be completed within
the first 2 h of the session to avoid loss of exercise train-
ing quality [24, 48]. All sessions will be supervised by a
member of the research team. Exercise training sessions
will consist of cycle exercise for both BFR-C and CYC
groups. Both BFR-C and CYC groups will complete a
total volume of 20 min cycling at a relative intensity for
each participant to be dictated by rating of perceived
exertion (RPE), similar to previous exercise and ESKD
studies [17, 49, 50]. This will also be compared to mea-
surements of percentage age-predicted maximum heart
rate (APHRmax) in order to determine if targeted RPE
needs to be adjusted to account for potential discrepan-
cies between patient subjective intensity and objectively
observed intensity. If participants are unable to maintain
the prescribed cadence at this workload for the full
duration, they will be instructed to complete as much of
each cycling bout as possible.
Age-predicted maximum heart rate
APHRmax will be used as a relative indicator of intensity
during exercise training sessions. Approximately 50–70%
of participant’s age-predicted APHRmax will be used as
an objective target to indicate whether participants in
BFR-C or CYC are exercising at the prescribed intensity
for this study. This will be achieved using a fingertip
heart rate monitor and pulse oximeter (CMS50, Contec
Medical Systems Co., Ltd., Qinhuangdao, Hebei Province,
China) placed on the second or third finger of the partici-
pant’s hand on the contralateral limb to their arterioven-
ous fistula. This will be measured and recorded during the
final minute of each period of active cycling within a
session to correspond with measures of RPE.
Blood flow restriction cycling group
The BFR-C group will complete an intermittent protocol
of 10 min cycling, 20 min rest, 10 min cycling. During
these sessions, participants in the BFR-C group will have
a blood flow restriction cuff fitted to the proximal end of
each thigh, which will be inflated continuously at 50% of
a pre-determined limb occlusion pressure (LOP)
throughout the full duration of cycling. Participants will
be required to cycle at an RPE of 15 (‘Hard’ on the Borg
6 to 20 scale [51]), expected to be equivalent to at least
60% of APHRmax for each 10 min cycling period. The
prescribed volume and intensity represents a balance be-
tween prior blood flow restriction protocols and those
utilised in the aerobic training components of HD
studies, while accounting for potentially very low levels
of physical function among the participants [6, 8, 52].
Blood flow restriction procedure
Blood flow restriction will be applied using an automatic
tourniquet system (A.T.S 3000, Zimmer Inc., OH, USA).
The ATS produces a defined, controlled pressure via
adjustable pneumatic cuffs (52 cm long, 10.5 cm wide;
bladder length 45 cm, bladder width 8 cm). The pressure
is regulated to control for changes in muscle contractile
pressures under the cuff in such a way that the occlusive
pressure applied to the limb is constant.
The cuffs will be applied to the proximal aspect of the
thigh prior to commencing exercise, and gradually in-
flated, as detailed by Abe et al. (2006) [25]. Blood flow
restriction pressure will be set at 50% of pre-exercise
resting LOP. LOP will be calculated during a familiarisa-
tion session for participants allocated to the BFR-C
group using a digital plethysmograph (Pulse Sensor,
Zimmer ATS 3000) applied to the second toe [40, 53]. A
seated or recumbent posture will be used for LOP as it
most closely matches the posture that will be used dur-
ing the exercise training sessions. To determine LOP, the
pneumatic cuffs are inflated to the point at which the ple-
thysmograph can no longer detect blood flow to the toe
(blood flow completely occluded). This will be done for
each leg and repeated to ensure accuracy (<20 mmHg),
and an average of these measures will be taken. The 50%
LOP that is to be applied during exercise training sessions
does not fully occlude the limb in this manner, and allows
for continuous blood flow during exercise.
Cycling group
The CYC group exercise training sessions will require
20 min continuous cycling at an equivalent intensity to
the BFR-C group. However due to the absence of blood
flow restriction, the equivalent intensity is often reported
to have a lower RPE and mildly reduced heart rate re-
sponse, regardless of exercise modality [38, 54, 55]. As
such, the target RPE will be 12 (‘light to somewhat hard’
on the Borg 6 to 20 scale [51]) for the CYC group, which
is expected to equate to at least 50% APHRmax. This in-
tensity is recommended for intradialytic aerobic exercise
in the Exercise and Sport Science Australia (ESSA) pos-
ition statement on exercise for chronic kidney disease
[20]. This volume is reflective of protocols used by other
studies examining exercise training among patients with
ESKD, and represents a “normal” exercise training
prescription for patients with ESKD [22, 56].
Progression
In order to ensure that training sessions maintain a suffi-
cient intensity for all exercising participants, resistance
applied to the pedals, cadence, or a combination of both
variables will be adjusted on a session-by-session basis
by a trained exercise physiologist such that the required
RPE target (indicative of sufficient subjective intensity) is
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achieved. This accounts for any illness or excessive fa-
tigue that may affect exertion during any given session.
A rolling two-week average of RPE will be monitored
(on the 6–20 Borg’s RPE scale [51]) to ensure progres-
sive overload is being achieved over the course of the 3-
month intervention.
Usual care control group
Participants allocated to the usual care control group will
receive no additional access to exercise training and will re-
ceive minimal advice regarding exercise training through-
out the study. Participants randomised to the usual care
control group will be given access to an accredited exercise
physiologist member of the research team, free of charge if
they would like to discuss the benefits of commencing
exercise training upon completion of the study.
Data collection
Data collection will occur at baseline (T1) and 12 weeks
(T2), with testing to be completed at the treating HD
unit prior to the commencement of the participants’ HD
session. Personal information, including relevant medical
history will be collected prior to the initiation of testing
or intervention upon receiving participant consent. This
will include patient characteristics of age, gender, time in
months that the participant has been receiving HD
(dialysis vintage), basic anthropometric measures
(height, weight, and BMI), relevant comorbidities and
medications, transplant status, and type of dialysis ac-
cess. Some or all of which may be taken, with approval,
from the case file at the HD unit. The remaining data
collected will include all measures of muscle function
and physical function. Body composition scans will be
performed on a non-dialysis day, separate from other
testing procedures for participants who opt-in to this as-
pect of testing. Additional pathology measurements will
include haemoglobin, albumin, potassium, parathyroid
hormone, phosphate, urea reduction ratio (URR), creat-
ine kinase and lactate. These measures will occur as part
of routine pathology tests where possible, or will be re-
quested out-of-cycle to coincide with the necessary
period of the training intervention. Data will be coded
and stored securely at Deakin University. Data collected
from those who withdraw from the study will not be
used for statistical analyses. This has been accounted for
when completing the power analysis, with an additional
20% added to the target sample size. Attrition may be
for a number of reasons, which will be ascertained upon
withdrawal where possible.
Primary outcome measures
Lower-limb muscle strength
Maximal lower limb muscle strength will be determined
using three-repetition maximum (3RM) knee extension
(HS-LE, Life Fitness, Victoria, Australia) [57]. A 3RM knee
extension test measures the maximum weight that can be
lifted for three consecutive repetitions of a knee extension
exercise with good technique and full range of motion. The
3RM result will be input into a formula to derive equivalent
one-repetition maximum for each participant [58].
Physical function
Objective physical function will be measured using the
30-s sit to stand test (STS30), the timed up and go test
(TUG), and the six-minute walk test (6MWT).
The STS30 measures lower limb muscle strength and
function and requires participants to stand from a chair
and then return to the seated position as many times as
possible in 30 s [59]. The test has also displayed strong
comparative validity to lower extremity 1RM strength test-
ing, particularly among community-dwelling older adults
[59]. It has also demonstrated a high level of reliability
among ESKD patients undergoing HD (ICC = 0.93) [60].
The TUG is a measure of dynamic balance and mobil-
ity requiring participants to stand from a chair, walk to
and then around a cone placed 3 m away, walk back to
the chair, and sit back down as quickly as possible. This
test will be repeated three times, and an average time taken
for accuracy purposes [61]. The TUG strongly reflects gait
speed among older adults, and has shown strong test re-
test reliability not only among older adults, but in ESKD
patients undergoing HD (ICC = 0.91–0.96) [62–64].
The 6MWT is a self-paced assessment of aerobic cap-
acity, and a strong index of all cause morbidity in older
adults [65]. It requires participants to walk laps of a
straight 30 m course with the objective to cover as much
distance as possible in the six-minute duration [65]. The
6MWT is a reliable measure for patients with ESKD
(ICC = 0.93–0.96) [60, 66]. It has also been validated
against ⩒O2max for patients with ESKD, with moderate
strength coefficients of correlation (r = 0.56–0.73) [11, 67].
Secondary outcome measures
Muscle cross-sectional area and body composition
Total and regional body composition (lean mass, fat
mass and percentage fat mass) will be assessed using
iDXA (Lunar iDXA, GE Healthcare, Madison, WI).
Muscle cross-sectional area around the femur diaphysis
at 25% and 50% of femur length will be assessed using
pQCT (XCT 3000, Stratec Medizintechnik, Baden-
Württemberg, Germany), allowing for knee flexor and
extensor musculature to be measured. Height and body
mass will be assessed using a portable stadiometer and
scales respectively.
Pathology measures
Pathology measurements will be taken during routine
collections completed by the treating hospital. The
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exercise intervention will be timed such that these rou-
tine pathology measures occur within the 4 weeks prior
to the commencement of the first training session (or
prior to the 3 month usual care monitoring period for
the CON). These additional measures will include
haemoglobin, albumin, potassium, parathyroid hormone,
and phosphate. URR will also be measured by the treat-
ing hospital as a part of patients’ quarterly pathology
tests, providing it is within the 4 weeks prior to patients
commencing their exercise intervention. If this cannot
be achieved in a timely manner, an additional measure
of URR will be requested for a single dialysis session
prior to the commencement of the exercise intervention.
Two additional measures of URR, creatine kinase and
lactate will also be required outside of the normal regi-
men for patients in either of the exercise training inter-
vention groups, once during the first week of the
exercise training intervention, and again during the final
week of the exercise training intervention. An additional
out-of-cycle measure of URR will also be required by
participants in the usual care control group, unless this
is scheduled to be completed within 2 weeks following
their 3-month monitoring period for this study as a part
of their quarterly routine pathology test. All measures
are conducted at the beginning and upon completion of
a single dialysis session to establish the difference in
each marker over the course of that session. This will
allow analysis of the impact of exercise and specific
exercise intervention types (BFR-C and CYC) on dialysis
adequacy, as well as providing objective proof that there
is no major tissue damage as a result of the intervention.
Physical activity levels
The Community Healthy Activities Model Program for
Seniors (CHAMPS) physical activity survey will be used
to assess participation in a comprehensive list of low,
moderate and vigorous physical activities [68]. This
questionnaire will provide valuable information about
changes in physical function and physical activity behav-
iour over the course of the study.
Symptom related quality of life
The POS-S Renal questionnaire will be given to patients
during the familiarisation session to assess their quality
of life in direct relation to the symptoms experienced as
a part of their condition [69]. This questionnaire pro-
vides valuable feedback about any changes experienced
by patients regarding quality of life and disease-specific
symptoms as a result of the intervention.
Statistical analysis
All statistical analyses will be performed using SPSS 22.0
(IBM Corp, Chicago IL, United States of America).
Participant characteristic and demographic data will be
presented using descriptive statistics, and compared using
independent t-tests for continuous variables and chi-
square tests for categorical variables. The distribution of
data will be assessed for normality with a Shapiro-Wilks
test (P > 0.05). Non-normally distributed data will be com-
pared using the Friedman non-parametric test. Otherwise,
comparisons between groups for all continuous primary
and secondary variables measured will be made using
one-way analysis of variance (ANOVA). Main effects will
be analysed using a Tukey post hoc test. A significance
level of P < 0.05 will be adopted for all statistical tests. All
data will be presented as means ± SEM unless stated.
Discussion and conclusion
This study is the first to explore the efficacy of blood
flow restriction aerobic exercise training among patients
with ESKD. Additionally, it is one of the first to explore
a battery of common clinical measures or physical func-
tion following a blood flow restriction aerobic exercise
training program. The main objective of the study is to
determine the effectiveness of blood flow restriction
aerobic exercise training for improving the strength and
physical function among patients with ESKD.
While exercise during dialysis is not a novel concept
in the broader literature, the current exercise recom-
mendations present a significant time and physical bur-
den for patients with ESKD and does not have an
established role in clinical practice. Therefore, this study
is important given the well documented deficits in
strength and physical function for patients with ESKD in
conjunction with the rarity with which any exercise is
adopted not only intradialytically, but in the broader
ESKD population. It may also be valuable to include
measures related to vascular stiffness (e.g. pulse wave
velocity and vascular-related microRNAs), as this has
also been shown to improve with exercise training,
and may be enhanced with the addition of blood flow
restriction [34, 70, 71].
It is expected that this study will provide an improved
understanding of the role that blood flow restriction
aerobic exercise training can play in providing an effica-
cious, time-efficient modality of intradialytic exercise for
patients with ESKD, which caters to the population’s lower
initial level of physical function and overall conditioning.
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Abstract 26 
Background: Patients with end stage kidney disease on dialysis have increased mortality and reduced 27 
physical activity contributing to impaired physical function. While exercise programmes have 28 
demonstrated a positive effect on physiological outcomes such as cardiovascular function and 29 
strength, there is a reduced focus on physical function. The aim of this review was to determine 30 
whether exercise programmes improve objective measures of physical function indicative of activities 31 
of daily living for end stage kidney disease patients on dialysis. 32 
Methods: A systematic search of Medline, Embase, the Cochrane Central Register of Controlled 33 
Trials, and CINAHL, identified 27 randomised control trials. Only randomised control trials utilising 34 
an exercise intervention or significant muscular activation in the intervention, a usual care, non-35 
exercising control group, and at least one objective measure of physical function was included. 36 
Participants were ≥18 years of age, with end stage kidney disease, undergoing haemo- or peritoneal 37 
dialysis. Systematic review of the literature and quality assessment of the included studies used the 38 
Cochrane Collaboration’s tool for assessing risk bias. A meta-analysis was completed for the six-39 
minute walk test. 40 
Results: Data from 27 studies with 1156 participants showed exercise, regardless of modality, 41 
generally increased six-minute walk test distance, sit-to-stand time or repetitions, grip strength, as 42 
well as step and stair climb times or repetitions, dynamic mobility, and short physical performance 43 
battery scores. 44 
Conclusion: From the evidence available, exercise, regardless of modality, improved objective 45 
measures of physical function for end stage kidney disease patients undergoing dialysis.  It is 46 
acknowledged that further well-designed RCTs are required.  47 
 48 
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1. Introduction 51 
End-stage kidney disease (ESKD) is near or complete and permanent kidney failure requiring renal 52 
replacement therapy (RRT) via dialysis or transplantation to account for kidney function that is 53 
inadequate to sustain life (71). The prevalence of ESKD is proportional to the escalating worldwide 54 
epidemic of lifestyle-related diseases such as type 2 diabetes and hypertension (28). Combined with 55 
an ageing population in many countries and approximately 1 in 8 people developing chronic kidney 56 
disease (CKD), of which 10% progress to ESKD, the result is almost double the already large number 57 
of patients requiring RRT over the last decade, with approximately 53% of these receiving 58 
haemodialysis (HD) (1, 44, 83). 59 
Among HD patients there is a strong link between the increase in mortality and the low levels of both 60 
objective and self-reported physical function (65). This is exacerbated by HD patients being 61 
significantly more sedentary than otherwise healthy inactive populations (38). In fact, HD patients 62 
classified as sedentary are more than 60% more likely to die each year compared with HD patients 63 
who are regularly physically active (63). While survival rates are slowly improving among HD 64 
patients, this is resulting in greater numbers of frail older adults on HD, and so frailty is also a well-65 
established predictor of both disability and mortality among HD patients (56). 66 
It is commonly suggested that aerobic exercise among HD patients improves exercise capacity 67 
measured by peak oxygen consumption (Vሶ Oଶ peak) (79). However, it has been previously highlighted 68 
that many of the studies that have measured Vሶ Oଶ peak have done so on more physically active 69 
patients with higher levels of physical function (65). By contrast, muscular strength may also be 70 
improved when progressive resistance training is incorporated into an exercise program for HD 71 
patients (11). Patient reported physical function as measured by the SF-36 quality of life questionnaire 72 
may also improve following exercise training for HD patients (79), although there is have been mixed 73 
outcomes regarding the SF-36, with a recent review with a primary focus on intradialytic exercise 74 
suggested that improvements on the SF-36 may not be as noteworthy as previously reported (91). 75 
However, given the strong relationship between physical function and outcomes for HD patients such 76 
as mortality, it is surprising that objective measures of physical function are used infrequently. The 77 
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six-minute walk test (6MWT) is the most common measure of physical function used by studies of 78 
exercise within HD patients, and while the 6MWT is a predictor of all-cause mortality and is also 79 
associated with cardiorespiratory fitness and endurance, it does not incorporate other domains of 80 
physical function such as strength, balance, or functional joint mobility (3, 70, 72). Additionally, the 81 
efficacy of exercise for dialysis patients may also vary between delivery of intradialytic compared 82 
with interdialytic exercise (46). 83 
Recent reviews on exercise for physical function among CKD patients have lacked a focus on 84 
objectively measured physical function among HD patients. The majority of reviews over the last 10 85 
years where physical function was an outcome have either not followed a systematic review process 86 
(2, 8, 25, 26, 34, 36, 37, 40, 47, 59, 61, 67, 68, 82, 86, 87), have included the full spectrum of CKD 87 
where level of physical function varies significantly (2, 4, 24, 25, 29, 30, 33, 34, 40, 47-49, 61, 64, 67, 88 
75, 86), have only included a specific modality of exercise such as aerobic or resistance exercise (7, 89 
11, 75, 91), have specifically focussed on solely intradialytic exercise (91), or have included studies 90 
that are not randomised controlled trials or controlled trials using matched controls (5, 10, 11, 39, 49, 91 
51, 64). Of the reviews that did meet these criteria, many are now dated, reviewing studies from 92 
before 2000, and thus do not include a number of contemporary training studies exploring exercise 93 
among patients on dialysis. Therefore, the purpose of this review was to systematically explore high 94 
quality examples of research using different modalities of exercise performed both intradialytically 95 
and interdialytically to determine if exercise improves objective measures of physical function among 96 
HD patients (ESKD; stage 5 CKD), with a focus on contemporary training studies. 97 
  98 
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2. Methods 99 
2.1 Study Design 100 
This systematic review was conducted in accordance with the Preferred Reporting Items for 101 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines. 102 
2.2 Search Strategy 103 
The electronic database search included MEDLINE, Embase, the Cochrane Central Register of 104 
Controlled Trials, and CINAHL. Search strategy utilised the following search strings in separate 105 
fields: [(kidney disease) OR (renal failure)] AND [(dialysis) OR (haemodialysis) OR (hemodialysis)] 106 
AND [(exercise) OR (training)] AND [(function**) OR (performance)]. References were also 107 
identified in the reference lists of previous systematic reviews in addition to the results of our 108 
electronic database search. Studies in this review were restricted to those conducted from the year 109 
2000 onwards to highlight contemporary exercise interventions among dialysis patients (see 110 
‘Participants, Interventions, Comparators’ below). 111 
2.3 Participants, Interventions, Comparators 112 
Database search results were imported into Endnote X8 (Thompson Reuters, Philadelphia, 113 
Pennsylvania, USA). Duplicates were removed, and screening was completed by title, abstract, and 114 
full text. Excluded articles were sorted into individual folders indicating the reason for exclusion until 115 
only articles for inclusion remained. This process was completed by two researchers independently. 116 
The relevant inclusion criteria are identified below and reasons for exclusions noted in the PRISMA 117 
flow chart (Figure 1): 118 
1. Language: only studies published in English were included in this review. 119 
2. Participants: patients aged at least 18 years of age with stage 5 chronic kidney disease 120 
(ESKD) undergoing either haemodialysis or peritoneal dialysis were included. Patients who 121 
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had received kidney transplant or were affected by acute kidney failure or injury were 122 
excluded. 123 
3. Study Design: only studies that employed a randomised control trial (RCT) design were 124 
included. Systematic reviews, narrative reviews, conference abstracts, editorials, letters or 125 
publications not-inclusive of original data were excluded. 126 
4. Intervention: studies must have included an exercise intervention in the form of aerobic, 127 
resistance, combined, or alternative types of progressive exercise or significant muscular 128 
activation in the primary intervention group or groups. 129 
5. Controls: control groups in these studies must have been usual care, non-exercising patients 130 
or undergoing only range of motion or passive exercises. 131 
6. Outcomes: must have included at least one objective measure of physical function indicative 132 
of activities of daily living (ADL). Subjective measures associated with physical function 133 
(questionnaires or surveys) were excluded. 134 
 135 
Examples of objective measures of physical function indicative of ADL include the 6MWT, 136 
variations of the sit-to-stand test, balance tests, or grip strength tests which have similarities in their 137 
execution to everyday activities. Measures excluded from this review include laboratory tests such as 138 
maximal strength testing, or graded exercise testing utilising measures of oxygen utilisation, 139 
ventilatory or lactate threshold, as these are not reflective of ADL. 140 
 141 
2.4 Assessment of Risk Bias 142 
The risk of bias of included studies was independently evaluated by two independent reviewers (MJC, 143 
PNB) using the Cochrane Collaboration’s tool for assessing risk bias (32). The overall quality 144 
assessment of the RCTs included analysis of both selection bias, detection bias, and attrition bias. 145 
Selection bias was examined through method of recruitment, protocol for randomisation, concealment 146 
of treatment allocation, and similarity of groups’ baseline characteristics. Detection bias included 147 
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blinding of assessors to intervention groups and possible blinding of participants. Attrition bias 148 
explored level of adherence of participants, completeness of follow up, and reported reasons for 149 
attrition. Contention between quality assessments was resolved through follow up consultation 150 
between reviewers. Each component of the bias assessment was assigned a rating of high, low, or 151 
unclear risk of bias, sufficient enough to notably impact results or the conclusions of the trial. 152 
2.5 Data Extraction 153 
Initial screening of information was based on titles and abstracts, and subsequent screening used the 154 
full text of identified articles. Information from identified studies that was extracted included basic 155 
study characteristics, mean participant age, dialysis vintage, dialysis type, sample size, intervention 156 
modality, duration and location, and measures of objective physical function. 157 
2.6 Statistical Analysis 158 
Sufficient data for a robust meta-analysis was only available for the 6MWT, although one study was 159 
excluded from the meta-analysis as data was unable to be obtained or estimated (52). All outcomes 160 
from the 6MWT were treated as continuous data. The absolute net differences for the change in mean 161 
distance walked on the 6MWT between intervention and control groups was used to combine study 162 
effect estimates (ES) in the meta-analysis. Outcomes of the 6MWT were analysed using a random-163 
effects meta-analysis due to the variability in the samples and interventions used (31). Heterogeneity 164 
was assessed statistically using the I2 statistic. Studies with an 𝐼2 of less than 40% were considered to 165 
have low heterogeneity (32). Subgroup analyses were conducted by exercise modality, and by timing 166 
of delivery (interdialytic compared with intradialytic). A funnel plot was used to examine potential 167 
publication bias of the included studies for the 6MWT. 168 
  169 
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3. Results 170 
3.1 Literature Search 171 
We retrieved 1615 articles in searches between January 2000 to 16th January 2019 from MEDLINE 172 
(215), Embase (1186), the Cochrane Central Register of Controlled Trials (160), and CINAHL (54). 173 
Duplicates were removed to refine the number of articles for screening down to 1313. Of these 1313 174 
articles screened for eligibility, 848 were excluded based on title or abstract. The full texts of the 175 
remaining 465 were evaluated based on the inclusion criteria for this review, of which 23 fulfilled the 176 
criteria and were included in the current review. An additional 4 studies were identified from the 177 
reference lists of the included studies and were added to the analyses for a total of 27 included studies. 178 
3.2 Study Selection and Characteristics 179 
Table 1 summarises the studies included in this review based on sample size, mode and duration of 180 
intervention, outcome measures, and main findings. The 27 studies included a total of 1156 181 
participants. Individual studies generally included small sample sizes, with only four studies 182 
examining more than the mean number of participants for all studies included in this review (46 183 
participants) (13, 53, 85, 90). Sample sizes ranged from n = 16 (23, 35) to n = 227 (53) inclusive of 184 
both intervention and control groups. Only one study used healthy participants as a comparison in 185 
addition to the control group required for inclusion in this review (18). One study included two 186 
additional groups besides the exercise intervention and non-exercising control that examined the 187 
addition of nandrolone decanoate to each condition, for the purpose of the present review the 188 
nandrolone decanoate was deemed an extraneous variable, and these two groups were excluded from 189 
the review (42). Most interventions ranged from 8 weeks to 26 weeks with none lasting longer than 190 
six months in duration. While most studies examined the effects of traditional aerobic or resistance 191 
exercise interventions, or a combination of the two, three studies utilised neuromuscular electrical 192 
stimulation (20, 74, 77), two studies utilised respiratory muscle training using resistance training 193 
principles (60, 69), one study employed whole body vibration training (23), and one study employed 194 
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Yoga as an exercise intervention (92). Similarly, eight of the included studies included an exercise 195 
intervention that was performed interdialytically (23, 45, 53, 60, 76, 81, 89, 92), while the remaining 196 
exercise interventions were performed intradialytically. Twenty-one of the 27 included studies were 197 
published during or after 2010 (Table 1). 198 
3.3 Risk of Bias Assessment 199 
Risk of bias was summarised for all included studies (Figure 2). Nineteen studies were rated as low to 200 
moderate risk of bias, primarily due to insufficient blinding procedures leading to possible detection 201 
bias. The remaining eight studies were rated as moderate to high risk of bias predominately due to 202 
insufficient reporting (20, 22, 27, 35, 52, 69, 85, 89). 203 
3.3.1 Selection bias 204 
As it was a requirement of the review that included studies be randomised control trials, most studies 205 
had adequate randomisation or participant allocation (13, 14, 16, 18, 23, 42, 45, 50, 55, 60, 62, 74, 76, 206 
77, 81, 84, 90, 92). Concealment of the randomisation method was only described in 18 of the 207 
included studies (13, 14, 16, 18, 23, 42, 45, 50, 53, 55, 60, 62, 74, 76, 77, 81, 84, 92). One study 208 
allocated participants to intervention or control group by dialysis shift, which appeared to provide a 209 
random representation of the whole sample as there was no significant difference in baseline 210 
characteristics between groups (22).  211 
3.3.2 Detection bias 212 
The blinding process of participants, nurses, or other health professionals was adequately described in 213 
only four of the included studies (18, 23, 42, 60). In total, only eight studies used blinded assessors for 214 
the outcome assessment (13, 18, 23, 60, 62, 84, 89, 92). 215 
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3.3.3 Attrition bias 216 
Most of the 27 studies adequately reported attrition of participants. However, in one study this 217 
reduced the size and power of the intervention group compared with control (55). In another of these 218 
studies all attrition (approximately 7%) was solely from the intervention group, of which 5 were for 219 
reasons relating to the intervention (85). Ten of the 27 included studies reported compliance as a 220 
percentage of the total exercise sessions possible (13, 14, 35, 42, 45, 53, 62, 76, 81, 84). Compliance 221 
ranged from 71% (45) to 93% (76). Only six of the studies identified the intention-to-treat principle 222 
when conducting their analysis (13, 18, 23, 53, 60, 84). 223 
3.3.4 Reporting Bias 224 
One study only presented the mean and variance of the change in measures of physical function from 225 
before to after the intervention, and did not report the means and variance for both before and after the 226 
intervention (84). One study reported baseline means and standard deviations but only the change data 227 
and not post-intervention means and standard deviations (13). Two studies presented data on their 228 
single measure of physical function as a figure but did not state the mean or standard deviation for 229 
either group at baseline or after the intervention (52, 89). 230 
3.3.5 Other sources of Bias 231 
Sample size calculations were presented in only ten of the included studies (13, 18, 23, 42, 45, 55, 60, 232 
74, 77, 81). This makes interpretation of the findings for the remainder of studies difficult, especially 233 
with varying levels of attrition and multiple studies noting the limitation of having small sample sizes. 234 
The funnel plot included with the meta-analysis (Figure 3) indicated the existence of some publication 235 
bias as the minor asymmetry appears to be due to the impact of smaller studies (35, 84), one identified 236 
as a higher risk of bias (22), and one with a markedly different modality of exercise compared with 237 
other included studies (76). 238 
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3.4 Modality and Duration of Interventions 239 
The primary modality of intervention was aerobic exercise for at least one intervention group in 240 
twelve studies, usually as cycling performed intradialytically, with main sets ranging from 10 to 45 241 
min duration per session (16, 20, 27, 35, 45, 50, 52, 53, 76, 84, 89, 90). The intensities of these 242 
aerobic sessions were primarily measured by rating of perceived exertion (RPE) at an equivalent of 9-243 
17 RPE on a 6-20 Borg scale (9, 15, 16, 35, 45, 52, 76, 84, 89, 90). Two studies used an intensity 244 
equivalent to 60% of peak power from a baseline cardiorespiratory fitness test (20, 27). One study 245 
used 90% of ventilatory threshold (50). One home-based study utilised an intermittent walking 246 
protocol, progressing over the training program towards continuous walking, totalling to 10 minutes, 247 
twice per day at a speed dictated by their performance on the 6MWT during pre-testing (53). One 248 
study utilised 20 to 40 min duration swimming sessions as the aerobic exercise modality (76). 249 
Resistance training was the primary intervention modality for at least one intervention group in nine 250 
of the included studies, predominately lower limb exercises using low-to-moderate loads for 1 to 3 251 
sets of 8 to 15 repetitions (13, 14, 16, 22, 42, 55, 69, 81, 84). Intensity or load used by participants in 252 
these studies was often evaluated by RPE which ranged from 9 to 17 on a 6-20 Borg scale (9, 13-16, 253 
81), or by a percentage of either a 1-repetition maximum (69) or a 3-repetition maximum strength test 254 
(42).  255 
A combination of aerobic and resistance exercise was used as a single intervention in four of the 256 
included studies, combining the same parameters as the individual aerobic and resistance 257 
interventions (18, 62, 84, 85). Neuromuscular electrical stimulation was utilised in three studies for 258 
between 20 and 60 min, with a pulse width ranging from 200 to 400 ms, at 10 to 80 Hz applied over 2 259 
to 20 s, followed by 10 to 50 s rest (20, 74, 77). Respiratory training was used in a second intervention 260 
group utilising the same resistance training variables as their resistance training intervention group: 3 261 
sets of 15 repetitions at 50% maximal effort (maximal inspiratory pressure) (69). Another study 262 
utilised respiratory training twice per day as 3 sets of 30 repetitions inhalation at 50% maximum 263 
inspiratory power (60). One study used 30 min of Yoga and relaxation exercise as their primary 264 
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intervention (92). Finally, one study used whole body vibration training involving 10 to 20 minutes 265 
(as 1 minute active and 30 second rest cycles) whereby a static semi-squat position was held during 266 
active periods under vibration at 35 Hz and an amplitude of 2 to 4 mm (23). 267 
3.5 Outcome Measures 268 
Six-minute walk test: of the 27 included studies, 18 assessed the 6MWT (13, 18, 20, 22, 23, 27, 35, 269 
45, 52, 53, 55, 60, 69, 74, 76, 77, 84, 90). Eight of these studies examined only an aerobic 270 
intervention (18, 27, 35, 45, 52, 53, 76, 90), three utilised a resistance training intervention only (13, 271 
22, 55), two studies used only electromyostimulation to increase muscle activity (74, 77), two studies 272 
examined more than one of the previously stated intervention types and/or a combination of them (20, 273 
84), one study consisted of both a resistance training group and a respiratory muscle training group 274 
(69), one study primarily used a respiratory training group (60), and one study consisted of a whole 275 
body vibration training group (23). A statistically and clinically significant increase in 6MWT 276 
distance was observed for the intervention groups in eleven of these studies (20, 22, 27, 35, 52, 53, 55, 277 
69, 70, 74, 76, 90) with a mean increase of 51.2 ± 111.6 m (7 - 26% increase). Of the eleven studies 278 
demonstrating statistically significant increases in their intervention groups, there were seven aerobic 279 
exercise groups (20, 27, 35, 52, 53, 76, 90), three resistance training groups (22, 55, 69), two 280 
electromyostimulation groups (20, 74), and one group using respiratory muscle training (69). While 281 
most control groups displayed no significant change in 6MWT distance from baseline to post-testing, 282 
a statistically significant decrease was observed in the control groups of two of the 16 studies 283 
assessing 6MWT, with a mean decrease of 39.9 ± 147.2 m (10 - 11% decrease) (22, 76). 284 
The results of the meta-analysis for the 6MWT indicate that overall exercise, regardless of modality 285 
and timing of delivery, improves distance walked on the 6MWT among patients with ESKD (ES = 286 
33.64 m, 95% CI [23.74, 43.54], P < 0.001; P for heterogeneity = 0.64, and I2 = 0%) (Figure 4a). A 287 
subgroup analysis for exercise modality was performed for resistance, aerobic, combined aerobic and 288 
resistance, respiratory and electromyostimulation (Figure 4b). Aerobic exercise interventions (ES = 289 
47.80 m, 95% CI [31.74, 63.87], P < 0.001; P for heterogeneity = 0.42 and I2 = 1.9%), resistance 290 
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exercise interventions (ES = 23.62 m, 95% CI [6.45, 40.79], P = 0.007; P for heterogeneity = 0.79, 291 
and I2 = 0%) and respiratory exercise interventions (ES = 22.82 m, 95% CI [0.39, 45.26], P =0.046; P 292 
for heterogeneity = 0.36, and I2 = 0%) were the only interventions to elicit significant improvements 293 
in distance walked on the 6MWT. A subgroup analysis was also performed for the timing of exercise 294 
delivery for interventions between interdialytic and intradialytic exercise sessions (Figure 4c). Both 295 
interdialytic (ES = 29.88 m, 95% CI [11.31, 48.45], P = 0.002; P for heterogeneity = 0.36, and I2 = 296 
8.3%) and intradialytic (ES = 36.11 m, 95% CI [23.82, 48.40], P < 0.001; P for heterogeneity = 0.64, 297 
and I2 = 0%) exercise interventions improved distance walked on the 6MWT, although this appeared 298 
to be slightly in favour of intradialytic exercise. 299 
Sit to stand tests: eleven studies assessed at least one version of a sit-to-stand test (22, 42, 50, 53, 55, 300 
62, 76, 77, 84, 85, 90). Intervention groups in these studies included aerobic exercise (50, 53, 76, 84, 301 
90), resistance training (22, 42, 55, 84), a combination of both aerobic and resistance exercise (62, 84, 302 
85), or electromyostimulation (77). The types of sit to stand test administered varied between the 5-303 
times sit to stand (42, 50, 53), 10-times sit to stand (22, 62, 76, 85, 90), Max-repetition sit to stand 304 
(55), 30-second sit to stand (77, 84), and the 60-second sit to stand (50, 90). Only two studies did not 305 
produce a significant improvement in sit to stand performance in their intervention groups (42, 84), 306 
while the other studies showed improvements between 6% and 70%, with a median improvement of 307 
15%. Conversely, only one study reported a significant reduction in sit to stand performance in their 308 
control group (16%) (22), while there was no significant change in performance seen in the other 309 
control groups. 310 
Grip Strength: six studies with interventions consisting of aerobic exercise (45, 76, 92), resistance 311 
exercise (22, 81), or Yoga (92) assessed grip strength. Four studies reported a significant increase in 312 
the grip strength of participants in their intervention group compared to controls (22, 76, 90, 92). Of 313 
these four studies, three measured grip strength in kilograms, with intervention groups significantly 314 
improving by 3.6 ± 13.0 kg (8 - 17% increase), while the one study measuring grip strength in mmHg 315 
reported a 22.3 ± 46.4 mmHg, or 14.9% improvement in the Yoga intervention group (92). Of the two 316 
studies that did not report a significant improvement in grip strength, one utilised only lower limb 317 
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aerobic exercise either on or off dialysis as an intervention (45), and the other used moderate intensity 318 
resistance exercise using elastic bands and sand bags (81).  319 
Timed up and go: two of the included studies measured timed up and go (TUG) performance 320 
following aerobic interventions (45, 76). Only Samara et al. found a significant improvement in TUG 321 
performance following 16 weeks of swimming, with time to completion decreasing by 0.9 ± 1.4 s 322 
compared with no significant change in time to completion for the control group (76). Koh et al. 323 
found no significant difference in TUG performance for either home-based or HD unit based aerobic 324 
exercise groups or controls (45). 325 
Step and stair climb tests: step tests were examined in four of the included studies (16, 42, 62, 90). 326 
However, no two studies examined the same step test. One study demonstrated significant increases in 327 
the number of step ups achieved in 4 minutes compared with controls, for both resistance training (69 328 
± 25 to 131 ± 31 steps) and aerobic exercise training (86 ± 36 to 142 ± 32 steps) interventions (16). 329 
Wu et al. also found improved stair climbing performance following 12 weeks of aerobic exercise 330 
with a reduction in the time taken to climb 22 steps (total height 3.3 m) decreasing from 29.1 ± 7.2 s 331 
to 27.3 ± 7.3 s, while there was no change in the performance of the control group (90). Neither of the 332 
other two studies measuring stepping or stair climb performance showed a significant improvement in 333 
performance or a difference from the control groups (42, 62). 334 
Balance tests: of the three studies that explored the effect of exercise intervention on balance 335 
performance among dialysis patients (23, 35, 81), none found a significant improvement in balance 336 
performance following intervention. However, Hristea et al. reported a decrease in balance 337 
performance, measured as centre of pressure on a force plate in millimetres squared, in the non-338 
exercising control group, which was significantly worse than the level of balance maintained by the 339 
intervention group (35). Song et al. found no difference in the duration of single leg balancing with 340 
eyes closed for either the intervention or control groups (81), and Fuzari et al. found no significant 341 
difference in measures of either static or dynamic balance (23). 342 
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Sit and Reach: Two studies reported functional hamstring flexibility as measured by the sit and reach 343 
test (76, 81). Samara et al. demonstrated a significant improvement in sit and reach performance of 344 
5.3 ± 8.8 cm following 16 weeks swimming compared with a significantly decreased performance of 345 
3.2 ± 12.4 cm from the control group (76). However, Song et al. reported no change in sit and reach 346 
performance following 12 weeks of moderate intensity resistance exercise compared with controls 347 
(81). 348 
Short Physical Performance Battery: two studies examined the Short Physical Performance Battery 349 
(SPPB) (14, 84). Both studies found that exercise intervention significantly improved SPPB scores 350 
regardless of modality (Aerobic, Resistance, or a combination of both) (14, 84), while control groups 351 
showed no change in SPPB scores in either study. Chen et al. showed the largest improvement of 2.0 352 
± 6.4 in SPPB score following 24 weeks of a whole-body resistance exercise program (14). 353 
Incremental Shuttle Walk Test: Wilund et al. was the only study to examine the Incremental Shuttle 354 
Walk Test (ISWT) (89). Following 16 weeks of intradialytic aerobic exercise, the intervention group 355 
improved their distance walked during the ISWT by 45 ± 16 m, compared with no change in the 356 
control group (89). 357 
Other measures of physical function: Additional measures of physical function were reported by three 358 
studies (42, 50, 81). These included the North Staffordshire Royal Infirmary (NSRI) walk test (50), a 359 
20 ft gait speed assessment (42), and a shoulder mobility assessment (81). Koufaki et al. reported no 360 
significant improvement in the NSRI walk test following 12 weeks of aerobic exercise  (50). Johansen 361 
et al. showed no significant increase in gait speed following 12 weeks resistance training (42). Song et 362 
al. showed no significant increase in shoulder mobility following 12 weeks resistance training (81). 363 
3.6 Intradialytic compared with Interdialytic exercise 364 
The majority of the intervention groups among the included studies underwent intradialytic exercise. 365 
Of 33 intervention groups that completed exercise, 8 performed interdialytic exercise outside the 366 
dialysis unit (23, 45, 53, 60, 76, 81, 89, 92), while the remaining 25 completed intradialytic exercise 367 
during their regular dialysis sessions. Overall, intervention groups improved objectively measured 368 
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physical function following exercise training on 57% of measurements. However, when examining 369 
these as intradialytic and interdialytic exercise, interdialytic intervention groups increased physical 370 
function on 47% of measurements, compared with 61% of measurements for intradialytic exercise 371 
groups. 372 
For the most consistently used measure of physical function, the 6MWT, there were five interdialytic 373 
intervention groups (23, 45, 53, 60, 76), and only two (40%) elicited a significant increase in distance 374 
walked (by ~12% each) (53, 76). Conversely, there were 18 intradialytic intervention groups who 375 
underwent the 6MWT (13, 18, 20, 22, 27, 35, 45, 52, 55, 69, 74, 77, 84, 90), 11 of which (61%) 376 
elicited a significant increase in distance walked (by 7-26%) (20, 22, 27, 35, 52, 55, 69, 74, 90). As 377 
detailed in section 3.5, meta-analysis comparing interdialytic and intradialytic interventions for the 378 
6MWT appeared to slightly favour intradialytic exercise for improving distance walked on the 379 
6MWT. The only other measure of physical function for which a comparison between interdialytic 380 
and intradialytic exercise can be made was grip strength. Among the included studies, there were four 381 
interdialytic intervention groups (45, 76, 81, 92) and three intradialytic exercise groups examining 382 
grip strength (22, 45, 90). Two of the four interdialytic (76, 92), and two of the three intradialytic 383 
exercise groups (22, 90) elicited a significant increase in grip strength following exercise intervention.  384 
  385 
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4. Discussion 386 
This systematic review consistently demonstrated that both aerobic and resistance exercise as well as 387 
similar means of muscular activation such as electromyostimulation and respiratory exercise had 388 
beneficial effects on objectively measured physical function indicative of activities of daily living 389 
(ADL) in ESKD patients on dialysis. Subsequent meta-analyses further supported the efficacy of 390 
exercise specifically for improving performance on the 6MWT. This is important for patients with 391 
ESKD, as there is a markedly higher prevalence of ADL disability (an inability to perform at least one 392 
key domain of everyday activities) among patients with ESKD when compared with community 393 
dwelling older adults (57). This is notable as ADL disability has been shown to be independently 394 
associated with a greater than three-fold increase in mortality for patients with ESKD of all ages (57). 395 
However, despite the notable association of physical function with mortality for patients with ESKD, 396 
physical function is not commonly assessed among these patients (67). Further, despite physical 397 
activity being strongly associated with improvements in physical function, exercise is not a 398 
component of the routine management of patients with ESKD on dialysis (66). 399 
Interestingly, measures of physical function that are more commonly associated with a specific 400 
physiological response, such as sit-to-stand tests with muscular strength or the 6MWT with aerobic 401 
capacity, also improved with exercise intervention modalities not traditionally associated with those 402 
physiological responses (21, 43, 58, 73). For example, of the thirteen intervention groups showing 403 
significant improvement in distance walked during the 6MWT compared with controls, three used 404 
resistance training interventions (22, 55, 69), two used electromyostimulation (20, 74), and one used 405 
only respiratory muscle training (69). Furthermore, the meta-analysis in the present review indicated 406 
that resistance and respiratory interventions improved distance walked during the 6MWT similar to 407 
aerobic based exercise interventions. In studies measuring shorter duration sit-to-stand tests more 408 
closely associated with lower limb strength, intervention groups showing significant improvement 409 
included four aerobic exercise interventions (50, 53, 76, 90) and one electromyostimulation group 410 
(77). This was also true for the intervention groups for which grip strength improved compared with 411 
controls, which included two aerobic exercise interventions (76, 90), and one yoga intervention (92). 412 
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Comparing interdialytic exercise with intradialytic exercise in the present review suggested not only 413 
was intradialytic exercise more commonly employed, but it demonstrated more frequent 414 
improvements in measures of physical function. This was evident with intradialytic exercise 415 
increasing physical function for 61% of measurements compared with 47% for interdialytic exercise. 416 
Distance walked on the 6MWT may have been the best indicator for this, as it significantly increased 417 
for 40% compared with 61% of measurements for interdialytic versus intradialytic exercise, 418 
respectively. Additionally, for the 6MWT the magnitude of the increases in distance walked appear to 419 
be larger for intradialytic (up to 26%) compared with interdialytic interventions (12%), although a 420 
greater number of interdialytic exercise interventions would be required to validate this comparison. 421 
Indeed, this was supported by the meta-analyses included with the present review, whereby the 422 
increase in distance walked during the 6MWT following exercise intervention was approximately 423 
21% greater following intradialytic exercise interventions compared with interdialytic exercise 424 
interventions (increasing by 36.11 ± 6.21 m, and 29.88 ± 9.38 m, respectively). This may be 425 
influenced by known issues with reduced compliance for interdialytic exercise programs (19), 426 
although this is difficult to determine in the present review, with only ten of the included studies 427 
reporting compliance. 428 
Collectively, this review indicates that exercise regardless of modality is beneficial for improving 429 
physical function among dialysis patients, it also suggests that physical function is a multi-faceted 430 
domain that may require multi-modal exercise to attain the greatest benefit. This aligns with the broad 431 
exercise recommendations for patients with ESKD, which recommend a combination of aerobic, 432 
resistance and flexibility exercises for up to 540 minutes per week, including exercise during and 433 
outside of dialysis (80). 434 
The results of this systematic review support the effectiveness of exercise for improving physical 435 
function, yet it remains an ongoing concern that clinical pathways for the delivery of physical therapy 436 
are largely non-existent (6). This was underscored by a recent editorial published in the British 437 
Journal of Sports Medicine (BJSM), calling for clinicians to adopt exercise programmes into standard 438 
practice for patients undergoing dialysis (19). The editorial further elucidated that improvements in 439 
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physical function among patients undergoing dialysis contribute to the prevention of some clinical and 440 
functional disabilities, reduces hospitalisations and mortality, and increases patient transplant 441 
eligibility (19). Additionally, the editorial highlights that not only is exercise during dialysis feasible 442 
regardless of age, it also displays notably higher compliance compared with exercise programmed 443 
outside of dialysis (19). 444 
A Cochrane review and subsequent update by Heiwe and Jacobsen (29, 30) also found improvements 445 
in physical function as well as other measures such as aerobic capacity and muscular strength in 446 
patients across the full spectrum of chronic kidney disease following various exercise interventions. 447 
The findings of our review support these findings for physical function, specifically for ESKD 448 
patients on dialysis. However, one limitation for both reviews, is the lack of consistency in the 449 
measures of physical function used by the included studies. While the 6MWT was employed by 16 of 450 
the 27 (64%) studies included in the present review (13, 18, 20, 22, 27, 35, 45, 52, 53, 55, 69, 74, 76, 451 
77, 84, 90), no other single measure of physical function was used in any more than 6 of the 27 (24%) 452 
included studies. Similarly, the inconsistencies in exercise prescription variables for the training 453 
components of these studies creates another limitation when trying to determine the effectiveness of 454 
specific exercise modalities or the effect of exercise on specific measures of physical function. 455 
A subsequent letter supporting the BJSM editorial also highlighted the paucity of high-quality RCTs 456 
of adequate power with any consistency in exercise prescription (54). This makes attempts to 457 
standardise intradialytic exercise prescription difficult. The studies included in the present review are 458 
examples of such high quality RCTs, but the broad prescription used in conjunction with overarching 459 
improvements in physical function may suggest that there is no single exercise prescription that is 460 
ideal among this population. Indeed, prescribing any exercise that is feasible to conduct during 461 
dialysis and can be tolerated by patients with ESKD is likely to provide significant benefit, and should 462 
therefore be incorporated into standard practice. 463 
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4.1 Limitations of the included studies 464 
While this review included robust, contemporary evidence of the effect of exercise, moderate risk of 465 
bias in some studies was still present (Figure 2). Namely, randomisation and concealment, and 466 
blinding of participants and personnel were of concern (78). Indeed, many studies were excluded from 467 
this review due to having no control group and/or a non-randomised allocation of participants. Even 468 
amongst those included in the review, randomisation and concealment was only sufficiently reported 469 
in 16 of the 27 included studies (13, 14, 16, 18, 42, 45, 50, 53, 55, 62, 74, 76, 77, 81, 84, 92). 470 
Additionally, only 4 studies indicated use of the intention-to-treat principle (13, 18, 53, 84); only 8 471 
included sample size calculations (13, 18, 42, 45, 55, 74, 77, 81); and only 10 reported compliance 472 
(13, 14, 35, 42, 45, 53, 62, 76, 81, 84), which is a noted concern for dialysis patients completing 473 
exercise programs (46, 88). While only 2 of the included studies adequately addressed blinding of 474 
participants, included studies were largely comparing exercise to, in most cases, a non-exercising 475 
control making blinding difficult as participants are able to determine when they are active compared 476 
to inactive. With regards to meta-analyses, the lack of consistent measures of objective physical 477 
function between studies made it difficult to present other meaningful meta-analyses of objective 478 
measures of physical function. 479 
4.2 Future directions for research 480 
As there appears to be benefits across multiple modalities of exercise, future research should aim to 481 
determine which exercise prescriptions provide the best value for time spent exercising. This is 482 
especially relevant due to the previously established reluctance of dialysis patients to commit time to 483 
exercising (17). Similarly, direct comparisons of exercise interventions delivered both intradialytically 484 
and interdialytically in conjunction with reporting of compliance for each method of delivery may 485 
help determine which method of delivery is more effective. Importantly, a continued emphasis should 486 
be placed on objective measures of physical function due to its relevance to dialysis patients. This 487 
should incorporate a holistic battery of physical function measures as it is apparent from this review 488 
that a single modality of exercise may improve physical function indicative of multiple physiological 489 
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outcomes, which may not be traditionally associated with that exercise modality. Finally, greater 490 
measures to account for the notably elevated levels of participant attrition seen among dialysis 491 
patients need to be made in future research in order to avoid the commonly reported limitation of 492 
studies being underpowered. This may potentially warrant greater allowances for dropout when 493 
calculating sample size, increased study recruitment times, or adopting multi-centre approaches to 494 
these types of training studies. 495 
4.3 Conclusions 496 
Physical function is a poorly examined and under treated area of patient care among people with 497 
ESKD undergoing dialysis. The results of this review indicate that exercise, regardless of modality, is 498 
indeed useful for improving physical function as measured by tasks reflective of everyday activities. 499 
Additionally, the meta-analysis provides evidence to support the value of intradialytic compared with 500 
interdialytic exercise for dialysis populations. However, despite the known impact that poor physical 501 
function has on the health outcomes of patients with ESKD undergoing dialysis, there is no 502 
established pathway for exercise delivery to these patients. Moderate intensity exercise can be 503 
delivered in numerous forms both during and outside of dialysis and this review demonstrates that 504 
such moderate intensity exercise improves physical function. However, the absence of clinical 505 
implementation of such programs is an area of concern in the overall management of patients 506 
undergoing dialysis. 507 
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9. Figure Legends 772 
 773 
Figure 1. PRISMA flow chart of study selection process. 774 
 775 
Figure 2. Risk of bias assessment for included studies evaluating changes in objective measures of 776 
physical function following exercise intervention among patients with end-stage kidney disease. 777 
 778 
Figure 3. Funnel plot for the effect estimates on distance walked during the six-minute walk test 779 
among patients with end-stage kidney disease following exercise intervention compared with usual 780 
care controls. 781 
 782 
Figure 4. Forest plots of the effect estimates with 95% confidence intervals for the distance walked 783 
during the six-minute walk test between exercise interventions and usual care control groups for a) all 784 
included studies b) subgroup analysis by exercise modality; c) subgroup analysis by timing of 785 
exercise intervention delivery (interdialytic versus intradialytic). 786 
 787 
  788 
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Table 1. Summary of studies evaluating changes in objective measures of physical function following exercise intervention among patients with 789 
end-stage kidney disease (values presented are means ± SD). 790 
Authors Year 
Sample (dialysis 
type, mean age, 
location, other) 
Dialysis 
Vintage 
(years) 
Study 
N  
Intervention Details 
Control Group 
Physical 
Function 
Outcome 
(exercise vs 
control) 
Duration Modality Location Prescription 
Cheema et 
al.(12) 
2007 Haemodialysis 
Age: 62.6 ± 14.2 
Australia 
 
5.4 ± 4.1 49 12 weeks Resistance HD Unit Free-weight exercises: 
(dumbbells for upper body, ankle 
weights for lower body), 3 times 
per week, 2 sets of 8 repetitions 
of 10 exercises (5 upper body, 5 
lower body) at intensity of 15 – 
17 on Borg’s RPE scale. 
 
Usual care ↔ 6MWT 
Chen et al. (14) 2010 Haemodialysis 
Age: 69 ± 13 
 
3.7 ± 4.1 44 24 weeks Resistance HD Unit Free-weight exercises: (ankle weights 
from 0.5 – 20 lbs). 2 times per 
week, 2 sets of 8 repetitions of 5 
exercises (4 lower limb, 1 core) at 
intensity of 6 out of 10 on a 
modified OMNI scale. 
 
5 Light flexibility 
exercises in 
semi-
recumbent 
position held 
for 20-30 sec 
each, 
repeated 
twice. 
↑ SPPB 
de Lima et al. 
(16) 
2013 Haemodialysis 
Age: 45.5 ± 11.2 
 
6.1 ± 4.2 
 
32 8 weeks Aerobic HD Unit Progressive cycle ergometry 3 times 
per week, for 20 min at intensity 
of 2 – 3 on the modified 1-10 
Borg’s RPE scale 
 
Usual care ↑ 4 min step test 
8 weeks Resistance  HD Unit Free-weight exercises: (ankle weights 
equivalent to 40% 1RM knee-
extension). 3 times per week, 3 
sets of 15 repetitions of 2 lower 
limb exercises. 
 
↑ 4 min step test 
DePaul et al. 
(18) 
 
 
2002 Haemodialysis 
Age: 54.5 ± 15.1 
 
4.4 ± 4.7 38 12 weeks Aerobic & 
Resistance 
HD Unit Progressive cycle ergometry, 3 times 
per week for 20 min at intensity 
of 13 on Borg’s RPE scale. 
 
30 min non-
resisted range 
of motion 
exercises 
↔ 6MWT 
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DePaul et al. 
(cont.) 
Resistance exercises: (seated knee 
flexion/extension machine) 3 
times per week, 1-3 sets of 10 
repetitions of 2 knee 
flexion/extension exercises at 50-
125% baseline 5RM over 12 
weeks 
Dobsak et al. 
(20) 
2012 Haemodialysis 
Age: 61 ± 7.8 
 
4.0 ± 2.1 32 20 weeks Aerobic HD Unit Cycle ergometry, 3 times per week for 
1-2 sets of 20 min at intensity of 
60% of the watts determined in 
an ergometric test. 
 
Usual care ↑ 6MWT 
20 weeks Electromyo-
stimulation 
HD Unit Neuromuscular electrical stimulation 
(dual channel battery-powered 
stimulators) 3 times per week, for 
60 min, with 200 µs pulse width, 
at a frequency of 10Hz (20 sec 
on, 20 sec rest) for both 
quadriceps and calves. 
 
↑ 6MWT 
Esteve Simó et 
al. (22) 
2014 Haemodialysis 
Age: 68.4 ± 16.4 
 
5.5 ± 6.3 40 26 weeks Resistance  HD Unit Resistance exercises (resistance bands, 
medicine balls, ankle weights, 
and dumbbells) 2 times per week, 
maximal repetitions and sets of 
12 exercises (5 upper limb, 7 
lower limb). 
 
Usual care ↑ 6MWT 
↑ Grip Strength 
↑ STS-10 
 
Fuzari et al. (23) 2018 Haemodialysis 
Age: 57.6 ± 8.9 
N/A 16 12 weeks Whole Body 
Vibration 
Off-HD Whole body vibration: 10-20 min 
(1min vibration 30 sec off) Static 
semi-squat during vibration; 
35Hz, 2-4mm amplitude 
 
Usual care ↔ 6MWT 
↔ Balance 
 
Groussard et al. 
(27) 
2015 Haemodialysis 
Age: 67.6 ± 4.1 
 
3.3 ± 0.7 18 12 weeks Aerobic HD Unit Progressive cycle ergometry, 3 times 
per week for 15-30 min at 
intensity of 55-60% of the watts 
determined in an ergometric test. 
 
Usual care ↑ 6MWT 
 
Hristea et al. 
(35) 
2016 Haemodialysis 
Age: 69.8 ± 11.8 
 
9.6 ± 14.9 16 26 weeks Aerobic HD Unit Progressive cycle ergometry, 3 times 
per week for up to 30 min at an 
intensity of 3 on the modified 1-
10 Borg’s RPE scale 
 
Usual care and 
dietary advice 
from a 
nutritionist 
↑ 6MWT 
↑ Balance 
 
Johansen et al. 2006 Haemodialysis 4.0 ± 2.7 40 12 weeks Resistance  HD Unit Free-weight exercises: (ankle weights), Usual care ↔ Stair Climb 
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(41) Age: 55.6 ± 13.7 
 
3 times per week, 2 sets of 10 
repetitions of 3 lower limb 
exercises at 60% 3RM. 
 
↔ Gait Speed 
↔ STS-5 
Koh et al. (45) 2010 Haemodialysis 
Age: 51.9 ± 12.8 
 
2.7 ± 2.3 44 26 weeks Aerobic HD Unit Progressive cycle ergometry, 3 times 
per week for 15-45 min at an 
intensity of 12-13 on Borg’s RPE 
scale. 
 
Usual care ↔ 6MWT 
↔ TUG 
↔ Grip 
Strength 
26 weeks Aerobic Home Home-based unsupervised walking, 3 
times per week for 15-45 min at 
an intensity of 12-13 on Borg’s 
RPE scale. 
 
↔ 6MWT 
↔ TUG 
↔ Grip 
Strength 
Koufaki et al. 
(50) 
2002 Continuous 
Ambulatory 
Peritoneal 
Dialysis & 
Haemodialysis 
Age: 54.2 ± 16.6 
 
3.5 ± 4.0 33 12 weeks Aerobic HD Unit Progressive cycle ergometry, 3 times 
per week progressing from 3 sets 
of 6-8 min, to 1 set of 30-35 min 
at an intensity 90% of the watts 
corresponding to ventilatory 
threshold determined in an 
ergometric test. 
 
Usual Care ↔ WALK Test 
↑ STS-5 
↑ 60STS 
Liao et al. (52) 2016 Haemodialysis 
Age: 62 ± 9 
 
6.4 ± 5.0 40 12 weeks Aerobic HD Unit Cycle ergometry, 3 times per week for 
30 min at an intensity of 12-15 on 
Borg’s RPE scale. 
 
Usual Care ↑ 6MWT 
 
Manfredini et 
al. (53) 
2016 Continuous 
Ambulatory 
Peritoneal 
Dialysis & 
Haemodialysis 
Age: 63.5 ± 13.6 
 
N/A 227 26 weeks Aerobic Home Home-based walking program, twice 
daily always on non-dialysis 
days, 3 times per week for 10 min 
at a metronome dictated speed 
equating to between 1.4 and 2.8 
km.h-1 depending on 6MWT 
performance. 
 
Usual Care ↑ 6MWT 
↑ STS-5 
 
Matsufuji et al. 
(55) 
2015 Haemodialysis 
Age: 69.8 ± 4.3 
 
13.6 ± 3.4 17 12 weeks Resistance HD Unit Repeated sit-to-stand exercise on 40cm 
chair (3 sec stand time and 3 sec 
sit time), 3 times per week for 5 
sets of half participants’ 
maximum repetitions. 
 
 
Passive upper and 
lower body 
stretching 
exercises 
↑ 6MWT 
↑ Max STS 
 
 
Medeiros et al. 
(60) 
2018 Haemodialysis 
Age: 36.4 ± 3.6 
6.8 ± 1.7 24 8 weeks Respiratory Off-HD  Inspiratory muscle training: twice per 
day; 3 sets of 30 inspirations at 
Usual Care ↔ 6MWT 
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50% of maximal inspiratory 
pressure. 
 
Molsted et 
al.(62) 
 
 
 
 
 
2004 Haemodialysis 
Age: 48.3 ± 8.4 
 
3.9 ± 3.1 33 22 weeks Aerobic & 
Resistance 
HD Unit Progressive cycle ergometry, 2 times 
per week for 15-20 min at an 
intensity of 17 on Borg’s RPE 
scale. 
 
 
Supervised resistance exercises: Step 
and circuit training, high and low 
impact aerobics, 2 times per week 
for 20-30 min, at an intensity of 
14-17 on Borg’s RPE scale. 
 
Usual Care ↔ Stair Climb 
↑ STS-10 
 
Pellizzaro et al. 
(69) 
2013 Haemodialysis 
Age: 48.3 ± 11.8 
 
4.9 ± 2.0 39 10 weeks Resistance HD Unit Free-weight exercises: (ankle weights) 
for knee extension, 3 times per 
week, for 3 sets of 15 repetitions 
at an intensity of 50% 1RM 
 
Usual Care ↑ 6MWT 
 
10 weeks Respiratory HD Unit Inspiratory muscle training using a 
unidirectional flow limiter, 3 
times per week, 3 sets of 15 
inspirations at an intensity of 
50% of maximal inspiratory 
pressure. 
 
↑ 6MWT 
 
Roxo et al. (74) 2016 Haemodialysis 
Age: 50.5 ± 17.8 
 
4.8 ± 3.7 40 8 weeks Electromyo-
stimulation 
HD Unit Neuromuscular electrical stimulation 
(four channel battery-powered 
stimulators) 3 times per week, for 
30 min, with 350 µs pulse width, 
at a frequency of 50Hz (2 sec on, 
10 sec rest) for quadriceps. 
 
Usual Care ↑ 6MWT 
 
Samara et al. 
(76) 
2016 Haemodialysis 
Age: 48.3 ± 13.3 
 
N/A 27 16 weeks Aerobic Pool Aquatic training on non-dialysis days 
(various swimming strokes with 
and without floatation aids), 3 
times per week, up to 60 min, at 
an intensity of 13-14 on Borg’s 
RPE scale. 
 
Usual Care ↑ 6MWT 
↑ TUG 
↑ Grip Strength  
↑ STS-10 
↑ Sit-and-Reach 
 
Schardong et al. 
(77) 
2017 Haemodialysis 
Age: 61.1 ± 5.2 
4.3 ± 4.4 21 8 weeks Electromyo-
stimulation 
HD Unit Neuromuscular electrical stimulation 
(four channel battery-powered 
Usual Care ↔ 6MWT 
↑ 30STS 
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 stimulators) 3 times per week, for 
20-36 min, with 400 µs pulse 
width, at a frequency of 50Hz (10 
sec on, 50-10 sec rest) for 
quadriceps. 
 
 
 
Song & Sohng 
(81) 
2012 Haemodialysis 
Age: 53.4 ± 11.3 
 
3.5 ± 3.7 40 12 weeks Resistance Off-HD Free-weight exercises: (resistance 
bands and sand bags), 3 times per 
week. 3 sets of 10-15 repetitions 
of 12 exercises (6 lower body and 
6 upper body exercises), at an 
intensity of 11-15 on Borg’s RPE 
scale. 
 
Usual Care ↔ Balance 
↔ Grip 
Strength 
↔ Sit-and-
Reach 
↔ Shoulder 
Mobility 
Thompson et al. 
(84) 
2016 Haemodialysis 
Age: 59.9 ± 6.5 
 
3.1 ± 0.7 31 12 weeks Aerobic HD Unit Progressive cycle ergometry, 3 times 
per week for 15-45 min at an 
intensity of 12-14 on Borg’s RPE 
scale. 
 
 
Non-progressive 
stretching 
exercises (2 
sets of 4 
exercises) 
↔ 6MWT 
↔ 30STS 
↑ SPPB 
12 weeks Resistance HD Unit Free-weight exercises: (ankle weights 
and Thera-Band), 3 times per 
week, for 1-3 sets of 4 exercises 
(all lower body), at an intensity of 
12-14 on Borg’s RPE scale. 
 
 
↔ 6MWT 
↔ 30STS 
↑ SPPB 
12 weeks Aerobic & 
Resistance 
HD Unit Progressive cycle ergometry, 3 times 
per week for 15-45 min at an 
intensity of 12-14 on Borg’s RPE 
scale. 
 
Free-weight exercises: (ankle weights 
and Thera-Band), 3 times per 
week, for 1-3 sets of 4 exercises 
(all lower body), at an intensity 
of 12-14 on Borg’s RPE scale. 
 
 
↔ 6MWT 
↔ 30STS 
↑ SPPB 
van Vilsteren et 
al. (85) 
2005 Haemodialysis 
Age: 54.7 ± 15.5 
 
4.5 ± 0.9 96 12 weeks Aerobic & 
Resistance 
HD Unit Pre-dialysis resistance exercises: 
(calisthenics, steps, free weights), 
2-3 times per week, 20 min at 
Usual Care ↑ STS-10 
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60% maximum (determined by 
RPE) 
 
Intradialytic cycling ergometry, 2-3 
times per week for 20-30 min at 
an intensity of 60% maximal 
capacity (determined by RPE) 
 
Wilund et al. 
(89) 
2010 Haemodialysis 
Age: 59.8 ± 4.2 
 
4.5 ± 0.9 17 16 weeks Aerobic Off-HD Progressive cycle ergometry, 3 times 
per week up to 45 min at an 
intensity of 12-14 on Borg’s RPE 
scale. 
 
Usual Care ↑ ISWT 
Wu et al. (90) 2014 Haemodialysis 
Age: 44.3 ± 2.5 
 
4.0 ± 2.8 65 12 weeks Aerobic HD Unit Intradialytic cycling ergometry, 3 
times per week for 15-20 min at 
an intensity of 12-16 on Borg’s 
RPE scale. 
 
Non-progressive 
stretching 
exercises for 
10-15 min 
↑ Stair Climb 
↑ 6MWT 
↑ Grip Strength 
↑ 60STS 
↑ STS-10 
Yurtkuran et al. 
(92)  
2007 Haemodialysis 
Age: 39.5 ± 12.3 
 
1.8 ± 1.2 37 12 weeks Yoga Off-HD Yoga (modified exercises – 7 postures 
and relaxation), 2 times per week 
for 15-30 min 
Usual care and 
home-based 
active range 
of motion 
exercises for 
upper limbs 
and spine 
 
↑ Grip Strength 
 
 791 
 792 
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Appendix C: 
 
Full table of pQCT results
296 
 Baseline values and within group changes  
 BFR-CYC CYC CON   Between-group effects 
 n Mean ± SD Mean (95% CI) n 
Mean ± SD 
Mean (95% CI) n 
Mean ± SD 
Mean (95% CI) 
Net diff, BFR-CYC v CYC 
(95% CI) 
25% right femur muscle density (mg/cm3) 
     Baseline 6 69.8 ± 5.4 4 70.5 ± 3.8 2 66.1 ± 1.0 
0.0 (-2.6, 3.4) 12-week 4 72.1 ± 3.7 4 69.8 ± 1.7 1 66.5 ± 0.0 
     ∆ 12-week 4 -0.7 (-1.6, 0.3) 4 -0.7 (-3.5, 2.1) 1 - 
25% right femur muscle CSA (cm2) 
     Baseline 6 55.3 ± 6.5 4 76.5 ± 37.3 † 2 58.3 ± 7.6 
0.5 (-1.2, 2.1) 12-week 4 58.3 ± 7.6 4 77.1 ± 37.7 † 1 54.9 ± 0.0 
     ∆ 12-week 4 1.1 (-0.3, 2.6) 4 0.6 (-0.1, 1.4) 1 - 
25% right femur muscle CSA (%) 
     Baseline 6 51.3 ± 13.4 4 51.2 ± 15.6 2 48.1 ± 2.1 
-0.3 (-1.8, 1.1) 12-week 4 51.1 ± 13.1 4 51.3 ± 15.2 1 46.9 ± 0.0 
     ∆ 12-week 4 -0.2 (-1.1, 0.7) 4 0.1 (-1.0, 1.3) 1 - 
25% right femur subcutaneous fat CSA (cm2) 
     Baseline 6 43.7 ± 21.7 4 52.9 ± 17.6 2 44.7 ± 4.3 
1.7 (-1.2, 4.5) 12-week 4 42.5 ± 20.3 4 52.4 ± 15.0 1 48.1 ± 0.0 
     ∆ 12-week 4 1.2 (0.2, 2.2) # 4 -0.5 (-3.2, 2.2) 1 - 
25% left femur muscle density (mg/cm3) 
     Baseline 6 69.4 ± 4.1 4 69.2 ± 1.5 2 65.0 ± 0.9 
1.1 (-0.6, 2.9) 12-week 5 71.4 ± 4.3 4 69.7 ± 1.3 1 64.7 ± 0.0 
     ∆ 12-week 5 1.6 (0.1, 3.1) # 4 0.5 (0.1, 0.8) # 1 - 
 
 
 
 297 
25% left femur muscle CSA (cm2)  
     Baseline 6 55.1 ± 7.9 4 73.0 ± 32.9 † 2 53.3 ± 4.6 
-1.7 (-4.1, 0.7) 12-week 5 55.3 ± 9.3 4 74.9 ± 34.9 † 1 51.5 ± 0.0 
     ∆ 12-week 5 0.2 (-1.5, 1.9) 4 1.9 (0.2, 3.7) # 1 - 
25% left femur muscle CSA (%) 
     Baseline 6 50.9 ± 13.6 4 50.3 ± 14.8 2 46.0 ± 4.1 
-2.0 (-3.3, -0.7) ^ 12-week 5 50.0 ± 15.2 4 51.4 ± 15.6 1 43.4 ± 0.0 
     ∆ 12-week 5 -0.9 (-1.8, -0.1) # 4 1.1 (0.1, 2.0) # 1 - 
25% left femur subcutaneous fat CSA (cm2) 
     Baseline 6 44.4 ± 20.7 4 54.0 ± 19.4 2 48.8 ± 3.5 
2.9 (0.7, 5.0) ^ 12-week 5 46.0 ± 23.0 4 52.7 ± 18.5 1 52.4 ± 0.0 
     ∆ 12-week 5 1.6 (0.6, 2.5) # 4 -1.3 (-3.3, 0.7) 1 - 
50% right femur muscle density (mg/cm3) 
     Baseline 6 72.4 ± 5.3 3 77.3 ± 5.9 2 67.5 ± 1.7 
2.7 (-2.0, 7.5) 12-week 5 73.8 ± 6.5 3 75.9 ± 2.0 1 70.0 ± 0.0 
     ∆ 12-week 5 1.4 (-1.5, 4.3) 3 -1.3 (-5.0, 2.3) 1 - 
50% right femur muscle CSA (cm2) 
     Baseline 6 96.8 ± 11.7 3 104.6 ± 49.9 2 97.0 ± 4.3 
0.9 (-1.9, 3.9) 12-week 5 98.2 ± 8.7 3 105.2 ± 50.6 1 94.1 ± 0.0 
     ∆ 12-week 5 1.4 (-0.7, 3.6) 3 0.5 (-0.5, 1.6) 1 - 
50% right femur muscle CSA (%) 
     Baseline 6 60.8 ± 14.8 3 58.3 ± 17.2 2 63.7 ± 4.6 
0.1 (-1.9, 2.0) 12-week 5 60.6 ± 15.5 3 58.0 ± 17.3 1 60.2 ± 0.0 
     ∆ 12-week 5 -0.2 (-1.4, 1.1) 3 -0.3 (-1.7, 1.1) 1 - 
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50% right femur subcutaneous fat CSA (cm2) 
     Baseline 6 56.4 ± 32.2 3 58.3 ± 27.5 2 44.3 ± 9.5 
0.3 (-5.2, 5.8) 12-week 5 57.1 ± 34.5 3 58.7 ± 24.6 1 51.9 ± 0.0 
     ∆ 12-week 5 0.7 (-2.4, 3.8) 3 0.4 (-4.5, 5.3) 1 - 
50% left femur muscle density (mg/cm3) 
     Baseline 6 73.6 ± 5.2 3 71.3 ± 1.3 2 66.8 ± 0.2 
1.5 (-5.0, 8.1) 12-week 5 74.8 ± 3.7 3 71.0 ± 4.2 1 66.4 ± 0.0 
     ∆ 12-week 5 1.2 (-3.3, 5.8) 3 -0.3 (-3.5, 2.9) 1 - 
50% left femur muscle CSA (cm2) 
     Baseline 6 92.6 ± 12.4 3 99.1 ± 43.7 2 95.1 ± 11.2 
0.2 (-5.3, 6.1) 12-week 5 94.4 ± 16.3 3 100.7 ± 44.0 1 89.8 ± 0.0 
     ∆ 12-week 5 1.8 (-2.5, 6.1) 3 1.6 (-0.0, 3.2) 1 - 
50% left femur muscle CSA (%) 
     Baseline 6 58.3 ± 15.4 3 57.5 ± 16.3 2 62.0 ± 8.1 
-0.5 (-2.5, 1.6) 12-week 5 57.7 ± 18.1 3 57.4 ± 15.9 1 56.7 ± 0.0 
     ∆ 12-week 5 -0.6 (-2.1, 1.0) 3 -0.1 (-0.6, 0.3) 1 - 
50% left femur subcutaneous fat CSA (cm2) 
     Baseline 6 59.6 ± 31.6 3 57.0 ± 24.4 2 47.0 ± 13.4 
1.2 (-1.9, 4.2) 12-week 5 62.3 ± 36.5 3 58.5 ± 23.6 1 57.7 ± 0.0 
     ∆ 12-week 5 2.7 (1.1, 4.2) # 3 1.5 (-1.5, 4.6) 1 - 
Data are: baseline unadjusted mean ± standard deviation (SD); within-group unadjusted mean absolute change with 95% confidence interval (CI); net difference (95% CI) were 
calculated by subtracting unadjusted within-group absolute changes from baseline to follow-up. # indicates significant change from baseline to 12 weeks (P < 0.05). ^ indicates 
significant main effect for group (between BFR-CYC and CYC; P < 0.01). † indicates CYC was significantly different to both BFR-CYC and CON. ABBREVIATIONS: 
BFR-CYC = Blood flow restricted cycling group; CYC = traditional cycling group; CON = usual care control group; CSA = cross-sectional are
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 Baseline values and within group changes  
 BFR-CYC CYC CON Between-group effects 
 n Mean ± SD Mean (95% CI) n 
Mean ± SD 
Mean (95% CI) n 
Mean ± SD 
Mean (95% CI) 
Net diff, BFR-CYC v CYC 
(95% CI) 
Total body lean mass (kg) 
Baseline 7 42.5 ± 3.7 4 50.1 ± 12.1 2 43.4 ± 2.9 
0.4 (-0.7, 1.5) 12 weeks 5 43.1 ± 4.4 4 50.3 ± 11.9 1 46.6 ± 0.0 
     ∆ 12-week 5 0.6 (-0.2, 1.3) 4 0.2 (-0.6, 1.0) 1 - 
Appendicular lean mass (kg) 
Baseline 7 18.3 ± 1.6 4 22.7 ± 6.8 2 19.0 ± 1.4 
0.4 (-0.3, 1.1) 12 weeks 5 18.6 ± 1.8 4 22.6 ± 6.8 1 20.1 ± 0.0 
     ∆ 12-week 5 0.3 (-0.1, 0.7) 4 -0.1 (-0.7, 0.5) 1 - 
Arm lean mass (kg) 
Baseline 7 4.7 ± 0.6 4 5.9 ± 2.3 2 4.8 ± 0.1 
0.2 (0.0, 0.5) ^ 12 weeks 5 4.8 ± 0.9 4 5.8 ± 2.1 1 4.8 ± 0.0 
     ∆ 12-week 5 0.1 (-0.0, 0.3) 4 -0.1 (-0.3, 0.1) 1 - 
Leg lean mass (kg) 
Baseline 7 13.7 ± 1.2 4 16.7 ± 4.6 2 14.1 ± 1.5 
0.1 (-0.5, 0.8) 12 weeks 5 13.6 ± 0.9 4 16.8 ± 4.7 1 15.3 ± 0.0 
     ∆ 12-week 5 0.1 (-0.2, 0.5) 4 0.0 (-0.6, 0.6) 1 - 
Total body fat mass (kg) 
Baseline 7 25.9 ± 11.7 4 33.8 ± 9.0 2 29.5 ± 5.9 
0.4 (-0.2, 1.1) 12 weeks 5 26.9 ± 12.3 4 34.4 ± 8.5 1 34.4 ± 0.0 
     ∆ 12-week 5 1.0 (0.6, 1.4)* 4 0.6 (0.1, 1.0)* 1 - 
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Total body fat mass (%) 
Baseline 7 35.1 ± 12.6 4 38.9 ± 2.0 2 39.2 ± 3.2 
0.4 (-0.1, 0.9) 12 weeks 5 35.9 ± 14.3 4 39.3 ± 1.8 1 41.3 ± 0.0 
     ∆ 12-week 5 0.8 (0.5, 1.1)* 4 0.4 (-0.1, 0.9) 1 - 
Arm fat mass (kg) 
Baseline 7 2.9 ± 1.3 4 3.4 ± 0.7 2 2.6 ± 0.9 
0.2 (-0.1, 0.5) ^ 12 weeks 5 3.0 ± 1.5 4 3.2 ± 0.6 1 3.6 ± 0.0 
     ∆ 12-week 5 0.1 (0.0, 0.2)* 4 -0.2 (-0.4, 0.0) 1 - 
Leg fat mass (kg) 
Baseline 7 6.6 ± 3.0 4 8.3 ± 1.6 2 6.6 ± 1.5 
-0.1 (-0.4, 0.3) 12 weeks 5 6.7 ± 2.8 4 8.5 ± 1.4 1 7.7 ± 0.0 
     ∆ 12-week 5 0.1 (0.0, 0.2)* 4 0.2 (-0.2, 0.6) 1 - 
Trunk fat mass (kg) 
Baseline 7 15.6 ± 8.3 4 20.9 ± 8.3 2 19.4 ± 3.5 
0.1 (-0.2, 0.5) 12 weeks 5 16.2 ± 8.2 4 21.4 ± 8.0 1 22.1 ± 0.0 
     ∆ 12-week 5 0.6 (0.4, 0.9)* 4 0.5 (0.2, 0.7)* 1 - 
Android fat mass (kg) 
Baseline 7 2.8 ± 1.7 4 3.9 ± 1.8 2 3.9 ± 1.1 
0.2 (-0.0, 0,3) 12 weeks 5 3.0 ± 1.7 4 3.9 ± 1.8 1 4.7 ± 0.0 
     ∆ 12-week 5 0.2 (0.1, 0.3)* 4 0.0 (-0.0, 0.1) 1 - 
Gynoid fat mass (kg) 
Baseline 7 3.6 ± 1.7 4 4.5 ± 1.1 2 3.9 ± 0.9 0.2 (-0.0, 0.3) 
12 weeks 5 3.7 ± 1.6 4 4.4 ± 0.9 1 4.7 ± 0.0 
 
     ∆ 12-week 5 0.1 (0.0, 0.1)* 4 -0.1 (-0.3, 0.1) 1 - 
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Abdominal visceral fat mass (kg) 
Baseline 7 1.6 ± 1.4 4 2.9 ± 2.3 2 2.7 ± 5.7 
0.2 (-0.2, 0.4) 12 weeks 5 1.7 ± 1.4 4 2.9 ± 2.3 1 2.7 ± 0.0 
     ∆ 12-week 5 0.1 (-0.2, 0.3) 4 -0.1 (-0.1, 0.0) 1 - 
Abdominal subcutaneous fat mass (kg) 
Baseline 7 1.1 ± 0.8 4 1.0 ± 0.8 2 1.2 ± 1.1 
0.0 (-0.2, 0.2) 12 weeks 5 1.2 ± 0.6 4 1.1 ± 0.9 1 2.1 ± 0.0 
     ∆ 12-week 5 0.1 (-0.1, 0.3) 4 0.1 (0.0, 0.2)* 1 -  
Data are: baseline unadjusted mean ± standard deviation (SD); within-group unadjusted mean absolute change with 95% confidence interval (CI); net difference (95% CI) 
were calculated by subtracting unadjusted within-group absolute changes from baseline to follow-up. * indicates significant change from baseline to 12 weeks (P < 0.05). ^ 
indicates significant main effect for group (between BFR-CYC and CYC; P < 0.05). ABBREVIATIONS: BFR-CYC = Blood flow restricted cycling group; CYC = 
traditional cycling group; CON = usual care control group.
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Participant Information Sheet/Consent Form 
Health/Social Science Research - Adult providing own consent 
 
Title 
The Effects of Blood Flow Restriction 
Exercise Training on Muscle Health and 
Physical Function among Patients with End 
Stage Kidney Disease 
Short Title 
 
Blood flow restriction exercise during dialysis 
  
Coordinating Principal 
Investigator/ Principal 
Investigators 
Mr Matthew Clarkson 
Dr Stuart Warmington 
Dr Steven Fraser 
Professor Paul Bennett 
 
Professor Lawrence McMahon 
Associate Investigators 
 
 
 
Location  Eastern Health  
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Part 1  What does my participation involve? 
 
1 Introduction 
 
You are invited to take part in this research project, which is measuring the 
tolerability, as well as heart rate and blood pressures responses to a technique 
called “blood flow restriction” during exercise for people on dialysis. You have been 
invited because you are an adult patient undergoing dialysis at Eastern Health. Your 
contact details were obtained when you expressed your interest in participating in 
this study.   
 
This Participant Information Sheet/Consent Form tells you about the research 
project. It explains the processes involved with taking part. Knowing what is involved 
will help you decide if you want to take part in the research. 
 
Please read this information carefully. Ask questions about anything that you don’t 
understand or want to know more about. Before deciding whether or not to take part, 
you might want to talk about it with a relative, friend or local health worker. 
 
Participation in this research is voluntary. If you don’t wish to take part, you don’t 
have to. 
 
If you decide you want to take part in the research project, you will be asked to sign 
the consent section. By signing it you are telling us that you: 
• Understand what you have read 
• Consent to take part in the research project 
• Consent to be involved in the research described 
• Consent to the use of your personal and health information as described. 
 
You will be given a copy of this Participant Information and Consent Form to keep. 
 
2  What is the purpose of this research? 
 
• People with chronic kidney disease often require renal dialysis when they reach 
end stage kidney disease to maintain health. Advanced chronic kidney disease 
requiring dialysis is associated with physical deterioration, resulting in 
decreased mobility and capacity for independence. 
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• Research highlights the functional benefits of exercise for people with end stage 
kidney disease including improved ability to perform activities of daily living and 
improved quality of life. However, the recommendations for exercise during 
dialysis are lengthy, and not commonly completed among people with end stage 
kidney disease 
• The aims of the project are to investigate the tolerability of blood flow restriction 
during cycling exercise for people with end-stage kidney disease, and the short-
term affect this has on heart rate and blood pressure. There is a body of 
evidence that demonstrates minimal increases in heart rate and blood pressure 
following low-intensity blood flow restriction training with cycling exercise, or 
similar. 
• Training with blood flow restriction cuffs at a low-intensity can produce physical 
functional improvements while eliminating the intimidation, and potential risk and 
negative stigma that surrounds high-intensity exercise in populations unlikely to 
complete it, or recommended not to complete it for medical reasons or 
functional limitations, as is often seen among patients with end-stage kidney 
disease. 
• This research has been funded by the Deakin University with in kind support 
from Eastern Health and will contribute to the fulfilment of a Doctor of 
Philosophy for Mr. Matthew Clarkson. 
• Patients for this research will also be recruited from dialysis units across 
Eastern Health. 
 
3 What does participation in this research involve? 
 
If you would like to take part in this project, you will need to sign the consent form 
attached to this document before you commence. 
Additionally, your renal specialist will be asked to approve your participation. This 
will be based on your health and potential risks, to ensure the exercise training does 
not interfere with your treatment.  
The exercise training will be conducted in your dialysis unit over a period of fifteen 
days, for a total of six sessions. Four sessions will occur during your dialysis 
treatment, and two sessions on a non-dialysis day. All participants will complete the 
same exercise training regime over the fifteen days, and will have heart rate and 
blood pressure monitored throughout. Participants will also be asked to provide 
perceptual responses for both effort required, and level of discomfort, if any, that is 
experienced during the exercise. 
A specially qualified instructor (exercise physiologist and/or exercise physiology 
trainees) will come to your dialysis sessions during this short study. They will deliver 
the exercise training sessions and work with you three times per week. Four of the 
exercise training sessions will be completed within the first two hours of your dialysis 
sessions, and two exercise training sessions will require attendance at the dialysis 
unit on two non-dialysis days, for which transport arrangements will be discussed 
with each participant. The total amount of exercise to be completed each session 
will be approximately 20 to 30 minutes. The instructor will ensure consistency and 
that exercise and testing measures are performed and documented as per research 
protocol. The instructor will remain with you during the exercise training, and you will 
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also be monitored by the nursing staff in the unit. You will be encouraged to inform 
staff if you feel uncomfortable during exercises, and your exercises may be modified 
to make you more comfortable or stopped if necessary. 
 
To evaluate your response to exercise, you will have your heart rate and blood 
pressure monitored not only at regular intervals throughout the exercise, but also at 
regular intervals in the 60 minutes that follow the exercise. 
We will also collect information from you regarding your age, gender, height, weight, 
and measurements of limb length and circumference.  
A familiarisation session will be conducted for all participants, during which blood 
flow will be restricted to the lower limbs using pressurised cuffs (similar to blood 
pressure cuffs) placed at the top of each thigh. Blood flow restriction will be 
gradually applied to acclimatise participants to the pressure that will be applied 
during training.  
For all participants the cuff pressure will be pre-determined separately for each limb 
prior to any physical tasks while the participant is seated (in their dialysis chair), 
which is representative of the level of the heart to the cuff height during the cycling 
exercise training sessions: 
1. With the restriction cuffs in place on the limb, a clip on device will be applied 
to the second toe of the appropriate foot. 
2. Following a 5 min rest period the automated measurement of the point at 
which blood flow to the limb stops will be performed using an inbuilt function 
of the machine where the restriction cuffs gradually inflate to produce a 
continuous rise in pressure until blood flow to the tissues is no longer 
detected at the toe. 
3. The results will then be used to set the cuff pressure for the cycling. 
4. If more than 20 mmHg, the average of three tests will be used. 
During training sessions, participants will cycle at a continual pressure equivalent to 
50% of their pre-determined limb occlusion pressure. This still allows for sufficient 
limb blood flow during the cycling exercise, and will not impact the effectiveness of 
the dialysis treatment. 
Training sessions will involve the following protocol, and will be conducted at dialysis 
clinics under Eastern Health. 
1. All cycling will be completed using stationary, electronically braked bikes 
positioned in front of the participants’ dialysis beds.  
2. All cycling sessions will be completed at a low intensity of 30 Watts, which is 
a conservative estimate of approximately 40% of patients’ maximum 
workload 
3. A 3 minute warm up will be completed prior to commencing the main cycling 
session (no blood flow restriction during this time). 
4. The main cycling session will be completed for a total of two 10 minute bouts 
with 20 minutes rest between, this will include blood flow restriction to the 
lower limbs on the days during which it is programmed. 
5. Following the cycling protocol participants will be required to complete a 5 
minute gentle cycle as recovery (no blood flow restriction during this time). 
Random inspections (including short interviews with participants) will be performed 
by the instructor during or around dialysis sessions. Reports will be provided to the 
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research management team at Deakin University on the progress of the study. 
Milestones (ethics, recruitment, etc.) will be reported at fortnightly research team 
meetings. 
This research project has been designed to make sure the researchers interpret the 
results in a fair and appropriate way and avoids researchers or participants jumping 
to conclusions. 
There are no costs associated with participating in this research project, nor will you 
be paid. You will not receive reimbursement or payment in kind for your participation 
in this research. 
 
4 Other relevant information about the research project 
 
Dialysis patients will be recruited from 3 Eastern Health dialysis units. We aim to 
recruit as many patients as possible from one dialysis unit before changing units, 
until a total of 10 participants complete the study. 
 
 
 
 
5 Do I have to take part in this research project? 
 
Participation in any research project is voluntary. If you do not wish to take part, you 
do not have to. If you decide to take part and later change your mind, you are free to 
withdraw from the project at any stage. 
 
If you do decide to take part, you will be given this Participant Information and 
Consent Form to sign and you will be given a copy to keep. 
 
Your decision whether to take part or not to take part, or to take part and then 
withdraw, will not affect your routine care, your relationship with professional staff or 
your relationship with Eastern Health. 
 
 
6 What are the possible benefits of taking part? 
 
Current recommendations indicate that exercise training can improve physical 
function and wellbeing. Findings from this study may be relevant to people with a 
range of chronic conditions, such as renal disease. Exercise has been found to have 
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positive effects for these individuals. Blood flow restriction during exercise training 
may enhance benefits without the need for other resistance training equipment. This 
study will provide valuable information regarding the parameters of blood flow 
restriction exercise prescribed to special populations. We cannot guarantee or 
promise that you will receive any benefits from this research. 
 
7 What are the possible risks and disadvantages of taking part? 
 
There are minimal risks associated with this research and you are unlikely to 
experience any changes during treatment. The exercise program is designed to 
provide low-intensity exercise and will take into account that you will be receiving 
dialysis and attached to dialysis equipment during this time. The program is suitable 
for people who do not routinely exercise. It will include low impact, warm up and cool 
down exercise. The addition of blood flow restriction cuffs feels like moderate 
pressure directly under the cuff, but is not fully restrictive (not enough pressure to 
cause numbness or tingling) as you may have experienced while having your blood 
pressure taken. Patients identified at risk will be excluded from the program. 
 
You will be supervised throughout the program by an exercise physiologist or 
trainee exercise physiologist and also monitored by nursing staff who will be readily 
available to respond to any concerns or discomfort you experience. You will be able 
to stop the exercises at any time and will be encouraged to report any unusual 
symptoms. Any risks will be reported immediately to the supervising renal specialist. 
 
If you feel upset or distressed as a result of your participation in the research 
project, the research team will be able to arrange for counselling or other 
appropriate support. Any counselling or support will be provided by qualified staff 
who are not members of the research team. This counselling will be provided free of 
charge. 
 
8 What if I withdraw from this research project? 
 
If you do consent to participate, you may withdraw at any time.  If you decide to 
withdraw from the project, please notify a member of the research team before you 
withdraw. They will inform you if there are any special requirements linked to 
withdrawing.  If you do withdraw, you will be asked to complete and sign a 
‘Withdrawal of Consent’ form; this will be provided to you by the research team. 
 
If you decide to leave the research project, the researchers will not collect additional 
personal information from you, although personal information already collected will 
be retained to ensure that the results of the research project can be measured 
properly and to comply with law. You should be aware that data collected up to the 
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time you withdraw will form part of the research project results.  If you do not want 
your data to be included, you must tell the researchers when you withdraw from the 
research project. 
 
9 What happens when the research project ends? 
 
If you wish to receive a summary of the findings, you can let the research team 
know today or at any stage of the project. Once the data has been analysed, you will 
receive a summary of the findings. You can let us know how you would prefer to 
receive this information, for example via email, post or in person at your dialysis unit. 
The project is scheduled for completion in December 2017 so it is anticipated you 
will receive this information around that time.  
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Part 2 How is the research project being conducted? 
 
10 What will happen to information about me? 
 
By signing the consent form you consent to the research team collecting and using 
personal information about you for the research project. Any information obtained for 
the purpose of this research project that can identify you (e.g., this consent form) will 
be treated as confidential and securely stored. Other information obtained for the 
purpose of this research project (e.g., physical assessment, survey responses) will 
be stored in a de-identified format. You will be assigned a code number so that the 
research team can match up the information collected about you at each stage of 
the project. Your information will only be used for the purpose of this research 
project only. It will only be disclosed only with your permission, except as required 
by law. 
 
Hard copies of data collected will be stored under lock and key in filing cabinets at 
Deakin University, which only the research team can access. Electronic copies of 
the data will be stored on password protected computers that only the research 
team can access. Only the research team will have access to the full set of data. 
 
The hard and electronic copies will be stored for seven years after publication, at 
which time paper copies of the data will be disposed of in confidential document 
waste bins and electronic forms of the data will be deleted. 
 
It is anticipated that the results of this research project will be published and/or 
presented in a variety of forums. In any publication and/or presentation, information 
will be provided in such a way that you cannot be identified. To protect your 
anonymity, all information will be aggregated and reported for the overall sample, 
with no individually identifying information reported. 
  
In accordance with relevant Australian and/or Victorian privacy and other relevant 
laws, you have the right to request access to the information about you that is 
collected and stored by the research team. You also have the right to request that 
any information with which you disagree be corrected. Please inform the research 
team member named at the end of this document if you would like to access your 
information. 
 
11 Complaints and compensation 
 
312 
 
Importantly, if you experience any serious symptoms or side effects during or 
following your participation in this project, please notify either the exercise 
physiologist or a member of staff in the dialysis unit straight away.  
 
If you suffer any distress or psychological injury as a result of this research project, 
you should contact the research team as soon as possible. Contact details for the 
principle investigator are provided on page 6. You will be assisted with arranging 
appropriate treatment and support. 
 
If you wish to make a complaint about any aspects of your treatment as a participant 
in this research project, information about who to contact is provided on page 6. You 
can contact either the person overseeing the ethical aspects of the research project 
at Eastern Health or the person overseeing the research project across all 
participating sites via Deakin University. 
 
12 Who is organising and funding the research? 
 
The principle investigator on this research project is Mr Matthew Clarkson who is a 
Doctor of Philosophy student at Deakin University and an Accredited Exercise 
Physiologist (AEP). 
 
The project is funded by Deakin University and will contribute to the fulfilment of a 
Doctor of Philosophy for Mr. Matthew Clarkson. 
 
 
No member of the research team will receive a personal financial benefit from your 
involvement in this research project (other than their ordinary wages). 
 
13 Who has reviewed the research project? 
   
All research in Australia involving humans is reviewed by an independent group of 
people called a Human Research Ethics Committee (HREC).   
 
The ethical aspects of this research project have been approved by the HREC of 
Eastern Health and Deakin University.  
 
This project will be carried out according to the National Statement on Ethical 
Conduct in Human Research (2007). This statement has been developed to protect 
the interests of people who agree to participate in human research studies. 
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14 Further information and who to contact 
 
The person you may need to contact will depend on the nature of your query.   
 
If you want any further information concerning this project or if you have any 
problems which may be related to your involvement in the project, you can contact 
the principle investigator: 
 
 Research contact person 
 
For matters relating to research at the site at which you are participating, the details 
of the local site complaints person are: 
 
Chairperson 
Eastern Health Human Research and Ethics Committee 
Ph: 03 9895 3398 
Email: ethics@easternhealth.org.au 
 
If you have any complaints about any aspect of the project, the way it is being 
conducted or any questions about being a research participant in general, then you 
may contact: 
 
Deakin University complaints and enquiries contact person 
Name Mr Matthew Clarkson 
Position Principal Investigator 
Telephone 0400 225 116 
Email mclarks@deakin.edu.au 
Name The Manager 
Position Office of Research Integrity, Deakin University 
Telephone 9251 7123 
Email Research-ethics@deakin.edu.au 
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              Consent Form 
Adult providing own consent 
 
 
Title 
The Effects of Blood Flow Restriction Exercise 
Training on Muscle Health and Physical 
Function among Patients with End Stage 
Kidney Disease 
Short Title 
 
Blood flow restriction exercise during dialysis 
  
Coordinating Principal 
Investigator/ Principal 
Investigators 
Mr Matthew Clarkson 
Dr Stuart Warmington 
Dr Steven Fraser 
Professor Paul Bennett 
 
Professor Lawrence McMahon 
Location  Eastern Health / Deakin University 
 
Declaration by Participant 
 
I have read the Participant Information Sheet or someone has read it to me in a 
language that I understand.  
 
I understand the purposes, procedures and risks of the research described in the 
project. 
 
I have had an opportunity to ask questions and I am satisfied with the answers I 
have received. 
 
I freely agree to participate in this research project as described and understand that 
I am free to withdraw at any time during the project without affecting my future care. 
 
I understand that I will be given a signed copy of this document to keep. 
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 Name of Participant (please print)    
 
 Signature    Date  
 
 
 
 
 Name of witness to participant’s signature (please print)   
 
 Signature    Date   
 
 
Declaration by Researcher† 
 
I have given a verbal explanation of the research project; its procedures and risks 
and I believe that the participant has understood that explanation. 
 
 
 Name of Researcher† (please print)   
  
 Signature    
Date 
  
 
† An appropriately qualified member of the research team must provide the explanation of, and 
information concerning, the research project.  
 
Note: All parties signing the consent section must date their own signature. 
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        Form for Withdrawal of Participation  
Adult providing own consent 
 
Title 
The Effects of Blood Flow Restriction 
Exercise Training on Muscle Health and 
Physical Function among Patients with End 
Stage Kidney Disease 
Short Title 
 
Blood flow restriction exercise during dialysis 
  
Coordinating Principal 
Investigator/ Principal 
Investigators 
Mr Matthew Clarkson 
Dr Stuart Warmington 
Dr Steven Fraser 
Professor Paul Bennett 
 
Professor Lawrence McMahon 
Associate Investigators 
 
 
Location  Eastern Health  
 
 
Declaration by Participant 
 
I wish to withdraw from participation in the above research project and understand 
that such withdrawal will not affect my routine care, or my relationships with the 
researchers or Eastern Health. 
 
 
 Name of Participant (please print)     
 
 Signature  
  
Date   
 
 
 
In the event that the participant’s decision to withdraw is communicated verbally, the Senior 
Researcher must provide a description of the circumstances below. 
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Declaration by Researcher† 
 
I have given a verbal explanation of the implications of withdrawal from the research 
project and I believe that the participant has understood that explanation. 
 
 
 Name of Researcher (please print)   
   Signature    Date  
 
† An appropriately qualified member of the research team must provide information concerning 
withdrawal from the research project.  
 
Note: All parties signing the consent section must date their own signature. 
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Appendix F: 
 
Patient Information and Consent Form 
(Study 2) 
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Participant Information Sheet/Consent Form 
Health/Social Science Research - Adult providing own consent 
 
Title 
The Effects of Blood Flow Restriction 
Exercise for Muscle Health and 
Physical Function in Dialysis Patients 
Short Title 
 
Blood flow restriction exercise during 
dialysis 
Protocol Number  
Coordinating Principal Investigator/ 
Principal Investigators 
Dr Margaret Fraenkel 
Mr Matthew Clarkson 
Dr Stuart Warmington 
A/Prof Steve Fraser 
Professor Paul Bennett 
Dr Catherine Brumby 
Dr Anna Munasinghe 
 
Professor Lawrence McMahon 
  
Location  Epworth Eastern/Eastern Health/Deakin University  
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Part 1  What does my participation involve? 
 
1 Introduction 
 
You are invited to take part in this research project, which is measuring the effect of 
a technique called “blood flow restriction” during exercise on muscle health and 
physical function of people on dialysis. This will be compared to a traditional 
exercise group without blood flow restriction, and a non-exercising control group. 
You have been invited because you are an adult with end stage kidney disease 
undergoing dialysis at Epworth Eastern. Your contact details were obtained when 
you expressed your interest in participating in this study.   
 
This Participant Information Sheet/Consent Form tells you about the research 
project. It explains the processes involved with taking part. Knowing what is involved 
will help you decide if you want to take part in the research. 
 
Please read this information carefully. Ask questions about anything that you don’t 
understand or want to know more about. Before deciding whether or not to take part, 
you might want to talk about it with a relative, friend or local health worker. 
 
Participation in this research is voluntary. If you don’t wish to take part, you don’t 
have to, and this will have no impact on your current care in any way  
If you decide you want to take part in the research project, you will be asked to sign 
the consent section. By signing it you are telling us that you: 
• Understand what you have read  
• Consent to take part in the research project 
• Consent to be involved in the research described 
• Consent to the use of your personal and health information as described. 
 
You will be given a copy of this Participant Information and Consent Form to keep. 
 
2  What is the purpose of this research? 
 
• People with chronic kidney disease often require renal dialysis to maintain 
health when kidney function becomes too low (i.e. end stage kidney disease). 
Both the kidney disease and the actual dialysis may accelerate physical 
deterioration, resulting in reduced mobility and may affect independence. 
• Research highlights the benefits of exercise for people with end stage kidney 
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disease including improved ability to perform activities of daily living and 
improved quality of life. However, the recommendations for exercise during 
dialysis are lengthy, and not commonly completed among people with end stage 
kidney disease 
• The aims of the project are to investigate the application of blood flow restriction 
during cycling exercise for people with end-stage kidney disease, and the 
physical improvements that result. There is a body of evidence that 
demonstrates increased muscle size and strength following low effort blood flow 
restriction exercise, beyond that of equivalent intensity exercise without the 
blood flow restriction. This would reduce the time commitments placed on 
patients to meet the exercise recommendations and require only low intensity 
exercise. 
• Training with pressurised cuffs at a low intensity can improve physical function 
while eliminating the intimidation, potential risk and perception of difficulty that 
surrounds high-intensity exercise in populations unlikely to complete it or 
recommended not to complete it for medical reasons or physical limitations, as 
is often seen among patients with end-stage kidney disease. 
• Exercise in healthy people has been shown to help keep the bacteria in your gut 
in a healthy balance. The healthy balance helps to reduce inflammation.  We 
want to see whether this also happens in patients with end-stage kidney 
disease. 
• This research has been funded by Deakin University with in kind support from 
Eastern Health Clinical School and will contribute to the fulfilment of a Doctor of 
Philosophy for Mr. Matthew Clarkson and Dr. Anna Munasinghe.  
• Patients for this research will be recruited from dialysis units across Eastern 
Health and Epworth Eastern. 
 
3 What does participation in this research involve? 
 
If you would like to take part in this project, you will need to sign the consent form 
attached to this document before you commence. 
You will be randomly allocated to one of the three previously mentioned groups 
using a computer-generated table of random numbers performed by a researcher 
independent to the study. This creates an equal chance of you being included in any 
of the three groups, which is essential for maintaining balance among the 
characteristics of patients allocated to each group. Also, regardless of your 
allocation to one of the two groups doing exercise or the standard care non-
exercising control group, your renal specialist will be asked to approve your 
participation. This will be based on your health and potential risks, to ensure the 
exercise training does not interfere with your treatment.  
The exercise will be conducted in your dialysis unit during your treatment over a 
period of three months. If you are allocated to the standard care non-exercising 
control group, your dialysis treatment will not change, but you will be asked to 
complete the same testing as the exercising groups. This information will be used as 
a comparison to the results of the other groups.  
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There will also be a requirement once at the beginning and once at the end of the 
three-month training period to complete testing and complete a short questionnaire 
prior to commencing a dialysis session. 
The sections below detail the assessments conducted at the start and the end of the 
study, and the details of the exercise interventions to be used during the study. 
Below is a simplified list of the assessments explained in more depth throughout this 
document: 
Mandatory tests for all participants: 
• Leg strength test 
• Measures of physical function: 
o 30-second sit to stand test 
o Timed up and go test 
o The six-minute walk test. 
• Questionnaire about physical activity habits 
• Questionnaire about dialysis related symptoms 
• Blood tests – routine measures related to kidney function (taken from dialysis 
lines)  
• Non-invasive measures of blood vessel stiffness 
Optional tests: 
• Blood test – markers of gut inflammation (taken from dialysis lines) 
• Two stool samples 
• Questionnaire about bowel habits 
 
You will also be asked if you are willing to attend an optional single session at 
Deakin University prior to the commencement of the three-month training period, 
and again upon conclusion of the training period. These sessions at Deakin 
University: 
• Will involve two forms of body scans that will be used to measure leg muscle 
and overall body composition changes following the duration of the study. 
− DXA scan: whole body scan involves lying still on a bed, while a moving 
arm scans over the body. This takes approximately five minutes to 
complete. 
− pQCT scan: While you are seated on a bed, your leg will be positioned 
so that a scanning ring can pass over one leg and scan its composition. 
This will be done for both legs and may take approximately twenty to 
thirty minutes to complete. 
• Are completely optional for you but provide valuable information to the study if 
you choose to attend. 
A specially qualified instructor (exercise physiologist and/or exercise physiology 
trainees) will come to your dialysis sessions each week. They will deliver the 
exercise training sessions and work with you three times per week for the full three-
month duration. The exercise training will be completed within the first two hours of 
your dialysis. The total amount of exercise to be completed each session will be 
approximately 20 minutes. The instructor will ensure consistency and that exercise 
and testing measures are performed and documented as per research protocol. The 
instructor will remain with you during the exercise training, and you will also be 
monitored by the nursing staff in the unit. You will be encouraged to inform staff if 
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you feel uncomfortable during exercises, and your exercises may be modified to 
make you more comfortable or stopped if necessary. 
 
To evaluate this project, you will be asked to complete physical assessments 
including: 
1. A strength test, involving weighted knee extensions; 
2. Three simple functional tests: 
− 30-second sit to stand test 
− Timed up and go test 
− The six-minute walk test. 
The physical assessment will be completed before you commence the exercise 
training program and will be repeated at the conclusion of the exercise training 
program. We will also collect information from you regarding your age, gender, 
height, weight, and measurements of limb length and circumference.  
During a familiarisation session for those allocated to the blood flow restriction 
group, blood flow will be restricted to the lower limbs using pressurised cuffs (similar 
to blood pressure cuffs) placed at the top of each thigh. Pressure will be gradually 
applied to acclimatise participants to the final pressure that will be applied during 
exercise.  
For those randomised to the blood flow restriction group, the cuff pressure will be 
pre-determined separately for each limb prior to any physical tasks while the 
participant is seated (in their dialysis chair), which is representative of the level of 
the heart to the cuff height during the cycling exercise training sessions: 
5. With the cuffs in place on the limb, a clip-on device will be applied to the 
second toe of the appropriate foot. 
6. Following a 5 min rest period the automated measurement of the point at 
which blood flow to the limb stops will be performed using an inbuilt function 
of the machine where the restriction cuffs gradually inflate to produce a 
continuous rise in pressure until blood flow to the tissues is no longer 
detected at the toe. 
7. The results will then be used to set the cuff pressure for the cycling. 
8. If there is a difference in pressure more than 20 units, the average of three 
tests will be used. 
During exercise sessions, participants in the group that have the pressure cuffs 
fitted will cycle at a continual pressure equivalent to 50% of the pressure required to 
completely stop blood flow to the limb. This still allows for some limb blood flow 
during the cycling exercise and will not impact the effectiveness of the dialysis 
treatment. The application of blood flow restriction during exercise involves a 
notable amount of pressure applied where the cuffs are fitted which may be 
perceived as being uncomfortable by some participants. 
Training sessions for the two exercising groups will involve one of two procedures 
and will be conducted at dialysis clinics under Epworth Eastern and Eastern Health. 
6. All cycling will be completed using stationary pedals positioned in front of the 
participants’ dialysis beds.  
7. Blood flow restriction group: 
a. The blood flow restriction group will cycle for 10 minutes with the 
cuffs inflated, then rest with the cuffs deflated and/or removed for 20 
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minutes, and then complete a second bout of 10 minutes cycling with 
the cuffs inflated. 
b. The cycling will be completed at a low-to-moderate effort (12-15 out 
of 20) determined by participants’ own ratings of how hard they 
perceive they are working. 
8. Non-blood flow restriction group: 
a. The non-blood flow restriction group will complete the same low-to-
moderate effort cycling, but will complete 20 continuous minutes, with 
no rest in between. 
Following the initial cycling protocol participants from each group will be required to 
complete a 5-minute gentle cycle as recovery (no blood flow restriction during this 
time). 
Additional Assessments 
Questionnaire:  
You will also be asked to complete two surveys which contain questions about 
quality of life and your involvement in community activities, once at the start and 
again at the conclusion of the study. These will take less than 5 minutes to 
complete.  
 
Blood tests: 
As part of the study we will collect results of pathology tests you already have done 
as part of your routine dialysis care. This includes key markers related to kidney and 
heart function. We will perform some additional tests as follows: 
• At study commencement: blood markers of kidney function and 
fatigue, and markers related to the elasticity of your blood vessels 
(around 5 teaspoons of blood). 
• At study conclusion: a repeat of the measures taken when 
commencing the study (around 5 teaspoons of blood). 
• These will be taken during your regular dialysis session by the 
dialysis nurse with no discomfort or additional burden to you. 
   
Other tests: 
You will also require an assessment of your blood vessels once only at the start and 
conclusion of the study. This assessment is non-invasive, will take 10-30 minutes to 
complete, and will be performed at the dialysis unit by a doctor or nurse just prior to 
your scheduled dialysis session. This assessment includes: 
• The use of a tiny ultrasound probe placed on the neck and the upper 
part of the leg (near the groin crease) to measure the stiffness of the 
large blood vessels in your body. It does not cause any discomfort. 
You will be lying down while the measurement is taken in a private 
area of the dialysis unit.   
• The use of a special type of blood pressure cuff on your upper arm, 
once only, and is very similar to having your blood pressure checked 
with a normal machine. This will also measure the stiffness of the 
blood vessels in your body.  
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Random inspections (including short interviews with participants) will be performed 
by the instructor during or around dialysis sessions. Reports will be provided to the 
research management team at Deakin University on the progress of the study. 
Milestones (ethics, recruitment, etc.) will be reported at fortnightly research team 
meetings. 
 
Optional Component 
 
We would like to see if exercise helps to reduce inflammation and promote a healthy 
balance of bacteria in your gut. This would require three things: 
 
1. A blood test: An extra 15mls (3 tubes) of blood from your dialysis lines at 
the start and end of the study, in addition to your routine bloods. This will 
cause no discomfort to you. 
2. Two stool samples: at the start and end of the study. 
3. A questionnaire about your bowel habits: 2 days prior to your stool 
samples. 
 
This research project has been designed to make sure the researchers interpret the 
results in a fair and appropriate way and avoids researchers or participants jumping 
to conclusions. 
There are no costs or out-of-pocket expenses associated with participating in this 
research project, nor will you be paid. You will not receive reimbursement or 
payment in kind for your participation in this research. 
 
4 Other relevant information about the research project 
 
Patients with end-stage kidney disease will be recruited from 3 Eastern Health 
dialysis units and from the dialysis unit at Epworth Eastern. We aim to recruit as 
many participants as possible from one dialysis unit before changing units, until a 
total of 60 participants complete the study. 
 
This research study involves exposure to a very small amount of radiation from the 
DXA and pQCT scans of your body. As part of everyday living, everyone is exposed 
to naturally occurring background radiation and receives a small dose of about 2 
millisieverts (mSv) each year. The effective dose you will receive from these scans 
of your body will be approximately 0.12 mSv. At these dose levels, no harmful 
effects of radiation have been demonstrated, as any effect is too small to measure. 
The risk is believed to be minimal. 
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If you have been involved in any other research studies that involve radiation, 
please inform us. Please keep this Patient Information and Consent Form that 
includes information about your exposure to radiation in this study for at least five 
years. You will be required to provide this information to researchers of any future 
research studies involving exposure to radiation. 
 
5 Do I have to take part in this research project? 
 
Participation in any research project is voluntary. If you do not wish to take part, you 
do not have to. If you decide to take part and later change your mind, you are free to 
withdraw from the project at any stage. 
 
If you do decide to take part, you will be given this Participant Information and 
Consent Form to sign and you will be given a copy to keep. 
 
Your decision whether to take part or not to take part, or to take part and then 
withdraw, will not affect your routine care, your relationship with professional staff or 
your relationship with Eastern Health/Epworth Eastern. 
 
 
6 What are the possible benefits of taking part? 
 
Current recommendations indicate that exercise training can improve physical 
function and wellbeing. Findings from this study may be relevant to people with a 
range of chronic conditions, such as kidney disease. Exercise has been found to 
have positive effects for these individuals. Blood flow restriction during exercise may 
enhance benefits without the need for other resistance training equipment (hand 
weights, resistance bands, weight machines, etc.). We cannot guarantee or promise 
that you will receive any benefits from this research. 
 
7 What are the possible risks and disadvantages of taking part? 
 
There are minimal risks associated with this research and you are unlikely to 
experience any changes during treatment. The exercise program is designed to 
provide low-intensity exercise and will take into account that you will be receiving 
dialysis and attached to dialysis equipment during this time. The program is suitable 
for people who do not routinely exercise. It will include low impact, warm up and cool 
down exercise. The addition of blood flow restriction cuffs feels like moderate 
pressure directly under the cuff, which may be uncomfortable to some patients, but 
is not fully restrictive (not enough pressure to cause numbness or tingling) as you 
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may have experienced while having your blood pressure taken. Patients identified at 
risk will be excluded from the program. 
 
You will be supervised throughout the program by an exercise physiologist or 
trainee exercise physiologist and also monitored by nursing staff who will be readily 
available to respond to any concerns or discomfort you experience. You will be able 
to stop the exercises at any time and will be encouraged to report any unusual 
symptoms. Any risks will be reported immediately to the supervising renal specialist. 
 
If you feel upset or distressed as a result of your participation in the research 
project, the research team will be able to arrange for counselling or other 
appropriate support. Any counselling or support will be provided by qualified staff 
who are not members of the research team. This counselling will be provided free of 
charge to participants at the expense of Deakin University. 
 
8 What if I withdraw from this research project? 
 
If you do consent to participate, you may withdraw at any time.  If you decide to 
withdraw from the project, please notify a member of the research team before you 
withdraw. They will inform you if there are any special requirements linked to 
withdrawing.  If you do withdraw, you will be asked to complete and sign a 
‘Withdrawal of Consent’ form; this will be provided to you by the research team. 
 
If you decide to leave the research project, the researchers will not collect additional 
personal information from you, although personal information already collected will 
be retained to ensure that the results of the research project can be measured 
properly and to comply with law. You should be aware that data collected up to the 
time you withdraw will form part of the research project results.  If you do not want 
your data to be included, you must tell the researchers when you withdraw from the 
research project. 
 
9 What happens when the research project ends? 
 
If you wish to receive a summary of the findings, you can let the research team 
know today or at any stage of the project. Once the data has been analysed, you will 
receive a summary of the findings. You can let us know how you would prefer to 
receive this information, for example via email, post or in person at your dialysis unit. 
The project is scheduled for completion in December 2017 so it is anticipated you 
will receive this information around that time. 
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Part 2 How is the research project being conducted? 
 
10 What will happen to information about me? 
 
By signing the consent form you consent to the research team collecting and using 
personal information about you for the research project. Any information obtained for 
the purpose of this research project that can identify you (e.g., this consent form) will 
be treated as confidential and securely stored. Other information obtained for the 
purpose of this research project (e.g., physical assessment, survey responses) will 
be stored in a de-identified format. You will be assigned a code number so that the 
research team can match up the information collected about you at each stage of 
the project. Your information will only be used for the purpose of this research 
project only. It will only be disclosed only with your permission, except as required 
by law. 
 
Hard copies of data collected will be stored under lock and key in filing cabinets at 
Deakin University, which only the research team can access. Electronic copies of 
the data will be stored on password protected computers that only the research 
team can access. Only the research team will have access to the full set of data. 
 
The hard and electronic copies will be stored for seven years after publication, at 
which time paper copies of the data will be disposed of in confidential document 
waste bins and electronic forms of the data will be deleted. 
 
It is anticipated that the results of this research project will be published and/or 
presented in a variety of forums. In any publication and/or presentation, information 
will be provided in such a way that you cannot be identified. To protect your 
anonymity, all information will be aggregated and reported for the overall sample, 
with no individually identifying information reported. 
  
In accordance with relevant Australian and/or Victorian privacy and other relevant 
laws, you have the right to request access to the information about you that is 
collected and stored by the research team. You also have the right to request that 
any information with which you disagree be corrected. Please inform the research 
team member named at the end of this document if you would like to access your 
information. 
 
11 Complaints and compensation 
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Importantly, if you experience any serious symptoms or side effects during or 
following your participation in this project, please notify either the exercise 
physiologist or a member of staff in the dialysis unit straight away.  
 
If you suffer any distress or psychological injury as a result of this research project, 
you should contact the research team as soon as possible. Contact details for one 
of the investigators are provided on page 9. You will be assisted with arranging 
appropriate treatment and support. 
 
If you wish to make a complaint about any aspects of your treatment as a participant 
in this research project, information about who to contact is provided on page 9. You 
can contact either the person overseeing the ethical aspects of the research project 
at Epworth Eastern or the person overseeing the research project across all 
participating sites via Deakin University. 
 
12 Who is organising and funding the research? 
 
The principal investigator on this research project is Dr Margaret Fraenkel, and the 
contact person is Mr Matthew Clarkson who is a Doctor of Philosophy student at 
Deakin University and an Accredited Exercise Physiologist (AEP). The investigator 
for the optional gut bacteria component is Dr Anna Munasinghe a kidney specialist 
and PhD candidate with Monash University. 
 
The project is funded by Deakin University and Eastern Health Clinical School and 
will contribute to the fulfilment of a Doctor of Philosophy for Mr. Matthew Clarkson 
and Dr. Anna Munasinghe.  
No member of the research team will receive a personal financial benefit from your 
involvement in this research project (other than their ordinary wages). 
 
13 Who has reviewed the research project? 
   
All research in Australia involving humans is reviewed by an independent group of 
people called a Human Research Ethics Committee (HREC).   
 
The ethical aspects of this research project have been approved by the HREC of 
Epworth Eastern, Eastern Health and Deakin University.  
 
This project will be carried out according to the National Statement on Ethical 
Conduct in Human Research (2007). This statement has been developed to protect 
the interests of people who agree to participate in human research studies. 
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14 Further information and who to contact 
 
The person you may need to contact will depend on the nature of your query.   
 
If you want any further information concerning this project or if you have any 
problems which may be related to your involvement in the project, you can contact 
an investigator listed below: 
 
 Research contact person 
 
Contact person for the optional component 
 
Please provide the HREC coordinator with the study number and the name of the 
Principal Investigator, for this study. 
 
For matters relating to research at the site at which you are participating regarding 
the way the project is being conducted or any questions about being a research 
participant in general the details of the local site complaints person are: 
 
Position HREC Coordinator 
Telephone Ph: 03 9426 8806 
Email Email: HREC@epworth.org.au 
 
If you have any complaints about any aspect of the project, the way it is being 
conducted or any questions about being a research participant in general, then you 
may contact: 
 
Name Mr Matthew Clarkson 
Position Investigator 
Telephone 0400 225 116 
Email mclarks@deakin.edu.au 
Name Dr Anna Munasinghe 
Position Investigator 
Telephone 03 9895 3333 via switchboard 
Email anna.munasinghe@monash.edu.au 
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Deakin University complaints and enquiries contact person 
Name The Manager 
Position Office of Research Integrity, Deakin University 
Telephone 9251 7123 
Email Research-ethics@deakin.edu.au 
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Consent Form 
Adult providing own consent 
 
Title 
The Effects of Blood Flow Restriction Exercise 
for Muscle Health and Physical Function in 
Dialysis Patients 
Short Title 
 
Blood flow restriction exercise during dialysis 
Protocol Number  
Coordinating Principal 
Investigator/ Principal 
Investigators 
Dr Margaret Fraenkel 
Mr Matthew Clarkson 
Dr Stuart Warmington 
A/Prof Steve Fraser 
Professor Paul Bennett 
Dr Catherine Brumby 
Dr Anna Munasinghe 
 
Professor Lawrence McMahon 
 
Location 
 
Epworth Eastern / Eastern Health / Deakin 
University 
 
Declaration by Participant 
 
I have read the Participant Information Sheet, or someone has read it to me in a language 
that I understand.  
 
I understand the purposes, procedures and risks of the research described in the project. 
 
I have had an opportunity to ask questions and I am satisfied with the answers I have 
received. 
 
I freely agree to participate in this research project as described and understand that I am 
free to withdraw at any time during the project without affecting my future care. 
 
I understand that I will be given a signed copy of this document to keep. 
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 I freely agree to participate in scans to be completed at Deakin University (Please 
Tick Box) 
 I freely agree to an assessment of my inflammation levels and gut bacteria 
(Please Tick Box) 
 
 
 Name of Participant (please print)     
 
 Signature  
  
Date   
 
 
 
 Name of witness to participant’s signature (please print)   
 
 Signature    Date   
 
 
Declaration by Researcher† 
 
I have given a verbal explanation of the research project; its procedures and risks 
and I believe that the participant has understood that explanation. 
 
 Name of Researcher† (please print)   
   Signature    Date  
 
† An appropriately qualified member of the research team must provide the explanation of, and 
information concerning, the research project.  
 
Note: All parties signing the consent section must date their own 
signature. 
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Form for Withdrawal of Participation  
Adult providing own consent 
 
Title 
The Effects of Blood Flow Restriction 
Exercise for Muscle Health and Physical 
Function in Dialysis Patients 
Short Title 
 
Blood flow restriction exercise during dialysis 
Protocol Number  
Coordinating Principal 
Investigator/ Principal 
Investigators 
Dr Margaret Fraenkel 
Mr Matthew Clarkson 
Dr Stuart Warmington 
A/Prof Steve Fraser 
Professor Paul Bennett 
Dr Catherine Brumby 
Dr Anna Munasinghe 
 
Professor Lawrence McMahon 
 
Location 
 
Epworth Eastern / Eastern Health / Deakin 
University 
 
Declaration by Participant 
 
I wish to withdraw from participation in the above research project and understand 
that such withdrawal will not affect my routine care, or my relationships with the 
researchers or Epworth Eastern. 
 
 
 Name of Participant (please print)     
 
 Signature  
  
Date   
 
In the event that the participant’s decision to withdraw is communicated verbally, the Senior 
Researcher must provide a description of the circumstances below. 
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Appendix G: 
 
CHAMPS & POS-S Renal Questionnaires 
(Study 2) 
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CHAMPS Activities Questionnaire for Older Adults 
 
 
 
 
 
CHAMPS: Community Healthy Activities Model Program for 
Seniors Institute for Health & Aging, University of California 
San Francisco Stanford Centre for Research in Disease 
Prevention, Stanford University (11/06/00) © Copyright 1998 
Do not reproduce without permission of the 
CHAMPS staff Contact: Anita L. Stewart, Ph.D., 
UCSF, anitast@itsa.ucsf.edu 
 
Date:  
Name or ID:   
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This questionnaire is about activities that you may have done in the past 4 weeks. The 
questions on the following pages are similar to the example shown below. 
INSTRUCTIONS 
If you DID the activity in the past 4 weeks: 
Step #1 Check the YES box. 
Step #2 Think about how many TIMES a week you usually did it, and write your response in the 
space provided. 
Step #3 Circle how many TOTAL HOURS in a typical week you did the activity. 
Here is an example of how Mrs. Jones would answer question #1: Mrs. Jones usually visits her friends Maria 
and Olga twice a week. She usually spends one hour on Monday with Maria and two hours on Wednesday with Olga. 
Therefore, the total hours a week that she visits with friends is 3 hours a week. 
In a typical week during the past 4 weeks, 
did you… 
 
1. Visit with friends or family (other than those 
you live with)? 
 YES How many TIMES a week?   
□ NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
 
If you DID NOT do the activity: 
•Check the NO box and move to the next question 
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In a typical week during the past 
4 weeks, did you … 
 
1. Visit with friends or family (other than those 
you live with)? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
2. Go to the senior center? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
3. Do volunteer work? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
4. Attend church or take part in church 
activities? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
5. Attend other club or group meetings? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
6. Use a computer? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
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In a typical week during the past 
4 weeks, did you … 
 
7. Dance (such as square, folk, line, ballroom) 
(do not count aerobic dance here)? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
8. Do woodworking, needlework, drawing, or 
other arts or crafts? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
9. Play golf, carrying or pulling your equipment 
(count walking time only)? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
10. Play golf, riding a cart (count walking time 
only)? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
11. Attend a concert, movie, lecture, or sport 
event? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
12. Play cards, bingo, or board 
games with other people? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
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In a typical week during the past 
4 weeks, did you … 
 
13. Shoot pool or billiards? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
14. Play singles tennis (do not count doubles)? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
15. Play doubles tennis (do not count singles)? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
16. Skate (ice, roller, in-line)? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
17. Play a musical instrument? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
18. Read? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
19. Do heavy work around the house (such as 
washing windows, cleaning gutters)? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
342 
 
In a typical week during the past 
4 weeks, did you … 
 
20. Do light work around the house (such as 
sweeping or vacuuming)? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
21. Do heavy gardening (such as spading, 
raking)? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
22. Do light gardening (such as watering 
plants)? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
23. Work on your car, truck, lawn mower, or 
other machinery? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
**Please note: For the following questions about running and walking, include use of a treadmill. 
 
24. Jog or run? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
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25. Walk uphill or hike uphill (count only uphill 
part)? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
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In a typical week during the past 
4 weeks, did you … 
 
26. Walk fast or briskly for exercise (do not 
count walking leisurely or uphill)? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
27. Walk to do errands (such as to/from a store 
or to take children to school (count walk time 
only)? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
28. Walk leisurely for exercise or pleasure? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
29. Ride a bicycle or stationary cycle? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
30. Do other aerobic machines such as rowing, 
or step machines (do not count treadmill or 
stationary cycle)? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
31. Do water exercises (do not count other 
swimming)? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
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In a typical week during the past 
4 weeks, did you … 
 
32. Swim moderately or fast? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
33. Swim gently? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
34. Do stretching or flexibility exercises (do not 
count yoga or Tai-chi)? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
35. Do yoga or Tai-chi? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
36. Do aerobics or aerobic dancing? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
37. Do moderate to heavy strength training 
(such as hand-held weights of more than 5 lbs., 
weight machines, or push-ups)? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
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In a typical week during the past 
4 weeks, did you … 
 
38. Do light strength training (such as hand-held 
weights of 5 lbs. or less or elastic bands)? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
39. Do general conditioning exercises, such as 
light calisthenics or chair exercises (do not 
count strength training)? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
40. Play basketball, soccer, or racquetball (do 
not count time on sidelines)? 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
41. Do other types of physical activity not 
previously mentioned (please specify)? 
 
 
 
 
YES How many TIMES a week?   
NO 
How many TOTAL 
hours a week did you 
usually do it?  
Less 
than 
1 hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
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